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Abstract 
Intensely luminescent cyclometallated platinum(II) complexes have been prepared 
containing N^C^N-coordinating ligands, based on 1,3-dipyridylbenzene. Exceptionally 
high quantum yields ( 0.85, degassed DCM, 298 K) are rationalised in terms of the 
particularly short Pt-C bond, which raises the energy of the normally deactivating d-d* 
state. Terdentate ligand functionalisation has been employed to obtain complexes with 
tuneable emission. Fluorination at the 3,5-aryl positions and/or placing electron-
releasing substituents at the 4-pyridyl position gave complexes with blue-shifted 
emission, whilst retaining a high quantum yield. Substitution of the chloride ancillary 
ligand for cyanide led to further blue-shifts. 
In general, these complexes undergo intermolecular interactions in solutions of higher 
concentration to form excimers. The excimers are emissive in their own right, and 
display broad, structureless emission bands at lower energy than the isolated molecules 
(monomers). The influence of substituents in the terdentate ligand and the identity of 
the coligand on the energy and relative intensity of excimer emission has been 
elucidated.  
Some complexes have been used as phosphorescent dopants in the fabrication of high 
efficiency organic light emitting devices (OLED)s. The colour of a device depends on 
the monomer-to-excimer emission ratio, which is controlled by varying the dopant 
concentration. At intermediate concentrations, white OLEDs, with properties 
approaching pure white light, have been obtained. 
Preliminary investigations into the utility of the complexes as bio-imaging agents in live 
cells are reported. The complexes which contain small substituents on the terdentate 
ligand enter cells rapidly, retaining their phosphorescence. These Pt(II) complexes 
appear to localise simultaneously in both the nucleus and mitochondria of cells, where 
their emission characteristics differ: the application of appropriate filter sets allows 
separate visualisation of the two organelles. A selection of iridium(III) complexes were 
also investigated as bio-imaging agents. These complexes localise in cytoplasm-based 
organelles, and do not appear to enter the nucleus. Both classes of organometallic 
complexes are shown to be suitable candidates for time resolved emission imaging 
microscopy (TREM).  
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CHAPTER ONE: 
Introduction 
 1.1 Overview 
Since the realisation of the photochemical properties of 
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typically significantly longer than fluorescence lifetimes, often being of the order of a 
microsecond rather than a nanosecond.
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Luminescent organometallic complexes find use in organic light emitting devices 
(OLEDs)8,9 sensors, light-energy conversion10 and more recently bio-imaging.11,12,13 A 
big draw for such research at present is the advancement of OLED technology, in which 
triplet-emitting organometallic complexes find use as phosphors, and their triplet-
harvesting ability offers a significant efficiency advantage over organic fluorophores. 
Interest initially focused around d6 metal complexes such as those of Ru2+, Ir3+ and 
Os2+, and investigations into luminescent d8 metal (e.g. Pt(II), Pd(II)) complexes only 
really took off in the late eighties. The delayed interest in luminescent d8 complexes can 
be attributed in part to the geometry of such species – whereas d6 complexes are 
generally octahedral, d8 complexes tend to be square planar, as a consequence of ligand 
field stabilisation. The more open geometry of a square planar complex lends itself to 
intermolecular interactions, and the complexes have a tendency to undergo inner sphere 
interactions with other molecules (including the solvent), generating multimolecular 
species such as aggregates, excimers and exciplexes.5,14 Formation of such species 
‘quenches’ the emission of the isolated molecules (monomeric emission) of the 
complex: an undesirable property of a luminescent species. Hence such complexes were 
initially less attractive than the co-ordinately saturated d6 analogues.  
However, in some cases these multimolecular species are emissive in their own right, 
where emission typically occurs at lower energy than the monomeric species.15,16,17,18,19 
The overall colour of light emitted then depends on the ratio of the intensity of 
monomer-to-multimolecular emission. This effect can be exploited in OLEDs, as a 
facile way to obtain white light emitting devices using a single phosphor material. 
 
1.2 Electronic Transitions 
Emission will normally occur from the lowest-energy electronic excited state. For 
organometallic species, to a first approximation, this state is usually classified as one of 
four possible electronic states, according to the predominant character of the orbitals 
involved. If some of these orbitals lie at similar energy, a degree of mixing may occur. 
As a consequence, the emission of such complexes may stem from an excited state 
containing an admixture of the various electronic transitions: 
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1. Metal centred (MC) d-d states. When a ligand binds to a transition metal, the 
five metal d-orbitals become non-degenerate in a manner determined by the 
symmetry. MC transitions occur between d-orbitals, which are localised on the 
metal. 
2. Metal-to-ligand-charge transfer (MLCT) states. Here the molecule becomes 
excited from a metal-centred orbital into a ligand-centred *-antibonding orbital 
(also known as d-*). 
3. Intraligand (IL) transitions. The molecule becomes promoted from a ligand 
centred -bonding orbital (or non-bonding orbital) to a higher energy *-
antibonding orbital (-*). The metal may sometimes have relatively little effect 
in such cases. 
4. Ligand-to-metal-charge-transfer (LMCT) states. In this case, the molecule is 
promoted from a ligand -orbital to a metal-centred d orbital. 
The relative energies of the above states may vary greatly depending on the nature of 
the ligand(s), the identity of the metal and its charge, and the geometry of the 
complex.20 There are therefore more possible available ways to tune the emission, 
compared with typical fluorescent organics.  
 
1.3 A Brief History of Luminescent Platinum(II) Poylpyridyl 
Complexes 
Many of the early d8 platinum(II) complexes prepared for luminescence studies were 
based on pyridine and polypyridine ligands, similar to those that had been successfully 
incorporated into the earlier luminescent d6 systems. Unfortunately, these Pt(II) 
complexes proved to be scarcely emissive in solution at room temperature because rapid 
non-radiative decay of the excited state occurs. For example, [Pt(bipy)2]2+ (the Pt 
analogue of [Ru(bipy)3]2+)21,1 is practically non-emissive at room temperature, as is 
[Pt(bipy)Cl2].16,22 It has been suggested that the non-emissive decay is associated with 
the structure of such complexes. Square planar Pt(II) complexes involving monodentate 
and/or bidentate ligands are prone to D2d distortions. Such distortions involve twisting 
out of the square plane, to form an approximate tetrahedral geometry. As a rule of 
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thumb, radiative emission is most likely when there is minimal distortion between the 
ground state and excited state. Figure 2 a) exemplifies this - in potential energy surface 
terms, a distorted excited state will be displaced relative to the ground state. If the 
minimum of the excited state lies at similar energy to one of the vibrational levels of the 
ground state, intersystem crossing and non-radiative relaxation will result.  
 
Figure 2: a) represents the energy minimum displacement of the excited state relative to the ground state, 
on population of the dx2-y2 orbital of a square planar d8 complex (also applies to other excited states that 
are significantly distorted relative to the ground state). b) represents excitation to an emissive state (e.g. 
MLCT or ILCT), followed by thermal conversion to a low lying metal-centred state and non-radiative 
decay. For simplicity, the effects of anharmonicity on the form of the potential energy curves is ignored.23 
[Pt(trpy)Cl]+ incorporates a tridentate terpyridyl ligand, 2,2':6,2''-terpyridine – such a 
ligand enforces rigidity in the system. D2d distortions are not possible here, so one might 
expect the complex to display room temperature luminescence. Unfortunately this 
a) 
b) 
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complex is also non-emissive in solution at ambient temperature, but for different 
reasons.18,24 There is significant strain within this molecule due to a less than optimum 
bite angle around platinum, enforced by the rigidity of the system.18 As a consequence, 
the ligand field splitting energy is relatively small and the * orbital is of similar energy 
to the strongly antibonding dx2-y2 orbital (d-d* state). At room temperature, thermal 
promotion from the excited state to this antibonding orbital occurs, accompanied by 
intersystem crossing and a non-radiative return to the ground state (Figure 2 b)). 
N
N N
Pt
Cl
 
Figure 3: The structure of [Pt(trpy)Cl]+.  
For such complexes to be luminescent at room temperature, one can envisage that either 
the emissive excited state must be of sufficiently low energy that thermal population of 
dx2-y2 becomes unfeasible, or that the dx2-y2 state is raised in energy, which can be 
achieved by increasing the ligand field strength.  
 
1.4 N^N^N Complexes of Pt(II) Displaying Room Temperature 
Luminescence 
Structural modification of the polypyridine ligands can influence the energy of the 
lowest excited charge-transfer state (here a MLCT state) relative to the deactivating d-
d* states.25,26 D. R. McMillin et al. found that by placing a substituent in the para-
position of the central pyridyl ring of a trpy system, one could lower the energy of the 
emissive excited state, thus increasing the gap between it and the deactivating d-d* 
state.25 Surprisingly, both electron withdrawing and electron releasing substituents were 
found to have this effect, though for different reasons. With electron withdrawing 
substituents, the energy of the MLCT state drops by a larger amount than the d-d* state, 
meaning that the energy difference is greater and thermal population of the deactivating 
d-d* state is unlikely. When electron releasing substituents are involved, mixing 
between the MLCT state and an ILCT state of similar energy occurs, again resulting in a 
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larger energy difference between the lowest excited state and the d-d* state (see Figure 
4).  
Placing aromatic substituents in the 4-position was found to increases the lifetime of the 
emissive state.27 However, as the fused ring system becomes larger and easier to ionise, 
although the lifetime increases, the energy of the emission decreases. The latter effect is 
attributed to a greater orbital mixing of the emissive MLCT state with an ILCT state. 
N
N N
Pt
Cl
CN
N
N N
Pt
Cl
NMe2
4'-CN-T
4'-NMe2 -T
                    
Figure 4: Excited state energies of various [Pt(4-X-terpy)Cl]+ complexes, compared to the unsubstituted 
[Pt(trpy)Cl]+ complex. The left side of the diagram represents the case where X is electron withdrawing 
(here, CN), and the right side shows what happens when X is electron releasing (here, NMe2).27 
N^N^N complexes involving more favourable bite angles around platinum have been 
prepared, and such complexes have recently been shown to exhibit room temperature 
luminescence with quantum yields as high as 4%.28,29 The complexes are based on 2,6-
di(8-quinolyl)pyridine and 2-(8'-quinolinyl)-1,10-phenanthroline ligands (e.g. 
complexes 1 and 2 respectively), and involve 6-membered chelating rings as opposed to 
the typical 5-membered chelating rings in the previously discussed terpyridine 
coordinating ligands (see Figure 5). Crystal structures and DFT results indicate that ring 
strain is significantly reduced in such systems. For example, the crystal structure of 2 
revealed a N^Pt^N bond angle of 93.0  within the 6-membered chelating ring, and a 
N^Pt^N bond angle of 82.2  in the 5-membered chelating ring29 (note, [Pt(trpy)Cl]+ 
chelating rings have N^Pt^N angles of 82 ),18 whilst DFT calculations on complex 1 
suggest a lateral N-Pt-N bond angle of approximately 180  (the [Pt(trpy)Cl]+ lateral 
N^Pt^N angle is 163.5 ).28 The more favourable bite angle that such 6-membered 
chelating ligands offer results in a stronger ligand field, shifting the deactivating d-d* 
state to higher energy, and reducing the likelihood of population of this non-radiative 
state via thermal promotion. 
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Figure 5: Structures of complexes 1 (left)28 and 2 (middle)29, which contain 6-membered chelating rings. 
Such complexes possess more favourable bite angles around platinum than 5-membered chelating ligands 
such as [Pt(trpy)Cl]+, and are luminescent at 298 K. 
A third route to obtaining room temperature luminescence is to replace the ancillary 
ligand (typically chloride) with a strong field ligand, a ligand that occurs higher in the 
spectrochemical series, such as an acetylide or cyanide.2,30,31,32,33,34,35,36,37 This increases 
the ligand field splitting, and shifts the deactivating d-d* state to higher energy, 
reducing its effect. This strategy has also been employed with complexes of derivatised 
bipyridines and other N^N ligands, affording N^N complexes with room temperature 
emission.38,39,40,41,42,43,44 
The fourth strategy involves the replacement of one of the donor nitrogens in the 
terdentate (or bidentate) polypyridyl system with a cyclometallating carbon – such 
systems are the focus of this review and the work described in subsequent chapters. 
Cyclometallated carbons induce strong ligand fields that may raise the energy of the 
metal-centred d-d* states sufficiently to reduce their deactivating ability.20,19,45 The 
remainder of this review will mainly consider various types of cyclometallated 
platinum(II) complexes involving aromatic chelating ligands based on combinations of 
pyridyl and phenyl rings. Particular consideration will be given as to how the 
luminescent properties can be altered by changing the intrinsic structure of the 
cyclometallating ligand, or by altering the functional groups attached.  
 
1.5 Pt(II) Complexes Containing Bidentate Cyclometallated Ligands  
The first cyclometallated Pt(II) complexes studied involved bidentate N^C type ligands 
(examples of structures are given in Figure 6).46,47 These complexes can be classified as 
homoleptic, which contain two identical N^C ligands simultaneously bound to 
platinum, i.e. [Pt(N^C)2],46 or heteroleptic,48,49,50,51 which contain one N^C ligand and 
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either a second bidentate ligand, L (e.g. bipyridine, acetylacetonate, ethylenediamine, 
etc.), or two monodentate ligands X and Y (e.g. halides, acetylides, etc.). Homoleptic 
complexes always form as the cis isomer, i.e. with carbon trans to nitrogen, due to the 
large trans effect of the cyclometallating carbon. The literature contains more examples 
of heteroleptic complexes, as these are generally easier to synthesise. Syntheses of 
homoleptic complexes typically require use of lithiated ligands, a route that is 
intolerable to many functional groups. On the contrary, reaction of K2PtCl4 with one 
equivalent of an N^C ligand forms a chloro-bridged dimer which can be cleaved under 
relatively mild conditions by a variety of monodentate or bidentate ligands, thus 
forming a heteroleptic complex.50,51,52 The nature of these “ancillary” ligands can 
significantly influence the photophysical properties of a heteroleptic complex.49,50,53 For 
example, [Pt(N^C)Cl2]- (where N^C = 2-phenylpyridine) does not emit from solution at 
room temperature – the chloride ancillary ligands occur low down the spectrochemical 
series, and do not confer a large ligand field splitting. As a consequence, the 
deactivating d-d* states are relatively close in energy to the excited charge transfer state, 
and thermal population is possible, leading to non-radiative decay. The complex does 
emit at low temperature (77 K), where this thermal promotion is prohibited.  
Ancillary ligands higher up the spectrochemical series such as acetylides, cyanide, 
bipyridine (bipy), acetylacetonate (acac), isocyanides, etc. lead to larger ligand field 
splittings.48,53,54 The deactivating d-d* states are moved to higher energy so that the 
probability of non-radiative deactivation (via thermal population of this state) is greatly 
reduced, and such complexes are often emissive at room temperature. The emission of 
luminescent N^C-type Pt(II) complexes based on phenyl pyridine (see Figure 6 for 
example structures) is typically red-shifted relative to the free N^CH ligand 
phosphorescence, with lifetimes on the microsecond timescale. Their emission has been 
assigned to emanate from a mixed 3LC-3MLCT excited state.48 
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Figure 6: Homoleptic complex [Pt(ppy)2] (top), and a selection of heteroleptic complexes involving ppy 
(bottom).46,48,53,54  
Functionalisation of the N^C ligand can alter the photophysical properties of such 
complexes,55 and a key study has been performed by Thompson et al.48 They considered 
a large selection of [Pt(N^C)(O^O)] complexes (Figure 7), where N^C was a derivatised 
aryl pyridine and O^O was either acetylacetonate (acac) or dipivaloylmethane (dpm). 
Beta-diketonate ligands such as acac are a popular ancillary ligand choice with 
heteroleptic N^C complexes, as they are easily incorporated and have minimal influence 
on the photophysics, allowing the N^C system to be studied directly. DFT calculations 
indicate that the HOMO is largely localised on the metal, the O^O ligand and the phenyl 
ring, whereas the LUMO is largely localised on the pyridine ring, with some phenyl 
contribution.  
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Figure 7: The large selection of Pt(II) complexes involving modified phenyl pyridine ligands, prepared 
by Thompson et al. in reference 48. 
All complexes were found to emit at 77 K and some also emit at room temperature. The 
emission of the derivatised phenylpyridine complexes varied between 438 and 525 nm 
in a 2-methyltetrahydrofuran glass at 77 K. Incorporation of electron withdrawing 
fluorine atoms on the phenyl ring resulted in blue-shifted emission, and this effect was 
enhanced when electron releasing groups were introduced in to the pyridyl ring 
(particularly at the 4-position, the position para to nitrogen). Complexes 4,6-dfp-4-
meopy and 4,6-dfp-4-dmapy gave the bluest emission (em = 438 and 440 nm 
respectively, 77 K glass). On the face of it, these complexes represent some of the bluest 
emitting cyclometallated platinum(II) complexes reported to date. Unfortunately, the 
luminescent efficiency and lifetime were found to decrease with increasing emission 
energy (see Table 1), and the blue-emitters were practically non-emissive at room 
temperature.  
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Table 1: Emission properties of the C^NPt(O^O) complexes at room temperature (2-
methyltetrahydrofuran solutions). This table was adapted from reference 48. 
C^N O^O max / nm 298K / µs 298K 
ppy acac 486 2.6 0.15 
p-tpy acac 485 4.5 0.22 
6-fppy dpm 476 <1.0 0.06 
4,5-dfppy acac 484 3.0 0.22 
4,6-dfppy acac 466 <1.0 0.02 
4,6-dfppy dpm 466 <1.0 0.02 
4,6-dfp-5-mepy dpm 472 <1.0 0.05 
4,6-dfp-4-meopy dpm 456 <1.0 <0.001 
4,6-dfp-4-dmapy dpm 447 <1.0 <0.001 
4-meoppy dpm 490 7.4 0.20 
 
In summary, cyclometallation in N^C systems successfully shifts the deactivating d-d 
state to higher energy compared to analogous N^N systems. Unfortunately complexes 
involving these bidentate ligands are still prone to D2d distortions. As a consequence, 
the photophysical properties are often far from optimum, with quantum yields only 
really reaching 0.25 for the most luminescent of such systems. One may expect that 
increasing the rigidity of the cyclometallating system will lead to enhanced luminous 
yields.  
 
1.6 Pt(II) Complexes Containing Terdentate Cyclometallated Ligands 
Such complexes can be classified as N^N^C, N^C^N or C^N^C, and the luminescence 
behaviour is dependent on the coordination pattern. To date, most work has been done 
on the N^N^C and N^C^N complexes, and examples of C^N^C complexes, which 
involve two cyclometallating sites, are still quite rare. “Pseudocyclometallates” (where 
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the cyclometallating carbon is replaced by an anionic nitrogen, oxygen or sulphur) are 
also being developed. 
N
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NN
Pt
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Pt
Cl
 
Figure 8: The “parent” complexes of the N^N^C (left), N^C^N (middle) and C^N^C (right) systems. 
 
1.6.1 N^N^C Systems 
In 1990, Constable showed that 6-phenyl-2,2’-bipyridine (phbpy-H) would bind to 
Pt(II) in a terdentate fashion.56,57 Che and co-workers realised the photophysical 
properties of such complexes, and have since devoted much time to the development of 
such systems, for a variety of applications. Similar complexes, in which the terminal 
pyridyl has been replaced by a pyrazolyl ring have recently been used in bio-imaging of 
live cells by Che et al. and Lam et al.  – this work will be covered in Chapter 5. 
The unsubstituted parent complex, [Pt(phbpy)Cl] displays room temperature 
luminescence (em = 565 nm,  = 0.025, degassed DCM).58 This is in contrast to 
[Pt(trpy)Cl]+, which is non-emissive in solution at room temperature, demonstrating the 
effect of larger ligand field splitting induced by the cyclometallating carbon. The 
emission spectrum is broad and the complex exhibits a lifetime of 0.51 µs. A 
solvatochromic response is observed upon changing the solvent – the emission blue-
shifts in the presence of more polar solvents (e.g. CH3CN). Based upon such 
observations, Che assigned the emission to occur primarily from a 3MLCT state. The 
lifetime was found to decrease with increasing concentration, suggesting self-quenching 
was occurring.  
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Figure 9: Emission spectra of [Pt(phbpy)Cl] in DCM (298 K) (- - -), CH3CN (298 K) (- . . _), DCM (77 K) 
(----) and CH3CN (77 K) (. . . .). the chart was taken from reference 58.  
For structures of the type [Pt(N^N^C)X], varying the nature of the ancillary ligand X 
and/or the substituents of the core cyclometallating ligand allows the photophysical 
properties to be tuned.59,60 Trends between substituents and the observed photochemical 
properties have been realised, and various groups are employing rational structure 
design to produce complexes with more desired characteristics. For example, an 
extensive study was undertaken by Che et al., who prepared a large series of 
[Pt(N^N^C)X] complexes based on a 6-aryl-2,2’-bipyridine tridentate system, 
incorporating a -alkynyl group as the ancillary ligand, X (see Figure 10).61 
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Figure 10: The extensive range of N^N^C complexes prepared by Che et al.61 
Most of the complexes prepared here were emissive in solution at room temperature ( 
= 0.001 – 0.08,  = 0.1 – 1.1 µs, degassed DCM), giving featureless emission spectra 
and exhibiting emission colours ranging from green (560 nm) to red (644 nm). In 
analogy with [Pt(phbpy)Cl], the excited state was assigned to a 3MLCT state for most 
complexes (for exceptions, see later). The electronic nature of the alkynyl substituent 
was found to influence the photochemical properties. For example, complexes 3-8 
contain a 4-substituted phenyl attached to the alkynyl ligand (i.e. R3). Substituents of 
electron releasing character were found to blue shift the emission and substituents of 
electron withdrawing character caused a red shift. Incorporation of a selection of 
substituents onto the terdentate ligand was also investigated. For example, incorporation 
of an electron withdrawing ethoxy-carbonyl group at R1 led to a dramatic red-shift – 
complexes 24 and 25 emit at 620 and 593 nm respectively, whereas the parent 
complexes 3 and 9, (in which R1 = H) emit at 582 and 560 nm. 
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Sun et al. have prepared a series of highly luminescent N^N^C complexes, and have 
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Figure 12: Structures of the alkoxyl complexes, 36 - 40, prepared by Sun et al. in reference 62. 
N^N^C systems where the terminal N-moiety is pyrazole have been prepared (Figure 
13), and show blue-shifted emission relative to the 6-phenyl-2,2’-bipyridine platinum 
complexes. For example, complex 41 emits from DCM solution at 516 nm, whereas 
[Pt(phbpy)Cl] emits at 565 nm.63 Pyrazine is a weaker -acceptor than pyridine, so it is 
expected that such systems will have higher energy * states (LUMOs), leading to 
greater HOMO-LUMO energy gaps. The pyrazine N^N^C complexes were found to 
exhibit acid/base sensitivity via the 1-pyrazolyl N-H. In the presence of base, complex 
41 deprotonates, loses the ancillary chloride ion, and forms a bimetallic complex (42). 
Deprotonation of complex 43 does not result in formation of the bimetallic complex, but 
the photophysical properties are sensitive to pH. In this case, deprotonation of complex 
43 with Et3N led to an increase in the emission intensity, and the effect could be 
reversed with the addition of trifluoroacetic acid.  
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Figure 13: Top – the acid promoted conversion of complex 41 to the bimetallic complex, complex 42, 
and bottom – structure of complex 43.62 
To sum things up, N^N^C complexes typically exhibit broad, featureless emission that 
emanates from a primarily 3MLCT state. The extent of mixing of this state with other 
charge transfer states depends on the structure and properties of the ligands associated, 
and in some cases, the nature of the lowest excited state can even be altered. Most of the 
complexes are emissive in solution at room temperature, and the photophysical 
properties largely depend on the associated ligands. The best N^N^C complexes exhibit 
quantum yields of around 0.25, similar to the best N^C bidentate systems, so there is 
still plenty of room for improvement.64   
 
1.6.2 N^C^N Systems 
Of the three cyclometallated terdentate possibilities, N^C^N Pt(II) complexes typically 
exhibit the best room-temperature luminescence properties. 1,3-Di(2-pyridyl)benzene 
(dpyb) is a very good ligand for Pt(II) – the symmetrical arrangement of the 
cyclometallating phenyl ring and two pyridyl groups confers a large ligand field 
splitting within such systems. Complexes involving these ligands typically exhibit high 
quantum yields. For example, the unsubstituted [Pt(dpyb)Cl] complex is highly 
emissive in DCM solution at room temperature, with a quantum yield of 0.60, which is 
an order of magnitude greater than the quantum yield of its regioisomer, [Pt(phbpy)Cl]) 
( = 0.025).19 In further contrast to analogous N^N^C systems, the emission spectra of 
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N^C^N complexes are usually highly structured (Figure 14), and the lifetimes are 
typically longer (several microseconds). The highest energy peak (v’ = 0) generally has 
the greatest intensity – this indicates that there is little difference in geometry between 
the excited state and ground state, and is testament to the rigidity enforced by the 
terdentate system. Based on experimental observations (structured emission profile, 
small Stokes shift, weak solvatochromism, etc.) and theoretical results, the emission of 
such complexes has been assigned to occur from primarily 3-* states, with significant 
3MLCT admixture.45,65,66  
 
Figure 14: Emission spectrum of a dilute sample of [Pt(dpyb)Cl] in DCM at 298 K (ex = 401 nm).  
Williams et al. found that it is possible to tune the emission of [Pt(N^C^N)Cl] 
complexes by varying substituents at the 4-phenyl position (Figure 15).67 The emission 
maxima varied (between 491 – 588 nm) with the electron donating ability of the 
substituent: electron donating groups red-shifted the emission, whereas electron 
withdrawing substituents led to a blue-shift (Note: complex 50 had slightly different 
excited state behaviour, but this will not be discussed here). All of the investigated 
complexes were highly luminescent ( = 0.45 – 0.68, degassed DCM) and displayed 
lifetimes in the microsecond regime (7.9 – 20.5 µs).  
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such terdentate systems.65 The ground and excited state geometries were calculated for 
each complex, and from a comparison of bond lengths, the trans influence of the 
platinum coordinating groups was assigned: aryl group > pyridyl group > chloride. The 
results indicated that the different coordinating geometries lead to different geometry 
relaxations. Of the cyclometallating systems, the N^C^N system was found to 
experience the smallest geometry change between the ground and excited states (least 
change in coordination bond lengths between the ground and excited state, and smallest 
bond-length alteration within the aromatic rings), and exhibited the largest spatial 
overlap between the transition orbitals. This is consistent with the experimentally 
observed trend, in which [Pt(N^C^N)Cl] systems exhibit the largest emission efficiency.  
A kinetic study was performed by van Eldik et al. to determine the relative reactivity of 
the three systems towards substitution reactions of the fourth monodentate ligand.71 The 
N^C^N system was found to display significantly higher reactivity than N^N^C – this is 
because the leaving group is trans to the cyclometallating carbon in the NCN system, 
and the trans influence is greater than the cis influence. The NCN was only slightly 
more reactive than the NNN system – the  high reactivity of the NCN system stems 
from the trans-labilising effect of the C-Pt bond, whereas the high reactivity of the 
N^N^N system is due to the increased electrophilicity of the Pt centre, owing to the 
three -accepting pyridine substituents of the terdentate frame.  
The photophysical properties can be modified by replacing the pyridine rings with other 
heterocycles, such as quinolines,72,28 pyrazoles73 or azaindoles.74 The bis-pyrazolyl 
analogue of [Pt(4-Me dpyb)Cl] (Figure 16) has been prepared (complex 51), and shows 
emission that is significantly blue-shifted (em = 455 nm, degassed DCM) relative to all 
previously reported bis-pyridyl systems (c.f. for [Pt(4-Me dpyb)Cl], max = 505 nm).73 
The pyrazole unit is a poorer -acceptor than pyridine, and as a consequence, the 
LUMO of such complexes lies at higher energy. Unfortunately, the quantum yield of 51 
is significantly lower than the values typical of bispyridyl systems ( = 0.02) 
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Figure 16: Structures of complex 51, the bis-pyrazolyl analogue of [Pt(4-Me dpyb)Cl], and complex 52, 
one of the unsymmetrical systems containing both a pyridyl and pyrazolyl heterocycle, reported in 
reference 73.  
Asymmetric systems, involving both a pyrazine and pyridine ring (e.g. complex 52) 
were also reported. These systems had higher quantum yields ( = 0.32-0.64), and 
emitted around 500 nm, similar to the dpyb complexes. DFT studies indicated that the 
LUMO-based orbitals of the unsymmetrical complexes were localised on the pyridyl 
ring, which is more stable than the electron rich pyrazole.   
Wada et al. have described a unique synthetic route to a different type of N^C^N system 
(see Figure 17).75 The route involves oxidative cyclisation of 3,5-
bis(anilinothiocarbonyl)toluene. The precursor ligand can itself bind to Pt(II) in a 
terdentate fashion, acting as an S^C^S pincer ligand.  
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Figure 17: Synthetic scheme used by Wada et al.75 to prepare complexes 53 and 54. 
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Both complexes exhibit phosphorescence, but to varying degrees. The S^C^S complex, 
complex 53 exhibited no luminescence in solution at room temperature, but emitted 
from a frozen glassy state at 77 K and from the solid phase. A broad structureless band 
was observed in the emission spectrum of the frozen glass (max  630 nm), and a 
lifetime of 3.7 µs was recorded. Based on a similarity of the photophysical properties of 
this complex with previous tertiary thioamide-based pincer Pt(II) complexes, the 
emission was assigned to a 3MLCT state. On the contrary, the emission of the N^C^N 
complex, complex 54 was assigned to a 3-* state. The emission spectrum was highly 
structured (max = 530 nm), and the lifetime was approximately three times greater than 
for 53 ( = 9.4 µs), indicating a smaller metal contribution to the excited state. This 
complex also emitted at room temperature, the spectrum being very similar to the 77 K 
spectrum.  
  
Figure 18: Excitation (- - -) and emission (_____) spectra of a) 53 and b) 54, in a frozen matrix of 
DCM/THF (3:2) at 77 K.75 
 
1.6.3 C^N^C Systems  
C^N^C complexes of platinum(II), incorporating 1,3-diphenylpyridine (dppy) as the 
terdentate ligand, were first reported by Von Zelewsky et al. back in 1991.76 The group 
prepared a selection [Pt(dppy)L] complexes for which the identity of ancillary ligand, L, 
was varied (L = Et2S, pyridine or pyrazine). The “cis” analogue of these complexes, 
[Pt(H-dppy)2] (which involved two diphenylpyridine ligands bound bidentately), was 
prepared for structural and photophysical comparison (Figure 19). Crystal structures 
revealed that the C-Pt bonds are longer in the terdentately-bound trans complexes than 
a) b) 
 in the analogous cis complex (
mutually opposing trans influence in the former.
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N^C^N and N^N^C), 
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providing a further non-radiative decay channel. On top of this, the closest singlet state 
with which the T1 state can undergo significant SOC is the S5 state, which lies at much 
higher energy (~ 13,500 cm-1). This large energy gap imparts a small SOC effect, which 
results in a small kr. It is thus the combination of a small kr and large knr that results in 
these complexes being non-luminescent at room temperature. 
In summary, most C^N^C complexes prepared to-date are non-emissive at room 
temperature, regardless of the ancillary ligand or substituents present on the terdentate 
framework. One may have expected that the luminescence properties would be greatly 
enhanced by having two cyclometallating sites held rigidly in a terdentate ligand. 
However, forcing the cyclometallating carbons trans to each other seems to disfavour 
luminescence. This effect is further emphasised by the strong tendency of bis N^C 
complexes to form the cis complex, where the cyclometallating carbon is always trans 
to the nitrogen donor of the other bidentate ligand.81,82   
 
1.7 Multi-Molecular Interactions/Species 
Figure 20 represents some of the possible fates of an excited species. The triplet excited 
state of phosphorescent organometallic species is typically quenched by triplet oxygen, 
which is why solution-based photochemistry is often performed on deaerated samples. 
In many cases, excited Pt(II) species can form inner sphere interactions with a ground 
state molecule, X, either forming an exciplex (excited electron donor-acceptor complex) 
when the ground state molecule is a different chemical species from the excited species 
(i.e. X  M) or an excimer (excited dimer) when the ground state molecule is of the 
same chemical species (i.e. X = M). Both are dissociative in the ground state. Formation 
of these excited multimolecular species results in depletion of M*, essentially 
quenching monomeric emission.33,83,84 However, sometimes decay of these binuclear 
species is also accompanied by the emission of light.37,40,48,67,77,85 
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Figure 20: Possible fates of a triplet excited state. 
Hence, intermolecular interactions can have a big impact on the photophysics of Pt(II) 
complexes30,86,87 Under certain conditions, Pt(II) complexes may also participate in 
intermolecular interactions in the ground state, resulting in aggregate formation. An 
aggregate may also have different photophysics from the isolated molecule. 
Pt(II) multimolecular species typically involve metal-metal (involving the vacant dz2 
orbitals) and/or - interactions (when planar aromatic ligands are present).16,88,89,90 
Such interactions have been identified in the solid state of many Pt(II) complexes, and 
emission from the solid state is often perturbed relative to the emission from 
solution18,91 In some cases, these intermolecular interactions lead to well ordered 
packing and the formation of extended structures, such as 1D chains92 and 2D sheets93,94 
in the crystal structure. Introduction of larger, bulky groups to the ligand framework can 
reduce (or in some cases remove) the tendency to form such intermolecular 
interactions.17,50,95,96 Similarly, for charged complexes, the nature of the counter ion can 
influence the formation of intermolecular interactions.30,97  
We will now examine the distinct photophysical properties of aggregates and excimers. 
As mentioned, these multimolecular species can be emissive, although this is not always 
the case. For example, terdentate N^N^C systems undergo self-quenching, with self-
quenching constants, ksq, of the order of 109 M-1 s-1, yet excimer emission is never 
observed.61 Related N^C^N complexes also undergo self-quenching to a similar extent, 
but often display excimeric emission from solutions of higher concentration.19,67 
Emission due to an aggregate or excimer always occurs at lower energy than the 
monomeric emission, and the emission is typically broad and structureless. However, 
excimers and aggregates are distinctly different species, and their lower energy 
emissions arise for different reasons.  
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1.7.1 Aggregates 
Aggregates are multi-molecular species that form in the ground state, and aggregation 
can occur in solution or in the solid phase.30 Many square planar Pt(II) complexes have 
been observed to form aggregates under certain circumstances,15,98,99,100,101,102 for 
example, altering the concentration, temperature and solvent polarity can influence the 
extent of aggregate formation. These aggregates often display different photophysical 
behaviour to the isolated molecules, with the absorption (and emission, for luminescent 
aggregates) of the aggregate typically occurring at lower energy. It is believed that such 
multimolecular species involve non-covalent Pt-Pt and/or - intermolecular 
interactions – such interactions are commonly noticed in the crystal structures of Pt(II) 
complexes. These favourable intermolecular interactions can influence the molecular 
packing, and the Pt(II) molecules often stack and form one-dimensional 
chains.18,92,100,103  
Rundle and Miller used MO theory to account for the tendency of square planar Pt(II) 
complexes to form aggregates.15,104,105 The stabilisation is attributable (in part) to 
overlap of 5dz2 and 6pz orbitals of adjacent metal centres.100 Figure 21 considers how 
these orbitals interact upon formation of a dimer (the simplest form of an aggregate).15 
The two 5dz2 atomic orbitals split to give a new antibonding and bonding molecular 
orbitals, and these orbitals have a2u and a1g symmetries respectively. The 6pz orbitals 
also split into an antibonding and bonding molecular orbital, with a2u and a1g 
symmetries respectively. Each complex had two electrons in their dz2 orbital, so four 
electrons are to be accommodated in the new MOs. The electrons fill the two lowest 
energy MOs, one of which is a bonding MO, and the other is an antibonding MO. Such 
an electron configuration would normally result in no net bonding. However, 
configuration interaction with the 6pz bonding and antibonding MOs (non-degenerate 
MOs of the same symmetry repel each other) results in stabilisation of the 5dz2 bonding 
and antibonding MOs, decreasing the total energy of the system, and leading to net 
favourable interactions.  
 Figure 21: MO scheme for a “dimer” consisting of two planar complexes a) without and b) with 
configuration interaction (redrawn from reference
MOs is determined by the number of molecules that are interacting. When many molecules are involved 
in the aggregate, MO’s with the same atomic orbital parentage will become very close in en
effectively forming an energy continuum (or energy band)
The MO description presented above only considers orbitals localised on the Pt centre. 
The ligands will also introduce orbitals to the total MO description (e.g. 
relative energies of all
literature, the low energy transition that occurs in aggregates is often described as a 
metal-metal-to-ligand charge transfer state (MMLCT
* states may equally account for such effects (see 
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accounting for the red
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emission by varying the steric bulk of surrounding ligands, or by varying the electronic 
nature of the ligands.17
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Figure 22: Schematic MO diagram illustrating d8-d8 and - interactions in binuclear Pt(II) polypyridine 
complexes (note: d*-* can also be represented as MMLCT). This figure was taken from reference 107. 
 
1.7.2 Excimers  
An excimer forms when a molecule in the excited state interacts with a ground state 
molecule of the same chemical species.108 Unlike aggregates, excimers exist only in the 
excited state.  
 
Figure 23: Potential energy surface interpretation of excimer emission (also applies to exciplex emission, 
where M and M* are different chemical species). 
Formation of excimers is a diffusion controlled process, so the extent of excimer 
formation is greater in solutions of higher concentration.83 But why do excited 
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Figure 24: Orbital interactions of excimers (A = B) and 
109.  
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in the ground state. It is therefore anticipated that the relative orientation of
109
 Upon excitation, one electron be
-filled HOMO and nucleophilic half-
ate. 
 polar or polarisable species (such as 
excimer formation, or a completely 
result in a net stabilisation of the 
).  
exciplexes (A  B) 
-acceptor (or acceptor-donor) interaction. 
-Pt interactions between the vacant d
 Upon return to the ground 
– intermolecular interaction 
 net stabilisation, as an equal number of 
 (Figure 25). As antibonding effects 
This dissociative ground state accounts f
 (note: we previously described that aggregates are stable 
29 
come from a 
comes promoted, 
filled LUMO. Hence, 
These orbitals can 
different molecule in 
 
– redrawn from reference 
As for 
z2 orbitals 
sly 
or the 
, and/or 
 interactions between 
and the factors that led to stabilisation of the aggregate must not apply here).
Figure 25: Orbital interactions of an A/B collision pair
It is often possible to distinguish between excimers and aggregates by monitoring 
absorption. Because aggregates exist in the ground state, low energy bands due to such 
species are often observed in both the absorption and emission spectrum. As excimers 
only exist in the excited state, their 
Comparing an excitation spectrum recorded at the monomer emission maximum with 
one recorded at the emission maximum of the low energy band can also be used to 
determine the origin of the multimolecular species
excimeric, then the excitation spectra will be identical, as the excimer originates from 
the same ground state species as the excited mono
differ if an aggregate is present, as in this case, the high and low energy bands observed 
in the emission spectrum arise from different ground state species. 
 
1.7.3 Examples of Pt Complexes Possessing Intermolecular Interactions
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Figure 28: The structure of complex 56, and its bimetallic analogue, complex 57.107 
A nice example of monomeric vs. excimeric emission has recently been demonstrated 
by Bruce et al.118 Here, [Pt(N^C^N)X] systems which incorporate long alkyl chain 
groups on the 5-pyridyl position of the N^C^N backbone have demonstrated the ability 
to form a liquid crystalline state. Structural analysis revealed that the liquid crystalline 
phase was composed of a columnar phase of anti-parallel complexes which are 
independent of one another, and contain no intermolecular interactions. Contrary to this, 
the sample prepared by fast cooling from the isotropic phase consists of a high degree of 
isotropic grain boundaries, and the molecules are in close contact. As a result, emission 
from the liquid crystalline state was found to be purely monomeric, whereas emission 
from this second phase was purely excimeric. 
 
 
 
 C6H13O
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Figure 29: a) Structure of one of the complexes containing a N^C^N ligand appended with long alkyl 
chains, prepared by Bruce et al.
of a sample of 58 that has been fast cooled from the liquid cry
and emission spectrum (bottom
isotropic phase. Insets show photographs of real samples of pure films sandwiched between glass 
slides.118 
 
1.8 Applications of Lumi
1.8.1 Sensors 
There is a high demand for species that are able to sense and react to their 
in a non-invasive way
formation of inner sphere interactions with other molecules (e.g. solvents), leading to 
sensory behaviour.120
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nescent Platinum Complexes
.
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34 
OC6H13
OC6H13
OC6H13
 
 
, ex = 420 nm) 
 
environment 
ctions are 
35 
 
sensitive to temperature, resulting in thermochromism,121,122 or are sensitive to certain 
vapours, leading to vapochromism54,86,123,124 In some cases, luminescent complexes 
have been appended with a binding group, where binding of the appropriate analyte 
alters the photophysical behaviour relative to the unbound complex.125,126,127,128,129 
Additionally, the triplet excited state of luminescent platinum complexes is usually 
sensitive to the presence of oxygen, and some complexes have been used in oxygen 
sensors. 
1.8.1.1 Oxygen Sensors 
The emission intensity of many phosphorescent complexes varies inversely with oxygen 
concentration. The potential of such complexes as oxygen sensors has been realised, and 
attempts have been made to produce organometallic complexes with optimum 
properties for this purpose.130,131,132 [Ru(bpy)3]2+ has been used in previous oxygen 
sensors, but the charged species tend to have poor solubility in organic solvents. W. W. 
S. Lee et al. report on the use of neutral dicyanoplatinum(II) complexes, [Pt(L)(CN)2] 
(where L = 4,7-diphenyl-1,10-phenanthroline or 4,4’-di-tert-butyl-2,2’bipyridine) as 
optical sensors for measuring oxygen concentration.130 These neutral complexes have 
greater solubility than [Ru(bpy)3]2+, and can be used to study microenvironments inside 
polymers. They are also less susceptible to interferents.  
A colorimetric luminescent oxygen sensor involving two luminophores with both 
different oxygen sensitivities and different emission colours has been developed by 
Evans et al.132 The first luminophore is a platinum octaethylporphyrin (PtOEP, complex 
59) (see Figure 30), which emits red light – this complex has a long phosphorescent 
lifetime, and in solution its emission was found to be very efficiently quenched by 
oxygen. The second luminophore, complex 60, is a N^C^N Pt(II) complex of 1,3,5-tri-
(2-pyridyl)benzene, and has a lower sensitivity to oxygen and emits in the green region 
of the visible spectrum. At low oxygen concentration, emission from the porphyrin 
dominates due to its larger molar extinction coefficient at the chosen excitation 
wavelength, and the overall emission appears red. As oxygen concentration increases, 
emission from the porphyrin becomes increasingly quenched, and eventually emission 
from 60 dominates. Physically, the oxygen sensor exhibits a “traffic light” response 
from red to green, as the oxygen concentration increases. 
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Figure 30: The colourimetric response of the oxygen sensor prepared by Evans et al., to different partial 
pressures of oxygen, and the two luminescent components used to prepare the device.132 
 
1.8.1.2 Sensor Based On Oxidation 
Some luminescent bis-cyclometallated Pt(II) complexes have been found to be highly 
reactive towards oxidative addition reactions.46,133,134 In some cases, the Pt (IV) 
products are also luminescent, with a different emission energy (blue-shifted) compared 
to the parent complex (Figure 31). Swager et al. have exploited this property to design 
sensors for cyanogen halides, which are toxic agents that are commonly used in 
chemical weapons.134 In the presence of a cyanogen halide, spontaneous oxidative 
addition occurs, resulting in a blue-shift in emission. Detailed structure-property 
investigations revealed that complexes that were twisted from the ideal square planar 
geometry, due to unfavourable sterics, reacted faster with CNBr than complexes with 
less distorted geometries. Additionally, these twisted Pt(II) complexes were generally 
non-luminescent in solution at room temperature, so oxidative addition resulted in a 
“switch-on” of emission.  
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Figure 31: One of the bis-cyclometallated Pt(II) complexes synthesised (top left), its oxidative addition 
product with CNBr (bottom left), and its emission spectra (right) taken before (dotted line) and after 
(solid line) exposure to CNBr for 15 s, demonstrating the complex’s capacity as a sensor for such 
molecules. Such oxidative addition reactions have been found to be stereospecific.134 
 
1.8.1.3 Analyte Sensors 
The sensor applicability of luminescent platinum(II) complexes covalently bound to 
analyte-binding groups has been investigated by several groups.35,125,135,136 Binding of 
the analyte can alter the electronic or steric environment of the platinum complex, 
affecting its luminescence properties. Tung et al. have reported such a sensor, which 
incorporates a square planar Pt(II) centre with an N^N^C cyclometallating ligand and an 
ancillary acetylide ligand that is connected to an azacrown, which is capable of 
chelating to Mg2+ ions.136 When no Mg2+ ions are present, the complex is non-emissive 
– a low energy LLCT excited state results in non-radiative decay back to the ground 
state. Binding to Mg2+ decreases the electron-donating ability of the acetylide ligand, 
which causes the LLCT excited state to shift to higher energy than an emissive MLCT 
state (Figure 32).    
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Figure 32: Top: structure of the cation sensor complex and Bottom: charts representing the effect of 
increasing concentrations of Mg2+ ions on the absorbance (left, inset = plot of A0/(A0-A) vs. [Mg2+]-1) and 
b) the emission (right, inset = plot of I0/(I-I0) vs. [Mg2+]-1) spectra. The emission spectra were obtained 
upon excitation at 465 nm.136 
A similar example involving a N^N^C Pt(II) complex has been reported by Guerchais et 
al.126 This complex involves a different azacrown, and is selective for Pb2+ cations. 
Binding of Pb2+ again affects both the absorption and emission spectra, but this time the 
emission intensity was found to decrease with increasing analyte concentration.  
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1.8.2 Organic Light Emitting Diodes (OLEDs) 
OLEDs are light emitting devices that have a luminescent ‘organic’ molecule in an 
emissive layer.137,138 Electricity is supplied to the device, and light is emitted at ambient 
temperature (electroluminescence).  
 
Figure 33: Schematic representation of a typical OLED structure.137 
Standard OLEDs contain multiple layers, each of which performs a single function, that 
additively result in the electroluminescence (Figure 33). These multilayered devices 
typically consist of a series of organic layers sandwiched between two electrodes. 
Indium tin oxide is generally used as the anode, as this material is transparent and 
allows light generated to escape from the device. A low-work function metal, such as 
aluminium or magnesium, is generally incorporated as the cathode. The organic layers 
typically consist of a hole transporting layer, an electron transporting layer and the 
electroluminescent (emissive) layer. More sophisticated devices also contain an exciton 
blocking layer between the hole transporting and emissive layers, which confines charge 
recombination to the emissive layer, improving the maximum efficiency of the device.  
 Figure 34: Basic working diagram of an OLED containing a luminescent dopant
Figure 34 represents 
applied across the device, holes get injected from the anode and electrons get injected 
from the cathode. The net charge separation across the device causes the electrons and 
holes to migrate towards the opposite electrod
same place, they will combine to form an exciton (a bound excited state consisting of 
the electron and the h
in the emissive layer
dopant. The dopant becomes excited, and on the decay back to the ground state emits 
light over the known and desired wave
Organometallic species are taking over from typical organic fluorophores
luminescent dopants, due to the additional ‘triplet harvesting’ ability offered.
refers to the fact that in a device, excitons are formed in particular spin
statistics predicts that 
singlet-to-triplet ratio of 1:3
that in some cases singlet states may be formed 
However, there will always be 
pass on their excitation energy into the corresponding excited states of the luminescent 
the working principles of an OLED. When an external voltage is 
e. If an electron and a hole end up in the 
ole, with overall charge neutrality). Charge recombination occurs 
, and the energy of the exciton is transferred to the 
length range.  
charge recombination in the emissive layer will form excitons in a 
. Some researchers believe that this ratio is not strict, and 
in greater than 25
excess of triplet states over singlet states.
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dopant. If we consider a typical organic fluorophore, decay from a triplet excited state to 
a singlet ground state is strictly forbidden. Hence in an OLED, the triplet energy is 
wasted as non-radiative decay to the ground state, limiting the efficiency of the OLED. 
Such non-radiative transitions release heat, which is also detrimental to the device. As 
already explained, luminescent organometallic species that involve a heavy metal atom 
such as platinum, iridium, ruthenium etc. involve significant spin-orbit coupling, 
resulting in faster intersystem crossing and faster decays from the triplet state. In 
OLEDs, such complexes can use both singlet and triplet excitons to produce light, 
meaning the maximum possible efficiency of such devices is 100%.  
OLEDs hold many advantages over liquid crystal display (LCD) systems, and so may 
begin to compete in the display technology market. Advantages include: 
• Self luminescence – this avoids the need for backlighting, allowing them to be 
thinner, lighter and more efficient 
• Lower power consumption – 20-80% less than typical LCDs, because light is 
only emitted from the desired pixels compared to the whole panel 
• Robustness – OLEDs can be deposited onto a wide variety of substrates, 
including flexible ones – it may be possible to produce roll-up TV screens 
• Wider viewing angle and aesthetic superiority 
So far, OLEDs have found wide usage in mobile phone screens, stereo faces and digital 
cameras, and it is expected that usage in larger applications such as TVs, computer 
screens and even ambient lighting will become increasingly popular, as the technology 
develops. 
 
1.8.2.1 Parameters Used to Measure OLED Performance 
Many parameters are used to describe the performance of an OLED.140 Such parameters 
include: 
• Internal Electroluminescence quantum efficiency, int – this is defined as the 
ratio of photons emitted to the number of electrons injected. This value can be of 
a similar order of magnitude to the photoluminescence quantum yield of the 
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dopant (i.e. the ratio of the number of photons emitted to the number of photons 
absorbed. However, this value also depends upon the charge-recombination 
efficiency. For example, if the dopant is a bright emitter, but charge 
recombination in the emissive layer is poor, the value of int will be much lower 
than the dopant quantum yield.   
• External electroluminescence quantum efficiency, ext – this relates the number 
of photons observed externally to the number of electrons injected. Its value is 
typically lower than int, as not all photons produced will leave the device as a 
consequence of refraction. The two values are therefore related by 
int = 2n2ext 
 where n is the refractive index of the medium. 
• The power efficiency, pow – this represents the ratio of output light power to 
input electric power, and is measured in W W-1. This value is related to ext via 
pow = ext – (Ep/V) 
where Ep is the average energy of the emitted photons and V is the voltage 
applied across the device. 
• The luminous efficiency lum is measured in lm W-1. It takes into account that 
the human eye is more sensitive to green light than red or blue, and is effectively 
a “correction” of the power efficiency to what we actually observe. lum is 
obtained by multiplying pow with the appropriate value from the eye sensitivity 
curve, S(), as determined by the Comission Internationale de L’Eclairage 
(CIE). 
  pow = powS() 
• CIE coordinates – The Commission Internationale de L’Eclairage (CIE) system 
of colourimetry provides a numerical description of colour (in terms of x and y 
colour coordinates), which is based on the eye’s sensitivity to light across the 
visible region.132 
• Colour rendering index (CRI) – this indicates the ability of the light produced by 
a device to reproduce the colours of various objects faithfully, when compared 
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with a reference illuminant. The value is typically a percentage. A high CRI 
indicates a similar performance to the reference. A low CRI indicates that the 
light produced distorts the true colours of objects relative to the reference. This 
is an especially important parameter in white OLED design. 
• The OLED brightness – defined as the amount of light emitted per unit area (cd 
m
-2). 
 
1.8.2.2 OLEDs Involving Luminescent Pt Complexes 
The first reported OLED containing a phosphorescent platinum complex was reported 
in 1998.141 The OLEDs involved a platinum porphyrin species, complex 59 (see Figure 
30 for structure), doped into an tris(8-hydroxyquinolinato)aluminium (Alq3) host, and 
were found to emit in the red region (max = 650 nm). Studies revealed that over 90% of 
the energy was transferred from Alq3, confirming that both singlet and triplet excitons 
were being utilised. A device displaying optimal characteristics was obtained when a 
molar ratio of 6% of 59 was employed in the emissive layer. For example, the device 
registered an external quantum efficiency of 4%. The characteristics of this device 
exceeded those of other saturated red-emitting devices reported at the time by an order 
of magnitude, demonstrating the efficiency improvements made possible by the 
additional participation of triplet excitons. However, the extremely long lifetime (~ 90 
µs) of 59 results in severe triplet-triplet annihilation at high current or higher dosing 
concentrations (Eqn. 1), affecting the quantum efficiency. Other Pt porphyrin systems 
have since been incorporated into OLEDs to give red and near-red emitting 
devices.142,143,144 Unfortunately, the quantum efficiencies of all devices suffer with 
increasing current, due to the long phosphorescent lifetimes of such complexes. 
4(3M* + 3M*)  1M* + 33M* + 4M     Eqn. 1 
Since the pioneering work with complex 59, many other luminescent platinum 
complexes have been investigated as phosphorescent dopants.102,145,146,147,148,149,150,151 
Apparently, the characteristic current (J0) at which the external quantum efficiency falls 
to 50% of its peak value due to T-T annihilation is inversely proportional to the square 
of the lifetime, so devices incorporating dopants with shorter phosphorescent lifetimes 
often display enhanced performances.152 For example, some of the [Pt(dpyb)Cl] 
 complexes shown in Figure 
have lifetimes of approximately 8 µs, almost an order of magnitude less than the 
porphyrin systems. T
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Good blue emitters are also relevant to the production of optimised white OLEDs, since 
white light requires coverage of the whole visible range. 
 
1.8.2.3 White OLEDs 
As well as being able to tune emission to give monochromatic emission with a desired 
wavelength, there is a strong desire to produce OLEDs with high efficiency white light 
output.8,157,158,159 Such white organic light emitting diodes (WOLEDs) could be used for 
general lighting applications, and offer lower preparation costs and greater efficiencies 
than existing sources. Various different approaches to WOLED production exist: 
• Preparing multilayer devices containing separate emitter layers, which include 
lumophores offering different colour emission (the lumophores collectively 
cover the visible spectrum, generating white emission)160,161,162,163  
• Mixing red, green and blue emitters (in correct proportion) in a single 
layer164,165,166  
• Use of a single dopant that emits from both monomer (blue) and excimer (red) 
states at the same time – the overall colour of light observed depends on the 
monomer: excimer emission ratio. The extent of excimer emission (relative to 
monomer emission) increases with concentration, hence the colour of a device 
can be controlled by simply varying the dopant concentration.  
Some of the cyclometallated polypyridyl Pt(II) complexes form emissive excimers (see 
earlier sections), so the latter principle can be exploited to generate WOLEDs. 
However, examples of such WOLEDs are still quite scarce. This method has several 
advantages over the previous two traditional methods. For example, excimer:monomer 
based devices only require one emissive layer. Devices which involve several emissive 
layers containing different luminophores require more complicated device architectures 
and are more costly to produce. Secondly, devices which contain several different 
luminophores are prone to colour degradation over time, as certain components degrade 
faster than others.  
Thompson et al. were the first to apply this strategy using phosphorescent emitters – 
structures of two of the first dopants examined for such behaviour are given in Figure 
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36 (note FPt1 is the same molecule as 4,6-dfppy mentioned in Section 1.5).167 Both 
complexes contain a (2-(4’,6’-difluorophenyl)pyridinato-N, C2) ligand, and exhibit 
monomeric emission in the blue region (~ 470 nm), and excimeric emission in the red 
region (~ 600 nm) of the visible spectrum. For devices incorporating FPt1, as dopant 
levels were increased, emission from the excimer rapidly appeared, and was found to 
dominate the spectrum at dopant levels of as low as 8%. White light emitting devices 
were prepared for dopant concentrations between 3 and 4%, but as emission from the 
host was not fully quenched at such low concentration, the device efficiencies were far 
from optimal. Doping concentrations of > 5% are typically required to efficiently 
quench host luminescence and achieve good carrier transport in phosphorescent 
OLEDs168,169  
N
Pt
O
O
F
F
N
Pt
O
O
F
F
FPt1 FPt2
 
Figure 36: Two of the initial Pt complexes used as single dopants to prepare WOLEDs. 
On the contrary, the additional isopentyl group on the O^O ligand of FPt2 confers an 
increase in steric bulk. As a consequence, FPt2 demonstrated a lower susceptibility to 
form excimers (smaller ksq), and devices displaying balanced monomer/excimer 
emission could be prepared using dopant concentrations of 10-12% (Figure 37). These 
devices did not suffer significant contamination from residual host luminescence. Good 
white light characteristics were reported for an optimised device containing 10% dopant 
– the device displayed CIE coordinates of (x = 0.36, y = 0.44), which are similar to 
those of natural white light (x = 0.33, y = 0.33), and had a maximum quantum 
efficiency of 3.3 ± 0.3% (lum = 7.3 ± 0.7 lm W-1) at 0.5 cd m-2.167,170,171 
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Figure 37: Electroluminescence spectra of devices containing FPt2 at 8, 10 and 12% dosage – notice the 
balanced monomeric/excimeric emission. Left inset: device structure, and right inset: Chromaticity 
diagram including the CIE coordinates of the devices and of pure white light.170 
The highly luminescent [Pt(dpyb)Cl] complexes reported by Williams et al. (Figure 15) 
also display excimeric emission from solutions of increasing concentration, and some of 
these complexes have been examined as dopants for WOLEDs. For example, devices 
containing varying amounts of complex 44 have been reported,153 and the emission of 
these devices spans the visible region of the spectrum (Figure 38). The device 
containing a dopant concentration of 15% gave emission that was closest to white light 
(CIE coordinates of x = 0.43, y = 0.43, note: CIE coordinates of an incandescent lamp  
x = 0.41, y = 0.41). This device displayed an impressive maximal efficiency of 15.5 ± 
0.2% ph/e (14.2 ± 0.2 cd/A) at 10 cd/m2. 
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Figure 38: CIE Chromaticity diagram of OLEDs containing various dopant concentrations of complex 44 
(image taken from reference 153). 
The CRI of such WOLEDs did not exceed 75, due to the excessive distinctiveness of 
individual components in the structured emission spectrum. This stimulated the 
development of an OLED incorporating both a [Pt(N^C^N)Cl] complex, 
(platinum(methyl-3,5-di(2-pyridyl)benzoate) chloride, and 4,4’,4’’-tris(N-(3-
methylphenyl)-N-phenylamino)triphenylamine (m-MTDATA) in the emissive layer.172 
m-MTDATA can act as an electron donor, and can form emissive exciplexes with the Pt 
species, that emit at an intermediate energy to the monomer and excimer emission 
bands. These OLEDs therefore have three emissive states contributing to the total 
emission:   1) monomeric emission, 2) excimeric 3) exciplex excited states. Greater 
coverage of the visible region was achieved, and an efficient WOLED displaying a 
remarkably high CRI value of 90 was obtained.   
Alternatively, examples exist where the emission from the excimer is used exclusively. 
For example, M. Cocchi et al. have prepared OLED utilising the near-infra red emission 
from [Pt(N^C^N)Cl] excimers.173 Whereas previous NIR devices suffered poor 
quantum efficiency and low power output, their devices were found to be highly 
efficient (>10% quantum efficiency). Such devices will have uses in biomedicine (for 
example, biological tissues only weakly absorb in the NIR region, allowing deeper 
penetration of the light source), and in the communication industry.174,175 
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1.8.3 Bio-Imaging 
A relatively new application of luminescent platinum complexes involves their 
incorporation into living cells and tissue as luminescent probes. This will be discussed 
in greater detail at the start of Chapter 5. 
 
1.9 Objectives  
Pt(II) complexes involving 1,3-di(2-pyridyl)benzene terdentate ligands often posses 
many attractive photophysical properties, and are desirable as phosphorescent dopants 
in OLEDs. For example, such complexes tend to have much higher quantum yields than 
related N^N^C and C^N^C systems. One of the main aims of the work reported in this 
thesis was to develop 1,3-di(2-pyridyl)benzene-type Pt(II) complexes with tuneable 
photophysical properties, by functionalisation of the terdentate ligand and/or 
substitution of the ancillary chloride. In particular, complexes exhibiting blue emission 
have been targeted.  A selection of groups has performed DFT calculations on the 
unsubstituted parent complex, 2,6-di(2-pyridyl)benzene Pt(II) chloride ([PtL1Cl]).45,65,66 
The predicted orbital contour plots have been used as an initial guide to aid rational 
structure design.  
Over the last few years, a small selection of groups has started to look at the 
applicability of luminescent organometallic complexes as bio-imaging agents.11,12,13 For 
example, our group studied the behaviour of [PtL1Cl] in cells – this complex enters the 
cell rapidly (within 5 min) and retains its emission.11 Furthermore, the complex 
localises in a subcellular organelle (the nucleus), which can be visualised using 
fluorescence microscopy. Another key aim of the work reported in this thesis was to 
screen a large selection of luminescent cyclometallated Pt(II) and Ir (III) complexes for 
their behaviour as bio-markers, and to perform some preliminary studies into the 
elucidation of intracellular binding and uptake routes. Another aim was to study 
intracellular behaviour of complex using time resolved emission imaging (TREM) – 
these complexes have phosphorescent lifetimes of the order of a few microseconds, 
making them suitable candidates for such a technique. 
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CHAPTER TWO: 
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2.1 Overview of the Synthesis of 1,3-Di(2-pyridyl)benzene Systems  
The project involved the synthesis and characterisation of platinum complexes 
incorporating variously functionalised 1,3-di(2-pyridyl)benzene ligands. A number of 
synthetic strategies have previously been employed in the synthesis of such ligands, and 
the main strategies involve either a cyclotrimerisation, a condensation reaction or a 
cross-coupling reaction (Figure 1). Each strategy has its own merits and disadvantages, 
which will now be discussed in turn. 
 
N N
Cyclotrimerisation Cross-coupling
Condensation Reaction
 
Figure 1: The three C's. Three routes that have been adopted to prepare 1,3-di(2-pyridyl)benzene systems. 
 
2.1.1 Cyclotrimerisation 
The synthesis of 1,3-di(2-pyridyl)benzene was first reported by Collin and Sauvage in 
1991 – the group adopted a cyclotrimerisation reaction that had previously been used to 
prepare the 1,4-isomer.1,2 The reaction involves 1,3-dicyanobenzene and acetylene 
precursors (Scheme 1), and proceeds under 10 atm pressure at 130  C in the presence of 
a cobalt catalyst, Co(Cp)(COD) (Cp = cyclopentadiene, COD = 1,5-cyclooctadiene). 
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Scheme 1: Synthesis of 1,3-di(2-pyridyl)benzene via cyclotrimerisation 
This reaction is high yielding (90%), but acetylene gas is potentially explosive under 
pressure, reducing the desirability of this methodology. Another downside is that it is 
difficult to introduce functionality into the terdentate system using this method, as 
functionalised precursors are not easy to obtain, and the use of asymmetrically 
substituted acetylenes will lead to several different regioisomers. 
 
2.1.2 Condensation Reactions 
Condensation reactions are often employed in the synthesis of bipyridine and 
terpyridine ligands, typically involving procedures based on Kröhnke annulations 
developed in the 1960s and 70s.3,4,5 The reactions involve the condensation of -
pyridinium methyl ketone salts and proceed through a 2,3-ene-1,5-dione.6 The 
methodology has been adopted by a few groups to prepare dipyridylbenzene systems 
(Scheme 2).7,8 However, this route is infrequently used by other groups, as 1,3-diacetyl 
benzene compounds are relatively rare. Nevertheless, one of the ligands prepared in this 
project by cross-coupling, HL7 (see Table 1), has also recently been prepared by a group 
in Japan using a Kröhnke synthesis (Scheme 2b).  
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Scheme 2: Synthesis of a) chiral pinocarvone-appended N^C^N ligand7 and b) 1,3-di(5-methyl-2-
pyridyl)benzene, HL7,8 via the condensation route. 
In the late 90’s Sauer developed a novel route for the synthesis of oligopyridines.9,10,11,12 
The method involves condensation of carboxamidrazones with 1,2-dicarbonyl 
compounds, giving a triazine intermediate. This species undergoes a [4+2] 
cycloaddition with a suitable electrophile (e.g. bicycle[221]hepta-2,5-diene or norborna-
2,5-diene) followed by [4+2] cycloreversions of nitrogen and cyclopentadiene. Bruce et 
al. have adapted the method for the synthesis of dipyridylbenzene ligands containing 
substituents on the 5-pyridyl position (Scheme 3).13 These reactions involve an initial 
condensation between benzene-1,3-dialdehyde and a hydrozone oxime precursor, which 
generates the triazine intermediate. The aryl triazine intermediate undergoes a 
cycloaddition with a suitable electrophile (e.g. 2,5-norbornene or 1-
morpholinocyclopentene), generating the 1,3-dipyridylbenzene derivative with 
elimination of nitrogen.  
a) b) 
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Scheme 3: Alternative condensation route employed by Bruce et al. to produce a selection of 
dipyridylbenzene ligands containing substituents on the 5-pyridyl position13 
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2.1.3 Cross-Coupling 
(PPh3)2PdCl2 (or other Pd(II) precursor)
(PPh3)2Pd0
Pd
X PPh3
ArPh3P
Pd
Ar' PPh3
ArPh3P
Pd
Ph3P Ar'
ArPh3P
Ar-X
Ar'-E
Ar-Ar'
E-X
Oxidative AdditionReductive Elimination
Trans-cis isomerisation
Transmetallation step
Reduction
 
Figure 2: Proposed general catalytic cycle for cross-coupling reactions.14,15 Here, Ar-X represents an aryl 
halide or triflate and E-Ar' represents the “metalloaryl” species. 
Palladium catalysed cross-coupling reactions are most commonly used to produce 1,3-
di(2-pyridyl)benzene ligands.16,17,18,19 These methodologies are extremely versatile, and 
are becoming increasingly used in the synthesis of a vast array of ligands, 
pharmaceuticals and extended organic systems. The method offers a route to more 
functionalised ligands than those previously discussed, as many of the ligand precursors 
can be prepared within a few steps from commercially available starting materials. Such 
reactions typically occur between an aryl halide or triflate and a “metalloaryl” species, 
and result in the formation of an aryl-aryl bond. The mechanism of cross-coupling is 
determined by the nature of the “metalloaryl” species, which can be, for example, an 
aryl-stannane (Stille reaction), an aryl-zinc reagent (Negishi reaction) or an aryl-boronic 
acid/ester (Suzuki reaction – note that boron is considered an honorary metal here). A 
generalised catalytic cycle is shown in Figure 2. Cross-coupling reactions to produce 
dipyridylbenzene systems can proceed via one of two routes, as shown in Scheme 4. 
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N N
N NE Hal Hal Hal E E
2 2
Route 1 Route 2
Pd (0) Catalyst Pd (0) Catalyst
E =    -SnR3 (Stille)
          -ZnR (Negishi)
          -B(OR)2 (Suzuki)
Hal =  Br
           I
           Cl
 
Scheme 4: The two possible cross-coupling routes to a 1,3-di(2-pyridyl)benzene 
Route 1 involves reaction between a 1,3-dihalogenated aryl core (typically a dibromo- 
or diiodo-derivative) and a 2-“metallo” pyridine. 1,3-Dichloro aryls are relatively 
unreactive, and require more sophisticated caltalysts which can increase the cost 
dramatically. Hence 1,3-dibromo and 1,3-diiodo aryls are commonly used. The majority 
of ligands prepared via this route have involved Stille reactions utilising a 2-
(trialkyl)stannyl pyridine, as such species can be readily prepared from the 2-bromo 
pyridine via an initial lithium-halogen exchange, followed by reaction with a tin 
electrophile (e.g. SnBu3Cl).16,18,19 The Stille cross-coupling reaction was initially 
proposed by Stille et al. in 1978.20 Stille found that selective ketone synthesis would 
result from a cross-coupling reaction between an organo-tin compound and an acyl-
chloride in the presence of a palladium catalyst. Since then, the Stille reaction has been 
greatly developed, and is widely used in organic synthesis of a vast array of 
compounds.21,22 The reaction can be generalised as the formation of a carbon-carbon 
bond between an organotin species and an sp2 hybridised organic halide, catalysed by 
palladium. The catalytic cycle shown in Figure 2 describes the general mechanism. 
However, differences in experimental observations between Stille reactions indicate that 
the precise mechanisms of individual reactions vary slightly, and are dependent on the 
reaction conditions employed (e.g. solvent polarity, the catalyst’s ligands, nature of the 
coupling partners, etc.).23  
In some cases, the addition of copper(I) salts can beneficially promote the Stille 
reaction, especially for sterically hindered systems and reactions involving 
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electronically disfavoured coupling reagents.24,25,26,27 How the copper species achieves 
this is dependent on solvent – in ethereal solvents copper acts as a scavenger for free 
ligand released from the catalyst during/before the oxidative addition with R-X.24,25 By 
mopping up the free ligand, copper reduces autoretardation of the associative 
transmetallation step. However in polar solvents, mechanistic evidence suggests that an 
additional transmetallation occurs between the organostannane and copper.26,27 This 
produces an organocopper species that is more reactive towards transmetallation with 
the palladium catalyst, thereby facilitating the Stille reaction.  
Tin species are highly toxic, so reactions involving such species are not ideal. Tin by-
products are also notoriously difficult to remove from the desired product.28 Suzuki-
Miyaura reactions involve palladium catalysed C-C bond formations between an aryl 
(or vinyl) halide and an aryl (or vinyl) boronic acid/ester.28,29,30,31 Unlike organo-
stannanes, boronic acid derivatives are relatively non-toxic, they are easier to handle 
and are stable once formed. On top of this, the removal of boron containing by-products 
is much easier to achieve than stannyl by-products. However, unlike other cross-
coupling reactions, Suzuki-Miyaura cross-couplings require the presence of a base (such 
as Na2CO3) to activate the aryl boronic acid/boronate and the catalyst.  
Unfortunately, pyridyl-2-boronic acids are unstable to protodeboronation. These 
electron-deficient species undergo transmetallation at a much slower rate than 
protodeboronation under standard Suzuki conditions, leading to poor conversions. As a 
consequence, there are very few examples of syntheses utilising pyridyl-2-boronic 
acids. Recently however, several successful attempts have been made into the creation 
of more stable or activated 2-pyridyl boronate esters, that may find use in future 
syntheses of 1,3-di(2-pyridyl)benzene systems.32,33,34 For example, Miyaura et al. have 
developed an air-stable 2-pyridyl triolborate that undergoes cross-coupling reactions 
with bromoarenes in dry DMF.33 In 2008, Buchwald et al. reported on lithium 
triisopropyl 2-pyridylborates that were stable up to month after their preparation.32 The 
borates were readily prepared in high yield from the respective 2-bromopyridine by 
lithium-halogen exchange, followed by immediate in-situ quenching of the anion with 
triisopropylborate. In the presence of a [Pd2(dba)3] catalyst and suitable phosphate or 
phosphine oxide ligand, most 2-pyridyl borates underwent Suzuki-Miyaura cross-
coupling reaction with aryl/heteroaryl iodides, bromides, and chlorides, resulting in high 
product yields. However, for highly electron-deficient boronates, the transmetallation 
step was very slow, and incomplete conversions were observed. Also, lithiation is an 
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essential step in the synthesis of the lithium triisopropyl 2-pyridylborates, which limits 
the functionality available on the heteroaromatic ring.  
Burgey et al. have developed an efficient Suzuki-Miyaura cross-coupling methodology 
involving 2-pyridyl pinacol boronates, where addition of copper(I) chloride 
significantly increases the yield.35 The pinacol boronates are more stable than the 2-
pyridyl boronic acids and the synthesis tolerates a wider array of functional groups than 
lithium triisopropyl 2-pyridylborates. Mechanistic studies indicate that the copper salt 
facilitates transmetallation of the boronate to the palladium complex, by forming a more 
reactive organometal species in situ. High yields were obtained with both electron rich 
and electron deficient 2-pyridyl pinacol boronates.  
A few groups have employed Negishi cross-coupling reactions to synthesise 1,3-
dipyridylbenzene systems.36,37 These reactions require initial preparation of a 
pyridylzinc chloride species, which is then cross-coupled with a 1,3-dibromobenzene in 
the presence of a palladium catalyst. Pyridylzinc chloride species are prepared via 
lithium-halogen exchange between 2-bromopyridine and nBuLi at -78  C, followed by 
nucleophilic substitution with ZnCl2. Previous group members tried to use this synthesis 
for 1,3-dipyridylbenzene ligands, but found the route to be very unreliable (low yields 
etc.), especially compared to the other cross-coupling methods. 
Fagnou et al. have reported a direct arylation synthetic route as an alternative to cross-
coupling, which avoids the need for such problematic “2-metallopyridines” altogether.38 
The reaction involves a pyridine N-oxide and an aryl bromide, which selectively couple 
via the pyridine N-oxide 2-position. The N-oxide is then removed under mild 
conditions. The direct arylation requires a palladium catalyst/ligand system {Pd(OAc)2 
and PtBu3-HBF4 were used here}, and the reactions are insensitive to the presence of 
water. High yields are reported to be attainable (74 – 97%), regardless of the electronic 
nature of the pyridine N-oxide or aryl bromide. To our knowledge, no one has used this 
route to produce dipyridylbenzene systems – another member of our group has recently 
attempted this, but has so far been unsuccessful. 
Route 2 involves reaction between a 2-halopyridine and a 1,3-diE-functionalised aryl 
core. Unlike the 1,3-dichloroaryl systems, 2-chloropyridines are sufficiently reactive  to 
undergo cross-couplings with standard catalysts. The “dimetallate” species benzene-1,3-
diboronic acid, and some of its derivatives have been employed in the preparation of 
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some 1,3-dipyridylbenzene systems.19,39 Reactions involving boronic acid-based 
metalloaryls tend to go more cleanly than those involving tin-based metalloaryls, and it 
is often easier to isolate the pure product. However, very few functionalised benzene-
1,3-diboronic acids have been reported to date, as the standard syntheses of such 
molecules typically involve harsh conditions that are incompatible with many 
substituents. This has limited the use of this route in preparation of the terdentate 
ligands. During the project, it was discovered that functionalised 1,3-dibromobenzenes 
(e.g. 1,3-dibromo-4,6-difluorobenzene, 1,3-dibromo-4,6-dimethylbenzene, etc.) could 
be converted into functionalised benzene-1,3-diboronic esters, that underwent Suzuki 
cross-coupling with 2-halopyridines (Section 2.2.2.1). This discovery has opened up 
new routes to highly functionalised dipyridylbenzene ligands, without the need for toxic 
tin species, examples of which will be discussed in subsequent sections of this chapter.  
 
2.2 Ligand Synthesis 
The dipyridylbenzene ligands prepared during the project were all made via cross-
coupling reactions, which involved either Suzuki or Stille methodology (Table 1). 
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Table 1: The selection of terdentate ligands prepared herein, the reactive precursors, and the reaction conditions employed. 
Ligand Precursors Synthetic 
Procedure 
Solvent Catalyst System Yield / % 
HL1 
N N
 
 
N
Br Br
SnBu3
 
 
Stille 
 
Toluene 
 
Pd(PPh3)2Cl2 
 
87 
HL2  
N N
F F
 
 
N
Br Br
SnBu3 FF
 
 
Stille 
 
Toluene 
 
Pd(PPh3)2Cl2 
 
53 
HL3 
NN
NO2
 
 
N
Br Br
SnBu3
NO2
 
 
Stille 
 
Toluene 
 
Pd(PPh3)2Cl2 
 
55 
HL4 
NN
NH2
 
 
N
Br Br
SnBu3
NH2
 
 
Stille 
 
Toluene 
 
Pd(PPh3)2Cl2 
 
31 
 
     
HL5  
NN  
 
N
Br Br
SnBu3
 
 
Stille 
 
Toluene 
 
Pd(PPh3)2Cl2 
 
43 
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Ligand Precursors Synthetic 
Procedure 
Solvent Catalyst System Yield / % 
HL7   
NN
 
 
N (HO)2B B(OH)2
Br
 
 
Suzuki 
 
DME/H2O (1:1) 
 
Pd(PPh3)4 
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HL8  
NN
 
 
N (HO)2B B(OH)2
Br
 
 
Suzuki 
 
DME/H2O (1:1) 
 
Pd(PPh3)4 
 
27 
HL9  
N N
F F
 
 
N
Br Br
SnBu3 FF
 
 
Stille 
 
Toluene 
 
Pd(PPh3)2Cl2 
 
27 
HL10 
 
N N
F F
 
 
 
 
N
Br Br
SnBu3 FF
 
 
Stille 
 
 
Stille 
 
Xylene 
 
 
Toluene 
 
Pd(PPh3)2Cl2 + PPh3 
 
 
Pd(PPh3)2Cl2 
 
88 
 
 
40 
 
HL11 
 
N N
F F
 
 
 
N
Br Br
SnBu3 FF
 
 
Stille 
 
Toluene 
 
Pd(PPh3)2Cl2 
 
39 
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Ligand Precursors Synthetic 
Procedure 
Solvent Catalyst System Yield / % 
HL12 
 
N N
F F
 
 
N
Br Br
SnBu3 FF
 
 
Stille 
 
Toluene 
 
Pd(PPh3)2Cl2 
 
58 
HL13  
 
 
NN
 
 
 
 
BrBr
N
SnBu3
 
 
Bpin BpinN Br
 
 
 
 
Stille 
 
 
 
Suzuki 
 
 
Toluene 
 
 
 
DME/H2O (1:1) 
 
 
Pd(PPh3)2Cl2 
 
 
 
Pd(PPh3)4 
 
 
9 
 
 
 
42 
 
HL14 
NN
 
 
BpinBpin
N
Br
 
 
Suzuki 
 
DME/H2O (1:1) 
 
Pd(PPh3)4 
 
95 
      
HL15 
 
N N
F F
MeO OMe
 
 
N
Br Br
SnBu3 FFMeO
 
 
Stille 
 
Toluene 
 
Pd(PPh3)2Cl2 
 
31 
 
 
 
 
 
 
72 
 
      
Ligand Precursors Synthetic 
Procedure 
Solvent Catalyst System Yield / % 
HL16   
N N
F F
OMe
 
 
FF
Br
N
OMe
N
SnBu3
 
 
Stille 
 
Toluene 
 
Pd(PPh3)2Cl2 
 
32 
HL17 
F F
N N
Me2N NMe2
 
 
 
N
Me2N Br F F
BpiBpin
 
 
 
 
Suzuki 
 
 
DME/H2O (1:1) 
 
 
Pd(PPh3)4 
 
 
51 
HL18 
NN
O2N NO2
 
 
 
 
N (HO)2B B(OH)2
BrO2N
 
 
Suzuki 
 
DME/H2O (1:1) 
 
Pd(PPh3)4 
 
38 
HL19 
NN
F F
 
 
 
 
 
NO2O2N
 
 
Fluorodenitration 
 
 
Fluorodenitration 
 
DCM 
 
 
DMF 
 
------------- 
 
 
------------- 
 
96 
 
 
72 
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Ligand Precursors Synthetic 
Procedure 
Solvent Catalyst System Yield / % 
 
     
HL20 
 
N N
F F
F3C CF3
 
 
N
FF
Bpin Bpin
F3C Cl
 
 
Suzuki 
 
DME/H2O (1:1) 
 
Pd(PPh3)4 
 
89 
HL21  
N N
F F
CF3MeO
 
 
N
N
FF
OMe
SnBu3F3C
 
 
 
Stille 
 
 
Toluene 
 
 
Pd(PPh3)2Cl2 
 
 
55 
HL22 
N N
FF  
 
N
F
Br
(HO)2B B(OH)2 
 
Suzuki 
 
DME/H2O (1:1) 
 
Pd(PPh3)4 
 
54 
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2.2.1 Ligands Prepared via Stille Cross-Coupling 
Stille cross-coupling reactions utilised during the project involved a 2-tri-n-butylstannyl 
pyridine species and a 1,3-dibromo aryl species (Scheme 4, Route 1), and were 
performed in toluene or xylene. Pd(PPh3)2Cl2 was added as catalyst. Reactants were 
degassed using freeze-pump-thaw methodology, and the reactions were heated at 120 C 
under nitrogen for three days. An inert atmosphere was crucial to prevent oxidation (and 
deactivation) of the palladium catalyst and to minimise homo-coupling reactions 
between the stannanes, both of which would have a detrimental effect on the yield. LiCl 
was also added to increase the yield – the compound is thought to stabilise the 
intermediate complex formed after oxidative addition, accelerating the reaction.  
The reactions were found to generate a significant amount of waste material, which was 
removed from the desired product by lengthy work-up followed by column 
chromatography. Stannyl by-products can be notoriously difficult to remove – they are 
insoluble in water so cannot be simply washed out. KF was added during the work-up to 
form insoluble tri-n-butyltin fluorides, which are subsequently filtered from the product. 
Sometimes, however, some tin residues remained after the full work-up and column; 
since the desired products were generally insoluble in hexane, several washings with 
this solvent were usually sufficient to remove the excess tin by-products. 
The Stille reaction gave a wide range of yields (27 – 88%), but most ligands were 
formed in moderate (40-50%) yield. The presence of an ionisable or protonable group 
(e.g. NH2, OH) on the central ring seemed to hinder the reaction, giving the low yields. 
Otherwise, there was no noticeable trend between yield and structure of the reactants.   
 
2.2.1.1 Preparation of Precursors 
 
1,3-Dibromobenzene and Derivatives 
1,3-Dibromobenzene and 3,5-dibromophenol are commercially available and were used 
as bought in the Stille reactions. 1,3-Dibromo-4,6-difluorobenzene was prepared by 
brominating commercially available 1-bromo-2,5-difluorobenzene with bromine in the 
presence of iron filings (Scheme 5)40,41 The bromine reacts with iron to form a Lewis 
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acid, FeBr3, which in combination with Br2 is an electrophilic source of bromine. This 
reacts with the aryl ring via electrophilic aromatic substitution. Bromination occurred 
selectively, despite using an excess of bromine, and a yield of 68% was obtained.  
F F
Br
Br2,
Fe
F F
BrBr  
Scheme 5: Preparation of 1,3-dibromo-4,6-difluorobenzene. 
1,3-Dibromo-5-nitrobenzene was prepared from 2,6-dibromo-4-nitroaniline. The 
reaction involves an initial nitrosation to give an aryl diazonium salt, followed by 
reductive deamination with H3PO2 (Scheme 6).42,43 The overall reaction was relatively 
high yielding (70%). Some of the 1,3-dibromo-5-nitrobenzene was reduced with 
Sn/HCl to give 3,5-dibromoaniline.44 
Br
NH2
Br
NO2
Br
N
Br
NO2
0 C
N HSO4
BrBr
NO2
H3PO2
H2SO4,
NaNO2
° BrBr
NH2
Sn,
HCl
 
Scheme 6: Synthetic route to 1,3-dibromo-5-nitrobenzene and 3,5-dibromoaniline. 
 
Pyridyl Stannane Precursors 
Table 1 shows the selection of 2-pyridyl stannanes used. Their synthesis involved a 
two-step process: initial lithiation at the 2-pyridyl position, followed by nucleophilic 
substitution with a tin electrophile (Bu3SnCl). The lithiation proceeded by one of two 
mechanisms, depending on the initial pyridyl starting material (Scheme 7). 2-Bromo 
pyridines were lithiated directly: mixing with n-butyllithium (n-BuLi) at 0  C resulted in 
lithium-halogen exchange.45 
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N Br
R
N
N Li
R
N SnBu3
R
R
ROUTE A
    nBuLi
 ROUTE B
 nBuLi,
 DMAE
SnBu3Cl
Route A Route B
R = 4-Me
4-CF3
H
3-Me
5-Me
6-Me
4-MeO
 
Scheme 7: Routes employed in the synthesis of 2-pyridyl stannanes. 
Fort and Gros have reported an alternative route to 4-functionalised-2-pyridyl 
stannanes. Here, a 2-bromo substituent is not necessary to achieve selective lithiation, 
and simple 4-functionalised pyridines can be used directly (Scheme 7, Route B). Some 
of the 4-functionalised-2-pyridyl stannanes (functionality = Me, CF3), were prepared via 
this route. In these reactions, n-BuLi was initially mixed with dimethylaminoethanol 
(DMAE), a coordinating molecule, in dry hexane.46 When the 4-functionalised pyridine 
is added, a mixed lithium aggregate intermediate is initially formed (Figure 3), where 
induced proximity effects and an enhancement of the acidity of the proton ortho to 
nitrogen cumulatively result in selective lithiation at the C-2 position. This method is 
only reliable for use with some 4-substituted pyridines, as a mixture of isomers would 
result from reaction with other n-substituted pyridines (n = 3, 5 and 6).  
N
R
Li
H
Bu
Li OHN
 
Figure 3: The mixed lithium aggregate intermediate in the ortho-directed lithiation/stannylation route. 
The synthesis of 4-methoxy-2-tri-n-butylstannyl pyridine via ortho-directed lithiation 
and its subsequent Stille cross-coupling gave unsatisfactory yields of 4-methoxy-2-tri-n-
butylstannyl pyridine. Hence, 2-bromo-4-methoxy pyridine was synthesised, in the 
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expectation that lithium-halogen exchange might prove more successful in providing 
access to the stannane. The synthesis of 2-bromo-4-methoxy pyridine was taken from 
reference 47, and involves four steps (Scheme 8): formation of the N-oxide of 2-
bromopyridine, nitration of 2-bromopyridine N-oxide, N-oxide removal and substitution 
of NO2 by MeO–. In pyridine N-oxides, the lone pair of the oxygen is delocalised round 
the aromatic ring, increasing the susceptibility towards electrophilic substitution 
(especially at the 4-position). Hence NO2+ generated by mixing concentrated sulphuric 
acid with fuming nitric acid attacks the 4-position via electrophilic substitution. 
Removal of the oxide was achieved with a phosphorus based reductant, PBr3. 
Phosphorus has an extremely high affinity for oxygen, forming a very stable P=O bond. 
Removal of the N-oxide removes the heightened nucleophilicity of the pyridine ring 
system, meaning the molecule is no longer susceptible to electrophilic aromatic 
substitutions (electronegative nitrogen would destabilise any cationic intermediate, and 
the free lone pair might attack an electrophile). The system has, however, become more 
susceptible to nucleophilic substitution. Dissolving sodium in methanol produces 
strongly basic/nucleophilic methoxide ions, which will attack at the electron deficient 
C-4 and displace the nitro group.  
Lithiation of 2-bromo-4-methoxy pyridine via lithium-halogen exchange, followed by 
stannylation proved successful, and 2-tri-n-butylstannylpyridine underwent Stille cross-
coupling to give the desired ligand, 1,3-di(4-methoxy-2-pyridyl)-4,6-difluorobenzene, 
HL15, (31% yield). The mono-substituted molecule, 1-bromo-2,4-difluoro-5-(4-
methoxy-2-pyridyl)-benzene was also isolated from this reaction (38%). Some of this 
was further reacted with 2-tri-n-butylstannylpyridine, and some with 2-tri-n-
butylstannyl-4-trifluoromethylpyridine, to give two asymmetric ligands, HL16 and HL21 
(Table 1). 
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N Br N Br N Br
NO2
O O
mCPBA,
Chloroform
RT,
3 days
96 % H2SO4,
98 % HNO3
130 °C,
3 h
N Br
NO2PBr3,
Chloroform
Reflux,
2 h N Br
OMe
Na,
MeOH
RT,
24 h
 
Scheme 8: Synthetic route to 2-bromo-4-methoxypyridine, taken from reference 47. 
A previous group member found that stannylation of 4-dimethylamino pyridine via 
ortho-directed lithiation gave very unsatisfactory yields. The failure of ortho-directed 
lithiation with both 4-dimethylaminopyridine and 4-methoxypyridine indicates that 
pyridyl substituents of greater electron donating character have a detrimental effect on 
this route. 2-Bromo-4-dimethylamino pyridine has been prepared, but the 
stannylation/Stille reaction route was not followed with this precursor, due to 
development of an alternative route to synthesis of ligands incorporating functionalised 
central phenyl rings (Section 2.2.2.1). 
It was found that the stannanes partly decompose during column chromatography, 
particularly when electron rich substituents are present, and are best used straight from 
the reaction work-up. An estimate of purity was gained from proton NMR, by 
comparing the integrals of the aromatic region with those of the aliphatic region.  
 
2.2.2 Ligands Prepared via Suzuki-Miyaura Cross-Coupling 
Ligands HL7, HL8, HL13, HL14, HL17, HL18, HL19, HL20 and HL22 were all prepared via 
Suzuki-Miyaura cross-coupling. The most commonly used base in Suzuki-Miyaura 
cross-coupling is Na2CO3; which was used throughout the project. The reactions were 
performed in a mixed dimethoxyethane/water solvent system (1:1), in the presence of a 
Pd(PPh3)4 catalyst. The reactions were degassed (freeze-pump-thaw methodology) and 
heated under nitrogen at 85  C for two days. The Pd(PPh3)4 catalyst was added just 
before heating to prevent initial decomposition. Initially, Suzuki-Miyaura reactions 
were performed utilising a low water content (DME/water, 6:1)19, but a previous group 
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member found that an increased water content (DME/water, 1:1) led to enhanced yields 
when using diboronic acids. This enhancement probably results from the increased 
solubilisation of benzene-1,3-diboronic acid, which creates a more homogeneous 
system.  The yield varied significantly between reactions (27 – 95%), but with no 
apparent trend amongst reactants. 
Benzene-1,3-diboronic acid is commercially available, and most ligands involving an 
unsubstituted central phenyl ring were prepared via Suzuki-Miyaura cross-coupling. 
There are very few examples of syntheses using benzene-1,3-diboronic acid in the 
literature (and even fewer involving functionalised benzene-1,3-diboronic acids)39,48,49,50 
During the project, a facile route to the formation of derivatized benzene-1,3-diboronate 
ester species was developed based on a transition-metal-catalysed cross-coupling 
initially proposed by Miyaura et al.51 (see Section 2.2.2.1). In his initial paper on the 
subject, Miyaura reported that 1,3-dibromobenzene would form a diboronate species 
under Miyaura conditions, however to our knowledge, no one has ever used the 
methodology to create functionalised aryl-diboronate systems. These aryl diboronate 
esters were found to react well under the Suzuki conditions employed with benzene-1,3-
diboronic acid, and were used to synthesise ligands HL13, HL14, HL17 and HL20 in 
moderate to excellent yields (42 – 95%). This was a big breakthrough, as the 
methodology has opened up a less toxic route to N^C^N units offering a greater extent 
of derivatisation.  
 
2.2.2.1 Synthesis of Precursors 
 
Aryl-1,3-diboronate esters 
Literature procedures for the synthesis of benzene diboronic acids typically involve 
lithium-halogen exchange between the bromobenzene precursor and nBuLi, followed by 
transmetallation with a trialkoxy borane {e.g. B(OPri)3, B(OMe)3, etc}, and finally 
hydrolysis with concentrated acid.39,52  Alternatively, boronic acids are produced via the 
addition of Grignard reagents to trialkoxy boranes at low temperature, again followed 
by hydrolysis53,54,55 Both routes involve harsh conditions and are incompatible with 
many functional groups, limiting the synthetic diversity.  
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Some aryl-boronate esters (e.g. pinacol esters) have been found to react via Suzuki-
Miyaura routes under similar conditions to aryl boronic acids, meaning acid hydrolysis 
is not always necessary. These compounds initially involved lithium-halogen exchange 
in their synthesis, so diversification was still difficult.56 However in 1995, Miyaura et al. 
reported a direct one-step synthesis of aryl-boronate esters from the aryl bromide or 
iodide.51 The mechanism involves a transition-metal-catalysed cross-coupling of a 
boron nucleophile with an aryl electrophile (Scheme 9), and is tolerant of a wider range 
of functionality on the aryl electrophile than previous lithiation routes.57,58,59 Miyaura 
found that the catalyst Pd(dppf)Cl2 generally gave the best results, and the reaction was 
favoured in polar solvents such as DMSO. Addition of a weak base was necessary to 
activate the catalyst; the highest yields and selectivities were obtained with KOAc.   
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Scheme 9: Miyaura cross-coupling catalytic cycle for formation of aryl boronic esters.51 
1,3-Dimethyl-4,6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene (Me2pin2) and 
1,3-difluoro-4,6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene (F2pin2) were 
prepared from their dibromo-precursors and bispinacolatodiboron (B2pin2) using the 
Miyaura cross-coupling route. Pd(dppf)Cl2 was used as catalyst, KOAc was added as 
the base and the solvent was dry DMSO. Dry DMSO was found to be essential – 
excessive homocoupling was observed when laboratory grade DMSO was initially used. 
Reactions were heated at 80  C for 12 h under a nitrogen atmosphere.60,61 The products 
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were purified via column chromatography and were obtained in high yield (69 – 86%). 
This method was tolerant of fluorine atoms on the aryl ring. The incorporation of this 
route into the total synthesis of the dipyridylbenzene ligands has led to increased 
chemical versatility and allowed greater functionalisation of such systems.   
 
2-Bromo-4-dimethylaminopyridine 
2-Bromo-4-dimethylaminopyridine was prepared via a two step process: ortho-directed 
lithiation of 4-dimethylamino pyridine, followed by reaction with CBr4 and purification 
by column chromatography.62 This was reacted with F2pin2 via Suzuki-Miyaura cross-
coupling, to give 1,3-di(4-dimethylamino-2-pyridyl)-4,6-difluorobenzene, HL17, in 
modest yield (51%). It has since been found that 2-bromo-4-methoxypyridine can also 
be prepared this way from 4-methoxypyridine, avoiding the initial lengthy synthesis of 
2-bromo-4-methoxypyridine presented in Scheme 8.  
 
2.2.3 Synthesis of a Tetradentate Ligand 
For reasons that will be discussed in Chapter 5, it was of interest to prepare a 
dipyridylbenzene ligand appended with a fourth ligating group, to occupy the fourth 
coordination site of Pt (II). A phenolic appendage was proposed, and ligand HL23 was 
targeted. Selective ortho-lithiation of anisole was achieved by metallating in the 
presence of an ortho-directing group, tetramethylethylene diamine (TMEDA).63,64 The 
substitution of an aryl-lithium species into the ortho-position of a pyridyl system is well 
represented in the literature,65,66 for example, Che et al. have reported on the synthesis 
of a system related to the targeted molecule, that involves 2-lithioanisole coupling with 
C6 of bipy (i.e. position next to the nitrogen).67 This method was used successfully in 
the preparation of ligand HL23 (Scheme 10).  
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Scheme 10: The synthetic route to HL23. 
 
2.2.4 Fluorination at the 4-Pyridyl Position 
The platinum(II) complex containing ligand HL19 was a desirable target, for reasons 
discussed in Chapter 3. Unfortunately neither 4-fluoropyridine nor 2-bromo-4-
fluoropyridine are commercially available. Only one article reporting the synthesis of 2-
bromo-4-fluoropyridine could be found.68 The method involved fluorodenitration of 2-
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bromo-4-nitropyridine with tetrabutylammoniumfluoride (TBAF); the former had 
already been prepared as an intermediate used in the synthesis of HL15. This reaction 
was attempted twice, but the desired product was never isolated. On consultation with a 
fluorine expert, the authenticity of the reported reaction was brought into question – the 
expert suggested that a fluorine atom on C-4 of pyridine would make this position 
extremely electron deficient, and open to attack by the nucleophilic nitrogen of another 
4-fluoropyridine. This process would continue, generating polypyridine species 
(Scheme 11). This is the reason why there are not very many 4-fluoropyridine based 
molecules in existence.  
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Scheme 11: Stipulated polymerisation reaction between the nucleophilic pyridine lone pair and the 
electropositive centre at C4. 
The expert thought that fluorodenitration of 1,3-di(4-nitro-2-pyridyl)benzene, 
HL18,would also lead to an intractable mixture of polymers. However, this synthesis 
was still attempted. Initially, HL18 was stirred at room temperature with four equivalents 
of TBAF in DMF. The reaction did not go to completion – some of the monofluorinated 
product was detected by NMR. A larger excess of TBAF was required to enforce full 
conversion. Nevertheless, the ligand, HL19 was prepared via the fluorodenitration 
method and was purified by column chromatography.  
The reaction was also attempted in DCM. The paper from which the initial procedure 
was adapted (reference 68) reports DMF to be the solvent of choice, as 
hydroxydenitration, a competing process is suppressed. Unlike the DMF reaction, 
fluorodenitration of HL18 in DCM did not occur at room temperature, however heating 
at reflux in DCM for 1.5 h gave the desired product without any trace of the side-
product. As in the DMF reaction, a large excess of TBAF (~ 4 equiv.) was required to 
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drive the reaction to completion. The DMF based reaction was lower yielding, possibly 
due to the difficulty of extracting the product from the DMF layer. 
 
2.3 Synthesis of Platinum Complexes 
 
2.3.1 Complexation to Pt (II) 
Two solvent systems are commonly used within the group for complexations of the 
terdentate ligands: 1) glacial acetic acid and 2) acetonitrile/water (3:1), and the general 
reaction scheme is presented in Scheme 12.18,19 Both systems involve heating at 120  C 
under nitrogen for 3 days, and give complexes in comparable yield. Where possible, 
ligands were complexed with K2PtCl4 in glacial acetic acid. The acetonitrile/water 
system requires the aqueous solution of K2PtCl4 to be degassed separately from the 
solution of ligand in acetonitrile. However, this solvent system proves invaluable when 
ligands containing acid sensitive groups required complexation, such as HL17. During 
complexation, most complexes were observed to precipitate out of solution as bright 
yellow or orange solids; the process is further facilitated by cooling prior to the work-
up. The complexes generally had low solubility, and the work-up involved a series of 
washings to remove any uncomplexed ligand and K2PtCl4.  
N N
K2PtCl4,
acetic acid
Or:
K2PtCl4,
CH3CN/H2O
(3:1)
N N
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Scheme 12: Complexation of the terdentate ligand to Pt (II). 
With the exception of ligands HL4 and HL19, complexation of the ligands via these 
routes succeeded, giving yields ranging from 32 to 81%, and mostly towards the higher 
end. Ligands HL8, HL12 and HL13 underwent lower yielding complexations (32 – 44%) 
– these ligands generate complexes that possess unfavourable steric interactions (see 
Section 2.4.3.1), which must hinder the complexation process.  
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Complexation of HL4 did not appear to work – an insoluble brown oil was obtained that 
could not be characterised. Complexation of HL19 led to a mixture of inseparable 
products – 1H NMR indicated that a complexation had occurred, (195Pt satellites were 
observed around some of the peaks), but the pyridyl proton J-values were much smaller 
than found in the ligand, indicating that the fluorine atoms had been replaced. Also, the 
molecular ion peak for the desired complex was absent from the ASAP mass spectrum, 
further suggesting decomposition of the ligand had occurred upon complexation. 
Complexation of this ligand failed with both solvent systems – this indicates that the 
fluorine-carbon bond must be relatively labile in HL19. 
Initially we thought that complexation of the potentially terdentate ligand HL23 in acetic 
acid would disfavour the necessary deprotonation of the OH group, so the complexation 
was performed in an acetonitrile/water solvent system. From this reaction we obtained a 
mixture of low solubility products that could not be separated or identified. The 
complexation was attempted in acetic acid – this time a complex was formed which was 
pure by NMR. There was some concern that the complex obtained involved the ligand 
bound terdentately with an ancillary chloride (Figure 4). Hence, the complex was mixed 
with silver triflate in acetone and stirred for 2 h (silver has a strong binding affinity for 
chloride). Isolation of the product revealed an NMR identical to the precursor, 
indicating that the non-chlorinated form was initially obtained from the complexation 
reaction.  
N N
Pt
Cl
N N
Pt
HOO
vs.
 
Figure 4: Possible binding modes of L23 to Pt (II). 
 
2.3.2 Substitution of the Ancillary Chloride by Other Halides or Cyanide 
These reactions proceeded via two steps: removal of the ancillary chloride followed by 
addition of the new ancillary ligand. Silver has a high affinity for chloride, so to remove 
the chloride, a slight excess of silver triflate was added to a suspension of appropriate 
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complex in acetone. The mixture was stirred at room temperature for 1-2 h, during 
which the acetone-ligated containing species dissolved and silver chloride precipitated. 
Upon removal of the silver chloride via centrifugation, a potassium salt of the new 
ancillary ligand was added to the acetone solution. Precipitation of the new complex 
was observed, and after 1-2 h stirring, the precipitate was isolated and washed 
accordingly.  
Solubility of the complex was found to increase on substituting the chloride with a 
heavier halide ion. On the other hand, the cyanide complexes were much less soluble 
than their chloro-analogues. The substitution reactions were high yielding (71 – 85%), 
and the proton NMR indicated that full conversion had occurred.  
 
2.3.3 Oxidation to Pt (IV) 
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Scheme 13: Oxidation of [PtLCl] to [PtLCl3]. 
A selection of the Pt (II) complexes ([PtL2Cl], [PtL7Cl], [PtL9Cl], [PtL10Cl], and 
[PtL11Cl]) were oxidised to their Pt (IV) analogues, by bubbling chlorine gas through a 
chloroform solution containing the Pt (II) complex for 30 min – 1 h.69 The colour of the 
solution appeared to lighten as soon as chlorine was added. 1H NMR and MS indicated 
that the oxidations were successful, and had gone to completion. However, 
photochemical analysis consistently revealed that trace amounts of the Pt (II) precursors 
still prevailed (Chapter 3, Section 3.5). The Pt (IV) complexes are charge-neutral and 
consist of the terdentate ligand and three chloride ligands. 
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2.4 Spectroscopic Characterisation 
 
2.4.1 Characterisation of Ligands and Ligand Precursors 
 
2.4.1.1 NMR 
The aromatic region of the proton NMR of the symmetric terdentate ligands was 
generally straightforward to assign, due to the recurrence of certain trends. Figure 5 
shows the generic numbering used for all symmetrical ligands prepared here – the 
pyridyl groups have been given priority over any substituent to aid comparison. 
N N
5'
4'
2'
1'2
3
4
5
6
 
Figure 5: General numbering scheme of the symmetric terdentate ligands. 
To describe the patterns observed in the proton NMR of such ligands, it is easiest to 
start by describing trends observed in the precursors. For example, the proton NMR of 
1,3-dibromobenzene consists of two triplets and a doublet at intermediate chemical 
shift. The triplet of lowest shift corresponds to proton H5' and the triplet of highest shift 
to H2', which is confirmed by the relative magnitudes of the J-couplings. The doublet 
occurring at intermediate shift obviously corresponds to H4', with a relative intensity of 
two protons. In comparison, 1,3-dibromo-4,6-difluorobenzene contains two triplets at 
higher and lower field only, and again the triplet at lowest chemical shift corresponds to 
H5'. In this molecule, H4' has been replaced by fluorine. These patterns are carried 
through to the respective terdentate ligands.   
Larger 3J- and 4J-values are observed for H5' and H2' respectively when fluorine 
occupies the C4' positions. This is because fluorine-19 is also a spin-active nucleus (S = 
½) and in these particular environments exhibit stronger coupling than protons.70 
88 
Between non-fluorinated and fluorinated analogues (e.g. HL1 and HL2), the 3J value of 
H5' typically increases from approximately 9 to 11 Hz. The 4J value of H2’ increases by a 
greater extent, from about 2 to 9 Hz. The proton-decoupled carbon spectra also show 
coupling to fluorine – for example, the 1J-coupling with C4', of approximately 250 Hz.  
2-Tri-n-butylstannylpyridine and 2-bromopyridine proton NMR spectra show a 
consistent trend of peak ordering, regardless of any additional substituent. H5 always 
occurs at the lowest shift, and H6 always occurs at the highest shift, with H3 and H4 
peaks occurring somewhere in-between. This trend was carried through to the ligand 
(Figure 6), where COSY spectra and the J-splitting pattern were used to check and 
confirm the assignments. In addition, the proton NMR of tri-n-butylstannyl pyridine 
species showed satellites around the H3 signal. Tin has three spin ½ nuclei (115Sn, 117Sn 
and 119Sn) hence the satellites arise through 3J coupling to tin.  
 
Figure 6: TOP: 1H NMRs of ligand precursors, 1,3-dibromo-4,6-difluorobenzene (left), and 2-tri-n-
butylstannyl pyridine (right), BOTTOM: 1H NMR of the resultant terdentate ligand, 1,3-di(2-pyridyl)-4,6-
difluorobenzene (spectra were acquired in CDCl3 at 400 MHz). 
For ligands containing a 3',5'-difluorinated central ring, a signal around _113 ppm 
occurred in the 19F spectrum. The fluorine atoms couple to both H2' (4J) and H5' (3J), so 
strictly, the peak should be assigned as a doublet of doublets. However, the magnitude 
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of the 4J and 3J couplings are so similar, that this peak appeared as a triplet with a J-
splitting of between 9 and 10 Hz, for all fluorinated ligands.  
 
2.4.1.2 Mass Spectrometry 
Electrospray-positive mass spectrometry was used to confirm the molecular weight of 
the ligands. Protonated and sodium-bound ions were typically observed in the mass 
spectra. This method is a relatively soft ionisation technique (compared to electron 
impact, EI, mass spectrometry for example), and as a consequence, fragmentation of the 
molecular ion was hardly ever observed. In most cases, the [M+H+] peak had an 
intensity of 100%. 
 
2.4.2 Characterisation of Complexes 
 
2.4.2.1 NMR 
The numbering scheme used for the complexes is slightly different to that of the ligand 
(Figure 7). Here, the platinum-bound carbon is given the priority. 
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Figure 7: Comparison of the numbering schemes used with the ligands and the complexes. 
Proton NMR spectra of the Pt (II) complexes display some significant differences 
(Figure 8) compared to the free ligand spectra. There is always one less signal in the 
aromatic region of a Pt (II) complex NMR – H2' of the ligand is lost upon 
cyclometallation. Secondly, well-resolved 195Pt satellites are observed around the signal 
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of H6 (3J  40 Hz). Other more subtle differences upon complexation include the signal 
due to H6 moving to higher shift (by approximately 0.5 ppm), and the signal due to H4' 
(i.e. H5' in the ligand) moving to lower shift (by approximately 0.5 ppm). The latter 
effect is due to increased shielding within the phenyl ring, which is brought about by an 
increase in electron density upon cyclometallation, and is consistent with results 
reported for similar systems.19 H5 stays at approximately the same position, and H3 and 
H4 are sometimes observed to change their relative positions.  
 
Figure 8: TOP: 1H NMR of the ligand, 1,3-di(2-pyridyl)-4,6-difluorobenzene (HL2) and BOTTOM: 1H 
NMR of the corresponding complex, [PtL2Cl]. The spectra are plotted on the same scale to aid 
visualisation of the relative shifts of peaks between ligand and complex. Notice the 195Pt satellites 
observed around the peak corresponding to H6 in the complex (spectra were acquired in CDCl3 at 400 
MHz). 
The fluorine spectra also differ between complex and ligand – complexes containing a 
symmetrical ligand incorporating a 3,5-difluorinated phenyl ring show a doublet around 
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_110 ppm that is often accompanied by 4J(195Pt) satellites (Figure 9b). The doublet 
splitting corresponds to 3J coupling of the 19F atom with H4'. The slight increase in 
chemical shift indicates that the fluorine atoms become more deshielded upon 
cyclometallation. The fluorine NMR spectrum of [PtL9Cl] is vastly different from all 
other complexes (Figure 9c) – here, a broad multiplet is observed at much higher field (-
92 ppm). In this complex, there is a steric interaction between the fluorine atoms and the 
methyl hydrogens. The close proximity of these atoms results in a non-bonding orbital 
overlap, which decreases the shielding around fluorine. Such through-space interactions 
are commonly observed in polycyclic arenes containing fluorine atoms and protons in 
close proximity.71 The observed peak is broad because the fluorine experiences some 
coupling interaction with the methyl protons via the through space interaction. This was 
confirmed by performing a proton-decoupled 19F NMR, which revealed only a singlet 
peak, accompanied by 4J(195Pt) satellites (Figure 9d). 
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a) 
b) 
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Figure 9: 19F NMR spectra of some representative species. a) 19F NMR spectrum of HL2, b) 19F spectrum 
of [PtL2Cl], c) 19F spectrum of [PtL9Cl] and d) Proton-decoupled 19F NMR spectrum of [PtL9Cl] (spectra 
a) and b) were acquired in CDCl3 at 376 MHz, and spectra c) and d) were acquired in CDCl3 at 470 
MHz). 
Changing the ancillary ligand led to subtle changes in the proton NMR. For example, 
substitution of the chloro ancillary ligand by cyanide results in a shift of all aromatic 
protons to lower chemical shift. This indicates that all aromatic protons are becoming 
increasingly shielded (cyanide is a better -donor than chloride).  
c) 
d) 
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For the halogenated series of [PtL1X], the signal due to H6 shifts to higher field as the 
size of the halogen increases (Figure 10). Otherwise, all other proton signals occur at 
very similar chemical shifts. 
Complex:               [PtL1I]                   [PtL1Br]                   [PtL1Cl]
   of H6 / ppm:         9.89                         9.56                          9.31δ
Increasing Chemical Shift
 
Figure 10: Chemical shifts of proton H6 from the series [PtL1X]. 
For the Pt (IV) complexes, all of the aromatic proton resonances of the ligand occurred 
at higher chemical shift than for the respective Pt (II) complexes. This is consistent with 
the increasing positive charge on platinum, reducing electron density on the ligand. The 
195Pt satellites around H6 show smaller J-coupling (3J ~ 20 – 25 Hz), indicative of a 
poorer overlap with the contracted orbitals of the Pt (IV) centre. For 3,5-difluorinated Pt 
(IV) complexes, the signals in the 19F spectra occur at higher chemical shift than the Pt 
(II) analogues (approximately _104 ppm) in line with the increasing positive charge. 
Analogous to [PtL9Cl], the fluorine signal of [PtL9Cl3] is broad due to a non-bonding 
orbital overlap with the methyl protons, and occurs at a higher chemical shift (_86.5 
ppm) than all other fluorinated Pt (IV) 19F signals.  
 
2.4.2.2 Mass Spectrometry 
Electrospray positive ion mass spectrometry does not work for most of the complexes 
produced here. Unlike the ligands, most of the complexes do not contain any available 
sites for protonation. Different ionisation techniques were sought to characterise the 
complexes. Electron ionisation (EI) mass spectrometry had been successfully used by 
previous group members to characterise related complexes. Unfortunately, the EI 
service used by the group was the Swansea-based EPSRC service, and only a limited 
number of samples could be sent per month.  
Matrix assisted laser desorption ionisation (MALDI) mass spectrometry was 
investigated – most complexes were at least sparingly soluble in chloroform. Compared 
to EI, MALDI is a soft ionisation technique, and is often used to characterise polymers 
and biomolecules. In the MALDI experiment, the complexes were mixed with a UV-
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absorbing compound, trans-2-[3,4-tert-butylphenyl]-2-methyl-2-
propenylidene]malonitrile (dctb) and placed in a vacuum chamber. On applying a 
vacuum, all of the solvent evaporates, leaving behind the sample within a “matrix” of 
the UV-absorbing chromophore. The chromophore is excited with a laser, and passes 
some of the excess energy to the complex, forming charged species. Low resolution 
MALDI mass spectrometry gave mass peaks corresponding to the whole complex. 
Unfortunately, in the high resolution experiment, the mass that was detected 
corresponded to the complex minus the ancillary ligand, which hindered full 
characterisation of complexes resulting from ancillary ligand substitution. A low 
intensity peak at [2M-Cl] is also commonly observed, which corresponds to a 
chlorobridged dimer. It is unclear whether this species forms during the MALDI 
experiment, or whether such species form during complexation – perhaps this is an 
intermediate during cyclometallation.  
A new technique, atmospheric solids analysis probe (ASAP) mass spectrometry has 
recently arrived in the department. ASAP uses an ambient ionization method, and can 
analyse a large array of substrates, including non-polar, high-melting point solids. This 
technique involves an atmospheric pressure ionization technique, where a hot 
desolvation gas is used to vaporise the sample, and the technique is ideally suited to 
analysis of the complexes. The complexes were input directly as solids, and the high 
resolution experiment returned peaks corresponding to the molecular ion and the 
molecular ion-minus-ancillary ligand. Sometimes however, the molecular ion peak is 
very weak, and the signal-to-noise ratio prevents accurate determination of this mass. 
When this was the case, the stronger peak corresponding to M – X (where X = ancillary 
ligand) has been reported. Furthermore, some of the masses reported correspond to the 
protonated molecule (e.g. [M+H+] was observed for [PtL11Cl]). Such species often 
appear in ASAP experiments, and result from proton transfer from ionised water 
clusters present in the source.72 Using ASAP mass spectrometry, it was possible to 
confirm and fully characterise the cyano-substituted and bromo-substituted complexes 
([PtL2CN], [PtL15CN], [PtL17CN], and [PtL1Br]).  
ASAP mass spectrometry was employed to confirm the identity of [PtL23]. Under 
standard operating conditions, the experiment always returned an isotopic envelope 
containing a mixture of peaks from the radical cation and the protonated molecule. In an 
attempt to see peaks corresponding to the molecular ion only, the ASAP experiment 
was carried out using a dry calibration source. Usually, a lock spray of methanol/water, 
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is employed. The spray contains a selection of molecules of known accurate mass, so 
that the experiment can be calibrated. In the dry experiment, heptacosa, (C4F9)CN, was 
used for calibration. This time, protonation did not occur, and a mass and isotope 
pattern that fit nicely with the theoretically predicted pattern for the radical cation was 
found. This further demonstrates that the ASAP experiment can be sensitive to 
moisture.72 
The Pt(IV) complexes were characterised by ASAP mass spectrometry – peaks 
corresponding to the subsequent loss of chlorine could be observed in the spectrum. 
Whilst analysing these peaks, it was noticed that the isotope pattern did not always 
occur as expected. For example, for Pt(IV) complexes that contained a 3',5'-
difluorinated aryl ring, peaks corresponding to [M-Cl] and [M-3Cl] did not give a good 
fit to the expected isotope patterns of the predicted radical cations – the observed 
envelope of peaks were one mass unit less than predicted. Instead, the experimental 
pattern gave a good fit to the expected radical minus a hydride ion (i.e. [(M-Cl)-H]. On 
the contrary, peaks corresponding to [M] and [M-2Cl] did give isotope patterns 
matching those predicted for the respective radical cation. The story gets more bizarre 
on considering the non-fluorinated Pt(IV) complex, [PtL7Cl3] – this complex behaved 
completely differently during the mass spectrometry experiment. Here, the envelope 
patterns of peaks corresponding to [M] and [M-2Cl] fit well with the theoretical pattern 
for “[M+H]+”, whereas peaks corresponding to [M-Cl] and [M-3Cl] gave isotope 
patterns that fitted nicely with the theoretical patterns of the radical cations. As already 
mentioned, protonated species are often observed in the ASAP experiment, especially if 
the sample is slightly wet. However, here, the protonation was not consistent for all 
peaks observed in the same experiment. The ASAP experiment is still quite new, so the 
reason behind this odd behaviour cannot be explained at present. The mass spectrometry 
team at Durham who discovered this effect plan to undertake further investigations to 
understand why this occurs. 
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2.4.3 Crystal Structures 
 
2.4.3.1 Crystal Structures of Pt (II) Complexes 
Some of the complexes were successfully crystallised via slow evaporation of solvent – 
complex [PtL2Cl] was obtained from a CH3CN/DCM/H2O mix (1:1:1), [PtL7Cl] was 
obtained from CDCl3, [PtL12Cl] was obtained from DMSO, [PtL13Cl] was obtained 
from a DCM/EtOAc mix (1:1), and all other crystals of Pt (II) complexes were obtained 
from DCM. Important bond lengths/angles are given in Table 2 (note: complete crystal 
data are given in Appendix 1). X-ray diffraction studies confirm the expected N^C^N 
terdentate coordination, with binding of the anticipated ancillary ligand trans to the 
cyclometallating carbon. Crystal structures for complexes [PtL9Cl], [PtL10Cl], [PtL1Br] 
and [PtL1I] reveal that these molecules lie on a crystallographic 2-fold axis that passes 
through the metal ion, the chloride ligand and the cyclometallating carbon. The crystal 
structure of the substituted parent, [PtL1Cl], which has been reported by Cárdenas et al. 
also displays this behaviour.17 All other complexes involve a slight deviation from the 
ideal C2v symmetry, as exemplified by the differing N-Pt-Cl and C-Pt-N bond angles 
within each complex. A similar observation was made on the structure of [PtL7Cl] by 
Suzuki et al.8  
 In most cases, the metal centre, the three coordinating rings and the ancillary ligand are 
approximately co-planar, with C-Pt-ancillary bond angles approaching 180  {[PtL12Cl] 
does not conform to this and will be discussed separately}. However, the N-Pt-N bond 
angles are distorted from linearity (but within the plane of the molecule), with angles 
approaching 160 , and it is best to describe the Pt (II) centre as existing in a distorted 
square planar geometry. This distortion reflects the less-than-optimum bite angle 
imposed by the terdentate ligand. Similar distortions are also found in Pt (II) trpy 
complexes, which involve similar 5-membered chelations.8,17,73,74 In the 1,3-
dipyridylbenzene complexes, the Pt-C and Pt-N bond lengths are approximately 1.91 Å 
and 2.03 Å respectively. These bonds are much shorter than corresponding bonds in 
related 6-phenyl-2,2’-bipyridine complexes (where Pt-C and Pt-N are approximately 
2.04 Å and 2.14 Å),19 reflecting the greater degree of orbital overlap, which results in 
the enhanced ligand field induced by N^C^N coordination. 
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Table 2: Selected bond lengths (Å) and angles (deg) of the Pt (II) complexes (All structures were 
acquired at 120 K). 
 
 
[PtL2Cl] [PtL9Cl] [PtL10Cl] [PtL11Cl] [PtL12Cl] 
Pt-C1' 1.917(4) 1.910(3) 1.909(9) 1.916(5) 1.910(5) 
Pt-Cl 2.3908(12) 2.4116(8) 2.397(2) 2.3923(12) 2.4259(13) 
Pt-N 2.029(4) 
and 
2.030(4) 
2.017(2) 2.027(5) 2.021(4) 
and 
2.028(4) 
2.064(4) 
and 
2.067(4) 
 
     
C1'-Pt-Cl 178.08(13) 180.0 180.000(1) 179.61(15) 155.61(16) 
N-Pt-N 162.00(15) 163.44(12) 161.9(3) 162.05(17) 160.78(17) 
N-Pt-Cl 98.96(10) 
and 
99.04(11) 
98.28(6) 99.04(14) 98.72(12) 
and 
99.23(12) 
101.62(13) 
and 
97.49(12) 
C1'-Pt-N 81.16(16) 
and 
80.85(17) 
81.72(6) 80.96(15) 80.92(19) 
and 
81.14(19) 
81.1(2) and 
80.70(19) 
 
 
 [PtL7Cl] [PtL13Cl] [PtL22Cl] [PtL1I] [PtL1Br] 
      
Pt-C1' 1.911(7) 1.934(8) 1.895(7) 1.914(7) 1.893(6) 
Pt-X 2.4171(15) 2.406(2) 2.3960(18) 2.7041(5) 2.5385(7) 
Pt-N 2.034(5) 
and 
2.051(5) 
2.010(7) 
and 
2.034(7) 
2.023(6) 
and 
2.022(6) 
2.049(4) 2.034(4) 
 
     
C1'-Pt-X 177.2(2) 173.4(2) 177.6(2) 180.0 180.000(1) 
N-Pt-N 162.2(2) 162.0(3) 161.4(2) 160.4(2) 161.5(2) 
N-Pt-X 97.22(16) 
and 
100.56(16) 
98.2(2) and 
99.76(19) 
99.41(17) 
and 
99.17(18) 
99.81(12) 99.27(10) 
C1'-Pt-N 80.7(3) and 
81.5(3) 
81.0(3) and 
81.1(3) 
80.5(3) 
and 
81.0(3) 
80.19(12) 80.73(10) 
 
In the [PtL1X] series, the length of the Pt-X bond increases in the order:  
I > Br > Cl 
This simply reflects the increase in size of halogen upon descending group 17. 
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Complexes Displaying Significant Structural Deviations 
 
[PtL12Cl] 
 
Figure 11: Molecular structure of [PtL12Cl] viewed at various orientations, with displacement ellipsoids 
at the 50% level. Selected bond lengths (Å) and angles (deg): Pt-C 1.910(5), Pt-N 2.064(5) and 2.067(4), 
Pt-Cl 2.4259(13), N-Pt-N 160.61(16), C-Pt-Cl 155.61(16). 
ORTEP diagrams for this complex at various orientations are shown in Figure 11 along 
with relevant bond lengths/angles. In [PtL1Cl] and most of the Pt (II) complexes 
characterised by X-ray diffraction here, C-Pt-Cl bond angles are approximately 180 , 
and the atoms lie within the plane of the molecule. In [PtL12Cl], the Pt-N-Cl bond angle 
significantly deviates from linearity (155.61(16) ), and the Pt-Cl bond protrudes from 
the plane encompassing the rest of the molecule. The deviation arises due to 
unfavourable steric interactions between the chloride and the methyl groups on the 6-
pyridyl position. Other, more subtle deviations such as elongation of the Pt-N bonds and 
contraction of the N-Pt-N angle also result from the unfavourable sterics (see Table 2). 
The Pt-N bonds in this complex are 2.064(4) and 2.067(4) Å, whereas these bonds are 
typically 2.03 Å in less hindered systems such as [PtL1Cl] and [PtL2Cl].  
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Table 3: Distance (Å) of the halide, X, from the plane calculated through the two pyridyl nitrogens and 
the cyclometallating carbon. 
 Distance of X from 
N^C^N Plane / Å 
[PtL1Cl] 0.036 
[PtL1Br] 0 
[PtL1I] 0 
[PtL2Cl] 0.114 
[PtL7Cl] 0.057 
[PtL9Cl] 0 
[PtL10Cl] 0 
[PtL11Cl] 0.001 
[PtL12Cl] 1.274 
[PtL13Cl] 0.366 
[PtL22Cl] 0.147 
 
Another way of assessing this deviation is to consider the distance of the chloride atom 
from a plane calculated through the two pyridyl nitrogen atoms and the cyclometallating 
carbon (Table 3). For most of the complexes, the chloride lies approximately co-planar 
with this calculated plane. However, for [PtL12Cl], the chloride lies 1.3 Å above the 
plane. 
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[PtL13Cl] 
 
Figure 12: Molecular structure of [PtL13Cl] viewed at various orientations, with displacement ellipsoids 
at the 50% level. Selected bond lengths (Å) and angles (deg): Pt-C 1.934(8), Pt-N 2.010(7) and 2.034(7), 
Pt-Cl 2.406(2), N-Pt-N 162.0(3), C-Pt-Cl 173.4(2). 
 
ORTEP diagrams for this complex at various orientations are shown in Figure 12. 
Significant steric repulsions between neighbouring phenyl and pyridyl methyl-groups 
cause the terdentate ligand to adopt a non-planar configuration within this complex 
(note, however, that the platinum coordination plane is approximately planar).  To 
quantify this effect, angles between planes of the phenyl and pyridyl rings were 
examined (Table 4). These values give an indication of the degree of distortion present 
in each complex – for a truly planar complex, angles between the planes of the aromatic 
rings should be zero, and a larger angle therefore indicates a greater deviation from 
planarity. Most of the complexes show only slight deviations from planarity (angles 
between planes ~ 0 – 5 ). However in [PtL13Cl], large angles exist between the planes (~ 
30 ), highlighting the severely distorted geometry.   
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Table 4: Calculated angles (deg) between planes formed by the aromatic rings. 
 Phenyl-Pyridyl 1 
(sd) 
Phenyl-Pyridyl 2 
(sd) 
Pyridyl-Pyridyl   
(sd) 
[PtL2Cl] 1.9(0.3) -0.4(0.3) 0.4(0.3) 
[PtL9Cl] 3.6(0.2) -3.6(0.2) 0 
[PtL10Cl] 0.9(0) -0.9(0) 0 
[PtL11Cl] 2.6(0.2) -1.8(0.2) 1.3(0.2) 
[PtL12Cl] 5(0.3) -0.9(0.3) 5.8(0.3) 
[PtL13Cl] 28.7(0.3) 33.9(0.3) 25.6(0.3) 
[PtL22Cl] 1.49(0.4) -5.4(0.4) 4.4(0.4) 
[PtL1Br] 0.9(0.4) -0.9(0.4) 0 
[PtL1I] 1.5(0.3) -1.5(0.3) 0 
Note: A difference in sign between the two phenyl-pyridyl interplane angles indicates that the nitrogen 
atoms of the two pyridyl rings lie on opposite sides of the plane created by the phenyl ring. 
 
Figure 13: Molecular structure of [PtL9Cl] viewed down the C2-axis. 
The effect is much smaller in the related complex, [PtL9Cl]. This complex contains 
methyl groups in the 3-pyridyl positions, and fluoro-substituents on the 3',5'-phenyl 
positions. Fluoro substituents are much smaller than methyl, and the calculated angles 
between the ring planes are much smaller than in [PtL13Cl]. However, the steric 
interactions between neighbouring phenyl fluorine substituents and pyridyl methyl 
groups do cause a slight distortion from planarity within the terdentate ligand of 
[PtL9Cl]. Considering the interplanar angles of the terpyridyl rings (Table 4), the plane 
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of the phenyl ring is twisted relative that of the co-planar pyridyl rings by 3.6 . These 
distortions can be best visualised by looking at the molecule along the phenyl-Pt-Cl axis 
(Figure 13). One can see that the plane of the central phenyl group is twisted relative to 
the side pyridyl rings. This distortion occurs to reduce any unfavourable eclipsing of the 
methyl and fluoro groups.  
 
Crystal Packing 
For all complexes (except [PtL7Cl]), the molecules arrange themselves in one-
dimensional stacking columns, similar to those reported for [PtL1Cl]. Within each stack, 
molecules adopt an antiparallel arrangement, effectively cancelling out the dipole 
moment of the nearest neighbour. The packing of [PtL13Cl] displays a feature which is 
unique to this complex – it also adopts a columnar packing, but when viewed from 
above, pairs of molecules appear to be making the one-dimensional columns (Figure 
14). The difference probably stems from the highly distorted geometry of this complex.  
In the crystal packing of [PtL7Cl], molecules form a two-dimensional sheet. This 
observation has also been made by Suzuki et al.,8 who suggest that the formation of 
one-dimensional stacking columns is impeded by methyl groups at the 5-pyridyl 
positions. This explanation seems unlikely, especially as the difluorinated complex 
[PtL11Cl], which also contains methyl groups attached to the 5-pyridyl positions, does 
form one-dimensional stacking columns.  
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Figure 14: Packing of [PtL13Cl] a) viewed along the a-axis, and b) viewed along the c-axis. Packing of 
[PtL9Cl] c) viewed along the c-axis and d) viewed along the b-axis. 
To estimate whether any significant - or Pt-Pt interactions exist in the crystal packing, 
centroid-to-centroid distances were analysed. Distances of less than 3.7 Å were taken to 
indicate the presence of such interactions. None of the complexes displayed significant 
Pt-Pt interactions in their packing, however some did exhibit - interactions (see Table 
5). Within the chains, the molecules pack in a head-to-tail fashion – hence the phenyl 
rings in neighbouring molecules are far apart and phenyl-phenyl intermolecular 
interactions do not occur. Complexes which do not appear in the Table 5 do not contain 
any significant intermolecular interactions. 
a) c) 
b) d) 
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Table 5: Pt (II) complexes containing intermolecular - interactions, and the distance spanned by the 
interaction (Å). 
 [PtL2Cl] 
(sd) 
[PtL7Cl] 
(sd) 
[PtL12Cl] 
(sd) 
[PtL13Cl] 
(sd) 
[PtL22Cl] 
(sd) 
Phenyl – 
Phenyl 
------ ------ ------ ------ ------ 
Pyridyl – 
Pyridyl 
------ 3.570(3) 3.632(3) 
and 
3.519(4) 
3.466(7) ------ 
Phenyl - 
Pyridyl 
3.598(2) ------ ------ ------ 3.613(2) 
 
2.4.3.2 Crystal Structures of Ligands 
 
Figure 15: Molecular structure of 5-mesityl-1,3-di(2-pyridyl)benzene at 120 K, with displacement 
ellipsoids at the 50% level.19 Note the head-to-tail disposition of the pyridyl rings. 
Crystals of ligands HL2, HL11 and HL22 have been isolated through slow evaporation of 
solvent (H2O/acetone, CDCl3 and CDCl3 respectively). The structures confirm the 
expected connectivity. Williams et al. have published crystal structures of two related 
ligands, 1,3,5-tris(2-pyridyl)benzene and 5-mesityl-1,3-di(2-pyridyl)benzene: their 
structures show a head-to-tail disposition of the pyridyl rings (Figure 15).19 This 
configuration may be adopted to reduce any electrostatic interaction between the 
nitrogen lone pairs. However none of the ligands isolated here adopt this arrangement.  
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Figure 16: a) ORTEP diagrams of HL2 viewed at two different orientations. Both pyridyl nitrogen atoms 
are below the phenyl ring, but the planes of the pyridyl rings are staggered about the plane of the phenyl 
ring to minimise electronic repulsions, and b) ORTEP diagrams of HL22 viewed at two different 
orientations. In this molecule, both pyridyl nitrogen atoms are facing the phenyl ring, and lie on the same 
side of the plane created by the phenyl ring. 
In the molecular structures of HL2 and HL11, both nitrogen atoms face downwards, 
away from the phenyl ring (see Figure 16 a). The phenyl fluoro-substituents disfavour 
the head-to-tail arrangement: this conformation would result in an unfavourable 
electrostatic interaction between lone pairs of fluorine and the spatially close nitrogen 
atom. In these ligands, a more substantial twist occurs (w.r.t. the plane of the central 
phenyl ring), to minimise any unfavourable electrostatic interaction between the 
nitrogen lone pairs (Table 6). In the molecular structure of HL22, both pyridyl rings are 
rotated so that the nitrogen atoms are facing the phenyl ring – there is no clear 
explanation as to why this ligand adopts this geometry over the head-to-tail 
arrangement. The arrangement adopted by HL22 resembles the transoid arrangement of 
pyridine units about the interannular bonds that is commonly found in the molecular 
structure of terpyridine ligands.75,76,77,78,79,80   
a) 
b) 
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Table 6: Angles (deg) between planes created by the aromatic rings 
 
 
 
 
Note: A difference in sign between the two phenyl-pyridyl interplane angles indicates that the nitrogen 
atoms of the two pyridyl rings lie on opposite sides of the plane created by the phenyl ring 
 
2.4.3.3 Pt (IV) Complexes 
 
 
Figure 17: The molecular structure of [PtL1Cl3] at 120 K with displacement ellipsoids at the 50% level. 
Selected bond lengths (Å) and angles (deg): Pt-C 1.945(4), Pt-Cl 2.3189(10), 2.3195(10) and 2.4457(11), 
Pt-N 2.055(3) and 2.052(3), N-Pt-N 161.30(15), C-Pt-Cl 91.85(11), 87.99(11) and 176.69(11), N-Pt-Cl 
90.30(10), 89.85(9) 90.70(9), 89.11(9), 97.72(11), 100.97(10), C-Pt-N 80.67(16) and 80.63(16) 
The crystal structures of [PtL1Cl3], [PtL12Cl3] and [PtL15Cl3] were obtained via slow 
evaporation of chlorinated solutions of the respective Pt (II) complex (DCM, CDCl3 and 
DCM respectively). Their formation indicates that the Pt (II) complexes are unstable to 
oxidation when dissolved in chlorinated solvents for prolonged periods. The complexes 
adopt an approximately octahedral geometry, and important bond lengths are given in 
 Phenyl-Pyridyl 1 Phenyl-Pyridyl 2 Pyridyl-Pyridyl 
HL2 33.6 -32.7 53.8 
HL11 39.4 -32.4 60.0 
HL22 34.0 33.9 37.6 
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Table 7. The Pt-Cl bonds are non-equivalent – within each complex, the longest Pt-Cl 
bond always corresponds to that which is trans to the cyclometallating carbon. This is 
consistent with a greater trans influence of an anionic carbon ligand compared to 
chloride. Compared to structures of the Pt (II) complexes, the Pt (IV) complexes possess 
longer Pt-C bonds (approximately 1.91 and 1.95 Å respectively). This elongation 
probably occurs to reduce steric interactions with the additional chloride ligands. 
Similar metal-carbon bond lengths are found in related iridium (III) complexes – Ir (III) 
is isoelectronic with Pt (IV). For example, the complex, Ir(N^C^N)(Cl)2(DMSO) 
(where N^C^N = 1,3-di(2-pyridyl)-4,6-dimethylbenzene) possesses a Pt-C bond length 
of 1.976(4) Å.81 
Table 7: Selected bond lengths (Å) and bond angles (deg) for the Pt (IV) complexes 
 [PtL1Cl3] [PtL12Cl3] [PtL15Cl3] 
Pt-C1' 1.945(4) 1.950(4) 1.940(3) 
Pt-Cl 2.3189(10), 
2.3195(10), 
2.4457(11) 
2.3095(10), 
2.3284(9), 
2.4515(10) 
2.3118(9), 
2.3151(9), 
2.4390(8) 
Pt-N 2.055(3), 2.052(3) 2.096(3), 2.105(3) 2.042(3), 2.048(3) 
 
   
C1'-Pt-Cl 91.85(11), 87.99(11), 
176.69(11) 
94.13(11), 
84.19(11), 
169.53(11) 
90.24(10), 
88.48(10), 
178.61(3) 
N-Pt-N 161.30(15) 160.76(12) 162.33(10) 
N-Pt-Cl 90.30(10), 89.85(9), 
90.70(9),89.11(9), 
97.72(11), 100.97(10) 
89.28(9), 88.63(9), 
91.22(9), 90.31(9), 
96.63(9), 102.61(9) 
88.19(8), 90.35(8), 
91.08(8), 90.00(8), 
99.64(8), 97.99(8) 
C1'-Pt-N 80.67(16), 80.63(16) 80.73(14), 
80.35(14) 
80.98(12), 
81.42(12) 
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CHAPTER THREE: 
Electronic Properties of the Complexes 
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 3.1 Introduction 
Platinum(II) complexes incorporating a 1,3-di(2-pyridyl)benzene ligand are generally 
highly luminescent, with lifetimes on the microsecond scale.1,2,3 For example, the parent 
complex, [PtL1Cl], exhibits a quantum yield () of 0.60 in degassed DCM at room 
temperature, and a lifetime at infinite dilution (0) of 7.2 µs. The absorption and 
emission spectra are typically highly structured (Figure 1). The absorption spectra 
typically consist of a series of very intense bands occurring below 300 nm ( > 20,000 
M-1 cm-1), and a series of intense bands occurring between 320-430 nm ( ~ 5,000 – 
10,000 M-1 cm-1). The former bands are due to ligand localised 1-* transitions (similar 
bands occur in the absorbance spectra of the uncomplexed ligands), and the latter are 
due to transitions involving the metal or induced within the ligand by the 
cyclometallation process. These include charge transfer transitions. The lowest energy 
band in this region is considered as the S1 peak, corresponding to the S0  S1 transition. 
Weak bands ( ~ 200 M-1 cm-1) are often observed at lower energy, which have been 
assigned to direct singlet-to-triplet (S0  T1) transitions. The highly structured emission 
spectra, the weak solvatochromic behaviour and small Stokes’ shifts suggest that the 
emission emanates from a primarily 3-* state, although recent theory implies that this 
state contains a significant 3MLCT admixture.3,4,5  
 
Figure 1: The absorption spectrum (black) and emission spectrum (red) of the unsubstituted parent 
complex, [PtL1Cl] (DCM, 298 K). The absorption region between 450-530 nm has been expanded (blue) 
to highlight the weak S0  T1 band and to demonstrate the small Stokes’ shift between this band and the 
highest energy emission maximum. 
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In emission, the highest intensity vibrational band is typically the one of highest energy, 
which corresponds to the electronic vibrational 0-0 origin of the T1  S0 transition (see 
Figure 1). The bands at lower energy (and intensity) correspond to transitions to higher 
vibrational levels of the ground state. The shape and highly structured nature of the 
spectrum indicates that little geometric rearrangement occurs between the ground and 
excited states – a testament to the rigidity of the system. The Franck-Condon principle 
is required to explain this. The principle states, “since electronic motions are much 
faster than nuclear motion, electronic transitions occur most favourably when the 
nuclear structure of the initial and final states are most similar”.6 This effectively means 
that the nuclear geometry is frozen during the electronic transition. In potential energy 
surface terms, the Franck-Condon-allowed electronic transitions are represented as 
vertical arrows between the ground and excited state (see Figure 2). When the 
equilibrium geometries of the excited and ground state are similar, the corresponding 
potential energy surfaces have minima at similar nuclear displacement, rxy. In this case, 
the most probable transition back to the ground state is the 0-0 transition, the transition 
of highest energy. However, if the equilibrium geometries of the excited and ground 
states are different, say the excited state minimum lies at a higher nuclear displacement, 
then the most probable transition back to the ground state may not be the 0-0 transition, 
and the emission spectrum will look different.  
 Figure 2: Potential energy curves for a
geometries, and b) a molecule with 
geometries. c) and d) represent the resultant emission profiles, respectively (Images have been a
and re-drawn from reference 
In solutions of elevated concentration, the complexes display significant self
via excimer formation (see Chapter 1, S
Excimers of these complexes are usually emissive. The broad, structureless excimer 
emission band grows in at lower energy, at the expens
emission (Figure 3).  
a) 
c) 
) a molecule with similar ground and excited state
significantly different ground and excited state equilibrium 
6).  
ection 1.7.2 for a more 
e of the structured monomer 
b) 
d) 
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Figure 3: Chart showing both the highly structured monomeric and broad, structureless, excimeric 
emission of [PtL1Cl] (10-4 M, DCM, 298 K) 
As a consequence of self-quenching (i.e. conversion of the monomeric excited state to 
the excimer), the lifetime (obs) is observed to decrease with increasing concentration. 
The lifetime (obs) of the excited state of the monomer can be determined by monitoring 
the temporal decay of emission around the monomer emission maximum. Over the 
concentration range studied (typically 10-4 – 10-6 M) the emission decay remains 
monoexponential.  The observed emission decay rate constant (kobs) is related to obs via 
      
kobs increases linearly with concentration and the results are well modelled by a Stern-
Volmer expression7,8 of the form       
where k0 is the emission decay rate constant at infinite dilution, and ksq is the rate 
constant of self quenching. Hence, a plot of kobs vs. concentration can be used to 
determine these two parameters (y-intercept and gradient respectively). 1/k0 is equal to 
the lifetime of the monomeric excited state at infinite dilution, 0, and ksq gives a 
measure of how prone the complex is to excimer formation.  
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3.2 DFT Calculations on [PtL1Cl] 
Various research groups have performed theoretical analysis of the parent complex, 
[PtL1Cl], and the individual atomic orbital contributions to the frontier molecular 
orbitals have been determined (Figure 4).3,4,5 The electron density plots predicted by 
Rochester et al. do not exactly match those predicted by Sotoyama et al. and Shi et al.. 
However, although the results differ to some extent, all are in general agreement that 
electron density of the HOMO-based orbitals is mainly localised down the central axis 
of the molecule (on the phenyl ring, the metal centre and the ancillary chloride), 
whereas electron density of the LUMO-based orbitals mainly lies on the * orbitals of 
the terdentate ligand, (especially on the lateral pyridyl rings).  
Additionally, Sotoyama et al. have performed DFT and TDDFT calculations on 
[PtL1Cl] to determine which of the frontier molecular orbitals are involved in the 
electronic transitions responsible for absorption and emission.4 Their results indicate 
that the S0  S1 transition (which corresponds to the S1 peaks observed in the 
absorption spectrum) mainly involves transition between the b1 and a2* states (i.e. 
HOMO  LUMO). On the other hand, the T1  S0 transition (observed in emission) 
involves transition between the b1* and b1 states (i.e. LUMO+1  HOMO). These 
theoretical results are in close agreement with the experimental. For example, the 
predicted and observed transition energies are similar. Also, the results predict a smaller 
difference in dipole moment between the S0 ground state and T1 (µz = -1.13) than 
between S0 and S1 (µz = -9.07), in agreement with the experimental observation that 
the absorption bands between 320 – 430 nm display significant negative 
solvatochromism, whereas the emission energy is scarcely affected by solvent.   
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Figure 4: Contour plots of the frontier molecular orbitals of [PtL1Cl], as predicted by a) Rochester et al.,3 
b) Sotoyama et al.,4 and c) Shi et al.5 
By considering the contour plots of the molecular orbitals involved in the important 
transitions (i.e. absorption and emission), it should be possible to design complexes with 
tuned photophysical properties. For example, placing substituents of defined electronic 
character in certain positions on the terdentate ligand will confer differing degrees of 
a) 
b) 
c) 
HOMO LUMO 
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stabilisation/destabilisation on the HOMO-based and LUMO-based orbitals, affecting 
the transition energies. Williams et al. have shown that the emission energy of such 
complexes could be tuned by varying the electron donor/acceptor character of a 4-
phenyl substituent.2 Complexes containing substituents of greater electron donating 
character were found to emit at lower energies. This is consistent with the HOMO being 
largely localised on the central ring: electron donating substituents should destabilise 
the HOMO, increasing its energy and decreasing the transition energy gap, accounting 
for the observed red-shift. The opposite has been found for electron withdrawing 
substituents.1  
What about pyridyl substituents? Since theory predicts that the pyridyl rings mainly 
contribute to the energy of the LUMO and LUMO+1, one could envisage that electron 
donating groups on the pyridyl rings would destabilise these orbitals leading to a blue 
shift (again, the opposite should be true for electron withdrawing groups).  
Thirdly, the ancillary chloride ligand is largely involved in the HOMO-based orbitals, 
but less in the LUMO. It therefore seems reasonable to assume that ligand substitution 
with a more electron withdrawing ligand should have a greater stabilising effect on the 
HOMO and increase the energy of the electronic transitions.  
With the theoretical atomic orbital calculations of the unsubstituted parent complex, 
[PtL1Cl], in mind, 1,3-di(2-pyridyl)benzene Pt(II) complexes that exhibit blue-shifted 
emission have been targeted. Figure 5 sums up our initial thoughts of how 
functionalisation of the terdentate ligand was expected to lead to a blue shift. By 
applying the reverse of this reasoning, complexes exhibiting red-shifted emission were 
then targeted, to see if the effect was upholded. Finally, substitution of the ancillary 
chloride ligand was considered.  
 Figure 5: Crude schematic showing how functionalisation of the terdentate ligand was expected to affect 
the relative energies of the frontier molecular orbitals, leading to a blue
represents the LUMO+1 state). E.W.G and E.D.G. represent an electron withdrawing group and electron 
donating group respectively. 
 
3.3 Electrochemistry
Cyclic voltammetry 
complexes in the more usual solvents (e.g. DCM and acetonitrile).
Tetrabutylammonium hexafluorophosphate
electrolyte, and the solutions were p
observed corresponded to irreversible processes 
these irreversible waves (
1
, and are reported relative to a Ferrocene/Ferrocinium (Fc/Fc
DMSO, the data were
between the different runs, so the data must be treated cautiously and as a
For this reason, it is difficult to see any trends between related complexes. 
 
 
-shift (note: “LUMO” here also 
 
 
was performed in DMSO, due to poor solubility of some of the 
 (0.1 M) was used as a supporting 
urged with nitrogen before each run. All signals 
– the peak potentials are reported for 
Table 1). The recorded values refer to a scan rate o
 not of good quality – there was considerable scatter in potential 
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Table 1: Electrochemical Data for the Pt(II) Complexes.  
Complex Epox  / V Epred / V Complex Epox / V Epred / V 
[PtL1Cl] 0.31 -2.24, -2.49 [PtL12Cl] 0.18 -2.15, -2.46 
[PtL2Cl] 0.31 -2.28, -2.61 [PtL13Cl] 0.36 -2.33, -2.55 
[PtL3Cl] 0.31 -2.43, -2.71 [PtL14Cl] 0.46 -2.18, -2.60 
[PtL5Cl] 0.36 -2.23, -2.60 [PtL15Cl] 0.37 -2.23 
[PtL6Cl] 0.16 -2.42, -2.63 [PtL16Cl] 0.35 -2.12, -2.50 
[PtL7Cl] 0.23 -2.32 [PtL17Cl] 0.21 -2.21, -2.54 
[PtL8Cl] 0.14 -2.25, -2.53 [PtL20Cl] 0.55 -2.15, -2.55 
[PtL9Cl] 0.30 -2.23, -2.50 [PtL21Cl] 0.50 -2.15, -2.51 
[PtL10Cl] 0.30 -2.22, -2.52 [PtL1I] 0.01 and 0.70 -2.19, -2.46 
[PtL11Cl] 0.15 -2.35, -2.62 [PtL1Br] 0.25 -2.19 
The values were determined from DMSO solutions at 298 K ( 10-4 M), in the presence of a 0.1 M 
tetrabutylammonium hexafluorphosphate supporting electrolyte. A scan rate of 100 mV s-1 was 
employed. All processes were chemically irreversible: Epox/Epred represents the peak potential of the 
irreversible oxidation/reduction (in volts).  All data are reported relative to Fc/Fc+ 
In analogy with data reported for related complexes,2 most of the complexes display one 
irreversible oxidation peak (see Figure 6 for an example). This has previously been 
assigned to a one-electron oxidation based on the Pt centre. The irreversibility of this 
peak makes it harder to determine the true value of the oxidation process. For a 
reversible process, one would record E1/2, which corresponds to the average of the 
forward and reverse waves, whereas for an irreversible process Epox is taken as the 
maximum of the solitary forward wave. Natural variation of the peak maxima between 
runs for a reversible process will at most only cause small alteration in the 
experimentally observed value of E1/2. For an irreversible process, natural variation of 
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the peak maximum makes it difficult to accurately determine E, as the value solely 
depends on the position of one peak.   
 
Figure 6: Cyclic voltammogram showing the irreversible oxidation peak observed for [PtL10Cl]. The 
scan was performed in DMSO, in the presence of a 0.1 M tetrabutylammonium hexafluorophosphate 
background electrolyte, at a scan rate of 100 mV s-1. The other complexes display similar profiles. The 
maximum is difficult to assign, due to the weakness of the signal and overlap of the band with the edge of 
the solvent window. 
For each complex, two irreversible reduction waves were observed; the first at around 
-2.2 V and the second around -2.6 V. Reduction mainly occurs on the terdentate ligand.2 
These reductions occur very near to the edge of the solvent window – this sharp rise in 
current may have a distorting effect on the true value of Epred. Like oxidation these 
peaks are irreversible, which again does not aid the measurement of the value of Epred. 
 
 
 
 
 
-4.5E-06
5.0E-07
5.5E-06
1.1E-05
1.6E-05
2.1E-05
-0.80 -0.60 -0.40 -0.20 0.00 0.20 0.40 0.60 0.80 1.00
Cu
rr
en
t /
 
A 
Potential / V (vs. Fc/Fc+)
123 
 
3.4 Photophysical Characterisation 
 
3.4.1 Modification of the Chelating Ligand, and the Photophysical Implications 
 
3.4.1.1 Substituents on the Phenyl Ring 
DFT calculations predict that atoms of the central phenyl ring make a significant 
contribution to the HOMO, and a lesser contribution to the LUMO-based orbitals. 
Therefore, placing electron-withdrawing substituents around this ring can be expected 
to have a greater stabilising effect on the HOMO, and lead to a blue shift. Conversely, 
electron-releasing substituents may be expected to destabilise the HOMO, leading to a 
red shift.  
 
2,6-Di(2-pyridyl)-3,5-difluorobenzene Platinum(II) Chloride, [PtL2Cl] 
 
Absorbance 
[PtL2Cl] was prepared, which possesses two inductively electron-withdrawing fluorine 
atoms at the 3' and 5' positions (see Chapter 2, Figure 7). The absorbance spectrum of 
the uncomplexed ligand was recorded and compared with that of [PtL2Cl] (see Figure 7 
and Table 2) – one can clearly see a similarity between the peaks occurring in the region 
230 nm – 300 nm, indicating that bands occurring in this region of the complex 
absorption profile are due to ligand localised 1-* transitions. Lower intensity bands in 
the range 310 – 380 nm are observed in the spectrum of complex [PtL2Cl] but are 
absent in the ligand absorption, confirming that these bands arise upon ligand 
coordination to platinum. These bands are likely to include MLCT transitions and 
intraligand transitions, induced by the formal deprotonation of the central aryl ring that 
accompanies metallation, and combinations of such transitions.  
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Figure 7: UV-vis absorption spectra of ligand L2H (blue) and complex [PtL2Cl] (red) in DCM at 298 K. 
Spectra have been normalised at 238 nm to aid comparison. 
  
 
Figure 8: Normalised UV-vis absorption spectra of complexes [PtL1Cl] (red) and [PtL2Cl] (blue) in 
DCM at 298 K. 
The latter set of bands were blue-shifted relative to those in [PtL1Cl] (Figure 8). Also, 
the lowest energy singlet absorption band occurring in the [PtL1Cl] spectrum appeared 
to be absent in the [PtL2Cl] spectrum. Perhaps this charge transfer band has blue-shifted 
so much that it has become hidden under the higher energy bands, although there is no 
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evidence from the extinction coefficient data to support this notion (Table 2). The ligand 
localised bands occurring below 300 nm were not affected by fluorine substitution. 
Weak bands were observed for [PtL2Cl] at 437 nm and 467 nm ( = 312 and 129 M-1 
cm-1 respectively). In agreement with reference 2, these bands correspond to direct 
singlet-to-triplet excitations (S  T), which are formally spin-forbidden processes, 
accounting for the weakness of the bands. 
Table 2: Solution-based photophysical properties of [PtL1Cl] and [PtL2Cl] (DCM, 298 K). 
Complex Absorbance max/nm 
( / L mol-1cm-1) 
Emission max/nm 0 degassed 
(aerated)/µsa 
lum degassed 
(aerated) 
[PtL1Cl]b 332 (6510), 380 (8690), 
401 (7010), 454* (270), 
485* (240) 
491, 524, 562 7.2 (0.50) 0.60 (0.039) 
[PtL2Cl] 320 (6690), 334 (9180), 
360 (7340), 374 (8500), 
437* (140), 467* (140) 
472, 502, 536sh 7.9 (0.67) 0.85 (0.087) 
aLifetime at infinite dilution, bPhotophysical data from reference 1, *Forbidden S  T absorption bands, 
sh = shoulder. NOTE: comprehensive photophysical data for all complexes (in DCM at 298 K) is listed in 
Table 29, which can be found at the end of this chapter. 
The absorption bands between 320 and 430 nm display negative solvatochromism – the 
peaks occur at lower energy in non-polar solvents such as CCl4 and higher energy in 
polar solvents such as CH3CN (see Figure 9 and Table 3). Solvatochromism indicates 
that a significant degree of charge transfer character is associated with these absorption 
bands. The relative destabilisation occurring in polar solvents indicates an excited state 
that is less polar than the ground state (lower dipole moment). Similar results were 
reported by Williams et al. for the parent complex, [PtL1Cl], and 4-aryl substituted 
complexes.1 The individual bands display different degrees of solvatochromism. The 
band around 380 nm exhibits an energy difference of 910 cm-1 between CH3CN and 
CCl4 solutions (max = 371 and 384 nm respectively), whereas the peak around 335 nm 
only differs in energy by 540 cm-1 between these extremes of polarity (max = 331 and 
337 nm respectively). The relative peak intensities within this group of bands change as 
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a function of solvent polarity – the higher energy transitions increase in intensity with 
increasing polarity. The grow-in of a band at lower energy (around 400 nm) is observed 
with decreasing solvent polarity – perhaps this band is of the same origin as the lowest 
energy absorption band present in the [PtL1Cl] absorption spectrum. With increasing 
solvent polarity, this band blue-shifts and overlaps with the higher energy absorptions. 
This may account for the increased relative intensity of these bands at higher polarity. 
 
Figure 9: UV-vis absorption spectrum of [PtL2Cl] recorded in various solvents at 298 K, demonstrating 
the solvatochromic behaviour. 
Table 3: Absorbance band maxima (nm) occurring above 300 nm for [PtL2Cl] in various solvents 
(298 K). 
Solvent Absorbance max/nm 
CCl4 323, 337, 368sh, 384, 404sh 
Toluene 323, 336, 366sh, 382, 398sh 
THF 322, 334, 364sh, 380 
CHCl3 321, 335, 360sh, 374 
CH3CN 318, 331, 357sh, 371 
0
0.2
0.4
0.6
0.8
1
1.2
300 320 340 360 380 400 420 440
Ab
so
rb
an
ce
 
/ a
.
u
.
 
Wavelength / nm
Acetonitrile
Chloroform
Tetrahydrofuran
Toluene
Tetrachloromethane
127 
 
Emission 
Just like [PtL1Cl], [PtL2Cl] emits from DCM solution at room temperature (298 K), and 
the emission spectrum is highly structured, with the 0-0 transition having the greatest 
intensity (Figure 10). The emission maximum (max) occurs at significantly shorter 
wavelength than [PtL1Cl]; 472 nm (21200 cm-1) and 491 nm (20400 cm-1) respectively, 
(E = 820 cm-1), indicating that the introduction of fluorine atoms in the 3' and 5' 
positions is an efficient method for blue-shifting the emission. These results are 
consistent with the DFT orbital predictions, which estimate that orbitals of the phenyl 
ring make significant contribution to the HOMO but essentially none to the LUMO+1.  
 
Figure 10: Emission spectra of [PtL1Cl] (red) and [PtL2Cl] (blue) in a dilute DCM solution (ca. 10-6 M) 
at 298 K (ex = 401 nm and 374 nm respectively). 
The emission of [PtL2Cl] displayed only a slight negative solvatochromism (Figure 11) 
– a maximum energy difference of 180 cm-1 was found between solutions of complex in 
the solvent polarity extremes (CH3CN and CCl4). The emission energy is much less 
sensitive to solvent polarity than absorption energies. This indicates little redistribution 
of charge, or change in dipole moment, occurs in the triplet excited state. 
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Figure 11: Emission spectra of a dilute sample of [PtL2Cl] (ca. 10-5 M) in various solvents (298 K, ex = 
374 nm). 
A quantum yield, , of 0.85 has been measured for [PtL2Cl] – this value is exceptionally 
high for platinum based phosphors. The quantum yield is 42% higher than that of the 
parent complex, [PtL1Cl] (0.60). However, the lifetime of the emissive state at infinite 
dilution, 0, is of a comparable magnitude to that of [PtL1Cl] (7.8 µs and 7.2 µs). This 
tells us something about the origin of the relative efficiencies of the two complexes:  
and 0 are related to the radiative and non-radiative rate constants of the excited state: 
      
      
Thus, the larger  of [PtL2Cl] but comparable 0 between the two complexes means that 
kr is larger and knr is smaller for [PtL2Cl], and this complex is a more efficient emitter 
(values for kr and knr are given in Table 4). 
Analogous heteroleptic bidentate complexes of a cyclometallating phenyl pyridine 
ligand have been prepared by Thompson et al. (see Figure 12).9 The room temperature 
quantum yields of the ppy and 4,6-dfppy complexes (0.15 and 0.02 respectively) are 
much lower than the quantum yields of [PtL1Cl] and [PtL2Cl] ( = 0.60 and 0.85 
respectively).  
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Figure 12: Chemical structures of bidentate N^C analogues, ppy and 4,6-dfppy.9  
Table 4 gives a comparison of the radiative and non-radiative rate constants (kr and knr 
respectively) for these four complexes.  As can be seen, knr for the bidentate complexes 
is significantly higher indicating a greater degree of non-radiative decay of the emissive 
state for these bidentate analogues. This effect has been attributed to the differing 
rigidity between the complexes. Unlike the rigid terdentate systems, bidentate 
complexes are prone to D2d distortions, which opens up another possible route to non-
radiative decay (Chapter 1, Section 1.3).  
Furthermore, the length of the Pt-C bond is much shorter in [PtL1Cl] than in ppy – the 
crystals structure of [PtL1Cl] revealed a Pt-C bond length of 1.91 Å,10 whereas DFT 
calculations on ppy predict a Pt-C bond length of 1.98 Å9 (note: a search of the CCSD 
revealed that complexes related to ppy, involving bidentate phenyl pyridine ligands 
possess Pt-C bonds of approximately 1.98 Å, indicating that the calculated bond length 
is probably quite reliable). The shorter Pt-C bond in the terdentate system will lead to a 
larger ligand field splitting. This means that the deactivating d-d* state will be at a lower 
energy in the bidentate systems compared with analogous terdentate complexes, and the 
probability of thermal promotion to this state will be greater for the bidentate 
complexes. Both of these factors account for the higher quantum yields of the terdentate 
complexes, relative to their bidentate analogues.  
 
 
 
 Table 4: Radiative and non
analogues ppy and 4,6-dfppy
 [PtL
kr  / s-1 83000
knr / s-1 48000
bThe quantum yields and l
from reference 9 and reference 
Although the bidentate complexes possess 
terdentate versions, the emission spectra of the bidentate complexes appear broader
contain a more significant green
green-yellow tail in the [PtLCl] systems is associated with the greater rigidity of the 
system, and as a conseque
appear bluer than those of 
purity than their bidentate analogues.
Figure 13: Emission spectra of dilute DCM solutions of [PtL
(bottom, left) and 4,6-dfppy 
irradiation are included as insets (this figure was taken from a talk given by A. Rausch, from the 
University of Regensburg)
-radiative rate constants of [PtL1Cl] and [PtL
 (DCM, 298 K). 
1Cl] ppyb [PtL2Cl] 
 58000 110000 
 327000 17000 
ifetimes used to calculate the rate constants of ppy 
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To help put the emission properties of [PtL2Cl] further into context, two related 
complexes prepared by other researchers will now be discussed (Figure 14).  [PtL27Cl], 
which was prepared by a former group member, exhibited red-shifted spectra relative to 
the parent complex. In this case, an electron-releasing methyl group has been 
incorporated at the 4'-position, and this has a greater destabilising effect on the HOMO, 
shifting the absorption and emission to lower energy (E = 19840 cm-1, max = 504 nm 
and  = 68%, degassed DCM, 298 K).1 
N N
Pt
Cl
[PtL27Cl]
N N
Pt
Cl
[PtL28Cl]
F
 
Figure 14: Structures of complexes [PtL27Cl] and [PtL28Cl]. 
The complex containing a fluorine atom in the 4' position, [PtL28Cl], has been prepared 
by the group of D. Roberto, Milan. The emission of this complex is red-shifted relative 
to [PtL1Cl] (509 nm vs. 491 nm). At a first glance, this result seems counterintuitive. 
However, fluorine has strange properties in that it can act as a strong inductive electron 
acceptor or as a mesomerically electron releasing group (due to p-orbital overlap). 
When fluorine occupies the 4' position (para to the metal), the electron-donating 
resonance effect seemingly dominates (Figure 15), resulting in increased electron 
density on the phenyl ring and platinum. This destabilises the HOMO relative to 
[PtL1Cl], accounting for the lower energy electronic transitions (Figure 16). 
N N
Pt
Cl
F
 
Figure 15: Representation of the electron-donating resonance effect of fluorine in [PtL28Cl]. 
 Figure 16: Schematic representation of 
based orbitals of [PtL2Cl] and 
 
2,6-di(2-pyridyl)-4-nitrobenzene 
 
Absorbance 
The complex containing an electron
[PtL3Cl], was prepared.
contains absorption bands at similar energies 
the relative energies of the HOMO-based orbitals and LUMO
[PtL28Cl], relative to [PtL1Cl]. 
Platinum(II) Chloride, [PtL3Cl]
-withdrawing NO2- group on the 4
 The absorption profile is similar to that of 
(Table 5, Figure 17).
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' position, 
[PtL1Cl], and 
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Figure 17: Normalised UV-vis absorption spectra of complexes [PtL3Cl] (red) and [PtL1Cl] (blue) in 
DCM at 298 K. 
 
Table 5: Solution-based photophysical properties of [PtL1Cl] and [PtL3Cl] (DCM, 298 K). 
Complex Absorbance max/nm   
( / L mol-1cm-1) 
Emission 
max/nm 
0 degassed 
(aerated)/µsa 
lum degassed 
(aerated) 
[PtL1Cl]b 332 (6510), 380 (8690), 
401 (7010), 454* (270), 
485* (240) 
491, 524, 562 7.2 (0.50) 0.60 (0.039) 
[PtL3Cl] 250, 285, 330, 388, 399, 
480* 
492, 515 0.78c 0.03 (0.02) 
aLifetime at infinite dilution, bPhotophysical data from reference 1, clifetime recorded for a dilute solution 
(absorbance < 0.05), *Forbidden S  T absorption bands, sh = shoulder. [PtL3Cl] was too insoluble to 
perform accurate concentration-dependent analysis, and extinction coefficients could not be obtained. 
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Emission 
The emission of [PtL3Cl] occurs at similar energy to [PtL1Cl], and the emission profile 
of the former complex is significantly less structured (Figure 18, Table 5). This result 
was unexpected; DFT orbital predictions for [PtL1Cl] indicate that the HOMO is largely 
localised on the central phenyl ring, and a big orbital contribution is made at position 4'. 
Electron withdrawing groups at this position should have a greater stabilising effect on 
the HOMO, leading to a blue-shift. The results suggest that factors other than the 
electron-withdrawing nature of the nitro group are also involved in determining the 
electronic transition energy, but these factors remain unknown. The less structured 
spectrum may indicate significant geometry change between the ground and excited 
state, or that significant electronic perturbation occurs within the molecule upon 
excitation. 
 
Figure 18: Normalised emission spectrum of dilute samples of [PtL3Cl] (red) and [PtL1Cl] (blue) in 
DCM at 298 K. Note the broader profile of [PtL3Cl]. 
[PtL3Cl] was only weakly luminescent in DCM at room temperature ( = 0.03). The 
quenching of emission by the introduction of a nitro group to an aromatic organic 
fluorophore is well reported in the literature – the nitro group introduces a lower lying 
non-radiative n-* state.12,13,14 It seems that the nitro group has had a similar effect on 
this complex. The complex was only sparingly soluble, which prevented determination 
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of the lifetime at infinite dilution. However, the lifetime of the dilute solution used to 
measure the quantum yield will be used as an approximation (obs = 786 ns). This 
lifetime is very short for such complexes.  
 
3.4.1.2 Exploring the Influence of the Substitution Position: Methyl Substituents on 
the Pyridyl Rings 
N N
Pt
Cl
R R
Me Me
R = H or F
 
Figure 19: Representation of the two series of isomers under study. The series involving R = F will be 
referred to as the 3',5'-difluorinated series, and the series involving R = H will be referred to as the non-
fluorinated series. 
The pyridyl rings make a significant contribution to the LUMO-based orbitals, and little 
contribution to the HOMO. We expected that addition of electron donating substituents 
to the pyridyl rings would destabilise the LUMO-based orbitals and lead to a blue-shift. 
Two series of isomeric complexes, [PtL5-8Cl] and [PtL9-12Cl], containing methyl groups 
on each of the free pyridyl carbons were prepared. The first series incorporates an 
unsubstituted central phenyl ring and the second series incorporates the 3,5-
difluorinated central ring (Figure 19). The latter were expected to show blue-shifted 
absorbance and emission relative to their non-fluorinated analogues, as established for 
the parent compounds, [PtL1Cl] and [PtL2Cl]. The absorbance and emission of the non-
fluorinated and fluorinated complexes will be discussed relative to these reference 
parent complexes.  
 
Absorbance 
The absorption spectra of both series of isomers show a set of strong absorption bands 
below 305 nm, and lesser intense charge transfer bands between 305 and 430 nm, 
typical of such complexes. As for the parent compounds, all of the fluorinated 
complexes i) absorb at higher energy than their non-fluorinated analogues ii) display a 
sharpening of the band occurring around 330 nm, iii) appear to “lose” the lowest energy 
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singlet absorption band in this region. Direct S  T absorption bands were observed in 
the high concentration absorption spectrum of all the complexes (Table 6 and Table 7). 
These bands were very weak (  200 M-1 cm-1) confirming the relative forbiddenness 
of these transitions.  
 
Table 6: Solution-based photophysical properties of complexes containing methyl n-pyridyl substituents 
(DCM, 298 K). 
Complex Absorbance max/nm  
( / L mol-1cm-1) 
Emission max/nm 0 degassed 
(aerated)/µsa 
lum degassed 
(aerated) 
[PtL1Cl]b 332 (6510), 380 (8690), 
401 (7010), 454* (270), 
485* (240) 
491, 524, 562 7.2 (0.50) 0.60 (0.039) 
[PtL5Cl] 322 (5180), 334 (5289), 
363sh (4383), 382 
(6333), 405sh (4299), 
459*sh, 489* 
497, 529, 565sh, 
 
7.74 (0.34) 0.51 (0.024) 
[PtL6Cl]c 326 (7820), 356 (6420), 
374 (8930), 400 (7040), 
479* (260) 
487, 521, 560 10.0 (0.04) 0.73 
[PtL7Cl] 335 (12350), 360 
(9150), 370 (11210), 
399 (8464), 455*sh 
(280), 490* (130) 
494, 528, 565sh, 11.1 (0.58) 0.13 (0.001) 
[PtL8Cl] 327 (6500), 339 sh 
(6030), 390 sh (6440), 
413 (6730), 492* (310) 
506, 529, 569sh ------d 0.03 (< 0.001) 
aLifetime at infinite dilution, bPhotophysical data from reference 1, cPrepared by a former group member, 
demission too weak to obtain lifetime, *forbidden S  T absorption bands, sh = shoulder. 
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Table 7: Solution-based photophysical properties of complexes containing a 3',5'-difluorinated aryl ring, 
and methyl n-pyridyl substituents (DCM, 298 K). 
Complex Absorbance max/nm    
( / L mol-1cm-1) 
Emission max/nm 0 degassed 
(aerated)/µsa 
lum degassed 
(aerated) 
[PtL2Cl] 320 (6690), 334 (9180), 
360 (7340), 374 (8500), 
437* (140), 467* (140) 
472, 502, 537sh 7.9 (0.67) 0.85 (0.087) 
[PtL9Cl] 323 (6030), 336 (8010), 
361 (6030), 375 (7110), 
444*(110),474* (90) 
487, 513, 555sh, 
656 ex 
7.3  (0.49) 0.39 (0.20) 
[PtL10Cl] 316 (8910), 329 sh 
(10790), 358 (9000), 372 
(11320), 433* (180), 
462* (150) 
467, 498, 529sh 7.9 (0.70) 0.87 (0.088) 
[PtL11Cl] 322 (5820), 336 (8620), 
358 (6330), 372 (6730), 
442* (110), 473* (80) 
478, 510, 543sh 10.5 (0.77) 0.67 (0.061) 
[PtL12Cl] 292 (13890), 329 (5550), 
341 (5980), 382 (6480), 
475* (120) 
494, 530, 565 sh ------b 0.02 (0.0007) 
aLifetime at infinite dilution, bemission to weak to obtain lifetime, *forbidden S  T absorption bands, sh 
= shoulder. 
On considering the absorption spectra of the fluorinated series, there is a degree of 
variation in energy with methyl position (Figure 20):  
4Me-  5Me- > H- > 3Me- > 6-Me 
(i.e. [PtL10Cl]  [PtL11Cl] > [PtL2Cl] > [PtL9Cl] > [PtL12Cl]) 
[PtL12Cl] absorbs at lower energy than all other complexes and has the least structured 
spectrum. The lowest energy band only varies slightly between all other isomers and the 
[PtL2Cl] reference. The maximum energy difference between the lowest energy peaks is 
700 cm-1. 
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The sharper peak around 330 nm varies in energy to a greater extent. The order of peak 
energy here is: 
[PtL10Cl] > [PtL2Cl] > [PtL11Cl] > [PtL9Cl] > [PtL12Cl] 
with a maximum energy difference of 1070 cm-1. The intensity of this peak (and the 
band around 355 nm) relative to the lowest energy band also seems to vary with the 
position of the methyl group, and the peak is most pronounced in the spectrum of 
[PtL11Cl]. Detailed theoretical investigations are required to determine the origin of this 
band. 
For the non-fluorinated series, the energy ordering of the lowest energy band within this 
region is:  
5Me- > 4Me- > H- > 3Me- > 6Me- 
(i.e. [PtL7Cl] > [PtL6Cl] > [PtL1Cl] > [PtL5Cl] > [PtL8Cl]) 
with an energy difference of 850 cm-1 between the extremes.  
For both series, the absorption bands between 320 and 430 nm display negative 
solvatochromism. As for [PtL2Cl] and [PtL1Cl], the peaks occur at lower energy in non-
polar solvents such as CCl4 and higher energy in polar solvents such as CH3CN. As 
found for [PtL2Cl], the difluorinated series experience a grow-in of a band at lower 
energy as solvent polarity is decreased. This can be seen in Figure 22 a), which 
compares the absorption profile of [PtL11Cl] in various solvents. 
Interestingly, for the non-fluorinated series, the lowest energy absorption band exhibits 
the most significant increase in energy with increasing solvent polarity. Figure 22 b) 
shows the solvatochromic behaviour of [PtL7Cl]. The lowest energy absorption shifts 
from 413 nm in CCl4 to 391 nm in CH3CN (E = 1360 cm-1), and changes appearance 
in the spectrum from a distinct band to a shoulder on the next lowest absorption peak. 
These results give more indication that the corresponding band in the difluorinated 
series is not absent in more polar solvents, but overlapping with higher energy 
transitions.  
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Figure 20: UV-vis absorption spectrum of the series of complexes containing n-methylated pyridyl rings 
and a difluorinated aryl ring, recorded in DCM 298 K. 
 
 
Figure 21: UV-vis absorption spectra of the complexes containing n-methylated pyridyl rings and a non-
fluorinated aryl ring, recorded in DCM 298 K. 
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Figure 22: UV-vis absorption spectra of a) [PtL11Cl] and b) [PtL7Cl] recorded in various solvents at 298 
K, demonstrating the solvatochromic behaviour.   
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Emission 
All of the difluorinated complexes emit at higher energy than their non-fluorinated 
analogues (Figure 23, Table 6 and Table 7). As found for [PtL2Cl], the emission spectra 
of these complexes are only weakly solvatochromic. For both series of isomers, the 
energy of emission was found to vary with methyl-group position in the following 
order: 
4Me- > H- > 5Me- > 3Me- > 6Me- 
In each series, the complex containing methyl groups on the 4-pyridyl positions, 
[PtL10Cl] and [PtL6Cl], emits at the highest energy (21400 cm-1 (467 nm) and 20500 
cm-1 (487 nm) respectively). The other isomers all emit at lower energy than the 
respective reference compound (i.e. [PtL1Cl] for the non-fluorinated series and [PtL2Cl] 
for the fluorinated series). Placing the electron donating methyl group at the 4-pyridyl 
position therefore has the most destabilising effect on the LUMO+1. This is consistent 
with the theoretical orbital predictions, which show that the 4-position makes the largest 
contribution to the LUMO+1 energy, and zero contribution to the HOMO. Furthermore, 
the HOMO electron density plot predicted by Rochester et al. indicates that the other 
pyridyl positions make some contribution to the HOMO energy: if this is the case, any 
destabilisation of the LUMO may be outweighed by destabilisation of the HOMO.  
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Figure 23: Normalised emission spectra of dilute samples of a) the difluorinated and b) the non-
fluorinated methyl isomers, in DCM at 298 K. 
The profiles of the [PtL8Cl], [PtL9Cl] and [PtL12Cl] emission spectra notably differed 
from those of all the other complexes. The bands were less structured and the peak 
ratios of the subsequent vibronic bands relative to the highest energy 0-0 band were 
higher. These ratios are given in Table 8 and Table 9. As mentioned in Section 3.1, a 0-
0 band of highest intensity indicates little geometry change between the ground and 
excited states. An increasing relative intensity of the 0-1 and 0-2 bands can therefore be 
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indicative of complexes that have a greater geometry difference between the ground and 
excited states. The crystal structure of [PtL12Cl] shows that this complex involves a 
distortion from planarity (Chapter 2, Section 2.4.3.1): the Pt-Cl bond protrudes from the 
mean plane created by the rest of the molecule. The molecule also contains significant 
strain, as exemplified by longer Pt-N bonds than found for all other complexes. It is 
reasonable to assume that [PtL8Cl], the non-fluorinated analogue of [PtL12Cl], will 
contain similar distortions.  
Table 8: Intensity of the 0-n vibronic bands relative to the intensity of the 0-0 vibronic band, for the 
difluorinated series of complexes 
 Intensity of 0-0 Intensity of 0-1 Intensity of 0-2 
[PtL2Cl] 1 0.54 0.21 
[PtL9Cl] 1 0.86 0.43 
[PtL10Cl] 1 0.55 0.23 
[PtL11Cl] 1 0.56 0.23 
[PtL12Cl] 1 0.70 0.36 
Table 9: Intensity of the 0-n vibronic bands relative to the intensity of the 0-0 vibronic band, for the non-
fluorinated series of complexes 
 Intensity of 0-0 Intensity of 0-1 Intensity of 0-2 
[PtL1Cl] 1 0.56 0.21 
[PtL5Cl] 1 0.66 0.27 
[PtL6Cl] 1 0.60 0.28 
[PtL7Cl] 1 0.58 0.24 
[PtL8Cl] 1 0.70 0.30 
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In the crystal structure of [PtL9Cl], the plane of the phenyl ring is slightly twisted with 
respect to the plane created by the pyridyl rings (Chapter 2, Section 2.4.3.1). However, 
this distortion is relatively small, and is unlikely to account for the significantly broader 
spectral profile. The effect is more likely to result from the inherent electronic 
perturbation within this complex – during characterisation, we noticed that the 19F NMR 
spectrum of this complex contained a broad multiplet that occurred at significantly 
higher chemical shift compared to all other isomers. The effect was due to a non-
bonding orbital overlap between the fluorine and methyl protons, which are in close 
proximity (similar observations have been reported in molecules containing related 
arrangements of atoms).15 This electronic perturbation will probably have an influence 
upon the photophysics.  The emission profile of [PtL5Cl], the non-fluorinated analogue 
of [PtL9Cl], is not so significantly different from the other complexes in its series.  
With the exception of the 6-diMe isomers, the quantum yields were high, in the range of 
0.4 – 0.9 for the difluorinated series, and 0.1 – 0.7 for the non-fluorinated series. 
Lifetimes were on the microsecond scale, in the range of 7.3 – 10.5 µs and 7.2 – 11.1 µs 
respectively. The aerated quantum yields are also quite good (as high as 0.20), 
indicating that these complexes are not terribly susceptible to quenching by O2 ( see 
Table 29, p.216 - 220).  
The quantum yields of [PtL8Cl] and [PtL12Cl] ( = 0.03 and 0.02 respectively) were 
extremely poor compared to most other Pt(II) complexes incorporating 1,3-di(2-
pyridyl)benzene ligands. Such poor luminescence could stem from a lower ligand field 
strength. Upon examination of the crystal structure of [PtL12Cl], we noticed that the 
Pt-N bonds were longer in this molecule (2.064 and 2.067 Å) than in all of its isomers 
(crystal structures for complexes [PtL9-11Cl] reveal Pt-N bond lengths in the range 2.017 
– 2.028 Å). The greater Pt-N bond lengths in [PtL12Cl] presumably occur to reduce 
unfavourable steric interactions between the 6-methyl groups and the ancillary chloride. 
The lengthened Pt-N bond implies a weakened interaction between the metal and the -
accepting pyridine groups, which would result in a lower ligand field around platinum.  
As a consequence, the deactivating d-d* state may exist at lower energy in [PtL12Cl], so 
that thermal population of this state is viable. Similar arguments presumably account for 
the poor quantum yield of [PtL8Cl], which also contains methyl groups on the 6-pyridyl 
position. 
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Also, as mentioned above, the crystal structure of [PtL12Cl] revealed significant 
distortion from planarity. The complex contains a C^Pt^Cl bond angle of 155.6 , 
which is far from the ideal of 180 . In terms of potential energy surfaces, distortions 
between the ground and excited state can result in the excited state energy minima being 
significantly displaced relative to the ground state minima (Chapter 1, Section 1.3). If 
the potential energy surfaces cross near the energy minima of the excited state, then 
intersystem crossing, followed by non-radiative relaxation to the ground state will 
compete with radiative decay. 
 
3.4.1.3 Photochemistry of a Sterically Demanding Complex 
[PtL13Cl] contains methyl groups on the 3-pyridyl and 3,5-phenyl positions. It is 
reasonable to expect that this complex would suffer even more inhibition to attainment 
of a planar geometry than [PtL9Cl], since methyl groups are larger than fluorine atoms. 
The crystal structure for [PtL13Cl] has been collected, and confirms these expectations 
(Chapter 2, Section 2.4.3.1). Whilst the coordination plane around Pt is approximately 
planar, the terdentate ligand contains significant distortions from planarity.  
N N
Pt
Cl
 
Figure 24: Representation of the unfavourable sterics that force [PtL13Cl] from planarity 
 
Absorbance 
The absorption spectrum of [PtL13Cl] contained the typical 1-* bands of higher 
intensity between 230 and 300 nm and charge transfer bands between 320 and 420 nm. 
The spectrum was less structured than for [PtL1Cl]. An isomer of [PtL13Cl] was 
prepared for comparison ([PtL14Cl]). This complex contains methyl substituents on the 
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5-pyridyl positions. The absorbance spectrum of [PtL14Cl] was more structured than 
[PtL13Cl], but the lowest energy absorbance bands occurred at very similar wavelength 
(387 and 386 nm respectively). Interestingly, the lowest energy singlet absorption band 
present in the absorption spectrum of [PtL1Cl] was absent in the absorption spectra of 
[PtL13Cl] and [PtL14Cl]. This band was also found to be absent in the absorption spectra 
of complexes containing 3',5'-fluoro substituents (Sections 3.4.1.1 and 3.4.1.2) – we 
initially thought that fluorination was causing this effect. However, the observations 
made here indicate that the effect is not due specifically to fluorine atoms, but to 
substitution in general at the 3,5-phenyl positions. 
 
Figure 25: UV-vis absorption spectra of complexes [PtL13Cl] (red) and [PtL14Cl] (green) and reference 
complex [PtL1Cl] (blue). 
 
Emission 
Despite the similarity in absorbance energy, the emission spectra were vastly different 
(Figure 26). [PtL14Cl] gives a structured spectrum, typical of most other 1,3-
dipyridylbenzene Pt(II) complexes. It emits at lower energy than [PtL1Cl] (499 nm and 
491 nm respectively, E = 330 cm-1), which is consistent with the DFT frontier orbital 
calculations, which predict a HOMO largely localised on the central phenyl ring. 
[PtL13Cl] displays a broad, featureless emission spectrum, that occurs at significantly 
longer wavelength than [PtL14Cl] (max = 546 nm and 499 nm respectively, E = 1,730 
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cm-1). The broad, structureless emission is probably associated with the non-planar 
ground state of this molecule, and probably indicates that the excited state and ground 
state geometries are significantly different. Both of these complexes are highly 
luminescent, and have lifetimes of the order of several microseconds (Table 10). 
Surprisingly, [PtL13Cl] has a higher quantum yield than both [PtL14Cl] and [PtL1Cl]. 
This seems counter-intuitive, as distortions tend to open up non-radiative decay 
pathways.  
 
Figure 26: Normalised emission spectra of dilute samples of complexes [PtL13Cl] (red), [PtL14Cl] (green) 
and [PtL1Cl] (blue), in DCM at 298 K. 
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Table 10: Photophysical data for complexes [PtL13Cl] and [PtL14Cl], with data for [PtL1Cl] included for 
reference. 
Complex Absorbance max/nm 
( / L mol-1 cm-1) 
Emission max/nm 0 degassed 
(aerated) /µsa 
lum degassed 
(aerated) 
[PtL1Cl]b 332 (6510), 380 
(8690), 401 (7010), 
454* (270), 485* 
(240) 
491, 524, 562 7.2 (0.50) 0.60 (0.039) 
[PtL13Cl] 327 sh (6300), 341 
(6100), 367 sh (4010), 
386 (5740), 488* sh 
(100) 
546br 7.7 (0.34) 0.75 (0.046) 
[PtL14Cl] 325 (6450), 343 
(6730), 374 sh (5190), 
387 (6010), 461* 
(100), 493* (90) 
499, 533, 573sh 11.9 (0.62) 0.55 (0.071) 
aLifetime at infinite dilution, bPhotophysical data from reference 1, *forbidden S  T absorption bands, 
sh = shoulder, br = broad 
 
3.4.1.4 Increasing the Electron-Donating Character of the 4-Pyridyl Substituent 
Amongst the isomers incorporating methyl groups in the pyridyl rings, substitution at 
the 4-position was found to generate the largest blue shift of emission. In order to try to 
induce a further shift to the blue, complexes containing more strongly electron-donating 
groups (-OMe, -NMe2) at this position were targeted. These groups should cause a 
greater destabilisation of the LUMO+1 than -Me. Previous results demonstrate that 
fluorinated complexes always emit at higher energy than their non-fluorinated 
analogues, so investigations here focused on complexes involving a 3,5-difluorinated 
phenyl ring. 
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Absorbance 
 
Figure 27: UV-vis absoption spectra of complexes containing a 3,5-difluorinated aryl ring and electron 
donating 4-pyridyl substituents (DCM, 298 K). 
The resolved lowest energy singlet band observed in [PtL1Cl] was absent from the 
absorption spectra of all of these complexes, consistent with 3',5'-substitution of the aryl 
ring being the cause of this effect. There was little variation in energy between the 
lowest two absorption bands within this series (Emax = 440 cm-1). However, both the 
energy and relative intensity of the sharp peak around 330 nm were dramatically 
affected by the nature of the 4-substituent (Emax = 2740 cm-1). The lowest energy 
absorption band varied with complex in the following order: 
[PtL15Cl]  > [PtL17Cl] > [PtL16Cl]  [PtL10Cl] > [PtL2Cl],   Emax = 440 cm-1 
Contrary to what was expected, [PtL15Cl] exhibited the highest energy absorption 
(Table 11). NMe2- is a more powerful electron-donor than MeO-, so [PtL17Cl] was 
expected to yield the largest blue-shift. Direct S  T absorptions were observed in 
higher concentration solutions of all complexes. The energy of this band did increase 
with increasing electron-donating character of the 4-substituent, and occurred at highest 
energy for [PtL17Cl]. 
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Table 11: Photophysical data for dilute solutions of complexes containing a 3,5-difluorinated aryl ring 
and electron donating 4-pyridyl substituents (DCM, 298 K) 
 Absorbance max/nm     
( / L mol-1cm-1) 
Emission max/nm 0 degassed 
(aerated)/µsa 
lum degassed 
(aerated) 
[PtL2Cl] 320 (6690), 334 (9180), 
360 (7340), 374 (8500), 
467* (130) 
472, 502, 537 sh 7.9 (0.67) 0.85 (0.087) 
[PtL10Cl] 316 (8910), 329 sh 
(10790), 358 (9000), 372 
(11320), 462* (140) 
467, 498, 529 sh 7.9 (0.70) 0.87 (0.088) 
[PtL15Cl] 294sh (6440), 306 (5680), 
352sh (5560), 368 (6810), 
427*sh (120), 445* (100), 
455* (70) 
461, 492, 519sh 7.60 (0.58) 0.71 (0.096) 
[PtL16Cl] 314 (6350), 326 (6790), 
355sh (6010), 372 (7570), 
436*sh (118), 464* (80) 
470, 502, 532sh 
 
6.02 (0.74) 0.75 (0.11) 
[PtL17Cl] 319 (6580), 352 sh 
(9310), 370 (13910), 443* 
(160) 
455, 485, 512 sh 4.7 (0.13) 0.60 (0.033) 
aLifetime at infinite dilution, *Forbidden S  T absorption bands, sh = shoulder. 
[PtL29Cl], the non-fluorinated analogue of [PtL15Cl] has been prepared by a previous 
group member, S. Develay. It was of interest to compare the photophysics of this 
complex with that of the other complexes containing 4-methyl substituents (prepared 
here). The absorption spectrum of this complex compared to [PtL6Cl] and [PtL1Cl] is 
shown in Figure 29. The absorption spectra of these three complexes possess a similar 
profile, and all of these complexes absorb at lower energy than their difluorinated 
analogue. The lowest energy singlet band occurs at similar energy for all three 
complexes, whereas higher energy singlet absorption bands show greater variation in 
energy between the complexes. These bands occur at highest energy for the [PtL29Cl], 
which contains the most powerful electron donating 4-pyridyl substituent (-OMe), of 
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this mini-series of complex. Again, the direct S  T band was found to increase in 
energy with increasing electron donor ability of the 4-substituent. 
N N
MeO OMe
Pt
Cl
N N
MeO OMe
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Cl
F F
[PtL27Cl] [PtL15Cl]
 
Figure 28: Molecular structure of [PtL29Cl], and its 3',5'-difluorinated analogue [PtL15Cl]. 
 
Table 12: Solution-based photophysical data of complex [PtL29Cl], with data for [PtL6Cl] and [PtL1Cl] 
included for comparison (DCM, 298 K). 
 Absorbance max/nm    
( / L mol-1 cm-1) 
Emission max/nm 0 degassed 
(aerated) /µsa 
lum degassed 
(aerated) 
[PtL1Cl]b 332 (6510), 380 (8690), 
401 (7010), 454* (270), 
485* (240) 
491, 524, 562 7.2 (0.50) 0.60 (0.039) 
[PtL6Cl]c 326 (7820), 356 (6420), 
374 (8930), 400 (7040), 
479* (260) 
487, 521, 560, 10.0 (0.34) 0.73 (0.04) 
[PtL29Cl]c 310 (224010), 368 
(24960), 401 (19200), 
464* (330), 475* (310) 
481, 515, 553 5.3 (0.37) 0.81 (0.05) 
aLifetime at infinite dilution, bPhotophysical data from reference 1, cComplexes prepared by a former 
group member, *Forbidden S  T absorption bands, sh = shoulder 
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Figure 29: UV-vis absorption spectra of [PtL29Cl] (blue), with [PtL1Cl] (red) and [PtL6Cl] (green) 
included for comparison (DCM, 298 K)  
 
Emission 
Increasing electron donor ability of substituent
Increasing energy of emission
NMe2-     >      MeO-      >      Me-     >     H-
 
Figure 30: Schematic representation of the relationship between emission energy and electron donor 
ability of the 4-pyridyl substituent 
The emission energy of the complexes discussed on pages 137 - 139 was found to 
increase with the electron donor ability of the 4-substituent, and [PtL17Cl] was found to 
emit at the highest energy, in line with the expectations (see Figure 31). Again, 
difluorinated complexes were found to emit at higher energy than non-fluorinated 
analogues. 
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Figure 31: Normalised emission spectra of complexes containing a 3,5-difluorinated aryl ring and 
electron donating 4-pyridyl substituents (DCM, 298 K). 
The high intensity of emission is retained in these new complexes incorporating the 
stronger electron donors, with  in the range 0.60-0.87. There is, however, some 
evidence of a trend of a slight decrease in the quantum yield and lifetime with an 
increase in emission energy for the symmetrical complexes. This could be because the 
excited state is becoming closer in energy to a higher lying non-radiative state, such as 
the d-d* state, so that there is an increased probability of non-radiative decay via this 
state at 298 K. 
 
Figure 32: Photograph of a degassed dilute solution (~ 10-6 M) of [PtL17Cl] (left) and [PtL13Cl] (right) 
irradiated with long-wave UV light (DCM, 298 K). The picture demonstrates nicely how modification of 
the terdentate ligand allows the colour of emission to be tuned. 
 
0
0.2
0.4
0.6
0.8
1
420 470 520 570 620
Em
is
si
o
n
 
In
te
n
si
ty
 
/ a
.
u
.
Wavelength / nm
[Pt(L17)Cl]
[PtL(15)Cl]
[PtL(10)Cl]
[PtL(16)Cl]
[PtL(2)Cl]
154 
 
[PtL17Cl] exhibits the bluest emission of all 1,3-dipyridylbenzene Pt(II) chloride 
complexes prepared to date, with an emission maximum occurring at 455 nm in DCM at 
ambient temperature. The spectrum is broader than the other 4-substituted complexes. 
Perhaps the strongly electron-donating nature of this substituent enforces a significant 
rearrangement of electron density between the ground and excited state. The emission 
of this complex is modulated by acid (Figure 33). Treatment with an excess of 
trifluoroacetic acid leads to a dramatic red-shift to 507 nm (E = 2250 cm-1). 
Protonation of the amine groups will attenuate their electron-donating ability, 
accounting for this effect. 
 
Figure 33: Normalised emission spectra of a dilute sample of [PtL17Cl] in DCM at 298 K, in the absence 
(blue) and presence (red) of trifluoroacetic acid (TFA). Inset: photograph of a dilute solution of [PtL17Cl] 
(~10-6 M), before (left) and after (right) addition of TFA. 
Thompson et al., who investigated analogous bidentate N^C systems (first discussed in 
Chapter 1, Section 1.5), found a similar response of emission energy to electron 
donating substituents placed on the pyridyl ring. For example,  incorporation of electron 
donating groups at the 4-pyridyl position gave complexes that exhibit high energy 
emission. Complexes 4,6-dfp-4meopy and 4,6-dfp-4-dmapy (Figure 34) were found to 
emit weakly at 456 and 447 nm respectively, from a 2-methyltetrahydrofuran solution at 
room temperature. Their terdentate analogues, [PtL15Cl] and [PtL17Cl] emit at 461 nm 
and 455 nm respectively from DCM at ambient temperature.  
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Figure 34: Structures of4,6-dfp-4meopy and 4,6-dfp-4-dmapy 
It was noticed that all of the bidentate complexes prepared by Thompson et al. possess 
emission maxima at slightly higher energy than their terdentate analogues. Therefore, in 
terms of optimising the energy for blue emission, addition of a second pyridyl ring has 
no benefit. However, addition of the second pyridyl ring to the ligand framework leads 
to a dramatic improvement in quantum yield. For example, [PtL15Cl] and [PtL17Cl] are 
highly emissive, with quantum yields of 0.71 and 0.60 (DCM, 298 K) respectively, 
whereas the bidentate complexes 4,6-dfp-4meopy and 4,6-dfp-4-dmapy are almost non-
emissive, with  < 0.01 (2-methyltetrahydrofuran, 298 K). This affect can be attributed 
to the increased rigidity and increased ligand field splitting within the terdentate system. 
Furthermore, the green-yellow emission tails of the terdentate complexes are less 
intense than their bidentate analogues (as discussed in Section 3.4.1.1), leading to 
enhanced blue colour purity.   
The unsymmetrical complex, [PtL16Cl], containing one MeO- substituent emits at only a 
slightly shorter wavelength than the [PtL2Cl] reference complex (470 nm, 21280 cm-1 
and 472 nm, 21190 cm-1 respectively), whereas the symmetrical di-methoxy complex, 
[PtL15Cl] emits at a significantly shorter wavelength (461 nm, 21690 cm-1). A similar 
effect was observed by Williams et al. when investigating related N^C^N complexes 
involving pyrazoles (initially discussed in Chapter 1, Section 1.6.2).16 Pyrazole is a 
poorer electron acceptor than pyridine.  The unsymmetrical complex, complex 52 which 
contained one pyrazole and one pyridine ring (Figure 35) displayed emission at similar 
energy to [PtL1Cl], whereas the symmetrical pyrazolate complex, complex 51 (i.e. two 
pyrazole rings) emitted at significantly higher energy.  
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Figure 35: A reminder of the molecular structures of complexes 51 and 52. 
DFT calculation results for the pyrazole-containing complexes indicated that the 
LUMO-based orbitals for the unsymmetrical complex were located on the lower energy 
pyridyl ring, and that the pyrazolate ring made essentially no contribution to these 
orbitals, accounting for the lower energy emission of the unsymmetrical complex 
relative to the symmetrical bis-pyrazole complex. Removal of the C2-symmetry in 
[PtL16Cl] probably alters the atomic contribution to the LUMO-based orbitals in a 
similar way. One can expect that the LUMO-based orbitals of the unsymmetrical 
complex will be mainly localised on the unsubstituted pyridyl ring, which is stabilised 
relative to the methoxy-substituted pyridyl. This would be consistent with the 
observation that the unsymmetrical complex emits at similar energy to [PtL2Cl]. These 
results demonstrate the necessity to place electron donating substituents on both of the 
4-pyridyl positions of the terdentate ligand, in order to bring about the maximal blue-
shift. 
 
 3.4.1.5 Incorporation of Electron-withdrawing CF3 Groups at the 4-Pyridyl 
Position 
As placing electron-donating groups at the 4-pyridyl position led to complexes with 
blue-shifted emission, it was expected that electron-withdrawing substituents at the 4-
pyridyl position should generate a red-shift. Synthesis of complex [PtL19Cl], which 
contains fluorine atoms on the 4-pyridyl position, was attempted but unfortunately the 
ligand degraded during the complexation reaction. 
Complexes [PtL20Cl] and [PtL30Cl] (this complex was prepared by a previous student, 
see Figure 36) contain electron-withdrawing CF3- groups at the 4-pyridyl position. 
[PtL20Cl] also contains the difluorinated phenyl ring. An unsymmetrical analogue of 
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[PtL20Cl], in which one of the CF3- substituents is replaced with an electron-donating 
MeO- substituent, has also been prepared ([PtL21Cl]). 
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Figure 36: Molecular structures of the complexes containing CF3 substituents on the 4-pyridyl positions. 
DCM solutions of [PtL20Cl] were found to exhibit thermochromism – on cooling to 77 
K, the yellow solution turned into a deep blue glass (see Figure 37). A change in colour 
could indicate that intermolecular interactions between the molecules changes upon 
cooling, which could stem from a change in the ground state geometry. Reference 17 
describes some bi-metallic N^C systems that exhibit thermochromism. At room 
temperature, intramolecular -interactions between the two Pt centres result in low 
energy, broad-featureless emission (from a 3MMLCT state). On cooling, a blue-shift in 
absorbance and emission occurs (both on the solid and in solution), and the spectra 
become more structured: the emission is more typical of a 3LC/3MLCT excited state. 
This indicates that on cooling, the geometry must change leading to an increase in Pt-Pt 
distance. The solid form of [PtL20Cl] does not change colour upon cooling, indicating 
that this is a solution-based effect. DCM solutions of the non-fluorinated analogue, 
[PtL30Cl], also displays some thermochromic behaviour, but less dramatically. Upon 
cooling to 77 K, the yellow solution forms a deep orange glass. 
 Figure 37: Thermochromism observed upon thawing from a 77 K 
[PtL20Cl], Bottom [PtL30Cl]
Absorption 
As expected, [PtL30
[PtL20Cl], absorbs at a similar 
[PtL1Cl], indicating that the 
involved in the absorptive
the 3',5'-fluoro substituents on the HOMO
an unusual spectral profile 
cm-1), along with a shoulder at 389 nm (
= 4820 L mol-1 cm
significantly different atomic orbital contributions to the 
(compared to C2v symmetrical [PtLX] systems), brought about by the asymmetry of the 
terdentate ligand.16 
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Figure 38: UV-vis absorption spectra of complexes containing 4-pyridyl CF3 substituents, with the 
absorption spectrum of [PtL1Cl] included for reference (DCM, R.T.). 
Table 13: Solution-based photophysical data of complexes containing CF3 4-pyridyl substituents, with 
data for [PtL1Cl] included for comparison (DCM, 298 K). 
 Absorbance max/nm 
(/L mol-1 cm-1) 
Emission 
max/nm 
0 degassed 
(aerated) /µsa 
lum degassed 
(aerated) 
[PtL1Cl]b 332 (6510), 380 (8690), 
401 (7010), 454* (270), 
485* (240) 
491, 524, 562 7.2 (0.50) 0.60 (0.039) 
[PtL20Cl] 334 sh (4470), 349 
(6510), 383 (8190), 486 
(170)* 
497, 527, 575 sh 5.6 (1.7) 0.59 (0.21) 
[PtL21Cl] 329 sh (4580), 338 sh 
(4440), 369 (4820), 389 
sh (3300), 427 sh (800), 
480* (150) 
495, 528, 573 sh 5.5 (0.67) 0.57 (0.038) 
[PtL30Cl]c 284 (27900), 348 (4690), 
400 (11400), 503* (200)  
518, 548 4.1d 0.37 (0.087) 
aLifetime at infinite dilution, bPhotophysical data from reference 1, cPrepared by a former group member, 
dAerated lifetime not reported, *forbidden S  T absorption bands, sh = shoulder. 
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Emission 
All complexes with 4-pyridyl CF3 substituents emit at lower energy than [PtL1Cl]. 
Amongst these four complexes, the emission of [PtL30Cl] occurs at the lowest energy 
(518 nm, 19310 cm-1). It is interesting to note that complex [PtL20Cl] emits at lower 
energy than [PtL1Cl], despite having fluorine atoms on the phenyl ring (497 nm/20120 
cm-1 and 491 nm/20370 cm-1 respectively). This indicates that the 4-pyridyl CF3- 
substituent has a greater stabilising effect on the LUMO-based orbital involved in the   
T  S transition, than phenyl 3',5'-difluoro substituents have on the HOMO. The 
unsymmetrical complex, [PtL21Cl], emits at the same energy as [PtL20Cl] – this gives 
further support to the theory that the LUMO-based orbitals are localised on the more 
stable pyridyl ring in unsymmetrical complexes.16 
 
Figure 39: Normalised emission spectra of dilute solutions of complexes containing 4-pyridyl CF3 
substituents, with the emission spectrum of [PtL1Cl] included for reference (DCM, 298 K). 
These complexes are highly luminescent, with quantum yields in the range of 0.4 – 0.6 
and the lifetimes are of the order of several microseconds. Of particular interest is the 
remarkably low sensitivity of [PtL20Cl] to quenching by oxygen. The quantum yield and 
lifetime of this complex in an air-saturated DCM solution at R.T. are 0.21 and 1.7 µs 
respectively. 
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3.4.1.6 Fluoro-substituents at the 5-Pyridyl Position 
 
Absorption 
Complex [PtL22Cl] contains electron-withdrawing fluorine atoms on the 5-pyridyl 
positions. The absorption profile of this complex contains the very intense bands 
between 230 and 300 nm that can be assigned to 1-* transitions, and the less intense 
charge transfer bands between 330 – 430 nm. The energies of the absorption bands (see 
Table 14) are comparable to those of the unsubstituted parent, [PtL1Cl]. The most 
significant difference between the absorption spectra of these two complexes is that the 
band around 400 nm appears only as a weak shoulder for [PtL22Cl]. It was previously 
shown that this band does not appear in the DCM based absorption spectra of 
complexes containing a 3',5'-disubstituted phenyl ring. Rather than being absent 
entirely, solvatochromism studies suggested that this band had shifted to higher energy 
and had become mixed with the band of second lowest energy. 
 
Figure 40: UV-vis absorption spectra of [PtL22Cl] (red) and [PtL1Cl] (blue), recorded in DCM at 298 K. 
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 Table 14: Solution-based p
comparison (DCM, 298 K)
 Absorbance 
(/L mol
[PtL1Cl]b 332 (6510), 380 
(8690), 401 (7010), 
454* (270), 485* (240)
[PtL22Cl] 341 (4590), 367sh 
(6110), 384 (87
460* (13
aLifetime at infinite dilution, 
sh = shoulder. 
Like [PtL20Cl], cooling solutions of [PtL
complex dissolves in DCM to give a yellow solution. On cooling to 77 K, the complex 
forms a deep red glass (
another colour change, forming a deep blue intermediate, before thawing completely 
and returning the yellow solution. The colour change is likely to correspond to differing 
degrees of intermolecular interactions at the different tempe
interest to follow the absorbance spectra of [PtL
temperature.  
Figure 41: Photographs of [PtL
nitrogen. The top left represents the sample after immediate removal from liquid nitrogen, and the bottom 
right represents a fully thawed solution
hotophysical data of complex [PtL22Cl], with data for [PtL
. 
max/nm 
-1
 cm-1) 
Emission max/nm 0 degassed 
(aerated) /µs
 
491, 524, 562 7.2 (0.50)
50), 
0), 492* (130) 
499, 533, 571sh 9.62 (0.67)
bPhotophysical data from reference 1, *forbidden S 
22Cl] results in a dramatic colour change. The 
Figure 41). During the thawing process
ratures 
20Cl] and [PtL22
 
22Cl] in DCM, at various stages of thawing after being frozen with liquid 
. 
162 
1Cl] included for 
a 
lum degassed 
(aerated) 
 0.60 (0.039) 
 0.61 (0.063) 
 T absorption bands, 
, the sample exhibits 
– it would be of 
Cl] as a function of 
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Emission 
The emission spectrum of [PtL22Cl] is structured, with the 0-0 vibronic band holding the 
greatest intensity and occurring at 499 nm. The emission is red shifted relative to 
[PtL1Cl] by 8 nm (E = 330 cm-1). This result is consistent with the DFT calculation 
results on [PtL1Cl], which predict that the LUMO will be largely localised on the 
pyridyl rings. In this case, fluorine atoms on the 5-pyridyl positions must have a greater 
stabilising effect on the LUMO-based orbitals than on the HOMO, reducing the 
HOMO-LUMO energy gap.  
 
Figure 42: Normalised emission spectra of dilute solutions of [PtL22Cl] (red) and [PtL1Cl] (blue), in 
DCM at 298 K. 
 
3.4.1.7 A Tetradentate Complex 
 
Absorption 
[PtL23] was prepared primarily to be tested within living cells as a bio-imaging agent. 
The complex involves a tetradentate ligand only. The absorption profile of this complex 
is quite different to the terdentate complexes (Figure 43). There are a series of very 
intense absorptions between 250-350 nm, which are probably due to ligand centred 
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transitions (1-*), accompanied by a weak band around 390 nm, which probably 
represents a charge transfer band. Unfortunately, the complex was of low solubility in 
DCM, and it was not possible to determine accurate extinction coefficients. 
 
Figure 43: UV-vis absorption spectra of [PtL23] (blue) and [PtL1Cl] (red), recorded in DCM at 298 K. 
 
Table 15: Solution-based photophysical data of complex [PtL23], with data for [PtL1Cl] included for 
comparison (DCM, 298 K). 
 Absorbance max/nm   
( / L mol-1 cm-1) 
Emission 
max/nm 
0 degassed 
(aerated) /µsa 
lum degassed 
(aerated) 
[PtL1Cl]b 332 (6510), 380 (8690), 
401 (7010), 454* (270), 
485* (240) 
491, 524, 562 7.2, (0.5) 0.60 (0.039) 
[PtL23] 286, 308 sh, 373 sh,  
390 
494, 523, 
560sh 
23, (2.8)c 0.08 (0.01) 
aLifetime at infinite dilution, bPhotophysical data from reference 1, clifetime recorded for a dilute solution 
(absorbance < 0.05 at ex), *Forbidden S  T absorption bands, sh = shoulder. [PtL23] was too insoluble 
to perform accurate concentration-dependent analysis, and extinction coefficients could not be obtained. 
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Emission 
[PtL23] exhibited a relatively broad emission profile, with max = 494 nm, which is 
slightly red-shifted compared to [PtL1Cl]. This is surprising, as [PtL23] absorbs at 
shorter wavelength than [PtL1Cl].  
Compared to the majority of terdentate complexes prepared here, the tetradentate 
complex is only weakly emissive in solution at room temperature ( = 0.08). If the bite 
angles around the Pt centre are not optimum, significant strain could reside in this 
molecule, and this may account for the poor emissive properties. Alternatively, the 
trans-arrangement of the anionic oxygen and cyclometallating carbon could be 
unfavourable for luminescence. As explained in Chapter 1, Section 1.6.3, C^N^C type 
complexes are usually non-emissive at room temperature, mainly because of the trans-
arrangement of the two strong-field cyclometallating carbon atoms. The lifetime of the 
dilute solution used to measure the quantum yield was recorded: obs = 23 µs. The 
excited state of this complex is much longer lived than the terdentate complexes (0 ~ 7 
µs): this indicates that S  T transition has lower allowedness, and that the excited state 
of [PtL23] contains a greater 3LC contribution and smaller 3MLCT contribution.18 
 
Figure 44: Normalised emission spectra of dilute samples of [PtL23] (red) and [PtL1Cl] (blue), in DCM at 
298 K. 
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3.4.2 Ancillary Ligand Substitution 
Much work has been done around substitution of the ancillary ligand(s) in related 
N^N^N, N^N^C and N^C complexes.19,20,21,22,23,24,25,26,27 Replacement of chloride for 
stronger field ligands such as acetylides and cyanide often causes the d-d* state to shift 
to higher energy, decreasing its deactivating effect, which is observed as an increase in 
quantum yield. These substitutions are also commonly accompanied by an increase in 
emission energy, which also results from the increased ligand field splitting energy. 
Very little research concerning ancillary ligand substitution in N^C^N complexes has 
been published to date.28,29 Rochester, a previous group member produced a series of 
N^C^N complexes involving pyridine- or phosphine-based ancillary ligands.28 These 
complexes had an overall charge of +1 and were unstable to decomposition in the 
presence of Lewis bases such as CH3CN. The emission energies of phosphine-
containing complexes are very similar to those of the analogous chloro-complexes, 
indicating that the 3LC excited state energy is not significantly affected by these 
ancillary ligands. Unfortunately, photophysical data for the pyridine complexes was not 
reported.  
 
3.4.2.1 Halide Exchange 
The bromo- and iodo- forms of [PtL1Cl] were prepared to study the effect of changing 
the ancillary halide. The emission was to be monitored at both room temperatures and 
cryogenic temperatures (Section 3.4.4.2) DFT calculations predict that the ancillary 
ligand makes a significant contribution to the HOMO, but minimal contribution to the 
LUMO-based orbitals. The electron withdrawing ability decreases on going down group 
17, so one might expect the HOMO to increase in energy from chloride to iodide. 
 
Absorption 
The absorption profiles of [PtL1Cl] and [PtL1Br] are practically identical. [PtL1I] 
absorption profile is similar in shape, but the charge transfer bands are red shifted by 
approximately 3 nm.  
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Figure 45: Normalised UV-vis absorption spectra of dilute solutions of [PtL1X], in DCM at 298 K. 
 
Table 16: Solution-based photophysical data of complexes [PtL1X] (DCM, 298 K). 
 Absorbance max/nm   
( / L mol-1 cm-1) 
Emission 
max/nm 
0 degassed 
(aerated) /µsa 
lum degassed 
(aerated) 
[PtL1Cl]b 332 (6510), 380 (8690), 
401 (7010), 454* (270), 
485* (240) 
491, 524, 562 7.2 (0.50) 0.60 (0.039) 
[PtL1Br] 334 (7180), 380 (9720), 
401 (8120), 453* (210), 
485* (180) 
491, 524, 562 9.9 (0.67) 0.61, (0.072) 
[PtL1I] 336 (4340), 385 (7130), 
404 (6050), 487* (160) 
491, 524, 562 8.4 (0.46) 0.57, (0.047) 
aLifetime at infinite dilution, bPhotophysical data from reference 1, *Forbidden S  T absorption bands. 
Emission 
The normalised emission spectra (DCM, 298 K) of the three complexes are identical in 
energy. Similar observations were made by Tsuzuki et al., who used these complexes as 
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phosphorescent OLED dopants.29 The relative band intensities (i.e. 0-0, 0-1, etc.) are the 
same for the [PtL1X] complexes, regardless of the identity of the ancillary halogen. This 
implies that the equilibrium geometries of the ground and excited states are very similar 
in all three complexes, and are not affected by increasing the size of the ancillary ligand 
from chloride to iodide. The quantum yields and lifetimes are also quite similar. 
Substitution of the chloride with other halides is therefore not a useful strategy for 
tuning photophysical properties. From these results, it appears as if the halide ligand is 
merely a spectator ligand, contrary to the DFT predictions. However, it may just be that 
the halides are too similar in character to invoke a significant change. To further 
examine whether the halide ligand makes any contribution to the photophysics of the 
individual complexes, the emission was monitored at cryogenic temperatures (Section 
3.4.4.2). At such low temperatures, the substates of the T1 state can be studied in detail.  
 
3.4.2.2 Substitution with Cyanide 
Cyanide lies much higher up the spectrochemical series than the halides, so substitution 
with cyanide should augment the ligand field splitting. For the Pt N^C^N complexes, 
this effect should increase the HOMO-LUMO energy gap and lead to a blue-shift in the 
photophysical parameters. Furthermore, cyanide has electron withdrawing properties, so 
should have a stabilising effect on the HOMO, further augmenting a blue-shift. 
Cyano-analogues of the two bluest complexes [PtL17Cl] and [PtL15Cl] were prepared, 
along with the cyano-analogue of [PtL2Cl]. The solubility of the cyano-complexes was 
significantly reduced with respect to the chloro-analogues, so much so that complete 
photochemical analysis was only possible for [PtL15CN] in DCM. [PtL17CN] and 
[PtL2CN] were soluble enough to obtain solution-based absorption and emission spectra 
(DCM, R.T.) and to determine some of the photophysical parameters. 
 
Absorption 
In absorption, the charge transfer bands of [PtL15CN] and [PtL2CN] were shifted to 
higher energy relative to their chloro analogues (see Table 17, Figure 46). This shift to 
higher energy was also observed for [PtL17CN], but was accompanied by the 
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appearance of a new sharp band at shorter wavelength (381 nm). The weak direct S  
T absorptions were observed for all cyano complexes.  
 
Figure 46: Normalised UV-vis absorption spectra of [PtL15CN] (blue) and [PtL15Cl] (red) (DCM, 298 K). 
Table 17: Solution-based photophysical data of complexes containing an ancillary cyanide ligand (DCM, 
298 K). 
 Absorbance max/nm 
( / L mol-1 cm-1) 
Emission 
max/nm 
0 degassed 
(aerated) /µsa 
lum degassed 
(aerated) 
[PtL2CN] 259, 285, 310, 319, 
334, 350, 433*, 463* 
468, 499, 527 8.5 (1.52)b 0.66 (0.19) 
[PtL15CN] 263 (14300), 303 
(5900), 315sh (4210), 
338sh (2890), 355, 
(3700) 440* (70) 
457, 488, 513 8.0 (0.58) 0.61 (0.17) 
[PtL17CN] 289, 319, 337sh, 355, 
381, 440* 
450, 477, 511 4.5 (0.167)b 0.41 (0.05) 
aLifetime at infinite dilution, blifetime recorded for a dilute solution (absorbance < 0.05 at ex), *forbidden 
S  T absorption bands, sh = shoulder. [PtL2CN] and [PtL17CN] were too insoluble to perform accurate 
concentration-dependent analysis, and extinction coefficients could not be obtained. 
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Emission 
In all cases, a blue-shift of the emission maximum was observed relative to the chloro 
analogue (see Table 18). The largest increase in energy was found between the PtL17 
cyano and chloro analogues (E = 240 cm-1). Compared to the chloro series, the cyano 
series have emission spectra with more significant green-yellow tails (i.e. the 0-1 and 0-
2 vibronic peaks have a higher intensity relative to the 0-0 peak, see Table 19). A 
representative pair of spectra are shown in Figure 47. 
Table 18: Comparison of highest energy emission maxima of cyano and chloro analogues. 
 X = CN 
max / nm (Energy / cm-1) 
X = Cl 
max / nm (Energy / cm-1) 
 
E / cm-1 
[PtL2X] 468 (21370) 472 (21190) 180 
[PtL15X] 457 (21880) 461 (21690) 190 
[PtL17X] 450 (22220) 455 (21980) 240 
 
Table 19: Table showing the intensity of the 0-n vibronic bands relative to the intensity of the 0-0 
vibronic band, for the cyano and chloro analogues 
 Intensity 0-0 Intensity 0-1 Intensity 0-2 
[PtL2CN] 1 0.66 0.31 
[PtL2Cl] 1 0.54 0.21 
[PtL15CN] 1 0.78 0.39 
[PtL15Cl] 1 0.64 0.27 
[PtL17CN] 1 0.99 0.55 
[PtL17Cl] 1 0.86 0.46 
 
171 
 
 
Figure 47: Normalised emission spectra of [PtL15CN] (blue) and [PtL15Cl] (red, DCM, 298 K). 
The quantum yields of the cyano-complexes were all reduced relative to the chloro-
analogues (see Table 17), but the complexes are still highly luminescent ( above 0.41). 
As for the chloro analogues, quantum yield was found to decrease with an increase of 
emission energy of the complex. Within the experimental error, the lifetime of 
[PtL15CN] was the same as that of the analogous chloro complex (0 = 7.1 and 7.6 µs 
respectively). This indicates a greater knr for the cyano-complex, which suggests that the 
higher lying excited state has become closer in energy to the deactivating d-d* state, and 
[PtL15CN] therefore has a higher probability of decay via this state at 298 K. Because of 
insolubility issues, it was not possible to determine 0 for [PtL2CN] and [PtL17CN]. 
Nevertheless, a value (obs) was recorded for the very dilute solutions used to measure 
the quantum yield, and these values were of a similar magnitude to the 0 values 
determined for the chloro analogues.  
[PtL17CN] is the bluest-emitting Pt(II) N^C^N complex reported to date (max = 450 nm, 
energy = 22200 cm-1). Its emission occurs at even higher energy than the bispyrazolyl 
complex, complex 51, reported by Williams et al.16 (max = 455 nm, energy = 22000 cm-
1). Another advantageous feature of this series of blue emitters is that they are much 
more luminescent than the bispyrazolyl complex ( > 0. 41 and  = 0.02 respectively). 
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3.4.3 Excimers and aggregates 
 
3.4.3.1 Self-Quenching 
As discussed in Section 3.1, the rate of emission decay of 1,3-dipyridyl benzene Pt(II) 
complexes decreases with increasing concentration. This is indicative of self-quenching 
or reaction of the excited state with ground state molecules.7 The emission decay as a 
function of concentration can be fitted to a Stern-Volmer equation, of the form shown in 
Eqn. 2 (see p. 117). From this, it is possible to determine the self-quenching rate 
constant, ksq – this value gives a measure of the affinity of the complex to form 
excimers (Table 20). 
For most of the complexes prepared here, ksq values are in the range of 2 – 6 x 109 M-1 s-
1
. These are of a similar magnitude to ksq values reported by Williams et al. for related 
complexes.2 However, for [PtL13Cl], the ksq value is 0.50 x 109 M-1 s-1 – this is 
significantly smaller than values obtained for the other complexes, indicating a lower 
propensity to self-quench. As previously discussed, the pyridyl and phenyl methyl-
groups are in close proximity in [PtL13Cl], resulting in a non-planar geometry (Section 
3.4.1.3). The non-planar geometry may hinder close approach of two molecules, 
accounting for a lower tendency to self-quench. Other groups have also noticed that 
sterics can influence self-quenching30,31,32 The relative size of a molecule will also 
influence ksq. For example, heavier molecules will diffuse through a solution more 
slowly, meaning excimers may take longer to form. Also, it seems that increasing both 
the electron donor or acceptor character of the 4-pyridyl substituent decreases the 
susceptibility of a complex to form excimers ([PtL6Cl] is an exception).  
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Table 20: Self-quenching constants of the 1,3-dipyridylbenzene Pt(II) complexes (the estimated 
uncertainty in each ksq value is ± 10 %). 
 ksq / 109 M-1 s-1   ksq / 109 M-1 s-1 
[PtL1Cl] 5.3  [PtL13Cl] 0.5 
[PtL1Br] 6.9  [PtL14Cl] 2.9 
[PtL1I] 6.1  [PtL15Cl] 2.9 
[PtL2Cl] 6.0  [PtL15CN] 2.3 
[PtL2CN] -----a  [PtL16Cl] 3.2 
[PtL3Cl] -----a  [PtL17Cl] 2.1 
[PtL5Cl] 3.0  [PtL17CN] -----a 
[PtL6Cl] 8.3  [PtL20Cl] 2.6 
[PtL7Cl] 3.9  [PtL21Cl] 2.0 
[PtL8Cl] -----a  [PtL22Cl] 5.6 
[PtL9Cl] 3.9  [PtL23] -----a 
[PtL10Cl] 5.1  [PtL29Cl] 3.2 
[PtL11Cl] 3.7  [PtL30Cl] 3.0 
[PtL12Cl] -----a    
aIt was not possible to determine a ksq value for [PtL8Cl] or [PtL12Cl] complexes, due to the weakness of 
their emission, and a difficulty in detecting their emission decay. Nor was it possible to determine a ksq 
value for [PtL3Cl], [PtL2CN] [PtL17CN] or [PtL23] due to their low solubility.  
 
3.4.3.2 Excimeric Emission 
Excimers of 1,3-dipyridyl benzene Pt(II) systems tend to be emissive, and excimeric 
emission occurs at lower energy than emission resulting from the isolated molecules 
(monomeric emission). This effect can be seen in Figure 48 for [PtL15Cl]; here the 
emission profile of a dilute sample (DCM at 298 K) is compared to emission profiles of 
solutions of increasing concentration. Note that this figure has been normalised with 
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respect to the monomeric emission (max = 461 nm). In reality, as concentration is 
increased, the excimeric emission grows in at the expense of the monomeric emission. 
The overall colour of light observed depends on the ratio of the monomeric-to-
excimeric emission, hence colour can be controlled simply by controlling concentration. 
This effect is being increasingly exploited in OLED design.   
For increased clarity, charts in this section comparing excimeric emissions will show 
only the range of emission associated with the excimer – in all cases, in the range of 
concentrations studied (10-4 – 10-6 M) monomeric emission was always present.  
 
Figure 48: Emission spectra of various concentrations of [PtL15Cl] (normalised at 461 nm) in DCM at 
298 K. Note the increasing contribution from excimer emission with increasing concentration (10-6 – 10-4 
M). 
Lifetime decay plots measured at monomeric and excimeric emission maxima tend to 
have the form shown in Figure 49. The decay measured at the monomeric emission 
maximum occurs “instantaneously” after excitation (i.e. within the instrument response 
time of about 1 ns). When monitored at the excimer emission maximum, the plot shows 
an initial grow-in followed by the decay. This initial grow-in corresponds to the 
timescale of formation of the excimer, which can only occur after excitation.33,34 
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Figure 49: Excited state decay curves of 1.7 x 10-4 M [PtL15Cl] in DCM at 298 K, emission monitored at 
461 nm (blue) and 627 nm (red). 
 
3.4.3.3 Variation of the Energy of the Excimeric Band 1: Modification of the 
N^C^N Chelating Ligand 
 
Modification of the Phenyl Ring 
Figure 50 shows the excimeric emission bands of [PtL1Cl] and [PtL2Cl]. As with the 
monomeric emission, the [PtL2Cl] excimer emits at higher energy than [PtL1Cl] (max = 
677 and 691 nm respectively, E = 300 cm-1). This energy shift is about 2.5 times less 
than found with the monomeric emission, indicating that fluorination in the 3,5-phenyl 
positions has a smaller impact on excimer energy. A saturated solution of [PtL3Cl] did 
not display excimeric emission. Either this complex does not form excimers readily, the 
solubility is too low, or like monomer emission, the excimer emission is very weak.  
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Figure 50: Normalised excimeric emission of [PtL2Cl] (blue) and [PtL1Cl] (red) from DCM solution at 
298 K. 
We attempted to see if the excimer band was solvatochromic (see Figure 51 and Table 
21). To observe excimer emission, the solution must be sufficiently concentrated – 
unfortunately, [PtL2Cl] was not sufficiently soluble in some of the solvents used to 
study monomeric solvatochromism. The complex was sufficiently soluble in DCM, 
toluene and CH3CN, so these solvents were investigated. As found for monomeric 
emission, the excimeric emission occurred at highest energy in the most polar solvent 
(CH3CN), and at lowest energy in the least polar solvent (toluene). The energy 
difference between the solvent extremes is 570 cm-1. For monomeric emission, the 
energy difference between CH3CN and toluene is only 190 cm-1, indicating that the 
energy of the excimer is more influenced by solvent than monomeric emission. This 
seems reasonable, as excimers involve intermolecular interactions that could easily be 
perturbed by solvent. 
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Figure 51: Normalised excimeric emission of [PtL2Cl] from various solvents at 298 K. 
 
Table 21: The position (and energy) of the excimeric emission maximum of [PtL2Cl] in various solvents. 
 max / nm (Energy / cm-1) 
Toluene 700 (14290) 
DCM 677 (14770) 
Acetonitrile 673 (14860) 
 
Methyl Substituents on the Pyridyl Rings 
With the exception of [PtL12Cl], the 3',5'-difluorinated isomers containing methyl 
groups on the pyridines ([PtL9Cl], [PtL10Cl] and [PtL11Cl]) all showed excimeric 
emission (see Figure 52a and Table 22). Like the monomeric emission, the energy of 
the excimer band varies with methyl position. The emission energy varied with 
substituent position in the following order: 
4Me- > 5Me- > H- > 3Me- 
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The excimeric band of [PtL9Cl] occurs at lower energy than the [PtL2Cl] reference, 
which was also the case for the monomeric emission. However, unlike the monomeric 
emission, the excimer of [PtL11Cl] emits at higher energy than [PtL2Cl]. The maximum 
energy difference, between [PtL10Cl] and [PtL9Cl] is 470 cm-1. This is a little less than 
the energy difference between their monomeric emission peaks (610 cm-1).  
Excimeric emission was not observed for [PtL12Cl] within the concentration range 
studied (10-4 – 10-6 M). Perhaps [PtL12Cl] does not form excimers because of its non-
planar ground state geometry (discussed in Chapter 2, Section 2.4.3.1), or maybe 
excimeric emission from this complex is just very weak (as with the monomeric 
emission). Unfortunately, ksq could not be determined for this complex, because the 
emission was too weak to be analysed by the same procedure as the other complexes 
(i.e. similar concentration ranges and excitation power per pulse). 
 
Table 22: Wavelengths (and energies) corresponding to the excimeric emission maxima of the two series 
of isomers containing n-methyl-pyridyl substituents (DCM, 298 K). 
 Excimeric Emission 
max/nm (Energy / cm-1) 
 Excimeric Emission 
max/nm (Energy / cm-1) 
[PtL1Cl] 691 (14470) [PtL2Cl] 677 (14770) 
[PtL5Cl] 692 (14450) [PtL9Cl] 681 (14680) 
[PtL6Cl] 674 (14840) [PtL10Cl] 660 (15150) 
[PtL7Cl] 688 (14530) [PtL11Cl] 673 (14860) 
[PtL8Cl] -----a [PtL12Cl] -----b 
aCould not assign an accurate value due to weakness of excimer emission, combined with overlap with 
monomer emission tail, bExcimer emission was not observed for the concentration range studied (10-6 – 
10-4 M). 
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Figure 52: Normalised excimeric emission of a) 3',5'-difluorinated complexes containing methyl 
substituents and b) their non-fluorinated analogues (DCM, 298 K). 
The excimeric emission of the non-fluorinated complexes ([PtL5-7Cl]) occur at slightly 
lower energy than their difluorinated analogue (approximately 300 cm-1). Of this series, 
[PtL6Cl] exhibits highest energy excimer emission, followed by [PtL7Cl], [PtL1Cl] and 
[PtL5Cl] (note that the excimer band maxima of the latter three complexes all occur 
within 4 nm of each other, so their excimeric emission occurs at the same energy within 
the experimental error).  
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In contrast to all other isomers, which displayed obvious excimeric emission at higher 
concentration, higher concentration solutions of [PtL8Cl] showed only a very weak band 
at lower energy. This band was assigned as excimeric emission, however it is 
superimposed on the monomeric emission tail, and its signal is distorted so that a true 
value of max cannot be ascertained. Like [PtL12Cl], [PtL8Cl] contains methyl groups on 
the 6-pyridyl position, so it is reasonable to think that similar steric repulsions will exist 
and the complex will adopt a non-planar ground state. Unfortunately, ksq could not be 
determined for this complex, because the emission was too weak to be analysed by the 
same procedure as the other complexes (i.e. similar concentration ranges and excitation 
power per pulse).  
 
[PtL13Cl] and [PtL14Cl] 
As mentioned in Section 3.4.3.1, [PtL13Cl] has a very low ksq value. In line with this, 
excimeric emission was not observed over the concentration range studied (10-6 – 10-4 
M). This further suggests that the significant distortions within the molecule prevent 
close approach of other complex molecules and sufficient overlap of orbitals. Its isomer, 
[PtL14Cl], does exhibit excimer emission, and intriguingly, whereas the monomeric 
emission was red shifted relative to [PtL1Cl], the excimeric emission is blue shifted 
(max = 678 nm) and occurs at similar wavelength to the [PtL2Cl] excimer (max = 677 
nm). This clearly demonstrates that substituents can affect monomer and excimer 
emission in different ways, and perhaps suggests that excimer emission energy is more 
receptive to the electronic nature of the pyridyl substituent.  
For all complexes (for which a suitable crystal was isolated), the molecular structures 
reveal a head-to-tail arrangement of neighbouring molecules (Chapter 2, Section 
2.4.3.1). It is possible that the excimer also involves a head-to-tail arrangement of the 
excited state and ground state molecule (Figure 53 gives a postulated arrangement of 
molecules in an excimer). In fact, the photophysical results may indicate that this is so. 
As previously mentioned, pyridyl substituents seem to have a greater influence on 
excimeric energy than phenyl substituents – in a head-to-tail arrangement, the pyridyl 
rings are likely to be involved in the intermolecular interaction (i.e. -), whereas the 
phenyl rings are too displaced to interact much with one another. Furthermore, the 
series of 1,3-dipyridylbezene complexes prepared by Williams et al., which contain 
differing substituents at the 4'-position (and no pyridyl substituents), all gave excimers 
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with energies comparable to [PtL1Cl] (between 690 – 700 nm), despite showing greater 
variation between their monomeric  emission energies.2 
Pt
N
N
Cl
Pt
N
N
Cl
 
Figure 53: Postulated arrangement of molecules in an excimeric interaction. 
 
4-Pyridyl Substituted Complexes: Electron Donating Substituents 
Excimer energy was found to increase significantly with increasing electron donating 
ability of the 4-pyridyl substituent (see Figure 54 a) and b), and Table 23). The energy 
separations between the excimeric emission maximum of each complex are summed up 
in Figure 55. 
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Figure 54: Normalised excimeric emission of a) 3',5'-difluorinated complexes containing electron 
donating 4-pyridyl substituents and b) their non-fluorinated analogues (DCM, 298 K). 
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Table 23: Wavelengths (and energies) corresponding to the excimeric emission maxima of the complexes 
containing electron donating 4-pyridyl substituents (DCM, 298 K). 
 
 Excimeric Emission    
max/nm (Energy / cm-1) 
 Excimeric Emission 
max/nm (Energy / cm-1) 
[PtL1Cl] 691 (14470) [PtL2Cl] 677 (14770) 
[PtL6Cl] 674 (14840) [PtL10Cl] 660 (15150) 
[PtL29Cl] 639 (15650) [PtL15Cl] 630 (15870) 
  [PtL16Cl] 660 (15150) 
  [PtL17Cl] 596 (16780) 
 
[PtL17Cl], which was found to have the highest energy monomeric emission, also has 
the highest energy excimeric emission (max = 596 nm, 16780 cm-1). The excimers of 
[PtL17Cl], [PtL15Cl], and [PtL29Cl] all emit at higher energy than the excimer of the 
unsymmetrical pyrazole/pyridine complex reported by Williams et al. (max = 650 nm, 
15400 cm-1), which to our knowledge is the highest energy excimer reported in the 
literature for N^C^N Pt(II) complexes.16  
 
[PtL17Cl] [PtL15Cl] [PtL10Cl] [PtL2Cl]
900 cm-1 720 cm-1 380 cm-1
[PtL29Cl] [PtL6Cl] [PtL1Cl]
810 cm-1 370 cm-1
Increasing Energy
220 cm-1 320 cm-1 300 cm-1
 
Figure 55: Energy separations between the excimeric maxima of complexes containing an electron 
donating 4-pyridyl substituent 
To re-The monomeric emission of the unsymmetrical complex [PtL16Cl] occurred at 
similar energy to [PtL2Cl] (see Section 3.4.1.4). However, the excimeric emission 
significantly differs between these two complexes: the excimeric emission of [PtL16Cl] 
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occurs at higher energy (15150 cm-1 and 14770 cm-1 respectively). The presence of the 
more electron rich 4-MeO-pyridyl ring in [PtL16Cl] appears to destabilise the excimer, 
despite having no effect on the monomer emission. Excimer formation involves an 
electron donor-acceptor interaction between an excited state and ground state 
molecule.35 The increased electron density in the substituted 4-MeO pyridyl ring of 
[PtL16Cl] may make the ground state a poorer -acceptor, weakening the interaction 
with an excited state molecule. This would account for the higher energy excimer 
emission relative to [PtL2Cl], which does not contain any pyridyl substituents. A similar 
observation was made by Williams et al., when comparing the excimeric emission of 
the unsymmetrical N^C^N pyrazole complex, complex 52, with that of [PtL1Cl] 
(Chapter 1, Section 1.7.3). 
 
4-Pyridyl Substituted Complexes: Electron Withdrawing Substituents 
Placing electron withdrawing CF3 groups at the 4-pyridyl position leads to a red shift in 
excimer emission relative to [PtL1Cl], regardless of whether or not fluorine substituents 
are present on the aryl ring (see Figure 56, Table 24). A similar observation was made 
for monomeric emission. Of this set of complexes, [PtL30Cl] displayed the lowest 
energy excimeric emission (max = 756 nm, 13230 cm-1). The excimeric emission of 
[PtL20Cl], the 3',5'-difluorinated analogue of [PtL30Cl], occurred at slightly higher 
energy (max = 733 nm, 13640 cm-1). Substitution of one CF3 group for an electron 
donating MeO- group in [PtL21Cl] slightly blue-shifted the excimeric band (max = 710 
nm, 14100 cm-1) relative to that of [PtL20Cl], indicating that the electron donating nature 
of MeO- had slightly offset the electron withdrawing effect of CF3.  In contrast, 
monomeric emission of these two complexes occurred at the same energy. This 
observation gives further support to the theory that the electronic nature of the 4-pyridyl 
substituent has a greater influence on excimeric emission than monomeric.  
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Table 24: Wavelengths (and energies) corresponding to the excimeric emission maxima of the complexes 
containing 4-trifluoromethyl-substituted pyridines (DCM, 298 K). 
 Excimeric Emission 
max/nm (Energy / cm-1) 
[PtL1Cl] 691 (14470) 
[PtL20Cl] 733 (13640) 
[PtL21Cl] 710 (14080) 
[PtL30Cl] 756 (13230) 
The excimeric emission of complexes [PtL20Cl], [PtL21Cl] and [PtL30Cl] remained 
weak, even from solutions of the highest concentration. The ksq values of these 
complexes are between 2 and 3 x 109 M-1 s-1, which are quite low when compared to 
most complexes investigated here. This indicates that such complexes have a lower 
propensity to form excimers. However, other complexes such as [PtL15Cl] and [PtL17Cl] 
have similar ksq values, yet display more intense excimeric emission bands. This could 
be because the excimers of [PtL15Cl] and [PtL17Cl] are more emissive than for the 
complexes involving CF3 pyridyl substituents. An experiment was designed to 
determine the relative brightness of the excimers, and is discussed in Section 3.4.3.5. 
 
Figure 56: Normalised excimeric emission of complexes containing electron withdrawing CF3 
substituents at the 4-pyridyl position (DCM, 298 K)  
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[PtL22Cl] 
As was found for the respective monomeric emission, the excimeric emission of 
[PtL22Cl] occurred at lower energy than [PtL1Cl] (707 nm and 691 nm respectively, E 
= 330 cm-1). Despite having an intermediate self-quenching constant (5.6 x 109 M-1 s-1), 
the intensity of this band remained weak at higher concentration. This implies that the 
complex readily forms excimers, but the luminescent efficiency of excimeric emission 
is low. 
 
Figure 57: Normalised excimeric emission of [PtL22Cl] (red), with that of [PtL1Cl] (blue) included for 
reference (DCM, 298 K). 
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3.4.3.4 Variation of the Energy of the Excimeric Band 2: Variation of the Ancillary 
Ligand 
 
Halide Exchange 
 
Figure 58: Normalised excimeric emission of the [PtL1X] series (DCM, 298 K). 
Excimeric emission occurred around 691 nm for both [PtL1Cl] and [PtL1Br], and at the 
slightly lower energy of 702 nm for [PtL1I], giving a maximum energy difference of 
only 230 cm-1. A similar situation was found when comparing the monomeric emission 
– substitution of the ancillary chloride of [PtL1Cl] with bromide or iodide hardly 
affected the energy. 
 
Substitution of Chloride for Cyanide 
Introduction of a cyanide ancillary ligand was found to significantly increase the energy 
of excimeric emission relative to the analogous chloride complex (by approximately 
800 cm-1, see Figure 59 and Table 25). This is significantly larger than the 
corresponding effect on monomer emission (~ 200 cm-1). Perhaps substitution with 
cyanide destabilises the donor-acceptor interaction necessary to form an excimer.  
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Figure 59: Normalised excimeric emission of a) [PtL15CN] (blue) and [PtL15Cl] (red) and b) [PtL17CN] 
(blue) and [PtL17Cl] (red) (DCM, 298 K). 
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Table 25: Comparison of the excimeric emission maxima of chloro and cyano analogues 
  [PtL17X] [PtL15X] [PtL2X] 
max / nm (Energy 
/ cm-1) 
 
X = Cl 
 
596    
(16780) 
 
630    
(15870) 
 
677  
(14770) 
  
X = CN 
 
 
569    
(17570) 
 
599    
(16690) 
 
643   
(15550) 
E (CN – Cl)        
/ cm-1  800 820 780 
 
3.4.3.5 Excimer Brightness 
The apparent intensity of excimeric emission varies between the complexes. To 
determine which complexes were the best excimeric emitters, the emission spectrum 
was recorded for a solution of each complex at a constant concentration (1.7 x 10-4 M, 
DCM, 298 K), and the intensities of emission were then compared (see Figure 60). Such 
knowledge could be useful in selecting suitable phosphorescent dopants for OLEDs. As 
can be seen from Figure 60, there is no apparent relationship between the energy of 
excimeric emission and the observed intensity of excimer emission, and complex 
[PtL9Cl], for which excimeric emission occurs at intermediate energy (compared to 
other Pt(II) complexes), has the most intense excimeric emission. 
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Figure 60: Excimeric emission of 1.7 x 10-4 M DCM solutions of the Pt complexes (298 K). This figure 
was used to compare the apparent intensity of excimeric emission between complexes. 
The apparent excimer intensity depends upon both the rate of excimer formation and the 
excimeric quantum yield. For example, some complexes exhibit bright excimeric 
luminescence, whilst having small ksq values (e.g. [PtL17Cl]). We can write an 
expression for the observed excimeric intensity: 
             
where Iobs is the observed intensity of emission, ksq is the self-quenching rate constant, 
[M] corresponds to the concentration of complex, krmon and knrmon correspond to the 
radiative and non-radiative decay rates of the excited monomer, obs corresponds to the 
lifetime of the monomer at that concentration, and em corresponds to the “brightness” 
of the excimer (takes into account the excimeric quantum yield).  
By dividing all of the emission spectra by ksq.obs ([M] is constant here), it should be 
possible to gain a crude approximation of the relative radiative efficiencies of excimeric 
emission. The emission spectra shown in Figure 61 are those from Figure 60 divided by 
ksq.obs. There appears to be a general trend by which the brightness of excimeric 
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emission decreases with decreasing excimeric emission energy. This trend appears to be 
following the energy gap law, which predicts that non-radiative decay will be more 
significant for systems with smaller T1-S0 gaps.     
 
Figure 61: This figure represents the emission spectra represented in Figure 60 divided by ksqobs for the 
individual Pt complexes. It gives a representation of the relative efficiencies of excimer emission. 
 
3.4.3.6 Mixed Excimer Effect 
It was of interest to consider what would happen to the excimeric emission if two 
complexes were mixed. In solutions of higher concentration, the excimeric emission of 
complexes [PtL15Cl] and [PtL5Cl] occur at significantly different wavelength (630 nm 
and 706 nm respectively, E = 1700 cm-1), making them suitable for such a study. 
Solutions containing a known ratio of these two complexes were prepared, and the 
emission spectra were recorded. To make the solutions, stock solutions of 2.4 x 10-4 M 
were prepared, and then mixed to the required ratios. An excitation wavelength of 376 
nm was selected, at which value the two complexes have equal excitation coefficients. 
Similar to solutions containing a single complex, the solutions of the mixed complexes 
displayed only one excimeric band. However, the energy maximum of the band was 
found to depend on the relative amount of the two complexes present (see Figure 62a).  
Hence, tuning of the excimeric band maximum between the extremes of the pure 
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complexes is possible – this effect could be utilised in white OLED design. A 
comparable effect was observed with other combinations of complexes, for example, 
Figure 62b shows the mixed excimer effect for [PtL17Cl] and [PtL1Cl] (max = 596 nm 
and 691 nm respectively, E = 2310 cm-1). 
 
 
Figure 62: Normalised excimeric emission of DCM solutions containing a) different ratios of 
[PtL5Cl]/[PtL15Cl] and b) different ratios of [PtL17Cl]/[PtL1Cl] (298 K). 
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It is not easy to tell whether the excimer bands from mixed solutions are due to a mixed 
excimer species, a sum of emission from the ‘pure’ excimers (formed between 
molecules of the same complex), or both. In an attempt to discover the origin of the 
excimer, the emission spectra of the two pure solutions were summed and normalised 
(w.r.t. excimer maximum), then superimposed with the spectrum obtained for the 50:50 
mixture (see Figure 63). The excimer bands have the same maximum energy, 
suggesting that the emission in mixed solutions could be a sum of the ‘pure’ excimers. 
However, the emission band of the 50:50 solution is narrower. In terms of white OLED 
fabrication, the identity of excimer configuration isn’t really important, just the energy 
of the excimer band.  
 
Figure 63: Comparison of the excimeric emission of a solution containing a 50/50 ratio of 
[PtL15Cl]/[PtL5Cl] (blue), with a spectrum created by taking the average of two spectra containing pure 
samples of [PtL15Cl] and [PtL5Cl] (red) (DCM, 298 K). 
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3.4.3.7 Aggregation Phenomena 
 
Behaviour in CH3CN/Water Mixtures 
As discussed in the introduction, the square planar geometry of platinum complexes 
lends itself to the formation of excimers and aggregates, and these bimolecular species 
are distinctly different. So far, we have only discussed excimers for these Pt(II) 
complexes, but aggregates also form under certain conditions.  
It was noticed that solutions of [PtLCl] complexes dissolved in CH3CN appear yellow, 
whereas CH3CN/H2O solutions containing a high water content appear pink. The 
absorption spectrum of solutions containing higher water content show a new band at 
lower energy, confirming that an additional species is absorbing, and that this species 
exists in the ground state. These observations may be rationalised in terms of aggregate 
formation - the intrinsic hydrophobicity and charge neutrality of these Pt(II) complexes 
lend themselves to the formation of aggregates when in contact with water.  
 
Figure 64: A 10 µM solution of [PtL2Cl] in CH3CN/ H2O (2:8), irradiated with long-wave UV light. 
The emission of the aggregate looks red under long-wave UV irradiation, as opposed to 
the blue/green emission of the monomer (Figure 64). If the concentration of complex is 
sufficiently high, the aggregate will precipitate out of solution and form a pink 
suspension. 
195 
 
 
Figure 65: Emission of [PtL2Cl] from acetonitrile solutions containing different water content. The 
legend refers to the percentage water content relative to acetonitrile, and the spectra have been normalised 
at the monomeric emission maximum (298 K). 
An experiment was designed to confirm the distinction between excimer and aggregate. 
In this experiment, we aimed to modulate the emission origin by slowly increasing the 
water content. A constant concentration of [PtL2Cl] was used throughout this 
experiment (4.4 x 10-5 M). This concentration is sufficient to give both monomeric and 
excimeric emission in 100% CH3CN solution. Solutions containing higher CH3CN 
compositions (100-85%) showed both monomeric and excimeric emission (around 470 
nm and 660 nm respectively), both of which shifted to higher energy as the amount of 
water increased (see Figure 65). This observation is consistent with the results of the 
solvatochromic studies described earlier (Sections 3.4.1.1 and 3.4.3.3), which implied 
that both the monomeric excited state and the excimer are destabilised in more polar 
media.   
Solutions containing between 25 and 50% H2O showed only monomeric emission – 
under  such conditions, the excimer is probably too unstable (high energy) to form. 
Above 50% H2O content, a broad, featureless aggregate band grows in at lower energy 
than the initial excimer emission occurred in solutions of lower water content (max  
725 nm). The intensity of this band relative to monomeric emission increases as the 
water content is increased, and the band can be tentatively assigned to an aggregate 
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rather than excimer. In this experiment, solutions of higher water content also showed a 
pink colouration, which has previously been ascribed to aggregate formation.  
 
Figure 66: Excitation spectra of [PtL2Cl] in a) pure CH3CN and b) a 1:9 CH3CN/water mixture, recorded 
at em 501 nm (blue) and 740 nm (red). 
The excitation spectra recorded for solutions containing 100% CH3CN and 1:9 
CH3CN/H2O, registered at higher (501 nm) and lower (740 nm) emission energy 
provide further support for the distinction between the origin of the two lower energy 
bands observed under the different conditions.36 In 100% CH3CN the excitation spectra 
at the two em are identical – confirming that the band occurring around 660 nm is 
excimeric. In 100% water, the excitation spectra at the two emission wavelengths are 
significantly different, indicating that they arise from the excitation of different ground 
state species. Such behaviour supports the notion that the band emitting around 725 nm 
is due to an aggregate. Similar results were observed for the [PtL15Cl] complex. 
Yam et al. have prepared similar studies on cationic terpyridyl Pt(II) systems involving 
acetylide ancillary ligands.37 Here, solutions of varying acetonitrile/diethyl ether content 
were prepared. As the proportion of ether was increased, solvent-induced aggregation 
was observed, and the new lower energy bands were assigned to a MMLCT state which 
resulted from increased Pt-Pt and - intermolecular interactions. Interestingly, the 
counter-ion was found to have a large impact on the extent of these intermolecular 
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interactions and hence aggregation. The counter-ion dramatically affected the colour of 
the solution – such systems show promise as colorimetric anion probes. 
 
Solid State Emission 
The solid state emission profiles were recorded for powder samples of the complexes 
(except for [PtL3Cl], [PtL8Cl], [PtL12Cl] and [PtL23], which were too weak). The solid-
state emission of many Pt(II) complexes depends upon the extent of intermolecular 
interactions, which are often sensitive to their environment. For example, intermolecular 
interactions can be perturbed by solvent or solvent vapour. For comparative purpose, all 
solids were obtained from the same solvent - the powders were obtained by dissolving 
each complex in DCM, then evaporating to dryness under a high vacuum. 38,39,40  
The solid state spectra were generally less structured, and there was no obvious trend 
between complex structure and emission energy/profile. Some of the complexes emitted 
at similar energy to the solution-based monomeric emission (e.g. [PtL1Cl], [PtL5-7Cl], 
[PtL9-11Cl], [PtL14Cl] and [PtL21Cl]) – these bands retained a degree of structure. Some 
of the complexes emitted at much lower energy than solution based monomeric 
emission (e.g. [PtL2Cl], [PtL17Cl], [PtL2CN], [PtL15CN] and [PtL17CN]) – these bands 
were typically broad and unstructured, and resembled aggregate/excimer emission. The 
remaining complexes displayed degrees of both types of emission in their profiles (see 
Figure 67 and Figure 68 for examples of solid state emission spectra).  
198 
 
 
Figure 67: Solid-state emission of the 3´,5´-difluorinated n-methylpyridyl isomers, [PtL9-11Cl]. [PtL12Cl] 
is not included because its emission was too weak to detect. 
 
Figure 68: Solid state emission of 3',5'-difluorinated complexes containing an electron donating 4-pyridyl 
substituent. 
The broad, unstructured emission at lower energy that was observed for some 
complexes is likely to arise from intermolecular interactions. In the powder, many 
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complex molecules will be sufficiently close to interact. It is not possible to say for 
certain what type of interactions exist in the powders, but the interactions may involve 
- interactions, Pt-Pt interactions, or a combination of both. From crystallographic 
data, we know that - intermolecular interactions occur in the crystal structure of some 
of the complexes (Chapter 2, Section 2.4.3.1). The Pt centres are always sufficiently 
displaced, and Pt-Pt interactions never occur. However, the powder is a more disordered 
phase than the crystal, so such interactions should not be ruled out, and the low energy 
emission may emanate from a 3MMLCT state.  
 
Figure 69: Solid state emission of [PtL11Cl] before (blue) and after (red) drying the complex under 
vacuum for an extra 2 h. 
[PtL11Cl] was one of the complexes which exhibited both structured and unstructured 
emission. After recording the initial powder spectrum, the sample was dried for an 
additional 2 h on the vacuum line. The powder spectrum was re-measured – the 
intensity ratio of the structured and unstructured emission had changed (the unstructured 
emission had gained intensity – see Figure 69). This further indicates that the solid state 
emission is very sensitive to its surroundings, and that the emission profile may differ 
between different samples of the same species. So, although we cannot say that the 
spectra recorded here represent the absolute solid state emission of each of the 
complexes, the spectra do show that emissive multimolecular interactions can occur in 
the solid state.  
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Solvent Effect on [PtL2Cl] 
The solid complex of [PtL2Cl] is sensitive to the presence of DCM. On evaporation 
from a DCM solution, the complex is initially obtained as a bright yellow solid. Further 
drying results in a marked colour change, giving a deep orange solid. The effect can be 
explained in terms of packing of the [PtL2Cl] molecules, which is evidenced in the 
respective powder emission spectra (Figure 70).  
 
Figure 70: Emission spectra of the yellow and orange solid forms of [PtL2Cl] 
The orange form shows only a broad structureless emission band, which occurs at lower 
energy than the solution based emission. In the powder, we can expect molecules to be 
sufficiently close to form intermolecular interactions, which probably accounts for this 
aggregate-like emission. The yellow form contains both structured emission at an 
energy comparable to the solution based monomeric emission, and a broad emission 
band at lower energy (surprisingly, the low energy component occurs at a different 
energy to the emission from the orange form). In the yellow form, DCM molecules may 
be interacting with the complex molecules, disrupting some of the intermolecular 
interactions. The relative intensity of the lower energy structureless band grew as the 
yellow sample was left over time. This was accompanied by a colour change back to 
orange, and probably represents the slower evaporation of the DCM molecules that 
were involved in weak interactions with the complex molecules.  
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3.4.4 Low Temperature Spectroscopy 
 
3.4.4.1 Emission at 77 K 
To obtain the emission spectra at 77 K, a small amount of complex was dissolved in a 
2:2:1 solvent mix of ether/isopentane/ethanol, and cooled with liquid nitrogen. This 
solvent mixture is chosen because it forms an inert transparent glass at 77 K. All 
complexes emitted at 77 K (see Table 26). The 77 K emission spectra of the complexes 
were more sharply structured than obtained at room temperature. The emission spectra 
of [PtL2Cl] at 77 K and 298 K are shown in Figure 71 as an example. For most 
complexes, the emission spectra at 77 K were slightly blue-shifted compared to room 
temperature, by approximately 200 cm-1. More significant blue-shifts were observed for 
[PtL8Cl], [PtL9Cl], [PtL12Cl] and [PtL13Cl] (520, 430, 420 and 530 cm1 respectively). 
All of these complexes have ground states that are distorted from planarity. The larger 
blue-shift observed on cooling is consistent with a requirement for a change in the 
conformation for maximal conjugation to be attained.2 
 
Figure 71: Emission spectrum of [PtL2Cl] recorded at 77 K in an EPA glass (blue), and at 298 K from a 
DCM solution (red). 
[PtL15Cl] exhibits a surprisingly large blue shift upon cooling to 77 K (780 cm-1). It is 
likely that the large shift stems from an intrinsic electronic effect within this molecule. 
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The analogous cyano complex, [PtL15CN], also exhibits a larger blue-shift than all other 
complexes (540 cm1), further indicating that the methoxy-substituents are intimately 
linked to the increase in energy observed at 77 K. The mono-methoxy functionalised 
complex, [PtL16Cl], does not display such a dramatic blue shift on cooling, indicating 
that the large shift is dependent upon the symmetrical substitution pattern in [PtL15Cl] 
and [PtL15CN], and is consistent with the theory that the LUMO-based orbitals of 
[PtL16Cl] will be localised on the unsubstituted pyridyl ring. 
For most complexes, the 0-0 transition remains the band possessing the greatest 
intensity at 77 K. Interestingly though, in the 77 K emission spectrum of [PtL20Cl], the 
0-1 vibrational peak intensity is greater than the 0-0 peak. At 77 K molecular motion is 
essentially frozen out – perhaps CF3-substituents enforce some significant distortion 
during the cooling process. This could tie in with the observation that concentrated 
DCM solutions of such complexes exhibit dramatic colour changes upon cooling 
(Section 3.4.1.5).  
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Table 26: The photophysical parameters of the complexes at 77 K, compared to 298 K. 
Complex Emission max at 77 K 
/nm 
Emission max at 
298 K /nm 
 E / cm-1 0 at      
77  K /µs 
[PtL1Cl] 486, 516, 548 sh 491, 524, 562 sh 210 6.4 
[PtL1Br] 486, 518, 550 491, 524, 562 sh 210 6.3 
[PtL1I] 486, 519, 553 sh 491, 524, 562 sh 210 3.9 
[PtL2Cl] 467, 478, 496, 526 472, 502, 536 sh 230 5.8 
[PtL2CN] 462, 474, 490 517 468, 498, 526 sh 280 12.6 
[PtL3Cl] 484 492, 515 340 0.6 
[PtL5Cl] 493, 527, 560sh 497, 529, 565 sh 160 6.0 
[PtL6Cl] 482, 516, 540sh 487, 521, 560 sh 210 6.3 
[PtL7Cl] 491, 526, 553 494, 528, 565 sh 120 7.1 
[PtL8Cl] 493, 519, 538 506, 529, 569 sh 520 6.3 
[PtL9Cl] 477, 508, 541sh 487, 513, 555 sh 430 5.6 
[PtL10Cl] 463, 482, 494, 520 467, 498, 529 sh 180 5.6 
[PtL11Cl] 473, 505, 530 478, 510, 543 sh 220 7.5 
[PtL12Cl] 484, 514 494, 530, 565 sh 420 0.7 
[PtL13Cl] 531 br 546 br 520 6.8 
[PtL14Cl] 493, 525, 563 499, 533, 573 sh 240 7.2 
[PtL15Cl] 445, 456, 472 461, 492, 519 sh 780 4.6 
[PtL15CN] 446, 477, 504 457, 488, 513 sh 540 7.9 
[PtL16Cl] 464, 499, 512 470, 502, 532 sh 280 6.3 
[PtL17Cl] 449, 478, 516, 539sh 455, 485, 512 sh 290 3.9 
[PtL17CN] 446, 477, 499sh, 540sh 450, 477, 503sh 200 7.9 
[PtL20Cl] 488, 522*, 558 497, 527, 575 sh 370 4.8 
[PtL21Cl] 496, 534, 553 sh 496, 528, 573 sh 0 3.8 
[PtL22Cl] 492, 528, 560sh 499, 533, 571 sh 290 6.2 
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3.4.4.2 Spectroscopy at Cryogenic Temperatures 
The high resolution excitation and emission spectra of [PtL1Cl] were measured at 
cryogenic temperatures (1.2 – 4.2 K), in the presence and absence of external magnetic 
fields, to gain further insight into the nature of the emitting state.41  
Based on experimental observations at room temperature (highly structured spectra, 
small Stokes’ shift, weakly solvatochromic emission, etc.), Williams et al. assigned the 
emission of [PtL1Cl] and related complexes to a primarily 3LC state.1 However, the 
lifetime of the T1 state is relatively short (7 µs) implying that there must be a significant 
contribution from the metal orbitals to the excited state to induce the necessary SOC. 
This idea is backed by theory. DFT calculations performed by Sotoyama et al. predict 
that the T1 and S1 states of such complexes contain significant 3MLCT admixture.4 They 
modelled [PtL1Cl] in the gas phase and found that the T1 and S1 states possess 25% and 
32% d* character respectively.  
Another way to assess the extent of metal contribution to the excited state is to 
determine the zero field splitting (ZFS) of the T1 state.42 Larger ZFS imply a greater 
SOC contribution and hence greater metal participation. Yersin et al. have created a 
scale that links the ZFS to the extent of MLCT character of the triplet state. The 
intrinsic properties of the T1 state cannot be measured at room temperature or 77 K, 
because of inhomogeneous broadening. 
To study the T1 state in detail, a low concentration of [PtL1Cl] was dissolved in n-
octane and cryogenically cooled to liquid helium temperatures. On cooling, the n-octane 
forms a polycrystalline host matrix, in which the platinum complex ‘guest’ molecules 
will lie in well defined positions (Shpol’skii matrix technique43). Applying this 
Shpol’skii technique results in highly resolved spectra, with line widths of a few cm-1 
(due to residual inhomogeneity). This is in contrast to the overlapping and relatively 
broad bands with half widths of approximately 500 cm-1 observed in the spectra 
measured in solution at room temperature.  
Sometimes the guest molecules can occupy several different orientations (sites) within 
the matrix. As a consequence, spectra obtained from Shpol’skii matrices often contain 
superpositions of spectra stemming from these different sites. It is possible to study one 
particular site in isolation (usually the most dominant site) by selective excitation with a 
dye-laser. Fortunately, all [PtL1Cl] molecules appear to occupy the same orientation 
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within the matrix, so site-selective excitation was not necessary here. The emission 
spectrum of [PtL1Cl] at 4.2 K is shown in Figure 72 (left), with the spectra recorded at 
300 K and 77 K overlaid for comparison. The distinct emission band occurring at 
20254 cm-1 corresponds to the electronic 0-0 transition from one specific substate of T1, 
the II substate. This was assigned based on the behaviour of the excitation and emission 
spectra at different cryogenic temperatures (Figure 72).  
 
Figure 72: Left: the emission spectrum of [PtL1Cl] in n-octane, recorded at different temperatures, and 
Right: the excitation spectrum and emission spectra of [PtL1Cl] recorded at cryogenic temperatures. 
The excitation spectrum at 4.2 K shows bands due to substates II and III. Substate I 
does not appear in the spectrum – its weakness indicates that substate I is largely 
forbidden, and therefore must contain less singlet admixture than II and III. The 
excitation and emission bands of substates II and III occur at the same energy indicating 
that these are purely electronic transitions. The relative intensity of the excitation peaks 
of substates II and III is 2.3. This represents the oscillator strengths of the transitions 
and indicates that II is a more allowed substate (i.e. contains a greater singlet 
admixture). This is borne out in the behaviour of the emission spectra at various 
temperatures – at higher temperatures, emission from substate II continues to dominate. 
Emission from substate I is observed at the lowest temperatures, 1.2 K and 1.7 K (and is 
accompanied by a lower energy phonon band), where thermal population of substate II 
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from substate I is not possible. The ZFS parameters of the emitting T1 state were 
determined from these electronic spectra: 
EII-I = 5.7 cm-1 
EIII-I = 9.9 cm-1 
The overall ZFS is 9.9 cm-1. The scale put together by Yersin et al. indicates that a ZFS 
of this magnitude is consistent with a mixed 3LC – 3MLCT state, containing a larger 
3LC contribution.42,44 
The emission spectrum of [PtL1Cl] at 14 K was recorded under several different 
magnetic field strengths (B = 0 – 12 T). As the field was increased the relative intensity 
of substate I also increased. Application of an external magnetic field induces mixing of 
the wavefunctions of the T1 substates (Zeeman effect), and the extent of mixing is 
proportional to the magnetic field strength. The greater degree of mixing of substate I 
with higher lying singlet states increases the allowedness of substate I, so that its 
emission dominates at higher field strength. The increased interaction at higher field 
also results in an increase in the splitting of the substates. At B = 0 T, the ZFS is 9.9 cm-
1
, whereas at B = 12 T the ZFS is 23 cm-1.  
Under normal conditions (B = 0 T), the relative intensity of the substate bands in the 
excitation spectrum indicate that substate II is most allowed, followed by substate III 
then substate I which is almost forbidden. The allowedness (oscillator strength) can also 
be approximated by measuring the individual decay times (lifetimes) of the substates. 
The shorter the lifetime, the more allowed the transition. A decay curve measured at 1.2 
K is shown in Figure 73. The decay is bi-exponential, and consists of a short component 
(300 ns) and long component (49.4 µs). The short component represents spin-lattice 
relaxation of II  I. The long component corresponds to the thermalised emission 
decay from all substates. At this temperature, emission from substate I will dominate.  
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Figure 73: Emission decay curve of [PtL1Cl] in n-octane at 1.2 K, after UV excitation at 355 nm. The 
emission was detected at the electronic 0-0 transition II  0 (20254 cm-1). 
To determine the individual emission decay of the substates, the temperature 
dependence of the thermalised emission decay was monitored (see Figure 74 a)). Along 
with the experimentally determined ZFS parameters, these data were fitted to Eqn. 5 to 
determine the lifetimes of the individual substates (values are given in Figure 74 a) 
inset).  
                          
The lifetime of substate I is significantly longer than that of substate II and III, again 
demonstrating the forbiddenness of this state. The ratio, kII/kIII is 2.4, and is in good 
agreement with the band intensity ratio (2.3) determined from the 4.2 K excitation 
spectrum. This indicates that substates II and III have comparable radiative and non-
radiative decay mechanisms. 
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Figure 74: Left: Thermalised emission decay of [PtL1Cl] in n-octane versus temperature after pulsed UV 
excitation at 355 nm. The emission was detected at the electronic 0-0 transition II  0 (20254 cm-1). The 
solid line represents a fit of Eqn. 5 to the experimental data. Right: the energy level diagram of [PtL1Cl], 
showing the individual properties of the T1 substates. 
A similar investigation was performed on [PtL2Cl]. This complex was dissolved in a n-
decane matrix, because the 1.2 K emission spectrum of [PtL2Cl] in n-octane was not 
highly resolved (indicates that the molecule doesn’t “fit” into the lattice sites of an n-
octane matrix). The total ZFS of T1 state in [PtL2Cl] was found to be 11.3 cm-1, which is 
slightly higher than that for [PtL1Cl], and indicates a greater MLCT contribution to the 
T1 state. The 1.2 K excitation spectrum of [PtL2Cl] revealed peaks corresponding to all 
three substates (see Figure 75), whereas the 1.2 K excitation spectrum of [PtL1Cl] only 
revealed peaks corresponding to substates II and III. 
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Figure 75: The excitation spectrum and emission spectra of [PtL2Cl] recorded at cryogenic temperatures 
(in n-decane). 
 
This observation indicates that substate I of [PtL2Cl] carries a higher allowedness than 
substate I of [PtL1Cl]. This was further confirmed upon analysis of the lifetimes of the 
individual substates: substate I of [PtL2Cl] has a much shorter lifetime than substate I of 
[PtL1Cl] (28 and 51 µs respectively).  
 
Figure 76: Left: Thermalised emission decay of [PtL2Cl] in n-decane versus temperature after pulsed UV 
excitation at 355 nm. The emission was detected at the electronic 0-0 transition II  0 (21135 cm-1).  Right: the 
energy level diagram of [PtL2Cl], showing the individual properties of the T1 substates 
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Halide Complexes 
The complexes, [PtL1Cl], [PtL1Br] and [PtL1I] were prepared to investigate the 
influence of the chloride ligand upon the photophysics. All complexes were found to 
emit at very similar energies (Section 3.4.2.1) with similar decay times, both at R.T. and 
77 K, indicating that the halide ligands were acting as spectator ligands (rather than 
chromophoric ligands). However, all theoretical studies on [PtL1Cl] predict that the the 
HOMO-based orbitals are partly located at the chloride ligand, whereas the LUMO-
based orbitals are not. This means that during the electronic transition, charge should be 
re-distributed from the chloride ligand, and the T1 state should be partly located at the 
chloride. We expected that detailed study of the T1 states would allow us to determine 
whether the halide ligand was truly ancillary, or whether the halide ligand was 
chromophoric (but resulting in subtle differences between complexes). 
 At cryogenic temperatures, the highly resolved spectra of the [PtL1Cl] and [PtL1Br] are 
very similar, however, [PtL1I] shows a larger splitting between substates I and II. From 
comparison of the energy level diagrams of the three complexes, we can see that the 
total ZFS increases slightly on going from Cl to Br to I. Hence, [PtL1I] contains the 
greatest 3MLCT character in its T1 state. This could be related to the fact that iodine is a 
heavier atom than bromine and chlorine, and has a greater spin-orbit coupling constant.  
 
Figure 77: Energy level diagrams of the series [PtL1X], showing how the ZFS increases with increasing 
size/mass of the halide (left: [PtL1Cl], middle: [PtL1Br] and right: [PtL1I]). 
These results indicate that replacement of the chloride ligand with bromide and iodide 
does have a small influence on the photophysical properties, despite the very similar 
behaviour observed at higher temperatures.  
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3.5 Pt(IV) Complexes 
While the photochemistry of cyclometallated Pt(II) complexes has been heavily 
investigated over the last few decades, much less research has been reported regarding 
the photophysics of cyclometallated Pt(IV) complexes. This may be because, in contrast 
to the respective Pt(II) complexes, the first platinum(IV) complexes prepared involving 
cyclometallated ligands were non-emissive at room temperature.45,46,47 
The first luminescent Pt(IV) complexes involving polypyridyl-type ligands were 
reported by Balzani et al.48 These complexes involve two cyclometallating ligands (2-
phenylpyridine or 2-(2-thienyl)pyridine), which introduce a sufficient ligand field to 
remove deactivating d-d* states to sufficiently high energy. Hence, creation of a 
stronger ligand field around Pt(IV) than Pt(II) is essential to observe luminescence. As a 
second example, [Pt(bipy)(CH3)3I] is emissive at room temperature, whereas 
[Pt(bipy)2Cl2]2+ emits only at 77 K. CH3- is a strong field ligand.49 
Platinum(IV) complexes of the form [PtLCl3] were prepared for several complexes, by 
passing chlorine gas through a chloroform solution containing the respective Pt(II) 
complex.50 These Pt(IV) complexes were found to absorb at higher energy than the 
respective Pt(II) complex (see Figure 78 for a representative example). 
 
Figure 78: Normalised UV-vis absorption spectra of [PtL9Cl3] (blue) and [PtL9Cl] (red). Measurements 
were performed in DCM at 298 K 
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These Pt(IV) complexes were only emissive at 77 K. Chloride is a weak field ligand, 
and the combination of three chlorides and one terdentate ligand does not create a 
sufficient ligand field splitting to allow emission at room temperature.  The 77 K 
emission of the Pt(IV) complexes occurred at higher energy than the analogous Pt(II) 
complex (see Table 27, and Figure 79 for a representative example). Unfortunately, 
although NMR indicated that the oxidation had gone to completion, emission from the 
Pt(II) precursor was always detected in the emission spectra of the Pt(IV) complexes. 
This was confirmed by comparing the 77 K and R.T. emission spectra, where emission 
from the Pt(II) species only was observed in the latter. The Pt(II) complexes are so 
emissive that trace amounts are sufficient to contaminate the Pt(IV) spectra.  
 
Figure 79: 77 K emission spectra of impure [PtL11Cl3] (blue) and [PtL11Cl] (red) from an EPA glass 
(spectra have been normalised at 474 nm). 
The Pt(IV) complexes had lifetimes in the range 1 – 2 s. The lifetimes are greater than 
those of the Pt(II) complexes by a factor of 105, which indicates a lesser contribution of 
the metal to the triplet state. In the higher oxidation state, the metal centred orbitals will 
be more contracted and will interact less with the ligand orbitals. 
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Table 27: 77 K emission and lifetimes of the Pt (IV) complexes (EPA) 
Complex Emission max at 77 K / nm 
(Energy / cm-1) 
0 at 77  
K / s 
[PtL2Cl3] 440 (22730) 1.3 
[PtL7Cl3] 462 (21650) 1.2 
[PtL9Cl3] 443 (22570) 1.0 
[PtL10Cl3] 439 (22780) 1.6 
[PtL11Cl3] 447 (22370) 1.3 
 
3.6 Application in OLEDs 
The complexes presented herein possess many properties that make them good 
candidates for OLED dopants. For example, the complexes are phosphorescent emitters, 
have high quantum yields, are charge-neutral and possess good thermal stability. 
Related complexes prepared by a previous group member were successfully 
incorporated into OLEDs, through collaboration with Drs V. Fattori and M. Cocchi 
from the Institute of Organic Photosynthesis and Photoreactivity, Bologna, Italy, giving 
devices with extremely high quantum efficiency and good performances.51 The colour 
of the device was tuned simply by varying the dopant concentration (i.e. 
excimer:monomer ratio). 
Some of the complexes reported here have been successfully incorporated into OLEDs 
as phosphorescent dopants ([PtL2Cl], [PtL6Cl], [PtL10Cl],52 and [PtL15Cl]53) – the 
properties of these devices are given in Table 28. Device architecture can play an 
important role in determining device efficiency – for example, the redox properties of 
the layers must be matched to the phosphorescent dopant, to achieve maximum 
emission (for more detailed descriptions, see reference 54). Here, the device architecture 
has been optimised to match the electronic properties of the [PtLCl] dopants: the typical 
device structure is shown in Figure 80. These devices consists of an indium-tin oxide 
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anode (ITO), N,N'-bis(m-tolyl)-1,1'-biphenyl-4,4'-diamine:bisphenol-A-polycarbonate 
(TPD:PC) and 4,4,4''-tris(N-carbazolyl-triphenylamine) (TCTA) hole transporting 
layers, an emissive layer consisting of the phosphorescent complex doped into a TCTA 
host matrix, a 3-phenyl-4-(1'-naphthyl)-5-phenyl-1,2,4-triazole (TAZ) electron 
transporting layer, and a LiF/Al cathode. The device is prepared by initially spin-
coating the TPD:PC layer onto the ITO anode, followed by subsequent vacuum 
deposition of all other layers. TCTA acts as an exciton blocking layer, preventing 
quenching by the non-radiative triplet of TPD, whereas TAZ acts as both an exciton and 
hole blocking layer, and the combined effect restricts the electron-hole recombination 
process within the emissive layer. Most devices prepared here display external quantum 
efficiencies in the range of 5 – 18.3% ph/e, power efficiencies of 0.47 – 11.8 lm/W and 
luminous efficiencies of 1.6 – 44.8 cd/A. The upper limits of these efficiencies are 
extremely high for such devices.  
 
Figure 80: The architecture of the LEDs, and the molecular structures of materials used. An energy level 
diagram is also shown, to help understand the exciton and electronic traffic within the devices. The 
HOMO values presented for each material correspond to their respective ionisation potentials, and the 
LUMO values correspond to the molecular electron affinity. The Fermi level positions for ITO and Al 
electrode contacts are added for completeness. The numbers correspond to electron volts and are relative 
to the vacuum level at zero energy.  
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Table 28: Performances of OLEDs prepared with [PtLCl] complexes. Each device is listed by 
concentration of the Pt complex in the emitting layer (at ~ 500 cd/m2). 
aAt ~ 10 cd/m2 
 
 
 
Complex Amount 
(%) 
Bias 
(V) 
j 
(mA/cm2) 
QE 
(%ph/e) 
PE 
(lm/W) 
LE 
(cd/A) 
CIE     
(x,y) 
CRI 
[PtL2Cl] 5 8.4 3.1 7.8 6.9 15.9 0.19,0.42 __ 
 
100 10.6 31.3 5.3 0.47 1.6 0.63,0.35 __ 
[PtL6Cl] 5 8.6 1.2 15.5 16.4 44.8 0.24,0.57 __ 
 
100a 19.0 9.6 0.1 0.02 0.1 0.57,0.40 __ 
[PtL10Cl] 5 8.8 1.5 13.0 9.3 26.0 0.18,0.35 __ 
 
10 8.7 1.7 18.3 11.8 32.7 0.27,0.37 63 
 
15 7.7 1.9 18.1 11.8 29.1 0.33,0.38 65 
 
20 7.6 2.6 14.9 8.3 20.2 0.45,0.38 68 
 
25 8.2 2.6 16.8 8.0 21.0 0.53,0.38 80 
 
100 8.7 3.7 14.7 5.0 13.9 0.61,0.38 __ 
[PtL15Cl] 5 11.8 4.7 6.1 2.8 10.7 0.18,0.27 __ 
 
10 11.4 3.6 7.6 3.8 13.7 0.23,0.30 __ 
 
15 11.6 2.5 10.9 5.4 20.0 0.28,0.32 70 
 
20 9.8 2.5 11.5 6.8 21.3 0.34,0.35 74 
 
25 10 2.1 13.6 7.9 25.0 0.39,0.37 78 
 
30 9.8 1.7 16.6 9.6 29.5 0.42,0.38 81 
 
35 10.8 1.7 17.0 8.7 30.0 0.47,0.39 80 
 
100 10 1.8 16.0 8.1 27.7 0.58,0.41 __ 
 The complexes under study all display blue/turquoise monomeric emission and 
red/orange excimeric emission, and the relative intensities are dependent upon 
concentration. Consequently, the colour of a device can be controlled by varying the 
dopant concentration.
dopant concentration for complex [PtL
concentration, through approximate white light emission
to emission occurring in the red region from the neat films. 
Figure 81: CIE chromaticity coordinates of OLEDs prepared with various concentrations of [PtL
These complexes, which display blue
previously investigated 1,3
white OLEDs, as they offer a greater coverage of the visible spectrum. Some of the 
devices prepared with these new complexes, using intermediate dopant concentrations, 
performed well as white light emitting devices (see 
consisting of 20% [PtL
very close to the equal energy point (0.33, 0.33) representing pure white light (see 
Figure 82). This device had a high CRI index of 74, and an external QE of 9.8
 Figure 81 shows how the CIE coordinates of a device varied
10Cl], from blue-biased emission at low 
 at intermediate concentration, 
 
-biased monomeric emission compared to 
-dipyridylbenzene Pt(II) systems,51 are better candidates for 
Table 28). For example, a device 
15Cl] dopant gave CIE coordinates of (0.34, 0.35), which are 
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10Cl] 
%.  
 Figure 82: a) The electroluminescence spectra of OLEDs containing various concentrations of [PtL
b) the CIE chromaticity coordinates of these devices and c) photographs of actual devices containing 
[PtL15Cl] (dopant concentration is given a
During the testing of [PtL
reported the use of [PtL
to ours (see reference
a) 
b) 
t bottom of each image). 
2Cl] as a phosphorescent dopant in OLEDs, 
2Cl] in another OLED device. The device composition differed 
 55). Jabbour also reported on the colour 
c) 
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15Cl], 
Jabbour et al. 
variation with dopant 
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concentration – for example, a blue device (CIE coordinates = 0.18, 0.32) incorporating 
2% [PtL2Cl] was prepared, with external QE of 8.6%, and a device consisting of 8% of 
this complex gave approximately white emission (CIE = 0.33, 0.36), with an external 
quantum efficiency of 9.3%. 
Our collaborators in Bologna realised that OLEDs displaying dual monomer/excimer 
emission may have application as horticultural lighting sources.56 They noted that plants 
tend to absorb in the blue and red regions of the visible spectrum, so under typical 
lighting, a large amount of energy is wasted. In contrast, the blue-biased monomeric 
emission and red excimeric emission observed from OLEDs involving our complexes 
can be tuned to give a good fit with the photosynthetic action spectrum of plants, 
resulting in minimal energy wastage. For example, a typical photosynthetic action 
spectrum shows an extremely good fit to the electroluminescence spectrum of an OLED 
containing 20% [PtL10Cl] (see Figure 83). Furthermore, a plant’s behaviour varies 
between seasons (morphogenesis). This behaviour is related to the position of the sun, 
i.e. the relative contributions of blue and red light. For example, provision of excess 
blue light stimulates greening and stem growth and enriches chlorophyll production 
whereas a greater red light contribution stimulates flowering, fruiting and seeding (the 
plants “think” winter is coming). By varying the OLED dopant concentration, it may 
therefore be possible to re-create the seasons, allowing control over plant 
morphogenesis.  
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Figure 83: a) Absorption spectra of chloroplast chlorophyll-a and -b, and carotenoids, and b) an action 
spectrum of photosynthesis (black) compared with the emission spectrum the OLED incorporating 20% 
[PtL10Cl] (red). Note the remarkable correspondence between the OLED spectrum and the action 
spectrum. 
 
3.7 Concluding Remarks 
A few groups have performed DFT calculations on the unsubstituted parent complex, 
[PtL1Cl] (Section 3.2). The calculations predict that the HOMO-based orbitals are 
localised along the central axis of the molecule (including the phenyl ring, the platinum 
centre and the ancillary ligand), and the LUMO-based orbitals are mainly localised on 
the lateral pyridyl rings. Using this as a starting point, rational structure modification 
has been employed to prepare complexes with tuneable emission. 
On considering the terdentate ligand, we realised that functionalisation of the phenyl 
ring should alter the energy of the HOMO-based orbitals more significantly than the 
LUMO-based orbitals. In most cases, experimental results agreed with theory. For 
example, placing fluorine at the 3,5-phenyl positions resulted in a blue shift – in these 
positions, fluorine is behaving as an electron withdrawing group, which causes greater 
stabilisation of the HOMO-based orbitals relative to the LUMO.   
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Placing electron donating groups on the lateral pyridyl rings was expected to have a 
greater destabilising effect on the LUMO-based orbitals, leading to a further blue shift. 
The validity of this assumption was assessed, by preparing two series of complexes 
containing methyl-substituents in each of the available pyridyl positions ([PtL5-8Cl] and 
[PtL9-12Cl]). Placing methyl-substituents at only one position, the 4-pyridyl position, led 
to a blue shift. Closer examination of the DFT results revealed two points, 1) the 
contour plots predicted by Williams et al. suggest that the other pyridyl positions also 
make a contribution to the HOMO-based orbitals, and 2) the 3-pyridyl position isn’t 
really involved in the LUMO-based orbitals. This may partly account for why placing 
methyl groups at the other positions did not lead to a blue-shift. 
To prepare complexes displaying increasingly blue-shifted emission, the 4-pyridyl 
position was functionalised with groups of greater electron donating character (-OMe 
and -NMe2). This led to complexes exhibiting the highest energy emission ever 
recorded for 1,3-dipyridylbenzene Pt(II) chloride systems (e.g. [PtL17Cl] and [PtL15Cl]). 
In further agreement with theory, incorporation of an electron withdrawing CF3-
substituent at the 4-pyridyl position led to a red-shift in emission (e.g. [PtL20-21Cl] and 
[PtL30Cl]). 
Substituting the ancillary chloride for cyanide led to a further blue-shift in emission – to 
our knowledge, [PtL17CN] and [PtL15CN] display the highest energy emission of any 
Pt(II) complex containing a terdentate ligand. Cyanide lies much higher up the 
spectrochemical series than chloride, and causes greater ligand field splitting. 
Furthermore, DFT predicts that the ancillary position makes a significant contribution to 
the HOMO, and cyanide is a more electron withdrawing group than chloride. On the 
contrary, substitution of chloride with other halides (Br- and I-) had virtually no effect 
on the room temperature emission – perhaps these ligands are too similar in character. 
Most of the Pt(II) complexes were found to be highly emissive from DCM solution at 
298 K, with quantum yields reaching as high as 0.87. The quantum yields of these 
complexes were found to be significantly higher than complexes involving analogous 
bidentate ligands, highlighting the importance of the extra rigidity conferred by the 
terdentate system. Unsymmetrical complexes ([PtL16Cl] and [PtL21Cl]) incorporating 
pyridyl rings which contain different substituents, show monomeric emission at similar 
energy to symmetrical complexes containing the most stable pyridyl ring (i.e. [PtL1Cl] 
and [PtL20Cl] respectively). This implies that the LUMO-based orbitals are localised on 
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the most stable pyridyl ring, which is consistent with the work of Williams et al. 
reported in reference 16.  
The emission profiles of complexes containing significant distortion from planarity 
([PtL8Cl], [PtL12Cl] and [PtL13Cl]) are much less structured, and the 0-1 and 0-2 
vibronic bands have higher intensity relative to the 0-0 band. These factors indicate that 
considerable differences in geometry exist between the ground and excited states. 
Furthermore, the quantum yields of [PtL8Cl] and [PtL12Cl] are very poor compared to 
most other complexes reported here ( = 0.03 and 0.02 respectively), in line with the 
idea that distortions disfavour radiative decay. However, the quantum yield of [PtL13Cl] 
is quite high ( = 0.75). The emission profiles of [PtL9Cl] and [PtL17Cl] are also 
broader with less structure. However, the crystal data for [PtL9Cl] indicates only slight 
deviations from planarity. Also, it seems reasonable to assume that [PtL17Cl] will be 
approximately planar (there are no unfavourable sterics). 19F NMR data for [PtL9Cl] 
indicate significant electronic perturbations exist in this molecule, through non-bonding 
overlap of the fluorine and methyl hydrogen atom orbitals (see Chapter 2, Section 
2.4.2.1). It is suggested that this electronic perturbation is responsible for the broader 
emission profile. Similarly, the NMe2 group is a very strong electron donor, and 
significant electronic reorganisation between the ground and the excited state may 
account for the broader profile of [PtL17Cl]. 
The Pt(II) complexes exhibited self-quenching via excimer formation in solution at 
elevated concentration. Self-quenching rate constants, ksq, were generally of the order of 
2-6 x 109 M-1 s-1, except for [PtL13Cl], which had a much lower ksq of 0.50 x 109 M-1 s-1. 
This complex contains significant steric interactions and distortions from planarity, 
which probably reduces the tendency to self-quench. The excimers of most complexes 
were found to be emissive, and the energy of this broad, structureless band was found to 
depend upon a) the nature of substituents present on the terdentate ligand and b) the 
identity of the ancillary ligand. However, the substituents altered the monomeric and 
excimeric emission to differing degrees. It seems that the nature of substituents on the 
pyridyl rings has more influence on excimeric emission energy than substituents on the 
phenyl ring – this may be related to the orientation adopted by the molecules forming 
the excimer.  
Excimeric emission was not observed for complexes [PtL8Cl], [PtL12Cl] and [PtL13Cl] 
under the concentration range studied (10-6 – 10-4 M). The extremely low ksq value 
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found for [PtL13Cl] indicates that this complex has a low propensity to form excimers. 
Unfortunately, ksq values for [PtL8Cl], [PtL12Cl] could not be determined due to the 
weakness of their emission. Therefore it is not possible to say whether these complexes 
have a low propensity to form excimers, or whether these complexes form excimers 
which only emit weakly (as found for monomeric emission).The Pt(II) complexes form 
aggregates in more polar solutions, which emit at lower energy than the monomer, but 
are distinctly different from excimers.  
The emission of the complexes has been examined at lower temperatures. Upon 
lowering the temperature, spectral resolution increases as the contribution from 
inhomogeneous broadening is reduced. At cryogenic temperatures (1.2 – 4.2 K), the 
spectra appear as individual bands with line-widths of a few cm-1 (residual 
inhomogeneity). Such high resolution allows the study of the individual substates of the 
T1 state. From this work, the zero-field splitting (ZFS) parameter could be determined – 
this value is useful in assessing the relative contribution of the metal to the excited state. 
ZFS parameters have been determined for [PtL1Cl] and [PtL2Cl] (9.9 cm-1 and 11.3 cm-1 
respectively). With reference to the scale devised by Yersin,44 the magnitude of these 
values indicates that the complexes emit from a state containing a 3LC/3MLCT 
admixture, but with a larger 3LC contribution. The ZFS parameters were determined for 
the [PtL1X] series of complex. The ZFS increases from 9.9 cm-1 for [PtL1Cl], to 13.1 
cm-1 for [PtL1I] – this indicates that [PtL1I] contains the greatest MLCT contribution to 
its T1 state. This could be related to the fact that iodine is much heavier, and has a 
greater spin-orbit coupling constant. These results indicate that the halogen atom does 
have a small influence on the photophysical properties, which would have been missed 
if only the room temperature and 77 K studies were considered. 
Some of these Pt(II) complexes have been incorporated into OLEDs as phosphorescent 
dopants (e.g. [PtL2Cl], [PtL6Cl], [PtL10Cl] and [PtL15Cl]). Devices ranging from blue 
emission to orange/red emission have been prepared for each complex investigated, 
simply by varying the concentration of complex (i.e. variation of the monomer:excimer 
ratio). Of particular note, devices displaying white emission have been prepared at 
intermediate concentrations – some of these WOLEDs have very similar CIE 
coordinates to pure white light (0.33, 0.33). For example, a device incorporating 20% 
[PtL15Cl] has CIE coordinates of 0.34, 0.35, and a CRI of 74. The OLEDs typically 
have external quantum efficiencies in the range of 5 – 18.3%, and devices at the top of 
this range are some of the most efficient OLEDs reported to date.  
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3.9 Comprehensive Photophysical Data 
 
Table 29: Photophysical data for the Pt(II) complexes, in DCM at 295 K 
Complex Absorbance max/nm      
( / L mol-1 cm-1) 
Emission max/nm 0 degassed 
(aerated) /µsa 
kSQ(self-
quenching)/109 
M-1 s-1 
lum degassed 
(aerated) 
kQ(O2 
quenching)/108 
M-1 s-1 
[PtL1Cl]b 332 (6510), 380 (8690), 
401 (7010), 454* (270), 
485* (240) 
491, 524, 562, 
691ex 
7.2 (0.50) 5.3 0.60 (0.039) 10.4 
[PtL2Cl] 320 (6687), 334 (9183), 
360 (7341), 374 (8498), 
437* (143), 467* (139) 
472, 502, 536sh, 
677ex 
7.9 (0.67) 6.0 0.85 (0.087) 6.2 
[PtL3Cl] 250, 285, 330, 388, 399, 
480* 
492, 515 0.78d (------)  ------f 0.03 (0.02) -----f 
[PtL5Cl] 322 (5180), 334 (5289), 
363sh (4383), 382 (6333), 
405sh (4299), 459*sh, 
489* 
 
497, 529, 565sh, 
706ex 
 
7.7 (0.34) 3.0 0.51 (0.024) 12.8 
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[PtL6Cl]c 326 (7820), 356 (6420), 
374 (8930), 400 (7040), 
479* (260) 
487, 521, 560, 
674ex  
10.0 (0.34) 8.3 0.73 (0.04) 12.6 
[PtL7Cl] 335 (12348), 360 (9145), 
370 (11206), 399 (8464), 
455*sh (284), 490* (130) 
494, 528, 565sh, 
688ex 
11.1 (0.58) 3.9 0.13 (0.001) 7.4 
[PtL8Cl] 327 (6503), 339 sh (6030), 
390 sh (6439), 413 (6733), 
492* (311) 
506, 529, 569sh  ------g -----g 0.03 (> 0.001) ------g 
[PtL9Cl] 323 (6030), 336 (8012), 
361 (6028), 375 (7105), 
444*(108),474* (85) 
487, 513, 555sh, 
681ex 
7.3  (0.49) 3.9 0.39 (0.20) 8.7 
[PtL10Cl] 316 (8905), 329 sh 
(10789), 358 (8997), 372 
(11323), 433* (179), 462* 
(150) 
467, 498, 529sh, 
660ex 
7.9 (0.70) 5.1 0.87 (0.088) 5.8 
[PtL11Cl] 322 (5823), 336 (8618), 
358 (6331), 372 (6729), 
442* (106), 473* (80) 
 
478, 510, 543sh, 
673ex 
10.5 (0.77) 3.7 0.67 (0.061) 5.3 
229 
 
[PtL12Cl] 292 (13885), 329 (5553), 
341 (5975), 382 (6475), 
475* (124)  
494, 530, 565sh ------g ------g 0.02 (0.0007) -----g 
[PtL13Cl] 327 sh (6302), 341 (6100), 
367 sh (4013), 386 (5735), 
488* sh (95)  
546br 7.7 (0.34) 0.5 0.75 (0.035) 12.8 
[PtL14Cl] 325 (6446), 343 (6725), 
374 sh (5191), 387 (6013), 
461* (100), 493* (85) 
499, 533, 573sh, 
678ex 
11.9 (0.62) 2.9 0.55 (0.039) 6.9 
[PtL15Cl] 294sh (6441), 306 (5683), 
352sh (5558), 368 (6809), 
427*sh, 445*, 455* 
461, 492, 519sh, 
630ex 
7.6 (0.58) 2.9 0.71 (0.068) 7.2 
[PtL16Cl] 314 (6348), 326 (6786), 
355sh (6013), 372 (7568), 
436*sh, 464* 
470, 502, 532sh 
660ex 
 
6.0 (0.74) 3.2 0.75 (0.079) 5.4 
[PtL17Cl] 319 (6580), 352 sh (9313), 
370 (13905), 418*sh 
(312), 443* (161) 
 
 
455, 485, 512sh, 
596ex 
4.7 (0.13) 2.1 0.60 (0.020) 34.0 
230 
 
[PtL20Cl] 334 sh (4470), 349 (6508), 
383 (8186), 453*sh (221), 
486 (171)* 
497, 527, 575sh, 
733ex 
5.6 (1.7) 2.6 0.59 (0.21) 2.6 
[PtL21Cl] 329 sh (4579),338 sh 
(4437), 369 (4820), 389 sh 
(3303), 427 sh (801), 480* 
(145) 
495, 528, 573sh, 
710ex 
5.5 (0.67) 2.0 0.57 (0.067) 
(0.038) 
2.0 
[PtL22Cl] 341 (4586), 367sh (6105), 
384 (8746), 460* (133), 
492* (126) 
499, 533, 571sh, 
707ex 
9.6 (0.67) 5.6 0.61 (0.10) 
(0.063) 
6.3 
[PtL23] 286, 308 sh, 373 sh, 390 494, 523, 560sh 23.0 (2.8)d ------f 0.08 (0.01) 1.4e 
[PtL25Cl] 375 (3328), 413sh, (3497), 
433sh (3506) 
554, 579sh 31.5 (0.15) 0.22 0.073 (0.011) 30.2 
[PtL26Cl] 320 (13490), 378 (3540), 
413 sh (3430), 436 (3730), 
504* (70)  
548, 580 24.1 (0.40) 0.28 0.31 (0.006) 11.2 
[PtL29Cl]c 310 (224010), 368 
(24960), 401 (19200), 
464* (330), 475* (310) 
 
481, 515, 553, 
639ex 
5.3 (0.37) 3.2 0.81 (0.05) 10.4 
231 
 
[PtL30Cl]c 284 (27900), 348 (4690), 
400 (11400), 503* (200) 
518, 548, 756ex 4.1 3.0 0.37 (0.087)  
[PtL1Br] 334 (7180), 380 (9720), 
401 (8120), 453* (210), 
485* (180) 
491, 524, 562, 
691ex 
9.9 (0.67) 6.9 0.61 (0.072) 6.3 
[PtL1I] 336 (4340), 385 (7130), 
404 (6050), 487* (160) 
491, 524, 562, 
702ex 
8.4 (0.46) 6.1 0.57 (0.047) 9.3 
[PtL2CN] 259, 285, 310, 319, 334, 
350, 433*, 463* 
468, 499, 527, 
643ex 
8.5 (1.5)d ------f 0.66 (0.19) 2.5e 
[PtL15CN] 263 (14300), 303 (5900), 
315sh (4210), 338sh 
(2890), 355, (3700) 440* 
(70) 
457, 488, 513, 
599ex 
8.0 (0.58) 2.3 0.61 (0.17) 7.3 
[PtL17CN] 289, 319, 337sh, 355, 381, 
440* 
450, 477, 511, 
569ex 
4.5 (0.17)d ------f 0.41 (0.05) 25.8e 
aLifetime at infinite dilution, bPhotophysical data taken from reference 1,  cComplexes prepared by previous group members, but data included for comparison, dlifetime recorded for 
a dilute solution (absorbance < 0.05), ekQ(O2) values calculated using lifetimes measured for dilute solution (rather than 0), flow solubility of the complex prevented determination of 
these values, gThese values could not be determined as the complexes were only weakly emissive, and their emission decay could not be detected, *Forbidden S  T absorption 
bands, sh = shoulder, ex = excimer, and br = broad. 
 
 
  
 
CHAPTER FOUR: 
Cation Sensor Complexes 
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4.1 Introduction 
The excited state energies of luminescent Pt complexes are often sensitive to local 
environment. Various groups have tried to take advantage of this sensitivity, by linking 
a luminescent complex to a group that is susceptible to binding a particular analyte. For 
example, luminescent Pt(II) complexes have been appended with crown ether and 
azacrown groups, which selectively bind certain cations.1,2,3 Binding of a cation perturbs 
the electronic environment within the molecule, affecting the environment around the 
Pt(II) centre and causing a change in the absorption and/or emission. The crown ether 
units themselves are non-emissive, and it is therefore difficult to detect cation binding 
without linkage to a spectroscopically active group (here, the Pt(II) complex).  
The group of J-L. Fillaut and V. Guerchais, Rennes, have been studying the ion 
selectivity of 3-hydroxyl/ethynyl flavone-appended metal complexes. Cornard et al. had 
previously demonstrated that free hydroxyflavones selectively bind to cations (in 
particular, Pb2+), and this binding could be followed by monitoring the absorption 
spectrum.4,5 Fillaut et al. initially thought that, by incorporating a 3-hydroxyflavone into 
the ligand structure of a luminescent metal complex, the absorbance and emission 
would shift into the visible region of the spectrum (and out of the UV-region where 
many organic species absorb and emit), aiding the sensitivity of detection. 
Ru
O
ORO
PPh2Ph2P
PPh2Ph2P
MeCN
R'
PF6
R           R'
1a        H           H
1b        H           OH
1c        CH3       H
 
Figure 1: Molecular structures of flavanol-based Ru complexes, 1a – 1c. 
In 2008, the group reported a series of flavanol-based alkynyl ruthenium complexes 
(Figure 1).6 The anion binding properties reported focus on complex 1a. Acetonitrile 
solutions of this complex absorb and emit in the visible region (em = 565 nm), and the 
emissive state has a lifetime of 2.1 ns, under both degassed and aerated conditions. This 
very short lifetime suggests that the emission is fluorescence, which emanates from a 
flavanol-based singlet state. This is despite the presence of the heavy metal – many 
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ruthenium coordination complexes emit via phosphorescence. This implies that in the 
excited state, the flavanol unit is effectively decoupled from the metal centre. The ion 
binding capability of this complex was tested with a selection of metal perchlorate salts 
(Li+, Na+, Ba2+, Ca2+, Cd2+, Mg2+, Co2+, Cr2+, Ni2+, Zn2+ and Pb2+) in acetonitrile. 
Absorbance and emission titrations were performed with each cation – addition of Na+, 
Ba2+, Ca2+, Mg2+, Co2+ and Cr2+ did not cause any significant changes in the 
photophysical spectra. In contrast, addition of Pb2+ resulted in a large red-shift in both 
absorbance and emission (Figure 2), which was accompanied by a decrease in quantum 
yield.  
 
Figure 2: Changes in a) the absorption and b) the fluorescence spectra of 1a (5 x 10-5 M), in air-
equilibrated CH3CN upon addition of Pb2+ cations in the form of their perchlorate salt (1 x 10-2 M). Taken 
from reference 6. 
These ion-binding studies led to the conclusion that this sensor bound to Pb2+ with a 1:1 
stoichiometry. The studies revealed that Ni2+ and Zn2+ cations also affected the 
fluorescence of the sensor, indicating a binding interaction. However, the fluorescence 
response was different to that observed upon binding to Pb2+. Addition of Ni2+ quenched 
the emission without causing any shift. Addition of a small amount of Zn2+ caused an 
initial decrease in intensity, but as the amount of Zn2+ was increased, an additional 
shoulder appeared at higher energy. The effects that these two cations have on emission 
are not as pronounced as the effect caused by Pb2+, and higher concentrations are 
required. Based on these results and previous studies by Roshall et al.,7,8 it was 
concluded that binding of Pb2+, Ni2+ and Zn2+ to the sensor involved formation of a 
chelating complex, in which the carbonyl and 3-hydroxy oxygen atoms participate. 
a) b) 
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In the same year,9 the group published results for other flavanol-based cation sensors. 
These sensors involved a luminescent Pt(II) complex bound to a flavone unit via an 
ethynyl linker (see Figure 3 for structures).  The sensors were charge-neutral, and 
contained bulky tert-butyl groups, which sterically inhibit undesirable intermolecular 
interactions. All complexes were highly emissive (max 565-570 nm, CH3CN, 298 K), 
and the emissive states were found to have relatively long lifetimes (12 – 20 µs) 
compared to related Pt C^N^N complexes that do not contain flavanoid substituents 
(e.g. for [Pt(tBu2-phbpy)(-CC-Ph)],  = 0.8 µs10). The emission was assigned to a 3IL 
state, associated with the appended flavones perturbed by the Pt centre.   
N
N
Pt
O
ORO
R =
OMe
O
OMe
Me2a
2b
2c
 
Figure 3: Molecular structures of Pt complexes 2a-2c, which contain a flavones-based alkyne ligand 
Complex 2b was found to have a high selectivity for Pb2+ binding. The photophysical 
properties of this complex were highly perturbed upon addition of Pb2+, but remained 
practically unaltered in the presence of all other cations tested (Figure 4). For example, 
with increasing Pb2+ concentration, the emission band at 565 nm decreased in intensity, 
and a new band at around 450 nm grew in intensity. 
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Figure 4: a) Changes in the absorption spectra of 2b (10-5 M), in CH3CN upon addition of Pb(ClO4)2. The 
inset shows the plot of A0/(A0 – A) against [2b]/[Pb2+]. b) The emission spectra of 2b (10-5 M), in CH3CN 
upon addition of Pb(ClO4)2 (ex = 393 nm). Images taken from reference 9. 
From the dramatic changes observed in the photophysics, it could be concluded that 
binding of Pb2+ causes a profound alteration in the excited state properties of the 
molecule. Further evidence as to how Pb2+ affected the excited state came from a closer 
examination of the distinct emission bands. It was found that the profile of the higher 
energy band, and the lifetime associated with it (1.7 ns, em = 450 nm) were similar to 
those of the free flavone acetylide unit.  Also, upon addition of Pb2+, the lifetime 
monitored at em = 570 nm is much shorter (~ 700 ns) than in the absence of Pb2+, and is 
of a similar magnitude to related N^N^C Pt(II) complexes that do not contain a flavone 
substituent. These effects have been rationalised as follows: upon binding to Pb2+, the 
highest occupied flavone-localised orbitals decrease in energy, breaking the partial 
conjugation with the Pt(II) centre that was initially responsible for the formation of the 
flavone triplet excited state. Effectively, interaction between the flavone-unit and 
Pt(C^N^N)(-CC) unit is lost, and  the new band around 450 nm corresponds to 
fluorescence from the 1IL state of the flavone. Furthermore, the origin of the band 
around 570 nm switches from a 3IL state associated with the appended flavone 
perturbed by the Pt centre, to a 3MLCT state associated with Pt unit, as the flavone 
orbitals become decoupled from those of the Pt(C^N^N)(-CC) moiety upon the 
addition of Pb2+. 
 
 
 
a) b) 
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It was speculated that sensor 2b binds to Pb2+ in the manner shown in Figure 5. The 
binding interaction involves the ketone oxygen and the terminal oxygen. The oxygen in 
the 3-position of the flavones is not involved in binding (complex 2a displayed no 
affinity for any of the cations tested, providing further evidence for this).  Furthermore, 
increasing the length of the polyether arm led to a loss of selectivity: complex 2c was 
found to bind to a greater selection of cations. 
N
N
Pt
O
OO
O
Pb2+
 
Figure 5: Postulated binding mode of complex 2b with Pb2+. 
The interaction between the complex and lead binding domain is quite remote – it was 
believed that the sensory properties could be improved if the two regions were directly 
linked (i.e. if the flavone was directly attached to the terdentate ligand). Based on this 
rationale, two new complexes have been prepared in collaboration with the group of 
Fillaut and Guerchais (structures shown in Figure 6). Our group specialises in the 
preparation of luminescent Pt(II) complexes involving N^C^N ligands. Such complexes 
often have superior photophysical properties compared to related N^N^C systems, as 
discussed in Chapter 1.  
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[PtL25Cl] [PtL26Cl]
Pt
Pt
Cl
Cl
 
Figure 6: The two new complexes prepared to be tested as cation sensors. 
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4.2 Synthesis  
 
4.2.1 Synthesis of Ligands HL24 – HL26 
The synthesis of these ligands could be envisaged by O-alkylation of 3,5-
dipyridylphenol (HL24). However, the yield of this compound from the Stille reaction of 
3,5-dibromophenol with 2-tri-n-butylstannylpyridine was only 15%. We therefore 
adopted the alternative strategy of O-alkylation prior to Stille coupling (see Scheme 1). 
3,5-Dibromophenol was alkylated with 1,2-dibromoethane using Williamson ether 
synthesis conditions (note, a 15-fold excess of 1,2-dibromoethane was used to minimise 
di-alkylation). In such alkylations, the presence of a carbonate base promotes generation 
of a highly reactive alkoxide ion in situ. The alkoxide attacks the alkylating group 
(usually a primary haloalkane) via an SN2 process. This reaction is disfavoured in protic 
and apolar solvents (such solvents lower the availability of free nucleophile), so 
acetonitrile and DMF are commonly used. Both solvents were tested here – acetonitrile 
is the preferred solvent, as it is much easier to isolate products from it. The second step, 
connecting the flavanoid group, is also a Williamson ether synthesis – these reactions 
proceeded well and were generally high yielding.  
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Table 1: The synthesis of ligands HL24 – HL26: the reactive precursors and the conditions employed. 
Ligand Precursors Synthetic 
Procedure 
Solvent Catalyst System Yield / % 
HL24  
               
N N
OH
 
 
         
  
N SnBu3
OH
Br Br
 
 
 
Stille 
 
 
Toluene 
 
 
Pd(PPh3)2Cl2 
 
 
15 
 
HL25 
           
O
O
OO
N
N
 
                       
O
OO
N
SnBu3
O
Br
Br
 
 
 
 
 
Stille 
 
 
 
 
Toluene 
 
 
 
 
Pd(PPh3)2Cl2 
 
 
 
 
29 
 
HL2
O
O
OO
O
N
N
 
 
O
OO
O
N
SnBu3
Br
Br O
 
 
 
 
Stille 
 
 
 
Stille 
 
 
 
Toluene 
 
 
 
Xylene 
 
 
 
Pd(PPh3)2Cl2 
 
 
 
Pd(PPh3)2Cl2 + PPh3 
 
 
 
29 
 
 
 
47 
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BrBr
OH
BrBr
O
Br
O
O
O
Br
Br O
O
HO
O
Pd(PPh3)2Cl2,
LiCl
Toluene
N
SnBu3
O
O
O O
N
N
K2CO3
Cs2CO3
dry CH3CN
1,2-dibromoethane,
  K2CO3,
      Cs2CO3
            dry CH3CN
Scheme 1: Synthesis of flavanoid appended ligand, HL25 (note: the same synthetic steps were taken to 
prepare HL26, but step 1 was performed in Rennes by P-H. Lano). 
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4.2.2 Synthesis of complexes [PtL25Cl] and [PtL26Cl] 
Complexation with Pt(II) was achieved by refluxing in acetic acid for 3 days. The 
respective complexes, [PtL25Cl] and [PtL26Cl] were obtained in moderate yield (35% 
and 53% respectively). Characterisation using 1H NMR and MS (ASAP) confirmed that 
the complexation reactions had been successful (see Chapter 2, Section 2.4.2). Slow 
evaporation of solvent (MeOH/DCM 1:1) gave crystals of [PtL25Cl] suitable for X-ray 
diffraction. The molecular structure confirms the expected connectivity – an ORTEP 
diagram is shown in Figure 7. 
 
Figure 7: Molecular structure of [PtL25Cl], with displacement ellipsoids set at the 50% level. Selected 
bond lengths (Å) and angles (deg): Pt-C 1.882(9), Pt-N 2.025(8) and 2.039(8), Pt-Cl 2.417(3), N-Pt-N 
161.0(3), C-Pt-Cl 178.1(3). 
As found for most of the [PtLCl] complexes (Chapter 2, Section 2.4.3.1), the [PtL25Cl] 
molecules pack in one-dimensional chains, in which neighbouring molecules are 
aligned in a head-to-tail fashion. The mean plane of the flavone unit is approximately 
parallel to the plane of the Pt N^C^N unit. 
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Figure 8: Packing of [PtL25Cl], as viewed along the b-axis. 
 
4.3 Photophysics 
 
4.3.1 Absorbance 
The absorption spectra of DCM solutions of these complexes contain very intense 
absorption bands between 230 and 320 nm, which can be assigned to ligand-based 1-* 
transitions, and intense bands occurring between 350 – 450 nm that can be assigned to 
charge transfer transitions (see Figure 9 and Table 2). The lowest energy absorption 
maxima occur at lower energy than most other complexes prepared during the project, 
possibly due to transitions with significant intraligand charge-transfer character.11 
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Figure 9: Normalised UV-vis absorption spectra of [PtL25Cl] (green) and [PtL26Cl] (red), with that of 
[PtL1Cl] (blue) included for comparison (DCM, 298 K). 
 
Table 2: Solution-based photophysical properties of [PtL25Cl] and [PtL26Cl] (DCM, 298 K), with that of 
[PtL1Cl] included for comparison. 
Complex Absorbance max/nm    
( / L mol-1cm-1) 
Emission 
max/nm 
0 degassed 
(aerated)/µsa 
lum degassed 
(aerated) 
[PtL1Cl]b 332 (6510), 380 (8690), 
401 (7010), 454* (270), 
485* (240) 
491, 524, 562 7.2 0.60 (0.039) 
[PtL25Cl] 375 (3328), 413sh, 
(3497), 433sh (3506) 
554, 579sh 31.5 (0.15) 0.07 (0.01) 
[PtL26Cl] 320 (13490), 378 (3540), 
413 sh (3430), 436 
(3730), 504* (70) 
548, 580 24.1 (0.40) 0.31 (0.006) 
aLifetime at infinite dilution, bPhotophysical data taken from reference 12, *Forbidden S  T absorption 
bands 
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4.3.2 Emission 
[PtL25Cl] and [PtL26Cl] emit at significantly lower energy than the majority of Pt(II) 
complexes prepared during the project {18050 cm-1 (554 nm) and 18250 cm-1 (548 nm) 
respectively}. Also, the emission profiles are broad and less structured (see Figure 10). 
The quantum yields are relatively low for Pt(II) complexes involving a 1,3-
dipyridylbenzene ligand, and the lifetimes are extremely long. The longer lifetimes 
indicate a smaller metal contribution to the excited state. The emission behaviour is 
comparable to complex 2b, prepared by the Rennes group, in the absence of cation. 
Perhaps the emission of [PtL25Cl] and [PtL26Cl] also emanates from a 3IL state localised 
on the flavanol unit, that has been perturbed by the presence of the heavy platinum.   
The complexes did not show excimeric emission under the concentration range studied 
(10-6 – 10-4 M). Their ksq values are very low compared to most Pt(II) complexes 
prepared here, indicating that the lack of excimer emission probably stems from a lower 
tendency to undergo intermolecular interactions than from the excimers being 
particularly weak emitters here. The large flavanoid substituents probably hinder close 
contact of two molecules, which is necessary for excimer formation.   
 
Figure 10: Normalised emission spectra of dilute samples of complexes [PtL25Cl] (green), [PtL26Cl] (red) 
with emission spectrum of [PtL1Cl] (blue) included for reference (DCM at 298 K). 
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4.4 Preliminary Cation Binding Studies 
The absorption and emission spectra of both complexes were monitored in the presence 
and absence of an excess of an array of cations. These experiments were performed in 
degassed acetonitrile, as both the complex and the metal salts were soluble in this 
solvent.  
For both [PtL25Cl] and [PtL26Cl], the lowest energy absorbance band was found to blue-
shift in the presence of cation (which was also visually apparent, as a “bleaching” of the 
yellow colour), but this effect was unselective to which cation was added. For a 
representative example, see Figure 11. 
 
Figure 11: UV-vis absorption spectra of [PtL26Cl] in the absence (red) and presence of certain cations 
{Ni2+ (green) and Pb2+ (blue)}. The spectra were recorded in CH3CN at 298 K. 
The emission of complex [PtL25Cl] was affected by all cations tested (see Figure 12). 
All cations had a quenching effect, but this effect varied between cation. For example, 
the quenching caused by addition of Ba2+ and Mg2+ was accompanied by the appearance 
of a new band at lower energy (~ 610 nm), whereas Pb2+, Zn2+ and Ca2+ just appeared to 
cause a similar reduction in intensity. The complicated emission responses observed 
with all cations tested therefore renders [PtL25Cl] unsuitable as a sensor for specific 
cations. 
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Figure 12: The emission spectra of [PtL25Cl] (2 x 10-5 M) in CH3CN, in the absence (dark blue) and 
presence of excess cations (see legend). The cations were added as their perchlorate salts. (ex = 400 nm, 
298 K). 
The emission intensity of [PtL26Cl] was also found to decrease in the presence of cation, 
and was accompanied by a switch of maximum peak intensity from the 0-0 vibrational 
band to the 0-1 vibrational band. This time however, the complex was more sensitive to 
Pb2+ cations – the emission was almost completely quenched in the presence of excess 
lead (see Figure 13).  
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
Figure 13: The emission spectra of [PtL26Cl] (2 x 10-5 M) in CH3CN, in the absence (dark blue) and 
presence of excess cation (see legend). The cations were added as their perchlorate salts. (ex = 398 nm, 
298 K). 
 
4.5 Concluding Remarks 
In summary, the photophysical properties of complex [PtL25Cl] are perturbed by all 
cations, and selectivity is low. The poor selectivity of [PtL25Cl] may be due to steric 
constraints present within the complex, preventing a binding site of suitable size from 
being created. [PtL26Cl] contains an extra CH2CH2O unit in the diethyl ether bridging 
arm, so should contain fewer steric constraints. The absorbance spectrum of complex 
[PtL26Cl] shows an unselective hypsochromic shift upon addition of all cations. Again, 
addition of all cations causes a decrease in intensity of emission, but with this complex, 
the effect seems most pronounced with Pb2+, which almost quenches the emission 
entirely. [PtL26Cl] therefore may have some application as a sensor for Pb2+ cations 
(perhaps at lower concentrations), but further work must be done (e.g. determination of 
binding constants) to say for sure. Regardless, [PtL26Cl] will never be as effective as a 
Pb2+ sensor as complex 2b previously prepared by the Rennes group, in which the 
absorbance and emission appear to respond solely to this cation. 
 
0.0E+00
5.0E+05
1.0E+06
1.5E+06
2.0E+06
2.5E+06
3.0E+06
450 500 550 600 650 700 750
Em
is
si
o
n
 
In
te
n
si
ty
 
/ a
.
u
.
Wavelength / nm
[Pt(L26)Cl] only
Ba2+
Mg2+
Zn2+
Ca2+
Pb2+
247 
 
4.6 References 
 
1. Q-Z. Yang, L.Z. Wu, H. Zhang, B. Chen, Z-X Wu, L-P. Zhang and C-H. 
Tung, Inorg. Chem., 2004, 43, 5195-5197 
2. V. W-W. Yam, R. P-L. Tang, K. M-C. Wong and K-K. Cheung, 
Organometallics, 2001, 20¸4476 - 4482 
3. P-H. Lanoë, H. Le Bozec, J. A. G. Williams, J-L. Fillaut and V. Guerchais, 
Dalton Trans., 2010, 39, 707-710 
4. L. Dangleterre and J-P Cornard, Polyhedron, 2005, 24, 1593 – 1598 
5. J. P. Cornard and J. C. Merlin, J. Molec. Struct., 2003, 651-653, 381 – 387 
6. J-L. Fillaut, J. Andris, R. D. Marwaha, P-H. Lano, O. Lohio, L. Toupet and 
J. A. G. Williams, J. Organometallic Chem., 2008, 693¸228 – 234 
7. A. D. Roshal, A. V. Grigorovich, A. O. Doroshenko, V. G. Pivovarenko and 
A. P. Demchenko, J. Photochem. Photobiol. A: Chem., 1999, 127, 89 
8. A. D. Roshal, A. V. Grigorovich, A. O. Doroshenko, V. G. Pivovarenko and 
A. P. Demchenko, J. Phys. Chem. A, 1998, 102, 5907  
9. P-H. Lano, J-L. Fillaut, L. Toupet, J. A. G. Williams, H. Le Bozec and V. 
Guerchais, Chem. Commun., 2008, 4333 – 4335 
10. W. Lu, B-X. Mi, M. C. W. Chan, Z. Hui, C-M. Che, N. Zhu and S-T. Lee, J. 
Am. Chem. Soc., 2004, 126, 4958 
11. D. L. Rochester, S. Develay, S. Záliš and J. A. G. Williams, Dalton Trans., 
2009, 1728-1741 
12. J. A. G. Williams, A. Beeby, E. S. Davies, J. A. Weinstein and C. Wilson, 
Inorg. Chem., 2003, 42, 8609-8611 
 
 
 
 
 
 
 
 
  
 
CHAPTER FIVE:  
Application of Luminescent Organometallics 
as Bio-imaging Agents 
  5.1 Introduction 
The living cell, often referred to as the building block of life, consists of a complex 
array of “machinery” (organelles), which carry out specific functions that are essential 
for life.1,2 For example, the mitochondria are associated with respiration and providing 
the cell with energy in the form of ATP, and the nucleus
genetic material and a large selection of proteins, controls the activities of the cell by 
regulating gene expression.
1.   
Figure 1: Diagram of a mammalia
Through cellular imaging, it is possible to study biological function, via the study of 
cellular dynamics. Diseases often target certain organelles, causing changes in 
morphology for example. By following such changes it may be possible to get a deeper 
understanding of how such a disease functions, potentially
of a suitable treatment. Drugs often work by binding to target biomolecules. Following 
these binding events will lead to a greater understanding of the drug
more effective drugs to be developed.
 
, which contains most of the 
 A basic representation of a eukaryotic cell is given in 
n eukaryotic cell, taken from reference 3. 
 leading
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Figure 
 
 to the development 
’s action, allowing 
 5.1.1 Fluorescence Microscopy
Microscopy is commonly used to observe the intracellular environment. The technique 
is direct and non-invasive, allowing cells to be observed in their natural state, without 
disruption of normal cellular function. A sub
very popular with biochemists, as the technique is highly sensitive and can be used to 
observe specific sub
luminescent stain prior to imaging; this stain should be of low toxicity. 
Fluorescence microscopes typically consist of a light source, an excitation filter, a 
dichroic mirror, an emission filter and a detector 
Figure 2 for an inverted fluorescence microscope. The inverted part simply refers to the 
fact that emission is detected below the sample. The excitation filter, dichroic mi
and emission filter are chosen to match the photophysical properties of the luminescent 
stain. The dichroic mirror acts to separate the excitation and emission beams 
dichroic mirror has an associated transition wavelength value, and wavelengths
this value (i.e. the excitation beam) will be reflected, but wavelengths longer than this 
value (i.e. emission) will be transmitted. The filter sets help to tune the excitation and 
emission wavelengths 
light that may have traversed the mirror, helping to improve the signal
Figure 2: Schematic diagram of an inverted fluorescence microscope, showing how the filters and 
dichroic mirror function to allow only emitted light from the sample to reach the detector.
 
-set of this, fluorescence microscopy
-cellular components. The cells must normally 
– a schematic diagram is shown in 
– the emission filter acts as a second barrier 
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With conventional wide-field fluorescence microscopy, the entire sample is illuminated 
at once. As a consequence, the whole sample is excited simultaneously (even 
lumophores outside the focal plane), and the detected fluorescence often includes a 
large unfocused background contribution. In comparison, confocal fluorescence 
microscopy offers greater resolution and the ability to create three-dimensional images.5 
This method utilises point-illumination, so that only a small section of the sample is 
illuminated at one time. To obtain the full image, the emission must be scanned over a 
regular raster, and the technique is often combined with scanning discs or moving 
mirrors. Because the technique focuses on a thin slice of the sample, confocal 
microscopy can be used to create 3D images.  
 
5.1.2 Luminescent Labelling Agents 
As discussed earlier, to apply fluorescence microscopy to imaging of the intracellular 
environment, cells must first be “marked” with a luminescent stain. Most commercially 
developed organelle stains are based on organic fluorophores, a selection of which are 
shown in Figure 3.6,7,8,9,10 The majority incorporate structures of extended conjugation, 
which absorb UV-light and emit in the visible region. Cells are dosed with the bio-
marker for a specified time length, during which, uptake (typically via diffusion) and 
site-specific localisation occurs.  
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Figure 3: A selection of commercial fluorophores. 
Such molecules can involve complicated syntheses and as a consequence can be 
expensive. Other downsides include photo bleaching with time and small Stokes’ shifts: 
overlap of the excitation and emission bands can lead to difficulties in finding 
appropriately matched filter sets. It is therefore desirable to target new lumophores with 
more optimal characteristics.  
Characteristics that should be considered during development of new lumophores 
include: 
• Low cytotoxicity – it is no good if the lumophore causes cell death, or induces 
morphological changes within the cell 
• Uptake – the lumophore should enter the cell without need for any chemical 
stimulated permeabilisation of the membrane, as this again may alter the natural 
behaviour. Low molecular weight, hydrophobic molecules are generally 
favoured. 
• Localisation – the lumophore should target a specific intracellular location, or 
involve a structure that can be readily appended with a non-luminescent 
targeting group 
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• Stability – the lumophore should be stable in the imaging environment, and 
should display good photostability (i.e. should not degrade upon excitation with 
light). 
Quantum dots (Qdots) have been employed in live cell fluorescence imaging.11 These 
are emissive nanoparticles of semiconducting material, which behave differently from 
the bulk or individual molecules. For example, the emission energy of Qdots is easily 
tuned by variation of the particle size, morphology or its constituents. Typically, the 
smaller the particle size, the higher the emission energy - it is therefore easy to tailor the 
photophysical parameters to the desired application. Qdots typically possess high 
quantum yields, large Stokes’ shifts, and narrow emission bands, and are inert to 
photobleaching.  
 
Figure 4: Solutions of monodisperse CdSe nanocrystals with increasing diameter (2 to 7 nm) from left to 
right. (Image taken from reference 12). 
Unfortunately, the inorganic components of Qdots (e.g. cadmium selenide) are highly 
toxic, so for live cell imaging purpose, the nanoparticles must first be coated with an 
inert shell. As a consequence Qdots suitable for bio-imaging can be expensive to 
produce. Also, in some cases, degradation of the protective coating has been observed, 
and the long term in vivo behaviour needs further study.13 Qdots are unresponsive to 
their local environment, so must also be appended with biorecognition molecules that 
are capable of targeting desired biomolecules.14  
Various lanthanide complexes have been developed as intracellular imaging 
agents.15,16,17,18 A large amount of this work has been undertaken by the Parker group, 
who are also based in Durham. These complexes display several advantages over 
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standard organic fluorophores: 1) larger Stokes’ shifts and narrow emission bands, 2) 
insensitivity to dissolved oxygen, 3) long emissive lifetimes (allowing time resolved 
spectral or microscopic acquisition) and 4) a good chemical stability profile.15 
Unfortunately, lanthanide ions are rather toxic, so sophisticated ligand systems are 
required, which completely encapsulate the ion. Secondly, direct excitation of the Ln3+ 
ion involves a parity (Laporte) forbidden transition, and is very inefficient (  1 M-1 
cm-1).16 Hence all lanthanide complexes require the incorporation of an antennae 
chromophore, further complicating the ligand architecture. The position and 
connectivity of this sensitizer group does allow the intracellular behaviour of the Ln3+ 
complexes to be varied. 
Organometallic systems incorporating heavy metal ions and polypyridyl ligands and/or 
their cyclometallated analogues are often luminescent, and as exemplified in Chapter 1, 
such complexes are often exploited in OLEDs and luminescent sensors. Recently, a few 
groups have started to look at the applicability of these organometallic complexes in 
luminescence-based live-cell imaging, and the initial reports look very 
promising.19,20,21,22,23,24 Such complexes often possess high quantum yields, large 
Stokes’ shifts, and a stability towards photobleaching: all of which are desirable 
properties of potential bio-markers. Unlike traditional fluorophores, functionalisation of 
the polypyridyl ligand structure is relatively easy, allowing facile incorporation of 
groups that target specific intracellular locations/biomolecules. Modification of the 
structure of the polypyridyl backbone also allows greater control over the photophysical 
properties of a complex. Additionally, the organometallic complexes involving 2nd and 
3rd row metals emit light via phosphorescence, a relatively long-lived process. Such 
complexes are thus suitable candidates for time-resolved emission imaging (Section 
5.1.5). One possible flaw is that phosphorescent organometallic complexes are 
quenched by oxygen, which results in the formation of oxygen in its singlet state. 
Singlet oxygen is much more reactive than triplet oxygen, and is toxic to living cells.  
 During this project, the intracellular behaviour of Pt(II) complexes and some related 
Ir(III) complexes have been studied, hence literature examples of related complexes will 
take up the rest of this introduction. It should be appreciated, however, that other 
phosphorescent organometallic systems (e.g. ruthenium23,25,26 and rhenium24,27,28,29) are 
also being investigated as probes for fluorescence cell imaging. 
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5.1.3 [Pt(trpy)R](+) Complexes and their Interaction with Biomolecules 
N
Pt
NN
R
Pt
NN
Cl
[Pt(trpy)R](+) [Pt(L1)Cl]
 
Figure 5: Structures of [Pt(trpy)R]+ and [PtL1Cl]. 
There are many examples of [Pt(trpy)R](+) complexes interacting with biomolecules in 
the literature.30,31,32 Aside from the difference in charge, the structure of these 
complexes is very similar to the 1,3-dipyridyl benzene Pt(II) complexes prepared during 
the project, and it might be expected that the [Pt(dpyb)X] complexes may interact 
similarly with biomolecules. In particular, if X is displaced by, for example, a water 
molecule, then the charge increases to +1, resembling even more closely the trpy 
systems. It is therefore important to consider the literature reporting these interactions. 
Furthermore, knowledge of the results of such in vitro studies may be useful in 
interpreting the results obtained from intracellular studies. 
Terpyridyl based Pt(II) complexes are well established as DNA intercalators.30,32,33,34,35 
The planar, extended aromatic structure of the trpy ligand inserts between the base pairs 
of DNA, and forms non-covalent intermolecular binding interactions with the DNA 
strand. These Pt complexes exhibit a preference for binding between G-C base pairs – 
the positively charged Pt(II) centre is stabilised via interaction with two guanine O6 
atoms.36 Intercalation results in modification of the physical properties of DNA (length, 
melt temperature, viscosity, etc.), and alters the UV-vis spectra of the complexes. 
Binding of the complexes to DNA also leads to induced circular dichroism. 
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Figure 6: Top: X-ray crystal structure of deoxycytidinyl-(3´,5´)-deoxyguanosine:[Pt(trpy)S(CH2)2OH]+ 
(2:2) looking down the a-axis, and Bottom: Schematic representation of a normal helix (left) and the 
neighbour exclusion binding (right) of an intercalator (shaded area) to a double stranded polynucleotide 
(demonstrating distortions to the DNA structure upon intercalation). Images sourced from reference 36. 
In addition to intercalation, covalent binding to DNA has been observed for [Pt(trpy)R]+ 
complexes containing labile Pt-ancillary bonds (i.e. Pt-Cl, Pt-O and Pt-N type 
bonds).30,37 For example, [Pt(trpy)Cl]+ and [Pt(trpy)OH]+ bind to DNA via both 
intercalation and covalent binding. Modelling studies involving DNA-base adducts have 
revealed that covalent binding of complex with DNA (platination) occurs at the N7 
position of guanine. 
[Pt(trpy)R]+ complexes can also bind to other biomolecules, such as proteins.38,39 Kostic 
et al. have screened the binding of [Pt(trpy)Cl]+ with amino acids, and have found that it 
binds only to three chemical moieties present in certain amino acids.38 These are the 
thiol of cysteine, the imidazole in histidine and the guanidine unit of arginine. Binding 
of complex to amino acids containing these groups was evident from the appearance of 
new bands in the UV-vis spectrum, the 1H and 195Pt NMR, and in the mass spectrum.  
[Pt(trpy)Cl]+ also binds to other sulphur-containing molecules, such as glutathione.32 
Glutathione is a tripeptide with antioxidant behaviour, that helps protect cells from 
reactive oxygen species such as free radicals and peroxides.40,41 In some cases, it plays a 
role in detoxification of foreign species that may enter the cell, via direct conjugation 
= [Pt(trpy)R]+ 
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with the toxin.42 Kinetic studies indicate that binding to thiol-containing biomolecules 
occurs approximately 300 times faster than binding to imidazole-containing molecules, 
suggesting a stronger interaction occurs between Pt(II) and sulphur than between Pt(II) 
and nitrogen.38 This observation is easily rationalised – platinum(II) is a relatively soft 
centre and sulphur is a soft donor, whereas nitrogen is a hard donor.  
 
5.1.4 Platinum in Cells 
Since the discovery of the anti-cancer behaviour of cis-platin in 1965,43 a vast amount 
of research has been conducted around the development of platinum-based 
drugs.44,45,46,47,48 As a consequence, most cell-based studies involving Pt(II) complexes 
have focused around the anticancer activity of such species, and the development of 
phosphorescent platinum complexes as imaging agents is a relatively new area. Some 
groups have developed intracellular oxygen sensors based on luminescent platinum-
porphyrin systems,49,50 but so far, only two groups (ours and Lam et al.) have studied 
the applicability of luminescent Pt(II) complexes as bio-markers for intracellular 
components. 
Platinum(II) complexes of the form [Pt(N^C^N)Cl], where N^C^N is a 1,3-di(2-
pyridyl) benzene ligand, have recently been explored as intracellular imaging agents by 
our group.19 These complexes rapidly enter the cell (within 5 minutes) and retain their 
emission. The cytotoxicity of the complexes in the three cell lines studied (human 
dermal fibroblast (HDF), melanoma C8161 and Chinese hamster ovary (CHO)) was 
relatively low, despite the complex being a moderately good sensitizer of singlet oxygen 
in aqueous media. This was accounted for by shielding of the complex by large 
hydrophobic biomolecules within the cell. Despite a structural similarity to anticancer 
drugs such as cis-platin (i.e. a labile Pt-Cl bond), the complex did not appear to be more 
toxic to the cancerous melanoma cells. 
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Figure 7: Determination of the intracellular localisation of [PtL1Cl] by co-staining experiments.19 CHO-
K1 cells were incubated with [PtL1Cl] (100 µM) and DAPI (300 nM) for 5 min, then fixed using 4% 
(wt/vol) paraformaldehyde. Samples were mounted for epifluorescence microscopy and visualised by 
using a magnification x 100 oil-immersion objective lense. Left: [PtL1Cl] localisation was identified by 
using the FITC channel (ex = 485 nm; em = 520 nm), Middle: DAPI was used to identify nuclei (ex = 
400 nm; em = 460 nm) and Right: Superimposed [PtL1Cl] and DAPI images (Scale bar: 5 µm). 
Confocal fluorescence microscopy and co-staining studies with DAPI indicate 
localisation of the platinum complexes in the nucleus, and optimum emission is 
observed from nucleoli. These platinum complexes were found to display readily 
detectable emission upon two-photon excitation in the near-infrared region. The 
application of two-photon excitation to bio-imaging has several advantages. Prolonged 
exposure to high energy UV radiation can damage cells (phototoxicity), or lead to 
photobleaching of the label, so the ability to excite the luminescent label with lower 
energy radiation is much preferred. Secondly, the relatively inert infra-red radiation can 
penetrate deeper into biological material than UV-radiation, meaning two-photon 
emission microscopy can be used to image tissues as well as isolated cells.  
 
 
Figure 8: A two-photon excitation high-resolution emission image of live CHO cells incubated with 
[PtL1Cl] obtained under 758 nm, 180 fs excitation (Scale bar: 10 µM). Image taken from reference 19. 
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The group of Lam et al. have recently published several reports involving 
[Pt(N^N^C)Cl] systems (N^N^C = a derivatised 2-phenyl-6-(pyrazol-3-yl)pyridine unit) 
as bio-imaging agents (see Figure 9).20,51,52 Like the related N^C^N systems just 
discussed, these complexes possess two-photon induced luminescence properties, and 
images can be obtained after only a 5 minute incubation of the cells with complex. The 
unsubstituted parent complex, complex A, which contains a proton bound to the 1-
pyrazolyl position, emits from within cells but does not appear to localise in any 
specific organelle.20 On the contrary, B, which contains a triphenylphosphonium group 
linked via the 1-pyrazolyl position targeted the nucleus, and in particular the cell 
nucleoli.51 Cytotoxicity studies revealed that this complex is a potent inhibitor of RNA 
synthesis. Isolation of nuclear components indicated that this complex did not bind to 
DNA or RNA, but bound to proteins, implying that the localisation in the nucleus is 
mediated by binding with nuclear proteins.  
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Figure 9: A selection of Pt(II) N^N^C complexes prepared by Lam et al., and investigated as intracellular 
imaging agents. 
Rational structure modification of complex A gave complex C.52 The incorporation of a 
hydrophobic C18 chain replacement of the ancillary chloride with a para-trisulfonated 
triphenylphosphine resulted in a water soluble complex with amphiphilic properties. 
This complex was rapidly taken up by cells and two-photon microscopy revealed that 
the complex targeted the cell membrane (Figure 10). Although the toxicity analysis 
indicated that this complex is not toxic at the dose and incubation length used to 
generate Figure 10, the cells look rather unhealthy (note the rather balled up appearance 
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of the cells, especially in Figure 10 d)). Perhaps the long chain present on the complex 
is having a destabilising effect on the membrane.  
 
Figure 10: a) Linear confocal microscopy image (ex = 400 nm) of HeLa cells after 30 min of exposure to 
complex C from Figure 9 (1 µg/mL in the culture medium). b) Two-photon (ex = 720 nm, filter band-
pass for em = 500 – 550 nm) confocal microscopy image after 30 min of exposure to complex C. c) A 
3.5x magnified duplicate of b. d) Bright field image of a and b (Scale bar: 20 µM). Images taken from 
reference 52. 
 
5.1.5 Time-resolved emission imaging 
The three fundamental emission parameters are wavelength, intensity and lifetime.19 To 
date, most luminescent imaging has made use of spatial variation of emission intensity, 
or differences in wavelength. Intensity is often influenced by uptake efficiency and the 
local environment, and intensity based imaging generates mainly qualitative results. 
Secondly, many biomolecules are naturally fluorescent, and spontaneous emission can 
interfere with the images obtained. Additional factors such as scattering, reflection and 
natural fluorescence of the microscope objective and immersion oil can all add to this 
interference, further reducing the contrast of the image.53 Recently, advances have been 
made into luminescent lifetime-based imaging. Unlike intensity, the lifetime of a 
luminophore is often independent of concentration, and can be calibrated absolutely. 
Temporal imaging therefore offers a more quantitative analysis, which is fully 
complementary to the more traditional luminescence microscopy techniques. 
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Most commercial bio-imaging agents are fluorescent, and therefore have lifetimes of the 
order of a few nanoseconds (0.5-20 ns). Fluorescence lifetime based imaging (FLIM) 
allows images to be created based on the lifetime of the bio-marker(s) – for example, 
intracellular areas can be discriminated if biomarkers with different fluorescent lifetimes 
are incorporated.54 This is particularly useful if the spectral properties of the bio-
markers are similar. In some cases, the lifetime of the marker is affected by the 
environment (i.e. changes in pH, oxygen concentration, etc.),55,56,57 and FLIM can be 
used to probe the surroundings of the fluorophore. As FLIM is used to study such small 
changes in lifetime, subnanosecond light sources and fast detectors are required, which 
can prove quite costly and involve complicated set-up. Another disadvantage is that the 
inherent autofluorescence of naturally occurring biomolecules also occurs on the 
nanosecond timescale, and so can still cause interference in the image. 
Time-resolved emission imaging microscopy (TREM), which makes use of longer 
lifetimes (hundreds of nanoseconds to milliseconds), potentially offers solutions to the 
problems faced by FLIM.53 The technique does not need such fast excitation or 
detection methods (can be performed with nanosecond lasers and slower gated 
detectors), and autofluorescence can easily be removed from the images by application 
of a time gate (time-gated emission imaging).  
 
Figure 11: Diagrammatic illustration of the concept of time gating to eliminate short-lived background 
fluorescence, and of time slicing to monitor the temporal decay of emission and obtain quantitative data 
(image taken from reference 19). 
A time-gated image simply requires a delay to be set between excitation and acquisition 
of the image. If the delay is long compared to the lifetime of autofluorescence (a few ns) 
but short compared to the lifetime of the lumophore (e.g. ~ of the order of 1 µs for 
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organometallic phosphors) then the gated image will be devoid of interference from 
autofluorescence. In the situation so described, a delay of 50 – 100 ns is ideal. The 
technique can be taken a step further if a series of delays are used with a finite gate time 
in each case (e.g. ~ 100 ns in the above example), during which the intensity is 
measured (see Figure 11). In this case, a plot of the emission for each time slice versus 
the delay time will yield the kinetics of decay of the luminophore. This can become 
powerful if the luminescence lifetime of the bio-marker is highly sensitive to the local 
environment or to binding with other species. 
Development of TREM has been hindered by a lack of suitable phosphorescent 
luminophores, which are both cell permeable and of low toxicity.19 Luminescent 
organometallic bio-markers may be ideally suited to TREM and time-gated imaging 
(e.g. long phosphorescent lifetime, high quantum yields, etc.). However, few have been 
investigated to date. Of these few cases, Haas et al. have used a time-resolved module to 
monitor the phosphorescence of Pt(II) porphyrin-based complexes from within strongly 
autofluorescent tissues and cells.58,59 These Pt(II) complexes were linked to antibodies 
which target specific biomolecules. Application of a delay between removal of the 
excitation pulse and acquisition of the luminescent image allowed the phosphorescence 
of the bio-marker to be detected in the absence of autofluorescence, improving image 
contrast. Unfortunately, the Pt(II) porphyrin complexes are quite cytotoxic – they have 
long phosphorescent lifetimes ( ~ 100 µs), which encourage sensitisation of singlet 
oxygen within the cell.  
One can envisage that complexes displaying shorter phosphorescent lifetimes should 
display lower toxicity via O2 sensitisation, and be more suitable as TREM agents. Pt(II) 
complexes of the form [Pt(L)Cl], where L = a 1,3-dipyridylbenzene system, typically 
exhibit lifetimes on the low microsecond timescale ( ~ 5 µs).  Such complexes have 
recently been investigated as TREM imaging agents by our group.19 The quantitative 
kinetics of the emissive decay could easily be monitored in different cells and even 
within different regions within the same cell. From these studies, the lifetime of 
[PtL1Cl] in the nucleus was determined (760 ± 100 ns).  
The analytical power of time-gated imaging was demonstrated by using the technique to 
study cells that were co-labelled with fluorescein and [PtL1Cl]. Fluorescein, with its 
emissive lifetime of 3.6 ns, labels living cells unanimously and provides a good model 
for autofluorescence. Images recorded immediately after the laser pulse were dominated 
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by fluorescein emission, and it was not possible to discriminate any intracellular 
regions. Images recorded after a 10 ns delay showed emission emanating from only 
[PtL1Cl], which localises in the cell nuclei. The majority of the fluorescein emission had 
decayed during the delay. 
 
Figure 12: Time-gated cellular imaging: live CHO cells pre-incubated with [PtL1Cl], imaged in the 
presence of a basic solution of fluorescein. The images were taken at 0 ns (Left) and at 10 ns (Right) 
delays after the 355 nm laser pulse (Scale bar: 10 µm, images taken from reference 19). 
 
5.1.6 Iridium Complexes as Bio-imaging Agents 
Iridium(III) complexes involving polypyridyl ligands or cyclometallated analogues are 
often highly luminescent. They typically possess large Stokes’ shifts and 
phosphorescent lifetimes of the order of a few microseconds. Very recently, reports 
involving such complexes as bio-imaging agents for live cells have started to appear 
amongst the literature.21,22,60,61,62 The first of these reports appeared in 2008, and 
involved two structurally related Ir(III) complexes, containing two 4,6-difluorophenyl 
pyridine ligands and a N^N ligand (Complexes 1  and 2, see Figure 13).22 In an aerated 
DMSO/PBS (pH 7, 49:1) solution at ambient temperature, complex 1 was found to emit 
at 530 nm, whereas complex 2 was found to emit at 643 nm (ex 360 nm), and both 
complexes had quantum yields exceeding 3%. The lower emission energy of complex 2 
was attributed to the higher level of conjugation in the N^N ligand. Cellular uptake of 
these complexes was found to be rapid – intense images were obtained after only 10 
min incubation with a 20 µM solution. Emission was observed from the cytoplasmic 
region of the cells. Spectrum scan experiments revealed intracellular emission maxima 
of 512 nm and 617 nm for cells dosed with complexes 1 and 2 respectively, confirming 
that the emission corresponded to the Ir(III) complexes. Cytotoxicity studies indicated 
that the complexes were relatively non-toxic (IC50  100 µM), and photostability studies 
revealed that the complexes were significantly more stable to photobleaching than 
DAPI, a commercially available stain for cell nuclei. 
263 
 
N
Ir
N
N
F
F
PF6
2
N
Ir
N
N
N
F
F
PF6
2
1
2
 
Figure 13: Confocal luminescence images (left) and luminescence intensity profile (right, recorded 
across the lines shown in a) and c)) of HeLa cells incubated with 20 µM of complex 1 (top) or 2 (bottom) 
in DMSO/PBS (pH 7, 1:49 v/v)  for 10 min at 25  C. The signal-to-noise ratios (I2/I1) and cytoplasm-to-
nucleus ratios are also shown (ex = 405 nm). Images and charts were taken from reference 22. 
Related complexes, incorporating long alkyl chains on the N^N ligand were prepared by 
Lo et al. – these complexes were also found to localise in the cytoplasm.62 Lo et al. 
believe that the complexes are interacting with hydrophobic organelles such as the 
endoplasmic reticulum, mitochondria and Golgi apparatus, however no co-staining 
studies were reported. Lengthening of the alkyl chain led to an increase in lipophilicity 
of the complex. The increase in lipophilicity was expected to correlate with increasing 
uptake and hence cytotoxicity, however this was not found to be the case. For example, 
the complex which contains the longest alkyl chain displayed the lowest cytotoxicity, 
despite being the most hydrophobic, and therefore most likely to cross the cell 
membrane. One possible suggestion for this was that the complex was so hydrophobic, 
that aggregation in the dosing solution reduced the tendency to enter cells. 
Internalisation was not observed for any complex when cells were dosed at 4  C: at this 
temperature, energy-dependent processes are suppressed, and lack of uptake therefore 
indicates an activated uptake route.63 
In 2009, Lo et al. investigated intracellular uptake of Ir(III) complexes containing biotin 
groups attached to the polypyridyl ligands.60 These complexes were found to possess 
low cytotoxicity (IC50 > 400 µM), whereas the un-biotinylated analogue prepared for 
comparison was found to be much more potent (3.2 ± 0.4 µM). In this case, the lower 
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cytotoxicity of biotinylated complexes did correlate with a lower lipophilicity and lower 
uptake rate (biotin is a relatively polar group). Like all previous examples, these Ir(III) 
complexes were all found to localise in the cytoplasmic region of the cell. The 
biotinylated complexes gave a punctate emission pattern from discrete vesicles within 
the cytoplasm, whereas for the non-biotinylated complex, emission from these discrete 
vesicles was accompanied by a more diffuse emission from throughout the cytoplasm. 
Uptake studies indicate that these complexes enter the cell via two distinct mechanisms 
– an energy-independent diffusion-based uptake, and an energy-dependent endocytosis 
pathway.  
 
5. 2 Aims 
The unsubstituted parent complex, [PtL1Cl], and related complexes containing 4'-phenyl 
substituents enter living cells and retain their emission. Through use of fluorescence and 
confocal microscopy, the complexes are found to localise in the cell nucleus, in 
particular the nucleoli. This localisation was confirmed by counterstaining experiments 
with a known nuclear-targeting fluorophore (DAPI). The rate of uptake was fast, as 
demonstrated by the very short dosage times required for imaging. Additionally, the 
long phosphorescent lifetimes emanating from the triplet emission of these platinum 
complexes makes them ideal candidates for time-gated and time-resolved imaging, 
relatively underexplored areas. 
The aim of this section of the project was to study the new complexes prepared in living 
cells, and to explore whether different substituents in the ligands would influence the 
intracellular localisations etc. Other complexes prepared by previous group members 
were also screened, as were a selection of iridium complexes. Aside from luminescence 
microscopy, the uptake of complex was also examined via other techniques including 
flow cytometry, and time-resolved imaging was used to determine intracellular lifetime. 
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5.3. Pt(II) Complexes as Bio-Imaging Agents 
 
5.3.1 Intracellular Localisation   
Two cell lines were studied – Chinese hamster ovary (CHO) and mouse skin fibroblast 
(NIH 3T3). Both are adherent cell lines, meaning the cells grow attached to the surface 
of the culture dish. For imaging purposes, cells were grown in twelve-well plates, each 
well containing a cover-slip, which the cells attached to. The cells require certain 
nutrients and growth factors to survive, so are cultured in water-based solutions 
containing these supplements (growth medium). CHO cells were maintained in F-12 
(Ham) medium, and NIH 3T3 cells were maintained in DMEM. In each case, the 
medium was supplemented with 10% (v/v) foetal bovine serum (FBS) and 1% penicillin 
and streptomycin.  
Stock solutions of complex were made up in the media appropriate for the cell line 
being studied. Unfortunately, these Pt(II) complexes are insoluble in a purely aqueous 
environment, so were first dissolved in the minimum amount of DMSO, prior to 
dilution. At high exposure, DMSO is toxic to cells, but cells can tolerate a small 
amount. After full dilution, the total DMSO content never exceeded 6%. Cytotoxicity 
studies (Section 5.3.7) with water/DMSO controls indicated that DMSO was non-toxic 
at this level, for the duration of the experiments. Cells were dosed with several 
concentrations of complex (0-100 µM) for a selection of dosage times (5 min – 24 h), 
then studied via fluorescence microscopy using a G365 excitation filter and either a 
FITCex (450-500 nm) or FITCem (515-565 nm) emission filter. For each complex, the 
emission filter chosen was that which gave best overlap with the position of the 0-0 
vibronic band, previously determined from solution-based emission experiments.  
 Figure 14: Bright field (left) and
species: a) NIH 3T3 cells dosed with [PtL
[PtL2Cl] (50 µM, 5 min, G365/FITCem), and c) CHO cells dosed with DAPI, a commercial nucle
(300 nM, 5 min, G365/TRICem)
After dosing with most complexes (
irradiation. Fluorescence micro
sub-cellular components, indicating that the complexes were localising in certain 
organelles. The localisation patterns of all of the emissive complexes were similar. Co
staining studies indicate
(Figure 14). The most intense emission was observed from distinct spots within the 
nucleus, which correspond to the nucleoli. Williams et al
findings for intracellular studies
also appears to localise in the nucleoli
 
a) 
b) 
c) 
 fluorescence microscopy images (right) of cells dosed with various 
11Cl] (50µM, 5min, G365/FITCex), b) CHO cells dosed with 
. 
Table 1), the cells appeared to glow under UV
scopy revealed that emission was occurring from distinct 
d that the complexes were localising in the nucleus of the cell
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Table 1: List of complexes screened for intracellular emission, the most appropriate filter sets and 
whether or not emission was observed from the nucleus. 
Complex Filter Set 
(Exn/Emn) 
Is Emission 
Observed 
from the 
Nucleus Upon 
Dosing with 
the Complex? 
Complex Filter Set 
(Exn/Emn) 
Is Emission 
Observed 
from the 
Nucleus Upon 
Dosing with 
the Complex? 
[PtL1Cl] G365/FITCem Yes [PtL14Cl] G365/FITCem Yes 
[PtL1Br] G365/FITCem Yes [PtL15Cl] G365/FITCex Yes 
[PtL1I] G365/FITCem Yes [PtL16Cl] G365/FITCex Yes 
[PtL1py]+ G365/FITCex Yes [PtL22Cl] G365/FITCem Yes 
[PtL2Cl] G365/FITCex Yes [PtL23] G365/FITCem No 
[PtL5Cl] G365/FITCem Yes [PtL25Cl] G365/FITCem No 
[PtL6Cl] G365/FITCem Yes [PtL30Cl] G365/FITCem No 
[PtL7Cl] G365/FITCem Yes [PtL31Cl] G365/FITCem No 
[PtL8Cl] G365/FITCem Yes [PtL32Cl] G365/FITCem Yesa 
[PtL9Cl] G365/FITCex No [PtL33Cl] G365/FITCem Yesa 
[PtL10Cl] G365/FITCex Yes [PtL34Cl] G365/TRICem Yesa 
[PtL11Cl] G365/FITCex Yes [PtL35Cl] G365/FITCem Yesa 
[PtL12Cl] G365/FITCem Yes [PtL36Cl] G365/FITCem No 
[PtL13Cl] G365/FITCem No [PtL37Cl] G365/FITCem Yesb 
aWeak/very weak emission observed, for all dosage concentrations (10 – 100 µM) and incubation lengths 
(5 min – 24 h) studied, bonly certain cells labelled (Section 5.3.5). 
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Figure 15: Structures of Pt(II) complexes not already discussed elsewhere. 
It appears that the size of the terdentate ligand is maybe affecting the ability of a 
complex to enter the nucleus. Complexes containing terdentate ligands with extended 
aromatic structure either do not show emission from the nuclei ([PtL25Cl], [PtL31Cl] and 
[PtL36Cl]), or are at best only weakly emissive ([PtL32-35Cl]), implying that cell entry is 
inhibited by the extended structures of these complexes. Most of the complexes 
containing smaller substituents do exhibit nuclear emission ([PtL9Cl] and [PtL13Cl] are 
exceptions, see Section 5.3.4). 
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Dosing solutions of complex were made up in the respective cell media: these solutions 
were only weakly emissive, and glowed red under long wavelength UV-irradiation. The 
complexes are hydrophobic, and the red emission probably emanates from an aggregate 
species which forms in the aqueous environment (see Chapter 3, Section 3.4.3.7). 
Phosphorescent emission is quenched by oxygen, which accounts for the weakness of 
emission of the aerated solution. The switch-on of blue-green emission upon entering 
the nucleus suggests that the complex has become sufficiently shielded from oxygen. It 
is likely that the complex molecules undergo binding interactions with one (or several) 
of the biomolecules present in the nucleus – perhaps the biomolecule surrounds the 
complex, effectively shielding it from oxygen. Also, the blue-green emission is 
characteristic of monomer emission, suggesting that the molecules of complex do not 
interact with each other within the nucleus. The nucleus is an environment rich in DNA, 
RNA and protein. DNA binding studies on structurally related Pt(II) trpy complexes 
have revealed that such complexes can both intercalate DNA and covalently bind with 
DNA via N7 of guanine. Other studies found that trpy complexes involving labile Pt-
ancillary bonds (e.g. ancillary = Cl) can also covalently bind to other biomolecules such 
as proteins, via basic amino acid substituents such as thiol and imidazole groups. It is 
expected that [Pt(dpyb)Cl] complexes would exhibit similar binding, but it is not 
possible to say at this stage whether localisation in the nucleoli involves binding with 
DNA, RNA, protein, combinations of all three or other. 
The brightness (intensity) of intracellular emission of the Pt(II) complex was found to 
depend on the dosage concentration, and to a lesser extent on the incubation time. 
Assuming that uptake is related to intracellular brightness, uptake of complex is 
extremely rapid; luminescent images could be obtained after only a 5 min incubation 
period (note: a more quantitative measure of uptake would involve the determination of 
platinum concentration per cell. This could be achieved by cell sorting/counting using 
Flow Cytometry, followed by ICP-MS, and should be considered for future studies). For 
5 min incubation, 50 µM dosage tended to give the best luminescent images. Lower 
concentrations suffered greater interference from autofluorescence of biomolecules, 
whereas cells dosed with higher concentrations looked less healthy.  The luminescent 
images of cells dosed with lower concentrations (> 20 µM) did improve slightly with 
increased incubation length (up to 24 h), however dosing with 50 µM for longer than 1 
h typically led to some cell death. Cytotoxicity studies (Section 5.3.7) are in agreement 
with these observations. 
 The intensity of emission was also dependent upon the identity of the complex. 
Complexes [PtL1X] 
images with the best contrast. 
good images (Figure 
be hindered, due to the 
monocationic Ir(III) 
positive charge possessed by such complexes actually facilitates entry into cells.
interior of a cell is at a relatively negative potential compared to the exterior: this leads 
to a potential-driven preferential uptake of 
of such species within th
decreasing membrane permeability.
Figure 16: Bright field images (right) 
b) CHO cells, dosed with [PtL
 
5.3.2 Flow Cytometry as a Means to Quantify Uptake
Flow cytometry is a technique used to count and analyse microscopic particles such as 
cells.23,25,64,65 It offers high
parameters, and multiple parameters may be simultaneously measured from the same 
sample. The technique uses hydr
b) 
a) 
(where X = Cl, Br or I), [PtL2Cl], [PtL11Cl] and [PtL
Another complex, [PtL1py]+ (py = pyridine)
16). We initially thought that uptake of charged molecules might 
need to cross the lipophilic membrane. Li e
complexes also enter cells.22 Coogan et al. 
cationic species, and therefore
e cells. A higher positive charge may disfavour uptake, due to a 
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that they pass through the laser beam one at a time. The laser light (from up to 3 lasers) 
is focused onto the single file stream of cells, and various detectors are arranged to 
record the scattered and luminescent light from the cells. This gives useful information 
about the individual particle. The information from each particle can be combined with 
that from all other particles to give an averaged picture, representational of the whole 
population.  
 
Figure 17: Schematic representation of a jet-in-air flow cytometer 
The basic set-up of detectors is described here: a detector is placed beyond the sample 
stream, approximately opposite the probe beam – this records the ‘forward’ scatter of 
light and gives information on the cell size. Other detectors are placed perpendicular to 
the beam – some detect the ‘side’ scatter, which gives information about the cells 
granularity, whereas other detectors include fluorescence detectors – very useful for 
cells containing a fluorescent tag (such as our complexes). The fluorescence intensity of 
each cell can be measured, and the data can be compiled in either a logarithmic or linear 
mode.  A few other groups have used mean fluorescence intensity values to quantify 
cellular uptake of luminescent organometallic complexes.25,61 Some groups have used 
the technique to measure cytotoxicity of a dopant, by co-staining with live (e.g. calcein, 
fluorescein) and dead (e.g. PI) fluorescent stains. In one case, Jiménez-Hernández et al. 
have used flow cytometry to prove that a luminescent ruthenium complex could itself 
act as a viability stain.23   
 Initial studies with flow cytometry and [Pt
can be useful in measuring cellular uptake of the 1,3
– the mean luminescence
measure of this. Figure 
concentration and incubation time
µM). For a fixed dosage time, at a certain concentration one can expect the cells to 
become saturated with complex, so that further increases would have no added effect, 
and the mean fluorescence intensity vs. dose plots (
it is possible that higher concentrations combined with higher dosage times were 
resulting in cell death (e.g. 100 µM for 1h) 
samples. This observation is in agreement with cytotox
Figure 18: Histograms showing number of cells vs. log luminescence intensity (
dosage concentrations of [PtL
The colours of the histograms 
green = 20 µM, orange = 50 
a) 
c) 
L2Cl] have demonstrated that the technique 
-dipyridylbenzene 
 intensity (450/40 nm) of the cell population 
18 demonstrates how uptake of complex increases with both 
 (for the concentration range inves
Figure 19) should plateau. However, 
– there were far fewer cells pr
icity studies (
2Cl] and a set dosage time: a) 5 min, b) 30 min, c) 1 h and d) 3 h dosage. 
correspond to the dosage concentration as follows: red = undosed cells, 
µM and blue = 100 µM.  
b) 
d) 
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Section 5.3.7). 
 
em = 450/40) for various 
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Figure 19: Plot of mean luminescence intensity (em = 450/40 nm) vs. dosage concentration of [PtL2Cl] at 
a set dosage time (see legend). 
 
5.3.3 Uptake Mechanisms 
Williams et al. report that [PtL1Cl] probably enters the cell via passive diffusion, a non-
activated process.19 Experiments were performed to see if complexes prepared here also 
enter the cell via passive diffusion. The first experiment involves monitoring uptake at 
4  C. At this temperature, active uptake processes such as endocytosis are inhibited. 
Therefore, a decrease in image intensity compared to 37  C would indicate an active 
uptake process. Cells were incubated in the fridge for varying time-lengths (15 min, 30 
min and 1h) before dosing with the complex. The dosing solution of complex was also 
placed in the fridge during this time. After a quick dosing with complex, cells were 
returned to the fridge and incubated for a further 5 min. Upon removal from the fridge, 
the coverslip was quickly rinsed with ice cold PBS, attached to the microscope slide and 
imaged. The rapidity of this process was essential, as warming to room temperature 
could re-instigate active processes. The intensity of emission did not decrease 
significantly upon 4  C incubation, suggesting a passive uptake.  
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To further check this, cells were dosed with a selection of drugs that inhibit or activate 
certain endocytotic uptake routes (Table 2). After 30 min incubation with each drug, 
cells were dosed with complex and incubated for a further 5 min. The intensity of the 
images obtained were compared – if complex was entering the cell via one of the 
activated routes, then inhibition of this route would result in a decrease in intensity. All 
images were of a similar brightness to the control sample, which contained cells dosed 
with complex only (5 min dosage). This further suggests that uptake is via a passive 
route.  
Table 2: Perturbation of endocytosis and intracellular trafficking 
Treatment Dosage Effect Mechanism 
Low temperature 
(4  C) 
- General inhibitor of activated 
processes, including 
endocytosis 
Energy depletion 
Chloropromazine 50 µM Specific inhibitor of clathrin 
mediated endocytosis (CME) 
Dissociation of clathrin 
lattice 
Filipin 1mg/mL Specific inhibitor of caveolae Cholesterol binding 
Amiloride 3 mM Specific inhibitor of 
macropinocytosis 
Inhibits the Na+/H+ 
exchange protein 
Wortmanin 300 nM Inhibitor of macropinocytosis Phosphatidyl inositol-3-
phosphate inhibitor 
Monensin 2 µM Inhibitor of endosome 
maturation 
Prevents endosome 
acidification 
Chloroquine 10 µM Disrupting endosomes and 
lysosomes 
Prevents endosome 
acidification and causes 
swelling to endosomes and 
lysosomes 
Poly-L-lysine  Disrupts interactions with cell 
membrane 
Non-specifically binds to 
cell membrane 
Sucrose 50 mM Inhibitor of clathrin mediated 
endocytosis 
Unselective inhibition of 
clathrin-coated pit 
Note: table adapted from reference 66. 
Propidium iodide (PI) is a well-known DNA intercalating agent. Upon binding to DNA, 
its emission intensity is enhanced 20-30 fold. However, PI is membrane impermeant, 
and can only enter cells with compromised membranes. Consequently, it is often used to 
 label dead cells. To test whether the membrane was becoming compromised upon 
uptake of the Pt(II) complexes, cells were cross
iodide is excited and emits at longer wavelength than the 
emission could be monitored 
and 620-625 emission filter combination)
the membrane is not a requirement for complex uptake
to Pt(II) complex without PI emission)
the toxicity of the Pt complexes. For example,
concentrations (50 – 
than 1 h), but start to die if exposed to such concentrations for extended dosing times. 
Cells dosed with lower concentrations (< 20 µM) remain v
dosings. More quantitative c
(see Section 5.3.7).   
Figure 20: Fluorescence microscopy images 
under various conditions: 
obtained using a G365/FITCex filter set (allows visualisation of [PtL
obtained using a 510/50/620
 
-dosed with PI (Figure 
Pt(II)
selectively by changing the filter set
. The results indicated that c
 (i.e. cells showed emission due 
. The studies also gave qualitative information
 cells incubated with higher 
100 µM) remain viable if the incubation time is kept short (less 
iable for much longer 
ytotoxicity studies were found to agree with these results
of cells co-dosed with PI (1.8 nM
20 µM, 3h (left), 100 µM, 3h (middle) and 50 µM, 10 min
2Cl] emission) and bottom: image
-625 filter set (allows visualisation of PI emission).
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, 5 min) and [PtL2Cl] 
 (right). Top: images 
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 5.3.4 Complexes Not Exhibiting Nuclear Luminescence
Dosing cells with certain complexes (
fluorescence images obt
region. However, similar images were obtained with un
biomolecules are themselves fluorescent, and the images obtained from the control 
demonstrate that the autofluorescence can be observed using the filter sets employed
(Figure 21). Indeed, this is one of the driving forces for development of TREM, as 
described in the introduction of this chapter.
whether or not the complexes were
intensities were comparable to autofluorescence, it is suspected that that these 
complexes do not emit 
Figure 21: Left: bright field 
b) cells dosed with [PtL9
filter set. 
As mentioned in Section 5.3.1
emission contain terdentate ligands with extended structures, or structures distorted 
from planarity. However, incubation of cells with [PtL
emission – this is unusual, this comple
methyl), and dosing with all other isomers ([PtL
non-fluorinated analogue ([PtL
a) 
b) 
 
Table 1) did not result in nuclear emission, but the 
ained did show weak emission emanating from the peri
-dosed ce
 This overlap makes it difficult to say 
 emitting from platinum-dosed cells. Since the 
significantly from inside cells.  
images and right: fluorescence microscopy images of a) undosed cells and 
Cl] (50µM, 5 min). Luminescent images were acquired using a G365/FITCex 
, most of the complexes that did not display
9Cl] also did not result in nuclear 
x only contains small substitue
10Cl], [PtL11Cl] and [PtL
5Cl]), led to nuclear emission. The lack of nuclear 
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emission cannot be attributed to a low solution-based quantum yield; for example, 
[PtL12Cl] has a much lower quantum yield in solution ( = 0.02 in degassed DCM, 298 
K), yet displays obvious emission from within the nucleus.  
 As already mentioned, complexes which localise in the nucleus may be binding to 
biomolecules covalently through displacement of the ancillary chloride ligand, or may 
be binding to DNA/RNA via intercalation. The complex, [PtL23], was prepared to assist 
the study of these possibilities – this complex contains a tetradentate ligand, and does 
not contain a labile chloride ligand. The terdentate framework should act as a cage, 
preventing covalent binding with biomolecules. On the other hand, if nuclear emission 
were to be observed from cells dosed with this complex, it would indicate that 
intercalation played a prominent role in the intracellular interactions of the complexes.  
N N
Pt
O
 
Figure 22: Structure of [PtL23]. 
Nuclear emission was not observed for cells dosed with this complex, suggesting that 
the intracellular interactions of complex involve covalent bonds. However, the crystal 
structure of this complex could not be obtained, so these results must be treated with 
caution – if the bite angles around platinum are far from optimum, significant strain 
may exist within the molecule, which may result in a deviation from planarity. 
Moreover, the compound is found to be only a weak emitter in solution ( = 0.08), and 
thus may emit poorly in the cell too. 
 
 
 
 5.3.5 Complex Displaying 
Upon dosage, most of the 
unselectively. However, th
substituent at the 4'-position, appears to be more selective
only entering a few of 
(10, 20 and 50 µM) and dosing times investigated
Figure 23: a) Structure of [PtL
of CHO cells labled with this complex (dosing: 50 
acquired using a G365/FITCem
Although the labelled cells appeared healthy
explanation is that the complex was 
membrane (i.e. dead cells). If this were the case, the complex would have applicability 
as a stain for dead cells.
The images obtained revealed that the luminescent species were labelling different cells, 
indicating that the complex was not sp
hypothesis. 
 To test whether incorporation of the complex and PI was mutually exclusive within the 
cell, cells were incubated with various combinations of saponin, complex and PI.  
Saponin is a surfactant that permeabilises cell membranes, allowing molecule
b) 
a) 
Selective Labelling of Cells 
Pt(II) complexes were found to label all of the cells 
e uptake of [PtL37Cl] which contains a carboxylic acid 
 (Figure 
the cells. This selective response was found for all concentrations 
 (5 min – 3 h). 
CO2H
N N
Pt
Cl
 
37Cl], and b) Bright field (left) and fluorescence microscopy
µM, 5 min). The fluorescence microscopy i
 filter set. Note that emission is only occuring from certain cells
 in the bright field image
entering only those cells 
23
 To test this, cells were cross-incubated with complex and PI. 
ecifically labelling dead cells, 
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 (right) images 
mage was 
. 
, one possible 
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refuting this 
s to enter 
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and leave the cell more freely. Cells incubated with just saponin and complex showed 
nuclear emission from all cells, which was detected with filter set 1 (G365/FITCem). 
Similarly, upon incubation with saponin and PI, PI labelled the nuclei of all cells – this 
emission was detected using filter set 2 (510/50/620-625), but could not be observed 
using filter set 1. When cells were incubated with saponin, complex and PI, nuclear 
emission from all cells was detected with both filter set 1 and 2. This observation 
confirms that the labels are not mutually exclusive. Perhaps the complex is only taken 
up by the cell at a certain point during the cell cycle (Figure 24). To test this, the cell 
cycle would have to be synchronised, and cells would have to be incubated with 
complex at certain points during the cycle.67 
 
Figure 24: Different phases of the cell cycle. During the first phase (G1), the cell grows. Once the cell 
reaches a certain size, it enters the second phase (S-phase) during which the chromosomes are duplicated. 
Once replication is complete, the cell then prepares itself for division (G2). Mitosis (M) then follows; 
during this phase, the cell divides into two daughter cells, which each get one copy of all duplicated 
chromosomes. After division is complete, the cells enter G1. They then may enter a resting phase (G0), or 
start the process over again (image taken from reference 67). 
 
 
 5.3.6 Observation-Wavelength
As discussed previously, most complexes involving smaller ligands show localisation in 
the nucleus, when emission is monitored around 500 nm. 
monitored using a longer
unchanged) a distinctly different localisation pattern was observed
emission is mainly observe
emission still apparent
cytoplasm - emission em
cytoplasm-based organelle. Many organelles exist in the cytoplasm, including the 
endoplasmic reticulum, golgi apparatus, mitochondria and lysosomes. 
Figure 25: Fluorescence microscopy images of NIH 3T3 cells
image acquired using a G365ex/FITCem em filter set, and Right: image acquired using a G365ex/660
710em filter set. 
Co-staining studies were performed to determi
emission. Lysosomal localisation was checked by co
and LysoTracker red
different areas of the cytoplasm
complex appears to be localising in a more “stringy” organelle.
MitoTracker redTM (MTR) strongly suggests
from the mitochondria (
-Dependent Localisation Profile
When the emission was 
-wavelength emission filter (660-710 nm; 
d within the cytoplasmic region (though
). The emission intensity is not homogeneous throughout the 
anates from discrete areas, indicating localisation within a 
 dosed with [PtL
ne the localisation of this low
-staining cells with 
TM
 (LTR). The complex and LTR were localising in distinctly 
 - the lysosomes appear as bright spots, whereas 
 that the lower energy 
Figure 26). 
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excitation filter 
 (Figure 25). Now, 
 with some nuclear 
 
 
1Cl] (50 µM, 5 min). Left: 
-
-energy 
Pt(II) complex 
the 
 Co-staining with 
emission emanates 
 Figure 26: Fluorescence microscopy images of CHO cells co
MitoTracker redTM (300 
image acquired using a G365ex/660
546ex/long-pass 590em filter set (this set allows visualisation of the MTR co
been altered. 
The mitochondria contain 
be the target of the commercial MitoTracker probes. 
related complexes have previously demonstrated an affinity for sulphur bi
Furthermore, the em
compared to the chloro
results from platinum
Another possibility 
concentration, and the red emission is d
determine the origin 
should help – a technique allowing such measurements will be available in the 
department in the near future
 
5.3.7 Cytotoxicity 
As discussed in the introduction
biological system under study 
these Pt(II) complexes. 
monitoring the metabolic activity of the cells after incubation with complex for 24 h. An 
MTT assay was used to 
2-yl)-2,5-diphenyltetrazolium bromide}
cytotoxicities of Pt-based anticancer drugs.
-stained with [PtL
nM, 30 min). Left: image acquired using a G365ex/FITCem filter set, Middle: 
-710em filter set, and Right: image acquired using a Conan 
an abundance of thiols.68 In fact, these thiols are expected to 
Platinum(II) 
ission of these sulphur adducts was significantly red
-analogues. It is therefore likely that the mitochondrial emission 
-linked thiols, where the ancillary chloride has been replaced. 
is that the complex accumulates in the mitochondria in high 
ue to an aggregate or an excimer. 
more conclusively, recording the intracellular emission spectrum 
. 
, intracellular probes should be of low toxicity to the 
– it is therefore important to determine the cytotoxicity of 
The toxicity of some of the complexes was investigated by 
measure the metabolic activity {MTT = 3
. Such assays are commonly used to determine 
69,70,71,72,73
 Yellow MTT gets reduced by 
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1Cl] (50 µM, 5 min) and 
-stain). Image contrast has 
is a “soft” centre, and 
nding19,31 
-shifted 
To help 
-(4,5-dimethythiazol-
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living cells to formazan, a purple dye, by mitochondrial reductase enzyme, which is 
only active in viable cells. The absorption intensity of formazan (here measured at 541 
nm) is proportional to the number of living cells present. By comparing the intensity of 
formazan absorption from cells which were previously incubated with complex with 
those that have not been incubated with complex (i.e. a control), the percentage of living 
cells can be determined. 
N N
NN
N
S
Br
N
N
NH
N
N
S
Mitochondrial
Reductase
 
Scheme 1: The reduction of yellow MTT to purple formazan. 
100 µL aliquots containing an approximately equal number of cells (1 x 104) were 
transferred to a 96-well plate and incubated overnight, during which, the cells attached 
to the surface of the microplate. The following morning, cells were dosed with varying 
concentrations of complex and incubated at 37  C for a further 24 h. After this time, the 
media was removed, the cells were washed with PBS and fresh media was added, 
followed by MTT. The cells were incubated for a further 4 h. The medium and MTT 
were then removed, followed by addition of DMSO (DMSO is added to solubilise the 
formazan dye). Measurements for each complex were repeated at least three times. The 
IC50 value (the concentration required to kill half the population of cells in the specified 
dosage time) was determined from a plot of the percentage of live cells against 
log[complex]. The average values of IC50 are given in Table 3. 
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Table 3: Cytotoxicity values of Pt(II) complexes, determined for a 24 h dose. The estimated uncertainty 
in each IC50 value is ± 25 %. 
Complex IC50 / µM 
[PtL1Cl] 45 
PtL2Cl] 28 
[PtL7Cl] 42 
[PtL8Cl] 7 
[PtL9Cl] 32 
[PtL10Cl] 10 
[PtL11Cl] 29 
[PtL12Cl] 14 
[PtL16Cl] 25 
[PtL35Cl] 45 
 
The IC50 values for the Pt complexes at 24 h dosing range from 7 to 45 µM. However, 
good quality images can be obtained after much shorter dosing periods. It was 
anticipated that cells would be able to tolerate higher concentrations of complex over 
shorter dosing periods. To test this, the cytotoxicity of [PtL1Cl] to cells was investigated 
after just a 1 h dose with complex. An alternate method to MTT assay was investigated 
here. This method involved staining cells with trypan blue – this diazo dye accumulates 
inside cells with compromised membranes (i.e. dead cells) but is excluded by living 
cells. The live and dead cells were counted using a haemocytometer, and this was 
repeated 4 times. Using this method, the IC50 value for a 1 h dose was found to be 68 
µM. This value is higher than the IC50 determined for a 24 h dose (45 µM) and indicates 
that cells can tolerate a higher dose of complex when incubated for shorter periods.  
Assessing the cytotoxicity using the trypan blue method is not as efficient as the MTT 
assay. It takes much longer to acquire data using the trypan blue method, as each sample 
must be prepared and counted individually. The MTT assay method is much more 
suited to screening a vast number of samples/parameters, as a large amount of data can 
be accumulated rapidly. 
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5.3.8 Time-Resolved Emission Microscopy (TREM) 
As discussed in Section 5.1.5, time resolved emission microscopy (TREM), is a 
complementary process to steady-state fluorescence microscopy. The technique can be 
used to discriminate luminescent species with similar spectral properties (i.e. excitation 
and emission wavelengths), as long as the lifetimes differ. This could prove invaluable 
in co-staining, where the excitation and emission parameters of commercial co-stains 
often overlaps. The inherent autofluorescence of biomolecules and residual background 
scatter of the lens etc. can often interfere with cellular images obtained via steady-state 
luminescence imaging. In theory, TREM can be used to generate images of greater 
contrast, by the removal of this autofluorescence and background scatter (provided that 
the bio-probe is sufficiently long lived).  
Development of TREM for use in biological systems has been hindered by a lack of 
suitable bio-imaging agents. The Pt(II) complexes prepared here seemed ideal 
candidates for TREM (i.e. exhibit intracellular emission and have solution-based 
lifetimes of the order of several microseconds), and cells dosed with some of the 
complexes have been imaged using the technique. The samples were excited with a Q-
switched Nd:YAG laser (355 nm), and emission was detected with either a long-pass 
420 nm or long-pass 475 nm emission filter. The resolution of this camera was not as 
good quality as for the fluorescence microscope used for live-cell imaging. This 
microscope was not built for such imaging purposes initially, hence images obtained 
using this microscope are of a poorer quality. Nevertheless, the data are more than 
adequate to demonstrate the power and potential of the technique using the Pt 
complexes as luminophores. The expected nuclear emission was observed, and the 
luminescent image was monitored at various delays after removal of the excitation 
pulse, for a constant acquisition (gate) time. The intensity of emission decreased with 
increasing delay. In most cases, emission was still observed after a delay of 2 µs 
(though the emission intensity was by then obviously much weaker than that of the un-
gated image). 
The intracellular lifetimes of the complexes were determined by selecting an area of the 
image corresponding to a cell nucleus, and monitoring the luminescent intensity of this 
area as a function of time. The data were fitted to an equation modelling the exponential 
decay of photoluminescence,  
                                                                   
where I0 is the amplitude, and 
decay was found to be mono
equation Eqn. 1 (Figu
determined. Lifetimes were of the order of 2 µs
observed intracellular emission
therefore must be due to the 
 
Figure 27: Emission kinetic trace obtained from the nuclei of live CHO cells incubated for 5 min with
50 µM solution of [PtL10Cl]. Solid line represents monoexponential fit to the data. Inset: luminescence 
images of the cells taken with a zero delay (left) and 1 
355 nm laser excitation, using a 475 nm lon
contrast and brightness have not been alte
 
 
 
Eqn. 1 
 is the lifetime of photoluminescence. 
-exponential, and the data generally gave a
re 27), from which the lifetime of the emission could be 
 (Table 4) which confirms that the
 was phosphorescence rather than fluorescence,
Pt(II) complex. 
µs delay (right). The images were recorded after 
g-pass emission filter. The time gate used was 200 ns.
red. 
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Table 4: Intracellular emission lifetimes of a selection of the Pt(II) complexes 
 Intracellular lifetime () 
/ µs 
[PtL1Cl] 2.1 
[PtL2Cl] 2.1 
[PtL5Cl] 1.7 
[PtL7Cl] 1.6 
[PtL9Cl] -----a 
[PtL10Cl] 3.5 
[PtL11Cl] 1.3 
[PtL12Cl] 1.9 
[PtL16Cl] 3.3 
[PtL35Cl] 1.6 
                                       aEmission could not be detected 
The TREM technique was used to try to clarify whether perinuclear emission observed 
from cells dosed with  [PtL9Cl] (see Section 5.3.4) was due to the complex or whether it 
was due to autofluorescence of the cells. However, no emission could be observed (even 
from the un-gated image). This emission was always relatively weak when observed 
with the fluorescence microscope, and perhaps the lower signal-to-noise ratio of this 
microscope/camera means that the emission cannot be distinguished from the 
background. 
 
5.3.9 Preliminary in vitro Investigations to Probe Interactions with Biomolecules 
We wanted to see if the platinum complexes would  bind to certain biomolecules in 
vitro – such studies may be able to shed some light on the intracellular binding 
interactions. As discussed in the introduction to this chapter, related [Pt(trpy)R]+ 
complexes bind to nucleic acids, and in some cases to other biomolecules such as 
proteins. Recently, structurally related cyclometallated complexes have been shown to 
bind to proteins.51,74 For example, detailed investigations on one of the N^N^C 
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complexes prepared by Lam et al., which also targets the cell nucleoli, revealed a strong 
binding interaction with protein and negligible interaction with DNA or RNA, 
suggesting that the complex interacts with nuclear proteins within the cell rather than 
with nucleic acids.51  
To probe interactions of our complexes with biomolecules, 10 µM solutions of complex 
in phosphate buffered saline (PBS) were prepared, and the emission was monitored 
before and after addition of the desired biomolecule. A small amount of DMSO (less 
than 1% of the final volume) was required for initial solubilisation. Three of the 
complexes, [PtL1Cl], [PtL2Cl] and [PtL9Cl] were investigated for binding. When cells 
are dosed with complexes [PtL1Cl] and [PtL2Cl], these complexes localise in the nuclei 
and emit brightly. On the contrary, complex [PtL9Cl] does not emit from the nucleus – it 
was therefore of interest to see how this complex would interact with biomolecules in 
vitro.  
 
5.3.9.1 Protein 
The protein investigated was bovine serum albumin (BSA) - BSA or immunoglubulin G 
(IgG) are used as standards in most protein detection methods.74 The emission of the 
PBS solution containing the complex (10 µM, 2.5 mL) was recorded before adding any 
BSA. The monomeric emission of these solutions was very weak, and accompanied by 
a more intense structureless band at lower energy (Figure 28). This band probably 
corresponds to an aggregate – we previously demonstrated that these complexes form 
such species in aqueous environments (Chapter 3, Section 3.4.3.7). This also accounts 
for the red-glow of the stock solutions made up in cell media (Section 5.3.1).     
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Figure 28: Normalised emission spectrum of a 10 µM solution of [PtL2Cl] in PBS (ex = 372 nm, 298 K).  
Initially, titration experiments were performed, where 3 µL aliquots of 0.8 mM BSA 
were added to the solution of complex (10 µM, 2.5 mL), which was held in a quartz 
cuvette. For all complexes, the intensity of monomeric emission appeared to increase 
dramatically with BSA concentration (Figure 29 a)). Similar results were found by Che 
et al. who were studying protein binding of carboxylic acid-appended [Pt(N^N^C)Cl] 
complexes.74 However, we later realised that the intensity also increased as a function of 
time, for a fixed BSA concentration. Figure 29 b) and Figure 29 c) show emission 
profiles of [PtL1Cl] (10 µM), initially mixed with 2 M and 22 M of BSA 
respectively, and monitored over 5 hours. One can see that in both cases, the monomeric 
intensity continues to increase throughout the experiment. This observation may imply a 
slow binding process between complex and BSA. Alternatively, the time-dependent 
intensity change may be due to slow solubilisation of the aggregate formed in the 
aqueous medium. The intensity of complex mixed with a lower concentration of BSA is 
practically double that of complex mixed with an excess of BSA at the end of the 
experiment. Perhaps too much BSA alters the refractive index of the solution 
significantly. It is therefore not straightforward to perform titrations based on 
concentration alone.   
Regardless of the kinetics/mechanism, these complexes clearly do bind to the protein. 
Addition of BSA appears to activate monomeric emission (and deactivate aggregate 
emission) – the complex may bind within a hydrophobic environment of the protein, 
which prevents intermolecular interactions between complex molecules. After “switch-
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on” of the monomeric emission by protein addition, the lifetimes were recorded – in 
each case, the lifetime was very long (> 15 µs), and was found to be constant with 
increasing time or BSA concentration. These lifetimes are even longer than those 
predicted for the complexes at infinite dilution (see Chapter 3, Table 29). The protein 
must be very effective at shielding the complex from oxygen, and maybe disfavouring 
non-radiative decay pathways that involve coupling of the excited state to molecular 
motions. 
Perhaps within the cell, complexes [PtL1Cl] and [PtL2Cl] are binding to nuclear 
proteins, accounting for the blue/green emission observed when cells are dosed with 
such complexes. If this is the case, it implies that complex [PtL9Cl] is for some reason 
excluded from the cell nucleus, as aerated aqueous samples of this complex also 
demonstrated a switch-on of luminescence upon addition of BSA. 
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Figure 29: a) Chart showing increasing monomeric emission intensity of a 10 µM [PtL1Cl] solution in 
PBS, with an increasing BSA concentration (ex = 401 nm, 298 K). b) and c), Charts showing increasing 
monomeric emission intensity of  [PtL1Cl] (10 µM solution in PBS), with time, after an initial addition of 
BSA (2 µM and 22 µM respectively). The emission was monitored over 5 h (ex = 401 nm, 298 K). 
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 Figure 30: Solutions of [PtL
10-6 M), under long wavelength UV
 
5.3.9.2 DNA 
The interaction of these three
Aldrich) in a PBS solution was monitored by emission
profile of 10 µM solutions of [PtL
the absence and presence of excess DNA. 
[PtL1Cl] and [PtL2Cl] 
response was much slower than with protein (
as significantly, and aggregate emission remained quite prominent
[PtL9Cl], although a slight increase in intensity was observed
monomeric emission remained very weak after 2h. 
[PtL9Cl] only interacts weakly with DNA.
1Cl] in PBS (10-5 M), in the absence (left) and presence (right) of BSA
-irradiation. 
 platinum complexes with DNA (calf
 spectroscopy
1Cl], [PtL2Cl] and [PtL9Cl] was monitored 
Addition of DNA to solutions of complexes 
also caused a “turn-on” of the monomeric emission, but the 
the monomeric intensity did not increase 
 upon DNA addition
These results therefore suggest
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, e.g. Figure 31). For 
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Figure 31: The emission of a solution of [PtL2Cl] (10 µM in PBS), containing excess DNA (calf-thymus, 
Aldrich), monitored over 2 h (ex = 372 nm, 298 K). 
Unfortunately, these experiments were hindered by precipitation of small particles that 
glowed green under long wavelength UV-irradiation. It is believed that these particles 
correspond to complex-bound-DNA (the particles would have glowed red if they were 
merely aggregates of complex)  
From these preliminary investigations, it is clear that such complexes can form 
interactions with biomolecules such as protein and DNA. However, the extent of such 
interactions is related to the structure of the complex, and subtle changes can have a 
large impact. Multiple variables, such as time and concentration of added biomolecule, 
affect the emission intensity and performing titrations is not straightforward and needs 
further investigation. To further probe interactions with DNA, other techniques such as 
circular dichroism, monitoring the viscosity of the DNA solution and monitoring the 
melt temperature of DNA, which are some of the many techniques used to probe 
interactions of [Pt(trpy)X]+ systems with DNA,32,35,75,76 should be considered. 
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5.4 Iridium(III) Complexes as Bio-Imaging Agents 
As well as the Pt(II) complexes, luminescent iridium(III) complexes involving 
polypyridyl ligands are prepared within our research group. Other groups have recently 
reported that complexes of the form [Ir(ppy)2(bpy)]+ and derivatives are amenable to 
fluorescence microscopy in cells.22,60,62 We were interested to see if a series of pyridyl 
benzimidazole-based cyclometallated complexes of iridium would also enter cells and 
localise in specific organelles. The structures of the iridium complexes investigated here 
are given in Figure 32. The complexes are comprised of bidentate or terdentate 
cyclometallating ligands, the latter being very similar to those described in this thesis 
with Pt, and include both cationic and charge-neutral compounds with essentially 
identical masses.  
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Figure 32: The series of iridium(III) complexes that were investigated as bio-markers for living cells 
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 5.4.1 Localisation 
These complexes absorb at similar wavelengths to the Pt(II) complexes, and emit 
between 500 nm and 600 nm. Therefore, a G365 excitation and FITCem (515-565 nm) 
emission filter were selected to monitor their intracellular luminescence. In contrast to 
the Pt(II) species, the iridium complexes did not emit from the cell nuclei. On the other 
hand, bright emission was observed from distinct areas within the cytoplasm, which 
differed between complexes containing exclusively bidentate ligands ([Ir(1)] – [Ir(5)]+) 
and those containing a terdentate ligand ([Ir(6)] – [Ir(7)]+).  
Complexes [Ir(1)] – [Ir(5)]+ appeared to localise in discrete vesicles dotted throughout 
the cytoplasm (Figure 33). The images were compared with fluorescent images of cells 
dosed with LTR. Unfortunately, co-loading the cell with an iridium complex and this 
co-stain could not be used to confirm co-localisation – emission due to the complexes 
also appeared in the detectable range of the co-stain. Nevertheless, the dotty localisation 
of complexes 1-5 throughout the cytoplasm looks very similar to the localisation profile 
of LTR, suggesting that these complexes are localising in the cell lysosomes. A similar 
punctate emission was observed recently in cells dosed with biotin-linked Ir(III) 
complexes – Lo et al. believe that these complexes are localising in endosomes.60 
As a further note, the images obtained with the LTR co-stain were always quite poor 
(even when a fresh solution of co-stain had been prepared from stock, immediately prior 
to imaging), suggesting room for improvement on the commercial co-stain front.  
   
Figure 33: Bright field (left) and
various species: a) cells dosed with LTR (
G365/FITCem), and c) cells dosed with [Ir(4)]
Complexes [Ir(6)] and 
within the cytoplasm
complexes [Ir(1)] – [Ir(
these complexes was thought to resemble
complexes, which had been
a) 
b) 
c) 
 fluorescence microscopy images (right) of CHO cells dosed with 
80 nM, 30 min), b) cells dosed with [Ir(2)] (10 
+
 (10 µM, 1 h, G365/FITCem). 
[Ir(7)]+, which involve a terdentate N^C^N
ic region, but the emission pattern differs from
5)]+ (Figure 34). At first sight, the more “stringy” localisation of 
 the lower-energy emission of 
 assigned to mitochondrial localisation. 
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µM, 5 min, 
 ligand, also localise 
 that observed with 
the Pt(II) 
 
 Figure 34: Bright field (left) and
(10 µM, 1 h, G365/FITCem)
Cells were dosed with both 
[Ir(6)] are shown in Figure 
the intracellular emission 
observed, the images are not identical, indicating that these complexes are localising in 
a different cytoplasm based organelle. 
cytoskeletal filaments suc
performed to verify the exact intracellula
Figure 35: Images of CHO cells co
min). Left: bright field image
allows visualisation of [Ir(6)] emission)
590em filter set (this filter 
 
 fluorescence microscopy images (right) of CHO cells dosed with [Ir(6)] 
. 
complex and a MTR co-stain. The i
35 (similar observations were made with 
intensity was significantly weaker). Although some overlap is 
Perhaps these complexes 
h as actin or tublin.1,2,77 However, further studies must be 
r localisation of these complexes.
-stained with [Ir(6)] (10 µM, 1 h) and MitoTracker red
, Middle: image acquired using a G365/FITCem
, and Right: image acquired using a Conan 546ex/long
set allows visualisation of the MTR co-stain). 
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mages obtained with 
[Ir(7)]+, although 
are binding to 
  
 
TM
 (250 nM, 30 
 filter set (this filter set 
-pass 
 5.4.2 Uptake 
All iridium complexes were found to enter 
complexes containing bidentate ligands, a 
concentrations as low as 10 µM could be used to obtain images of good contrast. 
Increasing the concentration at this incubation 
image. In fact, longer incubation 
detrimental to image quality 
spots, assumed to correspond to a higher local concentration of 
bright spots swamped the emission from
intracellular emission of complexes containing terden
was inherently weaker, but could be improved 
complexes, the best images were obtained when 10 µM solutions were incubated with 
the cells for 1 h.  
Figure 36: Comparative images of CHO cells dosed with [Ir(2)] (10 
a) 5 min, b) 1 h, c) 4 h, d) 24 h. Image contrast and brightness have not been adjusted. The fluorescence 
microscopy images (top) were acquired using a G365/FITCem filter set
     
    
implying that the iridium complexes can
However, image intensity was often slightly l
have investigated biotin
with their complexes, where a
complexes were also taken up by the cell via an active route.
a) 
the cell rapidly (within 5 min)
5 min incubation involving dosing 
time did not improv
times and/or higher dosing concentrations proved 
– high intensity emission was observed from certain bright 
 the rest of the sample
tate ligands 
by increasing the dosing time. For these 
µM), for varying incubation lengths: 
. 
       
 C.  C, the cells were still highly luminescent, 
 enter the cells via a non

-linked phenylpyridine complexes, made similar obse
dditional uptake inhibition studies indicated that these 
60
b) c) 
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e the quality of the 
complex, and these 
 (Figure 36). The 
([Ir(6)] and [Ir(7)]+) 
 
-activated pathway. 
C. Lo et al., who 
rvations 
 Uptake via both an 
d) 
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energy-independent route and an energy-activated route may also occur for our 
complexes (experiments with uptake inhibitor/activator drugs should be performed to 
check this). 
As for the Pt(II) complexes, uptake could be monitored using flow cytometry. Figure 37 
shows histograms representing the luminescence intensity of a population of cells, 
which have been incubated with a certain concentration of the stated complex for a set 
incubation time. The average luminescence intensity of the population increases with 
both dosage concentration and incubation length. From the results, complex [Ir(1)] has a 
much lower intracellular luminescence intensity than the other two complexes 
investigated ([Ir(2)] and [Ir(3)]+). This result is consistent with the imaging experiments 
– longer acquisition times were required to capture images of cells dosed with [Ir(1)]. 
For the longer incubation period (4 h), cells dosed with the two highest concentrations 
(100 µM and 1000 µM) have a similar mean luminescence intensity. This implies that 
saturation has almost been reached, and that further increases in concentration for this 
incubation length will have little effect.  
 Figure 37: Histograms showing number of cells vs. log luminescence intensity (
dosage concentrations of [Ir(X)], and a set dosage time of 1 h (left) and 4 
correspond to CHO cells dosed with [Ir(1)], the middle plots correspond to CHO cells dosed with [Ir(2)], 
and the bottom plots correspond to CHO cells dosed with [Ir(3)]
correspond to the dosage conce
and green = 1000 µM.  
+
. The colours of the histograms 
ntration as follows: red = undosed cells, blue = 1
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em = 530/40) for various 
h (right). The top plots 
0 µM, orange = 100 µM 
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5.4.3 Cytotoxicity 
The cytotoxicity of complexes [Ir(1)] – [Ir(3)]+ and [Ir(6)] – [Ir(7)]+ was determined via 
MTT assay (Table 5). Cells were dosed with various concentrations of each complex for 
24 h. Complexes [Ir(2)] and [Ir(3)] demonstrated relatively low cytotoxicity – the IC50 
for these complexes occurs outside the concentration range studied (0 – 200 µM). The 
other three complexes had IC50 values similar to those of the Pt(II) complexes. It seems 
that the cytotoxicity is related to the intrinsic structure of the ligands – a similar 
observation was made by Lo et al.62 Additionally, the higher toxicities of [Ir(6)] and 
[Ir(7)]+ compared to [Ir(2)] and [Ir(3)]+ may be associated with their differential 
intracellular localisation.  
 
Table 5: Cytotoxicity values determined for the Ir(III) complexes, over a 24 h incubation. The estimated 
uncertainty in each IC50 value is ± 25 %. 
Complex IC50 / µM 
[Ir(1)] 35 
[Ir(2)] > 200 
[Ir(3)]+ > 200 
[Ir(6)] 10 
[Ir(7)]+ 39 
 
5.4.4 Time-Resolved Emission Microscopy 
The intracellular emission lifetimes of the iridium complexes are given in Table 6. All 
lifetimes are around 1 µs, confirming phosphorescence. As found for the Pt(II) 
complexes, the emission intensity followed a monoexponential decay, and the decay 
data gave a good fit to Eqn. 1 (see p. 285). 
 Table
 
 
Figure 38: Emission kineti
h with a 10 µM solution of [Ir(3)]
luminescence images of the cells taken with a zero delay (left) and 1 
recorded after 355 nm laser excitation, using a 475 nm
200 ns. Image contrast and brightness have not been altered
 
 6: Intracellular emission lifetimes of the Ir(III) complexes
 Intracellular lifetime () / µs 
[Ir(1)] 0.91 
[Ir(2)] 1.20 
[Ir(3)]+ 1.07 
[Ir(5)]+ 1.13 
[Ir(6)] 0.88 
[Ir(7)]+ 1.18 
c trace obtained from the perinuclear region of live CHO cells incubated for 1 
+
. Solid line represents monoexponential fit to the data. Inset: 
µs delay (right). The images were 
 long-pass emission filter.
.  
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 The time gate used was 
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As mentioned in Section 5.3.8, TREM should be able to distinguish between emitters 
with similar excitation and emission wavelengths, on the basis of time, if the lifetimes 
differ. To test this, cells were co-loaded with an iridium complex, and either Hoechst or 
DAPI, which are commercial nuclear stains. These stains possess similar excitation and 
emission wavelengths to the iridium (and platinum) complexes, and it was not possible 
to discriminate emission from each luminophore from steady state images. However, 
these nuclear stains emit light via fluorescence, hence have much shorter lifetimes. 
(note, Williams et al. did manage to selectively image cells co-stained with [PtL1Cl] and 
DAPI using steady-state microscopy, by exciting the Pt(II) complex at the weak S0 T1 
absorption band. Unfortunately, attempts to re-create this failed, possibly because 
excitation around this forbidden band resulted in an emission intensity that was too 
weak to detect using the apparatus in Durham).19    
Cells were dosed with an iridium complex (10 µM and 50 µM) for 1 h, and Hoechst 
(350 nM) was added for the last 5 min. The cells were then studied using TREM (Figure 
39). In the –1 µs delay image (i.e. the image was acquired over the excitation pulse), 
extremely bright emission is observed from within the nucleus. This emission was 
accompanied by a much weaker punctate emission from the cytoplasm, which was of 
slightly higher relative intensity for cells dosed with 50 µM Ir complex. However, in the 
0 µs delay image, the nuclear emission is not observed, and only bright emission from 
the cytoplasmic region is seen. Though the intensity of this emission does decrease with 
increasing delay, emission from the cytoplasm can still be observed after a delay of 1 
µs.  
 Figure 39: Left: fluorescence microscopy images of
and Hoechst (350 nM, 5 min), taken at various time delays after excitation (
b) 0 µs delay, and c) 1 µs delay. 
from monitoring emission from a perinuclear region of the cells. Solid line represents monoexponential fit 
to the data. The lifetime determ
[Ir(2)] only. Similar images were taken for cells dosed with other 
 
These observations are easily rationalised. In the 
primarily from the fluorescent Hoechst
yield than the Ir complexe
actually waits for ~ 5
image. The lifetime of Hoechst has been determined to be 3.6 
waiting period, most of the
intensity will have diminis
order of 1 µs, hence their emission dominates in the 0 µs delay image. Such novel 
experiments further demonstrate the power of the TREM
selectively observe differe
setting a time delay between excitation and acquisition of the image
 
 live CHO cells co-stained with [Ir(2)] (10 
ex
The time gate used was 200 ns. Right: Emission kinetic trace obtained 
ined from the decay was the same as that determined for cells dosed with 
Ir(III) complexes and Hoechst
–ve delay image, emission is obse
: this must have a higher intracellular quantum 
s. The term “0 µs delay image”, is not quite true 
 ns after removal of the excitation pulse, before recording the 
ns, so durin
 emission from Hoechst will have decayed and hence its 
hed. The iridium complexes have intracellular lifetimes of the 
 technique 
nt subcellular compartments of the same sample, simply by 
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µM, 1 h) 
 = 355 nm): a) -1 µs delay, 
. 
rved 
– the camera 
g this brief 
– it is possible to 
. 
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5.5 Concluding Remarks 
The majority of Pt(II) complexes that have been screened here were found to enter cells 
and retain their luminescence (of the few complexes which did not appear to enter cells, 
most contained larger, more bulky ligands, which probably hindered their entry). 
Uptake of complex was found to be rapid, and good quality luminescent images could 
be obtained after only a 5 min dosage. The complexes appear to localise in the nucleus 
of the cells, and in the mitochondria – it is possible to selectively image each organelle 
separately, by choosing the appropriate filter set. G365/FITCex and/or G365/FITCem 
filter sets were best for observing the blue/green emission of Pt(II) complex from the 
nucleus, and a G365/660-710 filter set was found to be best for observing the red 
emission of Pt(II) complex from the mitochondria. Cytotoxicity studies indicate that the 
complexes are of low toxicity, and remain non-toxic for the duration of the imaging 
experiments.  
A selection of cyclometallated complexes of Ir(III) containing a pyridyl benzimidazole-
based ligand were also examined for suitability as bio-markers in living cells. These 
complexes also entered the cells rapidly (within 5 min). However, the intracellular 
localisation was very different from the Pt(II) complexes – the Ir(III) complexes did not 
enter the nucleus, but instead appeared to localise in organelles based in the cytoplasm. 
Complexes containing only bidentate ligands gave a punctate staining pattern, similar to 
that observed when cells are stained with LysoTracker RedTM. Complexes [Ir(6)] and 
[Ir(7)]+, which also contain a terdentate ligand, appear to localise in a different 
cytoplasm-based organelle, with a more filamentous structure, but the identity of this 
organelle remains uncertain, and requires further investigation. Again, cytotoxicity 
studies indicate that the complexes are of low toxicity, and remain non-toxic for the 
duration of the imaging experiments.  
Flow cytometry was used to measure cellular uptake of the luminescent complexes, by 
monitoring the mean luminescence intensity of a population of cells. The results show 
that uptake of complex increases with both dosage concentration and incubation time. 
The intracellular emission lifetimes have been determined using TREM. The lifetimes 
are approximately 1-2 s, which confirms that the emission is due to phosphorescence 
and hence emanates from the organometallic complex. The suitability of the 
organometallic complexes for TREM has been demonstrated by monitoring the 
emission from cells co-dosed with an organometallic complex and a commercial 
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fluorophore (e.g. Hoechst). The two luminophores have similar excitation and emission 
parameters, but vastly different lifetimes. We have shown that it is possible to 
selectively image different areas of the cell based on lifetime. When an image was 
recorded without incorporation of a time delay, emission from the brighter organic 
fluorophore dominated. However, when a suitable time-delay was incorporated between 
removal of the excitation pulse and acquiring the image, only emission from the 
phosphorescent organometallic complex was observed. 
The field of using organometallic complexes as bio-imaging agents is still in its infancy, 
and much work is required to fully understand why certain complexes target certain 
organelles (e.g. more detailed binding studies, further investigation into uptake 
mechanisms, etc.), and what overall effect such complexes have on the cell. Through 
such studies, it should become possible to design specific complexes to target certain 
areas/biomolecules, and it may be possible to design complexes of lower cytotoxicity. 
The results presented here give some indication of the possibilities offered by 
luminescent organometallic species, and it is anticipated that this area of research will 
grow rapidly over the next few years.  
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6.1 Materials and Equipment 
 
6.1.1 General Experimental 
The following solvents: DCM, MeOH, DMSO, EtOAc and EtOH, were obtained as 
analytical reagent grade, and were used as supplied. Acetonitrile was obtained as HPLC 
grade. Dry DMSO was obtained from Aldrich and stored under nitrogen. Other dry, air-
free solvents (THF, hexane, toluene and ether) were obtained by passing the HPLC-
grade solvent through a Pure Solv 400 solvent purification system. All other solvents 
were laboratory grade, and were used as supplied. Water was purified using the 
“PuriteSTILL Plus” system and had a conductivity of 0.04 S cm-1. All reagents were used 
as supplied by commercial sources unless otherwise stated in the methods section. 
Reactions requiring an inert atmosphere were carried out using Schlenk-line techniques 
under an atmosphere of dry nitrogen. 
Thin layer chromatography was carried out using neutral aluminium oxide plates 
(Merck Art 5550) or silica plates (Merck Art 5554), both of which are fluorescent under 
short-range UV irradiation (254 nm). Column chromatography was performed using 
neutral alumina (Merck Aluminium Oxide 90, activity I, 70-230 mesh) or silica (Merck 
Silica Gel 60, 230-400 mesh) 
 
6.1.2 Characterisation Techniques 
1H NMR spectra were recorded in the appropriate solvents on Mercury-400, Varian-
200, Varian-500 or Huple-VNMRS-700 MHz instruments. 13C spectra were recorded at 
126 MHz on the Varian Inova-500 or at 176 MHz on the Huple-VNMRS-700 MHz. 19F 
NMR spectra were recorded at 376 MHz on the Mercury-400, at 470 MHz on the 
Varian-500, or at 188 MHz on the Varian-200. Chemical shifts are quoted relative to the 
appropriate protio-solvent resonance. All J values are given in Hz, and are quoted to the 
nearest 0.5 Hz. 
Low-resolution electrospray mass spectra (ES) were recorded using a Thermo Finnigan 
LTQ FT mass spectrometer, with methanol as the carrier solvent. Low resolution ASAP 
mass spectra were recorded on a Xevo QToF mass spectrometer (Waters, Ltd, UK) and 
MALDI on an Autoflex II ToF/ToF MS (Bruker Daltonik, GmbH), using trans-2-[3,4-
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tert-butyl phenyl]-2-methyl-2-propenylidene]malonitrile (dctb) as the matrix element. 
Accurate ES mass spectra were obtained using either a LCT Premier XE mass 
spectrometer (Waters Ltd, UK) or a LTQ FT mass spectrometer (Thermo-Finnigan 
Corporation). Accurate MALDI mass spectra were obtained using a LTQ FT mass 
spectrometer (Thermo-Finnigan Corporation), and accurate ASAP spectra were 
recorded with a Xevo QToF mass spectrometer (Waters, Ltd, UK). High resolution 
electron impact (EI) mass spectrometry was performed at the EPSRC National Mass 
Spectrometry Centre, Swansea. 
Elemental analysis was performed using an Exeter Analytical E-440 elemental analyser. 
Melting points were determined on a Gallenkamp 889339 capillary melting point 
apparatus. 
Crystallographic data for all reported structures were collected at 120 K. X-ray 
diffraction data for [PtL1Cl3] and [PtL13Cl] were collected on an Oxford Diffraction 
Gemini S Ultra diffractometer using graphite monochromated Mo K radiation ( = 
0.71073 Å).  The data were collected and integrated using Oxford Diffraction CrysAlis 
software.1  X-ray diffraction data for [PtL11Cl] was collected at 120 K on a Nonius 
Kappa CCD diffractometer using graphite monochromated Mo K radiation ( = 
0.71073 Å); data were collected using the strategy calculated by the COLLECT software 
(Nonius, 1999)2 and integrated using HKL Scalepack.3 The remaining X-ray diffraction 
data were collected at 120 K on a Bruker APEX CCD diffractometer. These data were 
collected using the SMART software, with subsequent data processing carried out in 
SAINT.4 All of the structures were solved by direct methods in SHELXS-97 and refined 
by full matrix least squares on F2 in SHELXL-97.5 
 
6.1.3 Photophysical Characterisation 
UV/Vis absorption spectra were measured using a Biotek Instruments UVIKON XS 
spectrometer operating with LabPower software. The sample was held in a quartz 
cuvette of 1 cm path length, and spectra were recorded against a reference of pure 
solvent held in a matched cuvette. Extinction coefficients were determined using a 
dilution method, and graphical application of the Beer-Lambert law:     
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where A() is the absorbance at a specified wavelength, c is the concentration of the 
absorbing species (mol dm-3) , l is the path length (cm) and  is the extinction 
coefficient (mol-1  dm3 cm-1). 
Solution-based emission and excitation spectra were acquired on a Jobin Yvon-Spex 
Fluoromax-2 spectrometer. All samples were contained within quartz cuvettes of 1 cm 
path length. Samples that were to be measured in the absence of air were placed in 
quartz cuvettes that were modified with appropriate glassware to allow connection to a 
high vacuum line. To remove air prior to the measurement, the sample was degassed 
within the cuvette by three freeze-pump-thaw cycles. Emission was recorded at 90  to 
the excitation source, and appropriate filters were used when required to remove second 
order peaks. All emission spectra were corrected after acquisition for dark count and for 
the spectral response of the detector. Excitation spectra were automatically corrected 
upon measurement for lamp output, through use of a beam splitter which directs 8% of 
the excitation light to a reference photodiode.  
The quantum yields were determined relative to a reference solution containing 2,6-
di(2-pyridyl)benzene-1-platinum(II) chloride ([PtL1Cl]). The quantum yield of this 
complex is well established as 0.60 in degassed DCM.6 To measure the quantum yield, 
a sample of complex in DCM was prepared so that the absorbance at the chosen 
excitation wavelength was below 0.1, to minimise inner filter effects. A solution 
containing [PtL1Cl] with similar absorbance intensity was prepared, and the emission 
spectra of the complex and reference were measured under identical conditions (i.e. 
same excitation wavelength, same slit size). The quantum yield was determined from 
the absorbance and emission data by use of equation 2:    
         
where  is the quantum yield of the sample,  is the quantum yield of the standard, 
Int and IntST are the overall intensities of the sample and standard respectively (obtained 
from integration of the respective emission spectrum), A and AST are the absorbance of 
the sample and standard at the chosen excitation wavelength, and n2 and n2ST are the 
refractive indices of the solvents (so not required here). The estimated uncertainty in the 
reported quantum yields is ± 20 %. 
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Lifetimes were determined using an Edinburgh Instruments OB 920 fluorimeter. 
Luminescence lifetimes of the complexes up to approximately 10 µs were measured by 
time-correlated single-photon counting method, using an EPL-375 pulsed-diode laser as 
excitation source (374 nm excitation, pulse length of 60 ps). The laser repetition rate 
was selected so that the pulse period was at least 5-10 times longer than the complex 
lifetime. The emission was detected at 90  to the excitation source, after passage through 
a monochromator using a Peltier-cooled R928. Lifetimes in excess of 10 µs were 
measured by multichannel scaling, and a xenon flash lamp was used as the excitation 
source (excitation wavelength matched to that of complex, pulse length of 2 µs). 
The lifetimes were obtained by least-squares fitting to a monoexponential decay of the 
form  
     
and goodness of fit was assessed from the residuals. 
Low temperature (77 K) experiments were performed using a glass vacuum cold finger 
apparatus built in house. A small amount of sample was dissolved in a 2:2:1 solvent mix 
of ether/isopentane/ethanol (EPA), and placed into a glass tube. The cold finger was 
filled with liquid nitrogen and the tube containing the sample was inserted. EPA forms 
an amorphous glass upon freezing, which has a very low propensity for cracking. 
For investigations at cryogenic temperatures, complexes [PtL1Cl], [PtL1Br] and [PtL1I] 
were dissolved in n-octane, and [PtL2Cl] was dissolved in n-decane, at concentrations of 
 10-5 M. The measurements were carried out on a He cryostat (Cryovac Konti Cryostat 
IT) in which the He gas flow, He pressure, and heating were controlled. For magnetic 
field experiments, an Oxford Instruments MD10 cryostat equipped with a 12 T magnet 
was used. A pulsed Nd:YAG laser (IB Laser Inc., DiNY pQ 02) with a pulse width of 
about 7 ns was used as the excitation source for emission spectra and lifetime 
measurements, using the third harmonic at 355 nm (28170 cm-1). For measurements of 
excitation spectra, a pulsed dye laser (Lambdaphysik Scanmate 2C) with Coumarin 102 
was operated. The spectra were recorded with an intensified CCD camera (Princeton 
PIMAX) or a cooled photomultiplier (RCA C7164R) attached to a triple spectrograph 
(S&I Trivista TR 555). Time-resolved emission spectra were recorded with a gated 
photon counter (Stanford Research Systems, Model SR 400). Decay times were 
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registered using a FAST Comtec multichannel scaler PCI card with a time resolution of 
250 ps.7 
Solid state emission was recorded using the Edinburgh Instruments OB 920 fluorimeter, 
and data was corrected by an in-built calibration curve. 
Cyclic voltammetry was carried out using a µAutolab Type III potentiostat with 
computer control, using GPES Manager software. A three electrode set-up was 
employed, consisting of a glassy carbon working electrode (GCE), a platinum flag 
counter electrode, and a platinum wire pseudo-reference electrode. The complex (~ 1 x 
10-3 M) was dissolved in a solution of DMSO containing a tetrabutylammonium 
hexafluorophosphate (0.1 M) background electrolyte. The solution was stirred and 
purged with nitrogen prior to the measurement. All measurements reported are reported 
relative to a Fc/Fc+ reference.   
 
6.1.4 Cellular Studies 
Two cell lines were chosen for cellular studies: Chinese hamster ovary (CHO) and 
mouse skin fibroblast (NIH 3T3). Both are adherent cell lines, and were maintained in 
exponential growth as monolayers in appropriate medium: F-12 (Ham) and Dulbecco’s 
Modified Eagle Medium (DMEM) respectively. For each cell line, the medium was 
supplemented with 10% foetal bovine serum (FBS) and 1% penicillin and streptomycin. 
To prevent overcrowding and build up of toxins (both of which could cause 
uncharacteristic behaviour of the cells) the cells were sub-cultured every three-to-four 
days.  
Sub-culturing was performed as follows: Sterile solutions of trypsin, PBS and fresh 
medium were warmed in a water bath to 37  C over 30 min. The culture flask containing 
the cells was removed from the incubator, and the old medium was removed. Cells were 
rinsed with sterile phosphate-buffered saline (PBS, pH 7.5) (6 mL), then incubated with 
trypsin (1.5 mL) for 3 min. During this time, the cells became detached from the surface 
of the flask. After gentle tapping of the flask, the trypsin suspension was transferred to a 
centrifuge tube, along with a washing with fresh medium (7 mL). The sample was spun 
at 1500 rpm for 3 min, during which the cells settled to the bottom of the tube. The 
trypsin/medium solution was poured off, and cells were re-suspended in fresh medium 
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(stock solution, 4 mL). Some of these cells (500-600 µL) were transferred to a fresh 
culture flask containing fresh medium (10 mL), and replaced in the incubator. If 
experiments were to be performed, cells were also transferred to the appropriate 
microplates at this stage. For cytotoxicity experiments, which require a known number 
of cells, cell counting was performed using a haemocytometer.  
 
6.1.4.1 Microscopy 
Cells were seeded in twelve-well plates containing glass coverslips, and allowed to 
grow to 60-80% confluence in an incubator set at 37  C and 5% CO2. At this stage, the 
old medium was removed and replaced with fresh medium containing the appropriate 
dosages of complex etc. Following incubation, the coverslips were removed and washed 
with sterile PBS, then mounted on a microscope slide and held in place with clear nail 
varnish. The cells were imaged straight away. Epifluorescence images were taken using 
a Zeiss Axiovert 200M epifluorescence microscope with a digital camera, and were 
processed using the Zeiss Axiovision software. A x 40 oil-immersion objective lense 
was used to visualize the image. The filter sets and dichroic mirrors were chosen to 
match the solution based photophysics of the complexes. G365 filters (Zeiss) were 
employed for excitation of all complexes. For the Pt(II) complexes, FITCex (450-500 
nm) or FITCem (515-565 nm) filters were used to monitor blue-green emission and a 
660-710 (Comar) filter was used to monitor the lower energy emission component. For 
Ir(III) complexes, the FITCem filter was used to monitor emission. 
 
6.1.4.2 Cytotoxicity 
 
MTT Method 
A suspension containing approximately 1 x 106 NIH-3T3 cells in DMEM media (10 
mL) was prepared from the 4 mL stock solution (prepared during sub-culturing). This 
was transferred to a 96-well microplate in 100 µL aliquots (i.e. approximate number of 
cells per well = 1 x 104), and the cells were incubated at 37  C and 5% CO2 overnight, 
during which time adhesion occurred. The following morning, cells were dosed (in 
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triplicate) with a selection of concentrations of the complex under study, and incubated 
for a further 24 h. The dosing media was then removed, cells were rinsed with sterile 
PBS (pH 7.5, 100 µL), and fresh medium was added (100 µL). 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT, 1.0 mM)8 was added to each well, and 
the cells were incubated for another 4 h. After this time, the culture medium was 
removed, and DMSO (150 µL) was added to each well. The 96-well plate was then 
shaken for 20 s, and the absorbance of each well at 541 nm was measured against a 
“blank” (a microplate containing only 150 µL DMSO per well) that had been recorded 
prior to the measurement (absorbance was measured using an Analytic Jena 
FLASHScan 530, using WinFLASH version 1.5 software). To get the percentage of live 
cells per concentration, the average absorbance for a given concentration was divided 
by the average absorbance of wells containing un-dosed cells.  
 
Trypan-blue Method 
Approximately 5 x 104 NIH-3T3 cells in DMEM (500 µL) were seeded into each well 
of two 12-well microplates. The cells were incubated at 37  C and 5% CO2 overnight, 
during which time adhesion to the base of the microplate occurred. The following day, 
cells were dosed (in duplicate) with a selection of concentrations of the complex under 
study, and incubated for a further 1 h. The media was removed, the cells were rinsed 
with PBS (500 µL), then incubated with trypsin (100 µl) for 3 min. The cells were 
transferred to a centrifuge tube. Media (500 µl) was used to rinse the well, and this 
washing was also transferred to the centrifuge tube. The sample was spun at 1500 r.p.m. 
for 3 min, during which the cells settled to the bottom of the tube. The solution was 
decanted, and sterile PBS (100 µL) was added. Trypan blue was then added (100 µL), 
and the mixture was left for 3-5 min. The number of dead and live cells was then 
counted using a haemocytometer (dead cells = blue, live cells = colourless). This was 
repeated four times.  
 
6.1.4.3 Flow Cytometry 
Flow cytometric analysis was conducted with a DakoCytomation Inc. MoFlo multi-laser 
flow cytometer (Fort Collins, CO, USA) operating at 60 Psi with a 70 µM nozzle. 
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Samples were interrogated with a 100 mW 488 nm solid state laser and a UV-laser 
operating at 50 mW. Luminescence signals were detected through interference filters: 
for Pt complexes, a 450/65 bandpass interference filter was selected, and for Ir 
complexes a 530/40 bandpass filter was used. Fluorescence signals were collected in the 
logarithmic mode. The data was analysed using Summit v4.3 (Beckman Coulter) 
software. 
For flow cytometric analysis, cells were seeded in twelve-well plates and grown to 70-
80% confluence. The old medium was then replaced with fresh media containing the 
desired complex dosage, and cells were incubated for set time lengths. After incubation, 
cells were detached from the plate by incubation with trypsin (200 µL) for 3 min at 37  
C. This cell suspension was placed in a centrifuge tube. The well was washed with 
media (1 mL), this washing was added to the centrifuge tube, and the sample was spun 
at 1500 rpm for 3 min. The supernatant was removed from the cell pellet, which was re-
suspended in sterile PBS (2 ml) and placed on ice. The cells were analysed by flow 
cytometry as soon as possible. Immediately prior to the analysis, the cell suspension 
was filtered through a 40 µM filter to remove any cell clumps. 
 
6.1.4.4 Time Resolved Emission Imaging 
Time-resolved microscopy was performed based upon time-gated detection as follows. 
The excitation source was a Q-switched Nd:YAG laser (UV FQ, Elforlight LtD) and its 
output is optical pulses at 355 nm through internal third harmonic generation with a 
temporal width of ~5 ns (FWHM). The microscope was a Leica 135 axiovert 
epifluorescence microscope. The laser excitation pulses were fed into the microscope 
through a beam expander and focused onto the sample using long working distances 
objective lenses (Zeiss LD plan neofluar, 10X, 40X or 63X). The photoluminescence 
was detected using a combination of dichroic mirrors and band pass or long pass filters. 
The photoluminescence signal was collected using a time-gated CCD camera (752 by 
582 pixels), (Imagex nanoCCD, Photonics Research Systems). In the excitation-
detection sequence, the CCD camera control unit triggered the laser with TTL pulse and 
the photoluminescence signals were acquired with a suitable delay and time gate 
combination.   
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The CCD camera system has 16 different time banks. Time-resolved 
photoluminescence microscopy decays can therefore be recorded using a constant gate 
with 16 different delays. These decays were subsequently analysed and fitted to model 
of exponential decay of the photoluminescence,  
( ) τ
t
o eItI
−
=     
where I0 is the amplitude and the τ is the photoluminescence lifetime.    
 
6.2 Synthesis of Ligands and Ligand Precursors 
The following compounds were prepared by literature procedures: 1,3-di(2-
pyridyl)benzene (HL1) and 2,6-di(2-pyridyl)benzene platinum(II) chloride ([Pt(L1)Cl]),9 
2-tri-n-butylstannyl pyridine,10 1,3-Dibromo-4,6-difluorobenzene,11,12 1,3-dibromo-5-
nitrobenzene,13 4-methyl-2-tri-n-butylstannylpyridine,14 2-bromo-4-
dimethylaminopyridine,15 2-bromopyridine-N-oxide, 2-bromo-4-nitropyridine-N-oxide, 
2-bromo-4-nitrropyridine and 2-bromo-4-methoxypyridine.16 Synthetic details of all 
other ligands, ligand precursors and complexes are given in the following sections. 
 
6.2.1 General Procedures 
Some standard procedures were used frequently in the synthesis of ligands and ligand 
precursors. The general details of such reactions will be given here to avoid repetition 
throughout the chapter. 
 
6.2.1.1 General Suzuki-Miyaura Procedure 
Benzene-1,3-diboronic acid (or a substituted benzene 1,3-diboronic ester derivative) and 
an n-substituted-2-bromopyridine were placed in a Schlenk tube and dissolved in 
dimethoxyethane (DME). A solution of aqueous 1M Na2CO3 was then added, a 
condenser was inserted and the mixture was degassed by five freeze-pump-thaw cycles. 
The solution was then subjected to a very high flow of nitrogen. The catalyst, 
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tetrakis(triphenylphosphine) palladium, Pd(PPh3)4, was added quickly as a solid. The 
mixture was heated at 80 °C for two days under nitrogen. After cooling to room 
temperature, the crude Suzuki product was washed with water (2 x 15 mL) and 
extracted into DCM (3 x 25 mL). The DCM solution was dried with MgSO4, filtered 
and the solvent was removed in vacuo. The product was purified with column 
chromatography. 
 
6.2.1.2 General Stille Procedure 
A 2-tri-n-butylstannyl pyridine derivative, a 1,3-dibromobenzene derivative, 
bis(triphenylphosphine) palladium dichloride {Pd(PPh3)2Cl2}, and LiCl were placed 
into a Schlenk tube. Toluene was added and a condenser was fitted. The mixture was 
degassed by five freeze-pump-thaw cycles, then placed under nitrogen and heated at 
120  C for three days. On cooling to room temperature, a saturated aqueous solution of 
KF (10 mL) was added, and the mixture was stirred for 30 min. The precipitated solid 
was removed by filtration and washed with water (2 x 15 mL) and toluene (3 x 30 mL). 
Aqueous NaHCO3 (10%, 50 mL) was added to the filtrate, which was then extracted 
into DCM (2 x 50 mL). The DCM portion was dried with MgSO4, filtered and the 
solvent was removed in vacuo. The crude product was purified with column 
chromatography. 
 
6.2.1.3 Stannylation of 2-bromopyridines via lithium-halogen exchange 
The appropriate 2-bromopyridine was placed in a 200 mL two-necked round-bottomed 
flask fitted with a condenser and suba seal. Dry THF (25 mL) was added to this under 
nitrogen and the reaction was cooled to -78 °C. nBuLi (1.1 equiv) was added slowly 
(over 20 min) and the reaction was stirred at -78 °C for a further 90 min. Tributyltin 
chloride (Bu3SnCl, 1.2 equiv) was then added under nitrogen, and the mixture was 
stirred at -78 °C for a further 2 h, then allowed to warm gradually to room temperature. 
Water (15 mL) was added to hydrolyse any remaining n-BuLi – this was stirred for 10 
min. The mixture was extracted into diethyl ether (3 x 30 mL), dried over MgSO4, then 
the solvent was removed in vacuo. 1H NMR was used to assess the purity of the 
stannane, and the crude product was used directly in Stille reactions.  
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6.2.1.4 Stannylation of 4-R-pyridines via ortho-directed lithiation 
A two-necked round bottomed flask (250 mL) was fitted with a suba seal and a 
condenser. The flask was attached to a nitrogen line via the condenser and purged with 
nitrogen. A solution of 2-(dimethylamino)ethanol was added to the flask under nitrogen. 
Dry hexane (25mL) was also added under nitrogen. The mixture was cooled to 0 °C, 
and n-BuLi was added dropwise over 20 min. The mixture was left stirring at 0 °C for a 
further 15 min. The 4-substituted pyridine in hexane (5 mL) was added under nitrogen. 
The mixture was stirred at 0°C for 1 h. The mixture was then cooled to -78 °C and 
treated with a solution of Bu3SnCl in THF (5 mL) under nitrogen. After stirring at -78 
°C for 1h, the mixture was warmed to room temperature, then cooled to 0 °C and water 
(15 mL) was added. The organic layer was then extracted three times with diethyl ether 
(3 x 20 mL) and dried with MgSO4. After filtration of the solution, the solvent was 
removed in vacuo. 1H NMR was used to estimate the purity of the stannane, and the 
crude product was used directly in Stille reactions.  
 
6.2.1.5 Double Borylation of functionalised 1,3-dibromobenzenes 
Dry DMSO (5 mL) was degassed in a 2-necked round bottom flask (left open to 
vacuum for 30 min) then placed under nitrogen. The appropriate 1,3-dibromobenzene, 
bispinacolatodiboron (B2pin2), Pd(dppf)Cl2 and KOAc were placed in a Schlenk tube, 
degassed (open to vacuum then back-filled with nitrogen x 3) and put under nitrogen. 
The dry DMSO was transferred across under nitrogen, and the mixture was heated at 
85  C for 18 h. On cooling to room temperature, the crude was washed with a mixture of 
50:50 EtOAc and water (50 mL), and the organic phase was collected. This was washed 
with water (2 x 30 mL) and brine (2 x 50 mL), dried with MgSO4, and the solvent was 
removed in vacuo. The crude product was purified by column chromatography (an 
iodine tank was used to visualise the TLC plate). 
 
6.2.1.6 Williamson Ether Synthesis 
Dry K2CO3 and Cs2CO3 were placed in a Schlenk with stirrer bar and dissolved in 
CH3CN. The bromo-electrophile and oxygen-based nucleophile were added, and the 
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reaction was placed under nitrogen. The mixture was heated at 80  C for four days. The 
reaction was allowed to cool to room temperature, then the mixture was washed with 
brine (2 x 20 mL) and extracted into DCM (3 x 30 mL). After drying with MgSO4 and 
filtering, the solvent was removed in vacuo. The crude product was purified by column 
chromatography. 
 
6.2.2 Synthetic Details and Characterisation 
 
HL2: 1,3-di(2-pyridyl)-4,6-difluorobenzene 
NN
FF
1´
2´
3
4
5
4´
2
6
5´
 
The ligand was prepared via the Stille methodology. Reagents: 2-Tri-n-
butylstannylpyridine (4.17 g, assumed 85% pure, 9.6 x 10-3 mol), 1,3-dibromo-4,6-
difluorobenzene (1.09 g, 4.0 x 10-3 mol), Pd(PPh3)2Cl2 (0.10 g, 1.5 x 10-4 mol) and LiCl 
(1.24 g, 2.93 x 10-2 mol). Solvent: toluene (6 mL). Purification: column chromatography 
(silica, hexane/ether gradient elution from 100/0 to 25/75). The desired product was 
obtained as a pale yellow solid (0.57 g, 53%), mp = 156-158 °C, Rf 0.54 (silica, 
hexane/ether 25/75). 1H NMR (500 MHz, CDCl3) H = 7.05 (1H, t, 3J(19F) = 11.0, H5´), 
7.28 (2H, m, H5), 7.77 (4H, m, H3 and H4), 8.63 (1H, t, 4J(19F) = 9.5, H2'), 8.74 (2H, dt, 
J(1H) = 5.0 and 1.0, H6), 13C {1H} NMR (126 MHz, CDCl3). C = 105.0 (t, J(19F) = 28.0, 
C5'), 123.0 (s, C5), 124.5 (t, J(19F) = 5.0, C3), 125.0 (dd, J(19F) = 11.0 and 5.0, C1'), 134.0 
(t, J(19F) = 5.0, C2'), 136.5 (s, C4), 150.0 (s, C6), 153.0 (t, J(19F) = 1.5, C2), 161.0 (dd, 
J(19F) = 254.5 and 12.5, C4'). 19F NMR (376 MHz, CDCl3) F = -113.4 (2F, t, J(1H) = 
9.5). HRMS (ES+): m/z 291.0707 [11%, M+Na+], 269.0886 [100, M+H+]; calcd for 
[C16H11F2 N2], 269.0885, calcd for [C16H10F2 N223Na], 291.0710. Anal. C16H10F2N2 
(268.25): calcd C, 71.63; H, 3.76; N, 10.44; found C, 71.52; H, 3.81; N, 10.43. 
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HL3: 1,3-di(2-pyridyl)-5-nitrobenzene 
NN
NO2
1´
2´
3
4
5
4´
2
6
5´
 
Ligand HL3 was prepared via the Stille method. Reagents: 2-Tri-n-butylstannylpyridine 
(3.33 g, assumed 85% pure, 7.7 x 10-3 mol), 1,3-dibromo-5-nitrobenzene (0.90 g, 
3.2 x 10-3 mol), Pd(PPh3)2Cl2 (0.084 g, 1.2 x 10-4 mol) and LiCl (0.992 g, 2.34 x 10-2 
mol). Solvent: toluene (5 mL). Purification: column chromatography (silica, 
hexane/ether gradient elution from 100/0 to 40/60). The desired product was obtained as 
a pale yellow solid (0.49 g, 55%), mp = 98 – 100 °C, Rf = 0.16 (silica, hexane/ether 
50/50). 1H NMR (500 MHz, CDCl3) H = 7.36 (2H, ddd, J(1H) = 8.0, 5.0 and 1.0, H5), 
7.87 (2H, td, J(1H) = 8.0 and 2.0, H4), 7.93 (2H, dt, J(1H) = 8.0 and 1.0, H3), 8.78 (2H, 
ddd, J(1H) = 5.0, 2.0 and 1.0, H6), 8.93 (2H, d, J(1H) = 2.0, H4'), 9.07 (1H, t, J(1H) = 2.0, 
H2'), 13C {1H} NMR (126 MHz, CDCl3) C = 121.0 (C, s, C3), 122. 1 (C, s, C2'), 123.6 
(C, s, C5), 131.1 (C, s, C4'), 137.4 (C, s, C4), 141.7 (C, s, C1'), 149.7 (C, s,C5'), 150.3 (C, 
s, C6), 155.0 (C, s, C2). HRMS (ES+): m/z 278.0923 [100%, M+H+]; calcd for 
[C16H12N3O2], 278.0924. Anal. C16H11N3O2 (277.27): calcd C, 69.30; H, 4.00; N, 15.16; 
found C, 66.65; H, 4.58; N, 13.27. 
 
3,5-Dibromoaniline 
NH2
BrBr
2
5
 
1,3-Dibromo-5-nitrobenzene (0.50 g, 1.8 x 10-3 mol) and Sn powder (1.50 g, 1.3 x 10-3 
mol) were placed in a round bottomed flask (100 mL) with  stirrer bar and fitted with a 
condenser. 5 M HCl was added (10 mL). EtOH was added in 5 mL portions until 
3,5-dibromo-1-nitrobenzene dissolved (35 mL total). The mixture was heated to reflux. 
Once at reflux, a further 20 mL of the 5 M HCl was added. The mixture was heated at 
reflux overnight. On cooling to room temperature, the solvent was removed in vacuo 
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leaving a pale yellow solid (protonated amine). Excess NaOH solution was added to 
basify the solution, which was then extracted into DCM (30 mL). The DCM portion 
was washed with a Na2CO3 solution (10%, 2 x 20 mL). The DCM phase was dried with 
MgSO4, filtered, and the solvent was removed in vacuo. The product was obtained as a 
brown oil (0.20 g, 45%). 1H NMR (300 MHz, CDCl3) H = 3.75 (2H, s, NH2), 6.73 (2H, 
d, J(1H) = 2.0, H2), 7.01 (1H, t, J(1H) = 2.0, H5) 
 
HL4: 1,3-di(2-pyridyl)-5-aminobenzene 
NN
NH2
1´
2´
3
4
5
4´
2
6
5´
 
This ligand, HL4, was prepared via the Stille method. Reagents: 2-Tri-n-
butylstannylpyridine (0.74 g, assumed 85% pure, 1.68 x 10-3 mol), 3,5-dibromo aniline 
(0.18 g, 7.2 x 10-4 mol), Pd(PPh3)2Cl2 (0.020 g, 3 x 10-5 mol) and LiCl (0.22 g, 5.24 x 
10-3 mol). Solvent: toluene (6 mL). Purification: column chromatography (silica, 
hexane/ether gradient elution from 100/0 to 0/100, then DCM/MeOH gradient elution 
from 100/0 to 95/5). The desired product was obtained as a yellow oil (0.055 g, 31%), 
Rf = 0.15 (silica, hexane/ether 25/75). 1H NMR (500 MHz, CDCl3) H = 3.5-4.1 (2H, br, 
m, NH2), 7.23 (2H, ddd, J(1H) = 7.5, 5.0 and 1.0, H5), 7.44 (2H, s, H4'), 7.74 (2H, td, 
J(1H) = 7.5 and 1.0, H4), 7.80 (2H, d, J(1H) = 7.5, H3), 7.93 (1H, s, H2'), 8.69 (2H, d, 
J(1H) = 5.0, H6), 13C{1H} NMR (126 MHz, CDCl3) C = 114.5 (s, C4'), 116.0 (s, C2'), 
121.0 (s, C3), 122.5 (s, C5), 128.5 (d, J = 12.2, C5'), 137.0 (s, C4), 141.0 (s, C3'), 149.7 (s, 
C6), 157.5 (s, C2). HRMS (ES+): m/z 248.1184 [100%, M+H+]; calcd for [C16H14N3], 
248.1182. 
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3-Methyl-2-tri-n-butylstannylpyridine 
N SnBu3
5
6
4
 
This stannane was prepared via the lithium-halogen exchange/stannylation route, using 
2-bromo-3-methylpyridine (1.50g, 8.72 x 10-3 mol), nBuLi (3.84 mL, 2.5M in hexanes, 
9.59 x 10-3 mol) and Bu3SnCl (2.84 mL, 1.05 x 10-2 mol). The desired product was 
obtained as an orange liquid (4.23 g, assumed 50% pure by mass, therefore 2.11 g, 
63%). 1H NMR (400 MHz, CDCl3), H = 0.7-1.7 (27H, m, 3Bu3), 2.35 (3H, s, CH3), 
6.99 (1H, dd, J(1H) = 8.0 and 5.0, H5), 7.30 (1H, ddd, J(1H) = 8.0, 2.0 and 1.0, H4), 8.52 
(1H, ddd, J(1H) = 5.0, 2.0 and 1.0, H6) 
 
HL5: 1,3-di(3-methyl-2-pyridyl)benzene  
NN
5´
4´
3
4
5
2´
2
6
1´
 
Ligand HL5 was prepared via Stille methodology. Reagents: 3-Methyl-2-tri-n-
butylstannyl pyridine (1.74 g, 4.54 x 10-3 mol), 1,3-dibromobenzene (0.487 g, 2.06 x 10-
3
 mol), Pd(PPh3)2Cl2 (0.054 g, 8 x 10-5 mol) and LiCl (0.63 g, 1.49 x 10-2 mol). Solvent: 
toluene (6 mL). Purification: column chromatography (silica, hexane:EtOAc, 100:0  
0:100). The desired product was obtained as an orange oil (0.230 g, 8.9 x 10-4 mol, 
43%) Rf = 0.24 (100% EtOAc). 1H NMR (500 MHz, CDCl3) H = 2.39 (6H, s, CH3), 
7.18 (2H, dd, J(1H) = 7.5 and 5.0, H5), 7.57 (5H, m, H4, H4' and H5'), 7.70 (1H, td, J(1H) 
= 1.5 and 0.5, H2'), 8.53 (2H, dd, J(1H) = 5.0 and 2.0, H6). 13C {1H} NMR (126 MHz, 
CDCl3) C = 20.0 (s, CH3), 122.4 (s, C5), 128.2 (s, C1'), 128.8 (s, C4'), 130.0 (s, C2'), 
131.2 (s, C3), 138.7 (s, C4), 140.8 (s, C5'), 147.2 (s, C6), 158.7 (s, C2). HRMS (ES+): m/z 
283.1207 [32%, M+Na+], 261.1387 [36, M+H+]; calcd for [C18H17N2], 261.1386. 
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HL7: 1,3-di(5-methyl-2-pyridyl)benzene 
NN
5´
4´
3
4
5
2´
2
6
1´
 
HL7 was prepared via Suzuki-Miyaura methodology. Reagents: Benzene-1,3-diboronic 
acid (0.11 g, 6.6 x 10-4 mol) 2-bromo-5-methyl pyridine (0.260 g, 1.5 x 10-3 mol), 
Na2CO3 (1M, 5 mL), Pd(PPh3)4 (0.091 g, 8 x 10-5 mol). Solvents: DME (5 mL), water 
(5 mL). Purification: Column chromatography (silica, hexane/EtOAc, 100:0  50:50). 
The desired product came off around 35% EtOAc and was isolated as a yellow oil 
(0.123 g, 72%). Rf = 0.57 (silica, 100% EtOAc). 1H NMR (400 MHz, CDCl3), H = 2.35 
(6H, s, 2CH3), 7.52-7.57 (3H, m, H5' and H4), 7.71 (2H, d, J(1H) = 8.5, H3), 8.01 (2H, 
dd, J(1H) = 8.0 and 1.5, H4'), 8.53 (2H, dd, J(1H) = 1.5 and 0.5, H6), 8.57 (1H, t, J(1H) = 
1.5, H2'), 13C{1H} NMR (126 MHz, CDCl3) C = 18.5 (C, s, 2CH3),  120.5 (C, s, C3), 
125.5 (C, s, C2'), 127.0 (C, s, C4'), 129.5 (C, s, C5'), 132.0 (C, s, C5), 137.5 (C, s, C4), 
140.0 (C, s, C1'), 150.0 (C, s, C6), 155.0 (2C, s, C2). HRMS (ES+): m/z 283.1210 [10%, 
M+Na+], 261.1385 [100, M+H+]; calcd for [C18H17N2], 261.1386.  
 
HL8: 1,3-di(6-methyl-2-pyridyl)benzene 
NN
5´
4´
3
4
5
2´
2
6
1´
 
Ligand HL8 was prepared via Suzuki-Miyaura methodology. Reagents: 
Benzene-1,3-diboronic acid (0.52 g, 3.2 x 10-3 mol), 2-bromo-6-methyl pyridine (1.26 
g, 7.28 x 10-3 mol), Na2CO3 (1M, 5 mL) and Pd(PPh3)4 (0.44 g, 3.8 x 10-4 mol).  
Solvents: DME (5 mL) and water (5 mL). Purification: Column chromatography (silica, 
DCM/MeOH, 100/0  92/8), giving the desired product as a pale yellow oily solid 
(0.22 g, 27%), Rf = 0.56 (silica, DCM/MeOH 99:1). 1H NMR (500 MHz, CDCl3), H = 
2.65 (6H, s, 2CH3), 7.12 (2H, dd, J(1H) = 7.5 and 0.5, H5), 7.57 (1H, t, J(1H) = 8.0, H5'), 
7.62 (2H, d, J(1H) = 7.5, H3), 7.67 (2H, t, J(1H) = 7.5, H4), 8.04 (2H, dd, J(1H) = 8.0 and 
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1.5, H4'), 8.57 (1H, t, J(1H) = 1.5, H2'), 13C{1H} NMR (126 MHz, CDCl3) C = 25.0 (s, 
2CH3), 118.0 (s, C3), 122.0 (s, C5), 125.5 (s, C2'), 127.5 (s, C4'), 129.5 (s, C5'), 137.5 (s, 
C4), 140.5 (s, C1'), 157.0 (s, C2). HRMS (ES+): m/z 261.1385 [100%, M+H+]; calcd for 
[C18H17N2], 261.1386. 
 
HL9: 1,3-di(3-methyl-2-pyridyl)-4,6-difluorobenzene 
NN
F5´
4´
3
4
5
2´
2
6
1'´
F
 
Ligand HL9 was prepared via Stille methodology. Reagents: 3-Methyl-2-tri-n-
butylstannyl pyridine (1.03 g, 2.7 x 10-3 mol), 1,3-dibromo-4,6-difluorobenzene (0.37 g, 
1.4 x 10-3 mol), bis-(triphenylphosphine) palladium (II) dichloride (0.38 g, 5 x 10-5 mol) 
and LiCl (0.42 g, 9.9 x 10-3 mol). Solvent: Toluene (8 mL). Purification: Column 
chromatography (silica, hexane/EtOAc gradient elution from 100/0 to 80/20). The pure 
product was obtained as a pale yellow oil (0.11 g, 27%). Rf = 0.26 (silica, 100% 
EtOAc), 1H NMR (400 MHz, CDCl3) H = 2.29 (6H, s, 2CH3), 6.99 (1H, t, J(19F) = 
10.0, H5'), 7.21 (2H, dd, J(1H) = 8.0 and 4.5, H5), 7.58 (3H, m, H2' and H4), 8.50 (2H, 
dd, J(1H) = 4.5 and 1.0, H6), 13C{1H} NMR (126 MHz, CDCl3) C = 20.5 (s, 2CH3), 
104.0 (t, J(19F) = 27.5, C5'), 123.2 (s, C5), 125.3 (dd, J(19F) = 15.0 and 6.0, C1'), 133.1 (s, 
C3), 134.3 (t, J(19F) = 5.5, C2'), 138.3 (s, C4), 147.3 (s, C6), 153.1 (s, C2), 159.8 (dd, 
J(19F) = 253.0 and 12.5, C4'). 19F NMR (376 MHz, CDCl3) F = -111.4 (2F, t, J(1H) = 
9.0). HRMS (ES+): m/z 319.10179 [4%, M+Na+], 297.1198 [100, M+H+]; calcd for 
[C18H14N2F223Na], 319.1017, calcd for [C18H15N2F2], 297.1198. 
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HL10: 1,3-di(4-methyl-2-pyridyl)-4,6-difluorobenzene 
NN
FF
1´
2´
3
4
5
4´
2
6
5´
 
The ligand, HL10, was prepared via the Stille methodology. Reagents: 4-Methyl-2-tri-n-
butylstannyl pyridine (0.23 g, 6.1 x 10-4 mol), 1,3-dibromo-4,6-difluorobenzene (0.075 
g, 2.8 x 10-4 mol), Pd(PPh3)2Cl2 (0.010 g, 1.4 x 10-5 mol) and triphenylphosphine (0.007 
g, 3 x 10-5 mol). Solvent: Xylene (7 mL). The mixture was heated under reflux at 160 
°C under a nitrogen atmosphere for 20 h. Purification: Column chromatography (silica, 
hexane/diethyl ether gradient elution from 0/100 to 100/0). The product was obtained as 
a pale brown solid (0.072 g, 88%), mp = 90 – 95 °C, Rf = 0.26 (silica, hexane/ether 
50/50). 1H NMR (300 MHz, CDCl3) H = 2.42 (6H, s, CH3), 7.02 (1H, t, J(19F) = 10.5, 
H5'), 7.09 (2H, ddd, J(1H)  = 5.0 and 1.0, H5), 7.58 (2H, s, H3), 8.52 (1H, t, J(19F) = 8.5, 
H2'), 8.56 (2H, d, J(1H) = 5.0, H6), 13C{1H} NMR (126 MHz, CDCl3) C = 21.5 (s, C7), 
105.0 (t, J(19F) = 27.0, C5'), 124.0 (s, C5), 125.0 (s, C1'), 125.5 (t, J(19F) = 4.0, C3), 134.0 
(s, C2'), 148.0 (s, C4), 150.0 (s, C6), 153.0 (s, C2), 161.0 (d, J(19F) = 242.0, C4'). 19F 
NMR (376 MHz, CDCl3) F = -113.5 (2F, t, J(1H) = 9.8). HRMS (ES+): m/z 297.1201 
[100%, M+H+]; calcd for [C18H15N2F2], 297.1198. Anal. C18H14F2N2 (296.31): calcd C, 
72.96; H, 4.76; N, 9.46; found C, 72.56; H, 4.81; N, 9.30. 
 
5-Methyl-2-tri-n-butylstannylpyridine 
N SnBu3
3
4
6
 
This stannane was prepared via the lithium-halogen exchange/stannylation route. 
Reagents: 2-Bromo-5-methyl pyridine (1.00 g, 5.81 x 10-3 mol), nBuLi (2.42 mL, 2.5M 
in hexanes, 6.06 x 10-3 mol), Bu3SnCl (1.89 mL, 6.96 x 10-3 mol) The product, 5-
methyl-2-tri-n-butylstannyl pyridine, was obtained as a yellow liquid (2.80 g, assumed 
70% pure by mass, therefore 1.96 g, 88%). 1H NMR (200 MHz, CDCl3), H = 0.83-1.70 
(27H, m, 3Bu3), 2.72 (3H, s, CH3), 7.29 (2H, m, H3 and H4), 8.58 (1H, s, H6). 
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HL11: 1,3-di(5-methyl-2-pyridyl)-4,6-difluorobenzene 
NN
F5´
4´
3
4
5
2´
2
6
1´
F
 
The ligand HL11 was prepared via Stille cross-coupling methodology. Reagents: 
1,3-Dibromo-4,6-difluorobenzene (0.30 g, 1.10 x 10-3 mol), 5-methyl-2-tri-n-
butylstannyl pyridine (0.99 g, 2.59 x 10-3 mol), Pd(PPh3)2Cl2 (0.029 g, 4.1 x 10-5 mol) 
and LiCl (0.33 g, 7.9 x 10-3 mol). Solvent: Toluene (10 mL). Purification: Column 
chromatography (silica, hexane/EtOAc, 100:0  0:100). The product,  1,3-di(5-methyl-
2-pyridyl)-4,6-difluorobenzene, was obtained as a white powder (0.13 g, 39%), mp = 
140-142 °C, Rf = 0.64 (silica, 100% EtOAc). 1H NMR (500 MHz, CDCl3), H = 2.40 
(6H, s, 2CH3), 7.01 (1H, t, J(19F) = 10.5, H5'), 7.58 (2H, dd, J(1H) = 8.0, and 2.0, H4),  
7.67 (2H, d, J(1H) = 8.0, H3), 8.50-8.60 (3H, m, H2' and H6). 13C{1H} NMR (126 MHz, 
CDCl3) C = 18.7 (s, CH3), 105.0 (t, J(19F) = 27.0, C5'), 123.9 (t, J(19F) = 4.5, C3), 124.7 
(dd, J(19F) = 11.0 and 5.5, C1'), 132.3 (s, C5), 133.4 (t, J(19F) = 4.5, C2'), 137.2 (s, C4), 
150.1 (t, J(19F) = 2.0, C2), 150.5 (s, C6), 160.3 (dd, J(19F) = 255.5 and 12.5, C4'). 19F 
NMR (376 MHz, CDCl3) F = -114.0 (2F, t, J(1H) = 10.0). HRMS (ES+): m/z 319.1018 
[9%, M+Na+], 297.1197 [100, M+H+]; calcd for [C18H14N2F223Na], 319.1017, calcd for 
[C18H15N2F2], 297.1198. Anal. C18H14F2N2 (296.31): calcd C, 72.96; H, 4.76; N, 9.46; 
found C, 70.53; H, 4.92; N, 8.93 
 
6-Methyl-2-tri-n-butylstannylpyridine 
N SnBu3
3
4
5
 
This stannane was prepared via the lithium-halogen exchange/stannylation route. 
Reagents: 2-Bromo-6-methyl pyridine (0.86 g, 5.0 x 10-3 mol), nBuLi (2.2 mL, 2.5M in 
hexanes, 5.5 x 10-3 mol), Bu3SnCl (1.63 mL, 6.01 x 10-3 mol) The product was obtained 
as a yellow liquid (2.75 g, assumed 50% pure by mass, therefore 1.37 g, 72%). 1H NMR 
(400 MHz, CDCl3), H = 0.8-1.8 (27H, m, 3Bu3), 2.53 (3H, s, CH3), 6.94 (1H, dd, J(1H) 
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= 7.0 and 1.0, H5), 7.17 (1H, d, J(1H) = 7.0, 4J(117/118Sn) = 16.0, H3), 7.35 (1H, t, J(1H) = 
7.0, H4). 
 
HL12: 1,3-di(6-methyl-2-pyridyl)-4,6-difluorobenzene 
NN
F5´
4´
3
4
5
2´
2
6
1´
F
 
The ligand, HL12, was prepared via Stille cross-coupling methodology. Reagents: 
6-Methyl-2-tri-n-butylstannyl pyridine (1.37 g, 3.6 x 10-3 mol), 1,3-dibromo-4,6-
difluorobenzene (0.49 g, 1.8 x 10-3 mol), Pd(PPh3)2Cl2 (0.051 g, 7 x 10-5 mol) and LiCl 
(0.53 g, 1.3 x 10-2 mol). Solvent: toluene (8 mL). Purification: column chromatography 
(silica, hexane/EtOAc gradient elution from 100/0 to 65/35). The pure product was 
obtained as a white powder (0.31 g, 58%), mp = 93 – 96  C. Rf = 0.72 (silica, 100% 
EtOAc), 1H NMR (700 MHz, CDCl3) H = 2.61 (6H, s, 2CH3), 6.98 (1H, t, J(19F) = 
10.5, H5'), 7.10 (2H, d, J(1H) = 8.0, H5), 7.51 (2H, d, J(1H) = 8.0, H3), 7.62 (2H, t, J(1H) 
= 8.0, H4), 8.49 (1H, t, J(19F) = 8.5, H2'). 13C{1H} NMR (176 MHz, CDCl3) C = 25.2 (s, 
CH3), 105.0 (t, J(19F) = 27.5, C5'), 121.5 (t, J(19F) = 4.5, C3), 122.2 (s, C5), 125.1 (dd, 
J(19F) = 11.5 and 5.0, C1'), 133.9 (t, J(19F) = 4.5, C2'), 136.8 (s, C4), 152.2 (s, C2), 158.8 
(s, C6), 160.6 (dd, J(19F) = 254.5 and 13.0, C4'), 19F NMR (376 MHz, CDCl3) F = 
-111.4 (2F, t, J(1H) = 9.0). HRMS (ES+): m/z 297.1196 [100%, M+H+]; calcd for 
[C18H15N2F2], 297.1198. Anal. C18H14F2N2 (296.31): calcd C, 72.96; H, 4.76; N, 9.46; 
found C, 72.66; H, 4.80; N, 9.50. 
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1,3-Dimethyl-4,6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene 
BBO
O O
O
2
5
 
This diboronate ester was prepared via the double borylation method. Reagents: 1,3-
dibromo-4,6-dimethyl benzene (0.253 g, 9.59 x 10-4 mol), bispinacolatodiboron (B2pin2, 
0.53 g, 2.11 x 10-3 mol), Pd(dppf)Cl2 (0.047 g, 5.75 x 10-5 mol) and KOAc (0.471 g, 
4.80 x 10-3 mol). Solvent: Dry DMSO. Purification: Column chromatography (silica, 
hexane/EtOAc 100:0  90:10). The product, 1,3-dimethyl-4,6-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)benzene, was obtained as a white crystalline solid (0.24 g, 6.59 
x 10-4 mol, 69%) Rf = 0.65 (silica, hexane/EtOAc 70:30). 1H NMR (500 MHz, CDCl3) 
H = 1.36 (24H, s, CH3), 2.53 (6H, s, CH3-ph) 7.00 (1H, s, H2), 8.15 (1H, s, H5), 13C 
{1H} NMR (126 MHz, CDCl3) C = 22.6 (s, CH3-Ph), 25.1 (s, CH3), 83.5 (s, C-
O(CH3)2), 131.8 (s, C2), 143.9 (s, C5), 148.0 (s, C1). HRMS (ASAP): m/z 357.2638 
[20%, M+H+]; calcd for [C20H33O410B2], 357.2638. 
 
HL13: 1,3-di(3-methyl-2-pyridyl)-4,6-dimethylbenzene 
N N
1´
2´
4´
5´
2
3
4
5
6
 
Synthesis of ligand HL13 was performed twice, via two different routes – Stille cross-
coupling and Suzuki-Miyaura cross-coupling (methods A and B respectively) 
Method A: 
Reagents: 1,3-dibromo-4,6-difluorobenzene (0.26 g, 9.9 x 10-4 mol), 2-tri-n-
butylstannyl-3-methylpyridine (0.83 g, 2.2 x 10-3 mol), Pd(PPh3)2Cl2 (0.026 g, 4 x 10-5 
mol), LiCl (0.29 g, 6.90 x 10-3 mol). Solvent: toluene (4 mL). Purification: The product 
was purified by column chromatography (alumina, hexane/EtOAc 100:0 50:50). The 
product was obtained as a pale yellow oil (0.024 g, 8 x 10-5 mol, 8.4%).   
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Method B: 
Reagents: 1,3-Dimethyl-4,6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene (0.07 
g, 2.0 x 10-4 mol), 2-bromo-3-methylpyridine (0.074 g, 4.3 x 10-4 mol), Na2CO3 (1M, 5 
mL) and Pd(PPh3)4 (0.023 g, 2 x 10-5 mol). Solvents: DME (5 mL) and water (5 mL). 
Purification: Column chromatography (alumina, hexane/EtOAc 100:0 50:50). The 
product was obtained as a pale yellow oil (0.024 g, 8 x 10-5 mol, 42%). Rf = 0.65 
(alumina, 100% EtOAc). 1H NMR (700 MHz, CDCl3) H = 2.11 (6H, s, CH3), 2.15 (6H, 
s, CH3), 7.00 (1H, s, H5´), 7.17 (2H, dd, J(1H) = 8.0 and 4.5, H5), 7.20 (1H, s, H2´), 7.56 
(2H, d, J(1H) = 8.0, H4), 8.49 (2H, d, J(1H) = 4.5, H6), 13C {1H} NMR (176 MHz, 
CDCl3) C = 19.1 (s, CH3), 19.2 (s, CH3), 122.3 (s, C5), 129.0 (s, C5´), 132.1 (s, C3), 
132.3 (s, C2´), 135.4 (s, C1´), 137.7 (s, C4´), 138.0 (s, C4), 146.7 (s, C6), 159.5 (s, C2). 
HRMS (ES+): m/z 289.1711 [100%, M+H+]; calcd for [C20H21N2], 289.1699. 
 
HL14: 1,3-di(5-methyl-2-pyridyl)-4,6-dimethylbenzene 
N N
5´
5
4
3
2´
1´
4´
6
2
 
Ligand HL14 was prepared via the Suzuki-Miyaura method. Reagents: 1,3-Dimethyl-
4,6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene (0.065 g, 1.8 x 10-4 mol), 2-
bromo-5-methyl pyridine (0.069 g, 4.0 x 10-4 mol), Pd(PPh3)4 (0.021 g, 2 x 10-5 mol) 
and Na2CO3 (1M, 5 mL). Solvents: DME (5 mL), water (5 mL). Purification: Column 
chromatography (silica, hexane/EtOAc 100:0  60:40). The product was obtained as a 
white powder (0.050 g, 1.7 x 10-4 mol, 95%). Rf = 0.45 (silica, EtOAc 100%). 1H NMR 
(500 MHz, CDCl3), H = 2.19 (6H, s, C5-CH3), 2.40 (6H, s, C4´-CH3), 7.18 (1H, s, H5´), 
7.33 (2H, d, J(1H) = 8.0, H3), 7.43 (1H, s, H2´), 7.53 (2H, dd, J(1H) = 8.0 and 1., H4), 
8.51 (2H, d, J(1H) = 1.5, H6), 13C {1H} NMR (176 MHz, CDCl3) C = 20.0 (s, C4´-CH3), 
30.1 (s, C5-CH3), 123.9 (s, C3), 131.1 (s, C2´), 131.2 (s, C5), 133.5 (s, C5´), 135.8 (s, C4´), 
137.0 (s, C4), 138.1 (s, C1´), 149.7 (s, C6), 157.1 (s, C2). HRMS (ES+): m/z 289.1719 
[100%, M+H+]; calcd for [C20H21N2], 289.1705. 
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4-Methoxy-2-n-tributylstannylpyridine 
N SnBu3
OMe
35
6
 
This stannane was prepared via the lithium-halogen exchange/stannylation route. 
Reagents: 2-Bromo-4-methoxy pyridine (1.12 g, 6.0 x 10-3 mol), n-BuLi (3.6 mL, 8.8 x 
10-3 mol) and SnBu3Cl (3.0 mL, 9.4 x 10-3 mol). The product was obtained as a brown 
oil (5.4 g, assumed 40% pure by 1H NMR, therefore 2.16 g, 5.4 x 10-3 mol, 91%) and 
used without further purification.  1H NMR (200 MHz, CDCl3) H = 6.65 (1H, m, H5), 
6.96 (1H, dd, J(1H) = 3.0 and 0.5, 4J(117/118Sn) = 22, H3), 8.53 (1H, dd, J(1H) = 6.0 and 
0.5, H6). 
 
HL15: 1,3-di(4-methoxy-2-pyridyl)-4,6-difluorobenzene 
6
5
4
3
21´
4´
2´
5'´
N N
H3CO
F F
OCH3
 
HL15 was prepared via the Stille methodology. Reagents: 4-Methoxy-2-tri-n-
butylstannylpyridine (4.57 g, assumed 40% pure by NMR, therefore 1.83 g, 4.6 x 10-3 
mol), 1,3-dibromo-4,6-difluorobenzene (0.57 g, 2.1 x 10-3 mol), Pd(PPh3)2Cl2 (0.054 g, 
8 x 10-5 mol) and LiCl (0.62 g, 1.46 x 10-2 mol). Solvent: Toluene (6 mL). Purification: 
Column chromatography (alumina, hexane/EtOAc, 100:0  0:100, then MeOH/DCM 
100:0  98:2. The desired product came off at 40% EtOAc, and a useful side product, 
1-bromo-2,4-difluoro-5-((4-methoxy)-2-pyridyl)benzene, came off at 10% EtOAc). The 
desired product had a slight impurity – to purify further, the solid was washed with 
hexane, filtered, and the residue was dissolved in DCM. The desired product was 
obtained as an off-white solid (0.21 g, 6.5 x 10-4 mol, 31%). mp = 113-114 °C, Rf = 
0.35 (alumina, hexane/EtOAc 60:40). 1H NMR (500 MHz, CDCl3) H = 3.90 (6H, s, 
OCH3), 6.80 (2H, dd, J(1H) = 6.0 and 2.0, H5), 7.01 (1H,t, J(19F) = 11.0, H5'), 7.90 (2H, 
d, J(1H) = 2.0, H3), 8.53 (1H, d, J(19F) = 6.0, H2'), 8.56 (2H, t, J(1H) = 6.0, H6). 13C {1H} 
NMR (126 MHz, CDCl3). C = 31.2 (s, OCH3), 105.2 (t, J(19F) = 27.5, C5'), 108.9 (s, 
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C5), 110.7 (t, J(19F) = 4.5, C3), 124.6 (q, J(19F) = 5.5, C1'), 133.9 (t, J(19F) = 4.5, C2'), 
151.1 (s, C6), 154.2 (t, J(19F) = 1.5, C2), 160.6 (dd, J(19F) = 255.0 and 12.5, C4'), 166.2  
(s, C4).  19F NMR (376 MHz, CDCl3) F = -113.0 (2F, t, J(1H) = 10.0). HRMS (ES+): 
m/z 329.1098 [100%, M+H+]; calcd for [C18H15F2N2O2], 329.1096. Anal. C18H14F2N2O2 
(328.31): calcd C, 65.85; H, 4.30; N, 8.53; found C, 64.98; H 4.10; N 7.95. 
 
1-Bromo-2,4-difluoro-5-(4-methoxy-2-pyridyl)benzene 
FF
Br
N
H3CO
4
5
6
3
2 5´
6´
2´
3´
4´
1´
 
1-Bromo-2,4-difluoro-5-(4-methoxy-2-pyridyl)-benzene was obtained as a side product 
from the synthesis of HL15. Purification: Column chromatography (alumina, 
hexane/EtOAc, 100:0  90:10). The product still contained a slight impurity – this was 
successfully removed by washing the solid with hexane. The product was obtained as a 
white semi-crystalline solid (0.20 g, 6.7 x 10-4 mol, 32%). Rf = 0.48 (alumina, 
hexane/EtOAc 90:10). 1H NMR (700 MHz, CDCl3) H = 3.90 (3H, s, CH3), 6.81 (1H, 
dd, J(1H) = 6.0 and 2.0, H5), 6.98 (1H, dd, J(19F) = 11.0 and 8.0, H3'), 7.27 (1H, d, J(1H) 
= 2.0, H3), 8.25 (1H, t, J(19F) = 8.0, H6'), 8.49 (1H, d, J(1H) = 6.0, H6). 13C {1H} NMR 
(176 MHz, CDCl3) C = 55.5 (s, OCH3) 104.6 (dd, J(19F) = 21.0 and 4.0, C5'), 105.7 (dd, 
J(19F) = 29.0 and 26.0, C3'), 109.09 (s, C5), 110.9 (d, J(19F) = 10.0, C3), 125.3 (dd, J(19F) 
= 12.5 and 4.0, C1'), 135.3 (s, C6'), 151.1 (s, C6), 152.8 (s, C2), 158.8 (dd, J(19F) = 60.0 
and 10.5, C4'), 160.2 (dd, J(19F) = 60.0 and 10.5, C2'), 166.3 (s, C4). 19F NMR (376 MHz, 
CDCl3) F = -113.9 (1F, q, J(1H) = 9.0), -103.1 (1F, q, J(1H) = 8.0). HRMS (ES+): m/z 
299.9833 [91%, 79Br, M+H+], 300.9867 [100, 81Br, M+H+]; calcd for [C12H979BrF2NO], 
299.9830. 
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HL16: 1-(4-methoxy-2-pyridyl)-3-(2-pyridyl)-4,6-difluorobenzene 
N N
H3CO
F F
2*
6
5
4
3
2 1´
3´
4´
2´
6´
5´
6*
5*
4*
3*
 
Ligand HL16 was prepared via the Stille methodology. Reagents: 
1-bromo-2,4-difluoro-5-(4-methoxy-2-pyridyl)-benzene (0.11 g, 3.7 x 10-4 mol), 
2-tri-n-butylstannyl pyridine (0.19 g, assumed 85% pure, 4.4 x 10-4 mol), Pd(PPh3)2Cl2 
(0.011 g, 2 x 10-5 mol) and LiCl (0.12 g, 2.7 x 10-3 mol). Solvent: Toluene (5 mL). 
Purification: Column chromatography (silica, hexane/EtOAc, 100:0  50:50, the 
product came off at 45% EtOAc). The product was obtained as a white solid (0.040 g, 
1.4 x 10-4 mol, 38%). Rf = 0.42 (silica, EtOAc 100%). 1H NMR (500 MHz, CDCl3) H = 
3.90 (3H, s, OCH3), 6.80 (1H, dd, J(1H) = 6.0 and 2.5, H5), 7.02 (1H, t, J(19F) = 11.0, 
H5'), 7.27 (1H, m, H5*), 7.29 (1H, t, J(1H) = 2.0, H3), 7.75 (2H, m, H3* and H4*), 8.53 
(1H, d, J(1H) = 6.0, H6), 8.60 (1H, t, J(19F) = 9.0, H2'), 8.72 (1H, dt, J(1H) = 5.0 and 1.0, 
H6*). 13C {1H} NMR (126 MHz, CDCl3) C = 55.5 (s, OCH3), 105.0 (t, J(19F) = 27.5, 
C5'), 108.9 (s, C5), 110.7  (d, J(19F) = 8.5, C3), 122.7 (s, C5*), 124.5 (d, J(19F) = 8.0, C3*), 
124.7 (m, C1' and C3'), 133.9 (t, J(19F) = 4.5, C2'), 136.7 (s, C4*), 150.0 (s, C6*), 151.1 (s, 
C6), 152.7 (d, J(19F) = 2.5, C2*), 154.2 (d, J(19F) = 2.5, C2), 159.7 (dd, J(19F) = 13.0 and 
6.5, C4'), 161.7 (dd, J(19F) = 12.0 and 5.0, C6'), 166.2 (s, C4). 19F NMR (188 MHz, 
CDCl3) F = -113.3 (1F, q, J(1H) = 10.0), -113.0 (1F, q, J(1H) = 10.0). HRMS (ES+) = 
m/z 299.0988 [100%, M+H+]; calcd for [C17H13F2N2O], 299.0991.  
 
1,3-Difluoro-4,6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene 
F F
BBO
O O
O
2
5
 
This diboronate ester was prepared via the double borylation method. Reagents: 1,3-
dibromo-4,6-difluorobenzene (0.30 g, 1.1 x 10-3 mol), B2pin2 (0.620 g, 2.4 x 10-3 mol), 
Pd(dppf)Cl2 (0.054 g, 7 x 10-5 mol) and KOAc (0.545 g, 5.6 x 10-3 mol). Solvent: Dry 
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DMSO (5 mL). Purification: Column chromatography (silica, hexane/EtOAc 100:0  
80:20). The product was obtained as a white crystalline solid (0.33 g, 9.6 x 10-4 mol, 
86%) Rf = 0.75 (silica, hexane/EtOAc 50:50). 1H NMR (500 MHz, CDCl3) H = 1.33 
(24H, s, CH3), 6.71 (1H, t, J(19F) = 10.0, H2), 8.11 (1H, t, J(19F) = 7.5, H5), 13C {1H} 
NMR (126 MHz, CDCl3) C = 25.0 (s, CH3), 84.2 (s, OC(CH3)2), 103.6 (t, J(19F) = 28.0, 
C2), 146.1 (t, J(19F) = 10.0, C5), 170.4 (dd, J(19F) = 259.0 and 14.0, C1), 207.5 (m, C4), 
19F NMR (376 MHz, CDCl3) F = -94.6 (2F, t, J(1H) = 8.5). HRMS (ASAP): m/z 
366.2076 [62%, 11B, M], calcd for [C18H2611B2F2O4], 366.1985.  
 
HL17: 1,3-di(4-dimethylamino-2-pyridyl)-4,6-difluorobenzene 
F F
N N
Me2N NMe2
6
5
4
3
2
2´
1´
4´
5´
 
Ligand HL17 was prepared via the Suzuki-Miyaura method. Reagents: 1,3-Difluoro-4,6-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene (0.100 g, 2.7 x 10-4 mol), 2-
bromo-4-dimethylaminopyridine (0.121 g, 6.0 x 10-4 mol), Pd(PPh3)4 (0.032 g, 3 x 10-5 
mol), Na2CO3 (1M in 3 mL water). Solvents: DME (3 mL), water (3 mL). Purification: 
The product was purified by column chromatography (alumina, hexane/EtOAc, 100:0 
 0:100, then DCM/MeOH 100:0  90:10) and was obtained as a white oily solid 
(0.050 g, 1.4 x 10-4 mol, 51%), Rf = 0.43 (alumina, 100% EtOAc).  1H NMR (700 MHz, 
CDCl3) H = 3.04 (12H, s, CH3), 6.45 (2H, dd, J(1H) = 6.0 and 2.5, H5), 6.90 (2H, d, 
J(1H) = 2.0, H3), 6.94 (1H, t, J(19F) = 10.5, H5'), 8.29 (2H, d, J(1H) = 6.0, H6), 8.35 (1H, 
t, J(19F) = 9.0, H2'). 13C {1H} NMR (176 MHz, CDCl3) C = 39.2 (s, CH3), 104.8 (t, 
J(19F) = 27. 0, C5'), 105.7 (s, C5), 107.4 (t, J(19F) = 3.5, C3), 125.5 (dd, J(19F) = 11.5 and 
5.0, C1'), 133.9 (t, J(19F) = 4.5, C2'), 149.7 (s, C6), 153.1 (s, C2), 154.9 (s, C4), 160.2 (dd, 
J(19F) = 254.0 and 12.5, C4'), 19F NMR (376 MHz, CDCl3) F = -112.8 (2F, br m). 
HRMS (ES+): m/z 377.1546 [22%, M+Na+], 355.1726 [100, M+H+]; calcd for 
[C20H21F2N4], 355.1729, calcd for [C20H20F2N423Na], 377.1548.  
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HL18: 1,3-di(4-nitro-2-pyridyl)benzene 
N N
O2N NO2
2´
4´
5´
1´
6
5
3
2
 
Ligand HL18 was prepared via the Suzuki-Miyaura method. Reagents: Benzene-1,3-
diboronic acid (0.37 g, 2.2 x 10-3 mol), 2-bromo-4-nitropyridine (1.0 g, 4.9 x 10-4 mol), 
Na2CO3 (5 mL of a 1M solution in water), Pd(PPh3)4 (0.32 g, 2.7 x 10-4 mol). Solvents: 
DME (5 mL), water (5 mL). Purification: Column chromatography (silica, 
hexane/EtOAc 100:0  40:60). The product was obtained as a creamy white solid 
(0.273 g, 38%), Rf 0.41 (silica, hexane/EtOAc 70:30). 1H NMR (700 MHz, CDCl3) H = 
7.71 (1H, t, J(1H) = 8.0, H5'), 8.00 (2H, dd, J(1H) = 5.0 and 2.0, H5), 8.21 (2H, dd, J(1H) 
= 8.0 and 2.0, H4'), 8.56 (2H, d, J(1H) = 2.0, H3), 8.86 (1H, t, J(1H) = 2.0, H2'), 9.03 (2H, 
d, J(1H) = 5.0, H6), 13C {1H} NMR (176 MHz, CDCl3) C = 113.3 (s, C3), 115.1 (s, C5), 
126.3 (s, C2'), 129.1 (s, C4'), 130.2 (s, C5'), 138.5 (s, C1'), 152.5 (s, C6), 155.4 (s, C4), 
160.1 (s, C2). MS (ES+): m/z 323.5 [M+H+]; calcd for [C16H11N4O4], 323. 
 
HL19: 1,3-di(4-fluoro-2-pyridyl)benzene 
N N
F F
2´
4´
5´
1´
6
5
3
2
 
This ligand was prepared via fluorodenitration of HL18, and two solvent systems were 
investigated. The procedures reported here are adaptations of the fluorodenitration of 2-
bromo-4-nitropyridine, reported in reference 17. 
Method A: 
1,3-di(4-nitro-2-pyridyl)benzene (0.072 g, 2.2 x 10-4 mol) was dissolved in DMF (3 
mL). A solution of tetrabutylamonnium fluoride (TBAF) in THF (1M, 0.25 mL, 8.9 x 
10-4 mol) was added, and the reaction was stirred at room temperature for 30 min. The 
mixture was poured into a 1:1 mixture of EtOAc:water (50 mL) and the organic layer 
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was extracted. The organic layer was washed with water (2 x 30 mL) and brine (2 x 30 
mL), then dried over Na2SO4 and filtered. The solvent was removed in vacuo. Proton 
NMR of the crude product indicated incomplete conversion. The reaction was repeated 
with the crude mixture. This time a larger excess of TBAF (0.5 mL, 1.8 x 10-5 mol) was 
added, and the reaction was stirred for 1 h. TLC indicated complete conversion at this 
point. The crude product was purified via column chromatography (silica, 
hexane/EtOAc, 100:0  50:50). The product obtained as a white powder (0.043 g, 1.6 x 
10-4 mol, 72%). 
Method B: 
1,3-di(4-nitro-2-pyridyl)benzene (0.025 g, 7.8 x 10-5 mol) was dissolved in DCM (5 
mL). A solution of tetrabutylamonnium fluoride (TBAF) in THF (1M, 0.1 mL, 3.1 x 10-
4
 mol) was added, and the reaction was stirred at 70  C for 30 min. TLC was used to 
check the reaction, and indicated incomplete conversion. More TBAF (0.6 mL, 2.0 x 10-
3
 mol) was added, and the reaction was stirred at 70  C for an additional 1 h. The 
mixture was poured into a 1:1 mixture of EtOAc:water (50 mL) and the organic layer 
was extracted. The organic layer was washed with water (2 x 30 mL) and brine (2 x 30 
mL), then dried over Na2SO4 and filtered. The solvent was removed in vacuo and the 
crude product was purified via column chromatography (silica, hexane/EtOAc, 100:0  
50:50). The product was obtained as a white powder (0.020 g, 7.5 x 10-5 mol, 96%). Rf 
= 0.70 (silica, 100% EtOAc). 1H NMR (500 MHz, CDCl3) H = 7.03 (2H, ddd, J(19F) = 
8.3, J(1H) = 5.5 and 2.5, H5), 7.57 (2H, dd, J(19F) = 10.5 and J(1H) = 2.5, H3), 7.63 (1H, 
t, J(1H) = 8.0, H5'), 8.09 (2H, dd, J(1H) = 8.0 and 2.0, H4'), 8.64 (1H, t, J(1H) = 2.0, H2'), 
8.70 (2H, dd, J(19F) = 9.0 and J(1H) = 5.5, H6), 13C {1H} NMR (126 MHz, CDCl3) C = 
108.7 (d, J(19F) = 17.0, C3), 110.5 (d, J(19F) = 17.0, C5), 125.9 (s, C2'), 128.3 (s, C4'), 
129.7 (s, C5'), 139.2 (d, J(19F) = 3.5, C1'), 152.2 (d, J(19F) = 7.0 C6), 160.4 (d, J(19F) = 
7.0, C2), 169.7 (d, J(19F) = 260.5, C4). 19F NMR (376 MHz, CDCl3) F = -102.7 (2F, q, 
J(1H) = 9.0). HRMS (ES+): m/z 269.0889 [100%, M+H+]; calcd for [C16H11F2 N2], 
269.0885. 
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HL20: 1,3-di(4-trifluoromethyl-2-pyridyl)-4,6-difluorobenzene  
F F
N N
F3C CF3
5´
2´
6
5
4
3
21´
4´
 
Ligand HL20 was prepared via the Suzuki-Miyaura method. Reagents: 1,3-Difluoro-4,6-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene (0.045 g, 1.2 x 10-4 mol), 2-
chloro-4-trifluoromethylpyridine (0.049 g, 2.7 x 10-4 mol), Na2CO3 (1M, in 2 mL 
water), Pd(PPh3)4 (0.017 g, 2 x 10-5 mol). Solvents: DME (2 mL), water (2 mL). 
Purification: The product was purified by column chromatography (silica, 
hexane/EtOAc 100:0  80:20), and was obtained as a white oily solid (0.040 g, 1.09 x 
10-4 mol, 89%), Rf = 0.42 (silica, hexane/EtOAc 80:20). 1H NMR (700 MHz, CDCl3) H 
= 7.12 (1H, t, J(19F) = 11.0, H5'), 7.51 (2H, dd, J(1H) = 5.0 and 0.5, H5), 8.04 (2H, s, H3), 
8.83 (1H, t, J(19F) = 9.0, H2'), 9.21 (2H, d, J(1H) = 5.0, H6), 13C {1H} NMR (176 MHz, 
CDCl3) C = 105.7 (t, J(19F) = 27.5, C5'), 118.5 (q, J(19F) = 3.5, C5),  119.9 (m, C3), 
123.1 (q, J(19F) = 270.0, CF3), 123.6 (dd, J(19F) = 10.5 and 5.0, C1'), 134.0 (t, J(19F) = 
4.0, C2'), 139.3 (q, J(19F) = 34.0, C4), 150.9 (s, C6), 153.6 (t, J(19F) = 1.5, C2), 161.4 (dd, 
J(19F) = 257.0 and 13.0, C4'). 19F NMR (376 MHz, CDCl3) F = -111.1 (2F, t, J'= 10.0), -
65.2 (6F, s). HRMS (ES+): m/z 405.0636 [15%, M+H+]; calcd for [C18H9F8N2], 
405.0633. 
 
2-Tri-n-butylstannyl-4-trifluoromethylpyridine 
N SnBu3
35
6
CF3
 
This stannane was prepared via the ortho-directed lithiation/stannylation route. 
Reagents: 2-(Dimethylamino)ethanol (0.8 mL, 8 x 10-3 mol), n-BuLi (6.4 mL, 2.5 M in 
hexanes, 1.6 x 10-2 mol), 4-trifluoromethylpyridine (0.50 g, 3.4 x 10-3 mol) SnBu3Cl 
(1.22 g, 1.02 mL, 3.7 x 10-3 mol). The product was obtained as a dark brown liquid 
(2.09 g, assumed 40% pure from NMR, therefore 0.84 g product, 57%). 1H NMR (400 
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MHz, CDCl3) H = 0.5-2 (27H, m, SnBu3 H), 7.29 (1H, m, H5), 7.56 (1H, quintet, J(1H) 
= 1.0, 4J(117/118Sn) = 16.0, H3), 8.90 (1H, dt, J(1H) = 5.0 and 0.5, H6). 
 
HL21: 1-(4-methoxy-2-pyridyl)-3-(4-trifluoromethyl-2-pyridyl)-4,6-difluorobenzene  
F F
N N
F3C OMe
6*
2*
6
1´
5
3
2
2´
4´
5´
5*
4*
3*
4
3´
6´
 
Ligand HL21 was prepared via the Stille methodology. Reagents: 1-Bromo-2,4-difluoro-
5-(4-methoxy-2-pyridyl)benzene (0.060 g, 2.0 x 10-4 mol), 2-tri-n-butylstannyl-4-
trifluoromethyl pyridine (0.11 g, 2.4 x 10-4 mol), Pd(PPh3)2Cl2 (0.0052 g, 7 x 10-6 mol), 
LiCl (0.059 g, 1.4 x 10-3 mol). Solvent: toluene (3 mL). Purification: The product was 
purified by column chromatography (silica, hexane:EtOAc, 100:0 30:70). The 
product was obtained as a yellow oil (0.040 g, 1.09 x 10-4 mol, 55%), Rf = 0.67 (silica, 
100% EtOAc). 1H NMR (700 MHz, CDCl3) H = 6.81 (1H, dd, J(1H) = 6.0 and 2.0, 
H5*), 7.05 (1H, t, J(19F) = 10.0, H5'), 7.30 (1H, t, J(1H) = 2.0, H3*), 7.47 (1H, dd, J(1H) = 
5.0 and 1.0, H5), 7.99 (1H, s, H3), 8.54 (1H, d, J(1H) = 6.0, H6*), 8.68 (1H, t, J(19F) = 
9.0, H2'), 8.89 (1H, d, J(1H) = 5.0, H6), 13C {1H} NMR (176 MHz, CDCl3) C = 56.5 (s, 
OCH3), 105.4 (t, J(19F) = 27.5, C5'), 109.0 (s, C5*), 110.9 (d, J(19F) = 9.0, C3*), 118.2 (q, 
J(19F) = 3.5, C5), 119.8 (m, C3), 123.1 (q, J(19F) = 270.0, CF3), 123.3 (dd, J(19F) = 11.5 
and 3.5, C3'), 124.9 (dd, J(19F) = 11.5 and 3.5, C1'), 134.0 (t, J(19F) = 4.0, C2'), 139.1 (q, 
J(19F) = 34.5, C4), 150.9 (s, C6), 151.1 (s, C6*), 153.8 (d, J(19F) = 2.5, C2*), 154.0 (d, 
J(19F) = 2.5, C2), 160.8 (dd, J(19F) = 256.0 and 12.0, C6'), 161.0 (dd, J(19F) = 256.0 and 
12.0, C4'), 166.3 (s, C4*). 19F NMR (376 MHz, CDCl3) F = -107.8 (1F, sept, J(1H) = 
13.0, F), -107.1 (1F, sept, J(1H) = 13.0, F), -65.3 (3F, s, CF3). HRMS (ES+): m/z 
367.0867 [100%, M+H+]; calcd for [C18H12F2N2O], 367.0864. 
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HL22: 1,3-di(5-fluoro-2-pyridyl)benzene  
NN
F
5´
4´
3
4
5
2´
2
6
1´
F
 
Ligand HL22 was prepared via the Suzuki-Miyaura method. Reagents: Benzene-1,3-
diboronic acid (0.17 g, 1.0 x 10-3 mol) and 2-bromo-5-fluoro pyridine (0.40 g, 2.3 x 10-3 
mol), Na2CO3 (1M in 5 mL) and Pd(PPh3)4 (0.14 g, 1.2 x 10-4  mol). Solvents: DME (5 
mL) and water (5 mL). Purification: column chromatography (silica, hexane/EtOAc, 
100:0  60:40). The product came off the column around 25% EtOAc, and was 
obtained as a white powder (0. 15 g, 5.6 x 10-4 mol, 54%). Rf = 0.76 (silica, 100% 
EtOAc). 1H NMR (500 MHz, CDCl3) H = 7.50 (2H, dd, J(19F) = 9.0, and J(1H) = 3.5, 
H4), 7.58 (1H, t, J(1H) = 8.0, H5'), 7.83 (2H, q, J(1H) = 3.5, H3), 8.00 (2H, dd, J(1H) = 
8.0 and 2.0, H4'), 8.56 (1H, t, J(1H) = 2.0, H2'), 8.57 (2H, d, J(19F) = 3.0, H6). 13C {1H} 
NMR (126 MHz, CDCl3) C = 121.7 (d, J(19F) = 4.0, C3), 123.8 (d, J(19F) = 19.0, C4), 
125.5 (s, C2'), 127.4 (s, C4'), 129.6 (s, C5'), 138.1 (d, J = 23.5, C6), 139.2 (s, C1'), 153.6 
(d, J(19F) = 4.0, C2), 159.2 (d, J(19F) = 256.0, C5). 19F NMR (376 MHz, CDCl3) F = -
129.8 (2F, q, J(1H) = 4.0). HRMS (ES+): m/z 291.0705 [14%, M+Na+], 269.0883 [100, 
M+H+]; calcd for [C16H11F2N2], 269.0885, calcd for [C16H10F2N223Na], 291.0704. Anal. 
C16H10F2N2 (268.25): calcd C, 71.63; H, 3.76; N, 10.44; found C, 71.13; H, 4.09; N, 
9.32 
 
2-(2-Methoxy-phenyl)-6-(3-pyridin-2-yl-phenyl)pyridine 
N N
OMe
2
3
4
5
6 1´
2´
3´
4´
5´
6´
2*
3*
4*
5*
6*
a
b
c
d
e
f
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The synthesis of this ligand precursor, and HL23 was based on a method reported for the 
synthesis of 6-(2-hydroxyphenyl)-2,2'-bipyridine in reference 18.  
Tetramethylethylenediamine (TMEDA) (0.26 mL, 1.7 x 10-3 mol) was transferred under 
nitrogen to a dry 100 mL two-necked round bottom flask. Dry ether (20 mL) was added 
under nitrogen, and the solution was cooled to 0  C in an ice bath. n-BuLi (0.68 mL, 1.7 
x 10-3 mol) was added dropwise (over 10 min), and the mixture was stirred for 15 min. 
Anisole (0.15 mL, 1.4 x 10-3 mol) was added at 0  C, and the mixture was stirred for 30 
min, before being allowed to warm to room temperature. The mixture was stirred for a 
further 2.5 h. The mixture was then transferred (over 20 min) under nitrogen to an ice-
cold solution of 1,3-di(2-pyridyl)benzene (0.30 g, 1.3 x 10-3 mol) in ether (20 mL), and 
the mixture was allowed to warm to room temperature overnight. Water (15 mL) was 
added slowly and with vigorous stirring (10 min). The mixture was extracted with ether 
(3 x 30 mL), dried with MgSO4, and the solvent was removed in vacuo. The crude 
product was dissolved in acetone and cooled in an ice bath. A saturated solution of 
KMnO4 was prepared in cold acetone, and added dropwise until a purple tint remained. 
The MnO2 by-product was removed by filtration through a celite plug. The filtrant was 
dried with MgSO4 and solvent was removed in vacuo. The crude product was purified 
by column chromatography (silica, hexane/EtOAc, 100:0  65:35), and the desired 
product was obtained as a pale yellow oil (0.13 g, 3.8 x 10-4 mol, 30%). Rf 0.60 (silica, 
hexane/EtOAc 50:50). 1H NMR (700 MHz, CDCl3) H = 3.86 (3H, s, CH3), 7.00 (1H, d, 
J(1H) = 8.0, He), 7.10 (1H, td, J(1H) = 8.0 and 1.0, Hc), 7.24 (1H, ddd, J(1H) = 7.5, 5.0 
and 1.0, H5*), 7.38 (1H, td, J(1H) = 8.0 and 2.0, Hd), 7.58 (1H, t, J(1H) = 8.0, H5'), 7.75-
7.88 (5H, m, H3, H4, H5, H3*, H4*), 8.20-8.70 (2H, m, H6', Hb), 8.40 (1H, dt, J(1H) = 8.0 
and 1.5, H4'), 8.68 (1H, t, J(1H) = 1.5, H2'), 8.72 (1H, ddd, J(1H) = 5.0, 1.5 and 1.0, H6), 
13C {1H} NMR (176 MHz, CDCl3) C = 55.9 (s, CH3), 111.7 (s, Ce), 118.8 (s, C3), 121.1 
(s, C3*), 121.3 (s, Cc), 122.5 (s, C5*), 124.0 (s, C5), 125.7 (s, C2'), 127.6 (s, C6'), 127.9 (s, 
C4'), 129.4 (s, C5'), 129.5 (s, Ca), 130.2 (s, Cd), 131.8 (s, Cb), 136.6 (s, C4*), 137.1 (s, 
C4), 140.0 (s, C1'), 140.5 (s, C3'), 149.9 (s, C6*), 155.7 (s, C6), 156.8 (s, C2*), 157.4 (s, 
C2), 157.6 (s, Cf).  HRMS (ES+): m/z 339.1494 [100%, M+H+]; calcd for [C23H19N2O], 
339.1492.  
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HL23: 2-(2-Hydroxy-phenyl)-6-(3-pyridin-2-yl-phenyl)pyridine 
N N
OH
2
3
4
5
6 1´
2´
3´
4´
5´
6´
2*
3*
4*
5*
6*
a
b
c
d
e
f
 
Pyridine (3.0 mL, 3.7 x 10-2 mol) and concentrated HCl (3.3 mL) were mixed in a 50 
mL round bottom flask, and the mixture was distilled to remove water. The mixture was 
then heated to 220 C for 5 min, giving pyridine hydrochloride (py.HCl). This was used 
directly in the next step without characterisation. The excess py.HCl was added hot to 
2-(2-methoxy-phenyl)-6-(3-pyridin-2-yl-phenyl)-pyridine (0.13 g, 3.8 x 10-4 mol) and 
the mixture was heated at 230 C overnight. The mixture was cooled and dissolved in 
dilute HCl. The solution was neutralised with NaOH, and the crude product was 
collected by filtration. This was dissolved in DCM, and further product was extracted 
from the aqueous phase with DCM. The DCM portions were combined, dried with 
MgSO4, filtered and the solvent was removed in vacuo. The crude product was purified 
by column chromatography (silica, hexane/EtOAc, 100:0  60:40), and the desired 
product was obtained as a pale yellow oily solid (0.12 g, 3.7 x 10-4 mol, 96%). Rf = 0.67 
(silica, EtOAc 100%), 1H NMR (700 MHz, CDCl3) H = 6.94 (1H, ddd, J(1H) = 9.0, 7.0 
and 1.0, Hc), 7.06 (1H, dd, J(1H) = 8.0 and 1.0, He), 7.27 (1H, ddd, J(1H) = 7.5, 5.0 and 
1.0, H5*), 7.34 (1H, ddd, J(1H) = 8.0, 7.5 and 1.0, Hd), 7.62 (1H, t, J = 8.0, H5'), 7.75 
(1H, d, J(1H) = 7.5, H5), 7.80 (1H, td, J(1H) = 7.5 and 2.0, H4*), 7.84 (1H, dt, J(1H) = 8.0 
and 1.0, H3*), 7.85 (1H, dd, J(1H) = 8.0 and 1.0, Hb), 7.87 (1H, d, J(1H) = 8.0, H3), 7.91 
(1H, t, J(1H) = 8.0, H4), 8.01 (1H, ddd, J(1H) = 8.0, 1.5 and 1.0, H6'), 8.10 (1H, ddd, 
J(1H) = 8.0, 1.5 and 0.5, H4'), 8.54 (1H, t, J(1H) = 1.5, H2'), 8.73 (1H, d, J(1H) = 5.0, 
H6*). 13C {1H} NMR (176 MHz, CDCl3) C = 117.9 (s, C3), 118.8 (s, Ce), 119.1 (s, Cc), 
119.2 (s, Ca), 119.2 (s, C5), 121.0 (s, C3*), 122.7 (s, C5*), 125.7 (s, C2'), 126.6 (s, Cb), 
127.6 (s, C6'), 128.3 (s, C4'), 129.8 (s, C5'), 131.8 (s, Cd), 137.2 (s, C4*), 138.8 (m, C4 and 
C1'),  140.5 (s, C3'), 150.0 (s, C6*), 154.9 (s, C6), 157.1 (s, C2*), 158.0 (s, C2), 160.2 (s, 
Cf). HRMS (ES+): m/z 325.1327 [100%, M+H+]; calcd for [C22H17N2O], 325.1335.  
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HL24: 1,3-di(2-pyridyl)-5-hydroxybenzene 
NN
OH
1´
2´
3
4
5
4´
2
6
5´
 
Ligand HL24 was prepared via the Stille methodology. Reagents: 2-Tri-n-
butylstannylpyridine (1.89 g, assumed 85% pure, 4.4 x 10-3 mol), 3,5-dibromophenol 
(0.50 g, 2.0 x 10-3 mol), Pd(PPh3)2Cl2 (0.051 g, 7 x 10-5 mol) and LiCl (0.59 g, 1.4 x 10-
2
 mol). Purification: The residue was purified with column chromatography (silica, 
hexane/ether gradient elution from 100/0 to 0/100) and the product was obtained as a 
white powder (0.073 g, 15%), Rf = 0.24 (silica, 100% ether). 1H NMR (700 MHz, 
CDCl3) H =7.29 (2H, ddd, J(1H) = 7.5, 5.0 and 1.0, H5), 7.60 (2H, d, J(1H) = 1.0, H4'), 
7.80 (2H, td, J(1H) = 7.5 and 2.0, H4), 7.83 (2H, dt, J(1H) = 7.5 and 1.0, H3), 8.11 (1H, t, 
J(1H) = 1.0, H2'), 8.69 (2H, ddd, J(1H) = 5.0, 2.0 and 1.0, H6), 13C {1H} NMR (176 
MHz, CDCl3) C = 111.5 (s, C4'), 118.3 (s, C2'), 121.6 (s, C3), 122.9 (s, C5), 137.8 (s, 
C4), 140.9 (s, C5'), 149.2 (s, C6), 156.8 (s, C2), 151.5 (s, C1'). HRMS (ES+): m/z 
249.1022 [100%, M+H+]; calcd for [C16H13N2O], 249.1022. 
 
1,3-Dibromo-5-(2-bromoethoxy)benzene 
O
BrBr
Br
4
2
 
This was prepared via the Williamson ether synthesis route. Reagents: 3,5-
Dibromophenol (0.20 g, 7.9 x 10-4 mol), 1,2-dibromoethane (2.24 g, 1.19 x 10-2 mol) 
K2CO3 (2.20 g, 1.59 x 10-2 mol) and Cs2CO3 (~10 mg).  The solvent used was CH3CN 
(20 mL). The product was obtained as a pale brown oil (0.26 g, 7.3 x 10-4 mol, 92%). 
This product did not need purifying. 1H NMR (400 MHz, CDCl3) H = 3.60 (2H, t, J(1H) 
= 6.0, CH2(Br)), 4.23 (2H, t, J(1H) = 6.0, CH2(O)), 6.99 (2H, d, J(1H) = 1.5, H4), 7.27 
(1H, t, J(1H) = 1.5, H2).  
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3-[2-(3,5-Dibromo-phenoxy)-ethoxy]-2-phenyl-chromen-4-one 
O
O
OOBr
Br
B
A
C D
H
G
F
E
K
J
I
 
This compound was prepared via the Williamson-ether synthesis route. Reagents: 
1,3-Dibromo-5-(2-bromo-ethoxy)-benzene (0.26 g, 7.3 x 10-4 mol), 3-hydroxy-2-
phenyl-chromen-4-one (0.18 g, 7.3 x 10-4 mol), K2CO3 (2.03 g, 1.7 x 10-2 mol) and 
Cs2CO3 (5 mg). The solvent used was dry CH3CN (40 mL). The product was obtained 
as a beige powder (0.28 g, 5.4 x 10-4 mol, 74%). 1H NMR (400 MHz, CDCl3) H = 4.13 
(2H, m, CH2), 4.50 (2H, m, CH2), 6.77 (2H, d, J(1H) = 1.5, H2), 7.21 (1H, t, J(1H) = 1.5, 
H1), 7.4-7.5 (4H, m, H6, H10, and H11), 7.56 (1H, d, J(1H) = 8.5, H8), 7.71 (1H, ddd, 
J(1H) = 8.5, 7.0 and 1.5, H7), 8.09 (2H, m, H9), 8.27 (1H, dd, J(1H) = 8.0 and 1.5, H5). 
MS (ES+): m/z 541.1 [52%, 81Br, M+Na+,], 539.1 [58, 79Br, 81Br, M+Na+], 537.1 [54, 
79Br, M+Na+]; calcd for [C23H1679Br2O423Na], 536.9. Anal. C23H16Br2O4 (516.16): calcd 
C, 53.52; H, 3.12; found C, 50.62; H, 3.41. 
 
HL25: 3-[2-(3,5-Di-pyridin-2-yl-phenoxy)-ethoxy]-2-phenyl-chromen-4-one 
O
O
OO
N
N
5´
4´
1´2
3
5 4
6
2´
A
H
G
F
EDC
B
M
L K J
I
O
N
 
Ligand HL25 was prepared via the Stille method. Reagents: 3-[2-(3,5-Dibromo-
phenoxy)-ethoxy]-2-phenyl-chromen-4-one (0.14 g, 2.7 x 10-4 mol), 2-tri-n-butylstannyl 
pyridine (0.26 g, assumed 85% pure, 6.1 x 10-4 mol), Pd(PPh3)2Cl2 (0.007 g, 1 x 10-5 
mol) and LiCl (0.082 g, 1.9 x 10-3 mol). The solvent used was toluene (10 mL). 
Purification of product was achieved via column chromatography (silica, 
hexane/EtOAc, 100:0  20:80). The product was obtained as a pale yellow solid (0.039 
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g, 29%). Rf (silica, 100% EtOAc) = 0.50. 1H NMR (700 MHz, CDCl3) H = 4.35 (2H, t, 
J(1H) = 4.5, CH2), 4.60 (2H, t, J(1H) = 4.5, CH2), 7.25 (2H, m, H5), 7.36 (1H, t, J(1H) = 
7.0, HO), 7.41 (3H, m, HN and HG), 7.48 (2H, s, H4'), 7.52 (1H, d, J(1H) = 8.0, HI), 7.66 
(1H, ddd, J(1H) = 9.0, 8.0 and 1.5, HH), 7.76 (2H, td, J(1H) = 7.0 and 1.5, H4), 7.77 (2H, 
d, J(1H) = 7.5, H3), 8.16 (2H, d, J(1H) = 7.5, HM), 8.20 (1H, s, H2'), 8.27 (1H, dd, J(1H) = 
8.0 and 1.0, HF), 8.69 (2H, dt, J(1H) = 4.5 and 0.5, H6). 13C {1H} NMR (176 MHz, 
CDCl3) C = 67.2 (s, CH2), 70.2 (s, CH2), 113.9 (s, C4'), 118.2 (s, CI), 118.4 (s, C2'), 
121.0 (s, C3), 122.6 (s, C5), 124.4 (s, CE or L), 124.9 (s, CG), 126.0 (s, CF), 128.6 (s, CN), 
129.1 (s, CM), 130.9 (s, CO), 131.0 (s, CE or L), 133.7 (s, CH), 137.0 (s, C4), 140.4 (s, CC), 
141.2 (s, C5' or 1'), 149.8 (2C, s, C6), 155.5 (s, CJ), 156.1 (s, CK), 157.1 (s, C2), 159.6 (s, 
C5' or 1'), 175.4 (s, CD). HRMS (ES+): m/z 513.1814 [100%, M+H+]; calcd for 
[C33H25N2O4], 513.1814. 
 
3-{2-[2-(3,5-Dibromo-phenoxy)-ethoxy]-ethoxy}-2-phenyl-chromen-4-one 
O
O
OO
O
Br
Br
1
9
87
6
5
3
2
10
16
15
14
13
12
11
17
21
20
19
4
18
 
This was prepared via the Williamson ether synthesis route. Reagents: Dry K2CO3 (1.10 
g, 8.0 x 10-3 mol), Cs2CO3 (~10 mg), 3,5-dibromophenol (0.12 g, 4.8 x 10-4 mol) and 
3-[2-(2-bromo-ethoxy)-ethoxy]-2-phenyl-chromen-4-one (0.14 g, 3.5 x 10-4 mol). 
Solvent: CH3CN (30 mL). Purification: The crude product was purified with column 
chromatography (silica, hexane/ether gradient elution, 100:0  60:40). The pure 
product was obtained as a yellow solid (0.090 g, 1.6 x 10-4 mol, 46%). Rf = 0.68 (silica, 
100% ether). 1H NMR (700 MHz, CDCl3) H = 3.68 (2H, t, J(1H) = 5.0, H7), 3.77 (2H, 
ddd, J(1H) = 6.0, 3.0 and 1.5, H6), 3.90 (2H, t, J(1H) = 4.5, H5), 4.32 (2H, ddd, J(1H) = 
6.0, 3.0 and 1.5, H8),  6.93 (2H, d, J(1H) = 1.0, H3), 7.22 (1H, t, J(1H) = 1.5, H1), 7.34 
(1H, t, J(1H) = 7.5, H13), 7.47 (3H, m, H20/21), 7.53 (1H, d, J(1H) = 8.0, H15), 7.67 (1H, 
ddd, J(1H) = 8.0, 6.5 and 1.5, H14), 8.16 (2H, dd, J(1H) = 7.0 and 4.0, H19), 8.25 (1H, dd, 
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J(1H) = 8.0 and 1.0, H12). 13C {1H} NMR (176 MHz, CDCl3) C = 67.9 (1C, s, C8), 69.0 
(1C, s, C7), 70.6 (1C, s, C6), 71.4 (1C, s, C5), 117.3 (2C, s, C3), 118.2 (1C, s, C15), 123.2 
(2C, s, C2), 124.3 (1C, s, C11), 124.9 (1C, s, C13), 126.0 (1C, s, C12), 126.8 (1C, s, C1),  
128.6 (s, C20 or 21), 129.1 (2C, s, C19), 130.9 (s, C20 or 21), 131.2 (1C, s, C18), 133.7 ( 1C, s, 
C14), 140.6 (1C, s, C9), 155.5 (1C, s, C17), 155.9 (1C, s, C16), 160.1 (1C, s, C4), 175.4 
(1C, s, C10). MS (ES+): m/z 584.9 [30%, 2Br = 81, M+Na+], 582.9 [100, 1Br = 79, 1Br = 
81, M+Na+], 580.9 [55, 2Br = 79, M+Na+]; calcd for [C25H2079Br2O5], 558. 
 
HL26: 3-{2-[2-(3,5-Di-pyridin-2-yl-phenoxy)-ethoxy]-ethoxy}-2-phenyl-chromen-4-
one 
O
O
OO
O
N
N
A
N
M
I
H
GFE
DC
B
J
Q
P
O
L
K
6
5
5´
2´
4´2
3
4
1´
 
Two attempts at making HL26 were pursued (both Stille reactions, but different solvent 
systems, toluene and xylene, methods A and B respectively). 
Method A:  
Reagents: 3-{2-[2-(3,5-Dibromo-phenoxy)-ethoxy]-ethoxy}-2-phenyl-chromen-4-one 
(0.090 g, 1.6 x 10-4 mol), tri-n-butyl-2-stannyl pyridine (0.l4 g, assumed 85% pure, 3.3 
x 10-4 mol), Pd(PPh3)2Cl2 (0.004 g, 6 x 10-6 mol) and LiCl (0.050 g, 1.2 x 10-3 mol). 
Solvent: Toluene (12 mL). Purification: Column chromatography (silica, 
hexane/EtOAc, 100:0  0:80, the product came off around 75% EtOAc). The pure 
product was obtained as a yellow oily solid (0.026 g, 4.7 x 10-5 mol, 29%).  
Method B: 
Reagents: 3-{2-[2-(3,5-Dibromo-phenoxy)-ethoxy]-ethoxy}-2-phenyl-chromen-4-one 
(0.21 g, 3.8 x 10-4 mol), tri-n-butyl-2-stannyl pyridine (0.35 g, assumed 85% pure, 8.4 x 
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10-4 mol), Pd(PPh3)2Cl2 (0.013 g, 2 x 10-5 mol), PPh3 (0.010 g, 4 x 10-5 mol) and LiCl 
(0.12 g, 2.8 x 10-3 mol). Solvent: xylene (8 mL). Purification: column chromatography 
(silica, hexane/EtOAc, 100:0  0:80, the product came off around 75% EtOAc). The 
pure product was obtained as a yellow oily solid (0.10 g, 1.8 x 10-4 mol, 47%), Rf 
(silica, 100% EtOAc ) = 0.47. 1H NMR (700 MHz, CDCl3) H = 4.13 (2H, q, J(1H) = 
7.0, CH2), 4.2-4.4 (6H, m, 3CH2), 6.72 (1H, dd, J(1H) = 8.5 and 0.5, HK), 6.73 (1H, td, 
J(1H) = 7.5 and 1.0, HI), 7.1-7.25 (6H, m, HJ, HO, HP and HQ), 7.25 (2H, dd, J(1H) = 7.5 
and 1.5, H5), 7. 66 (3H, m, H4 and HH), 7.78 (2H, ddd, J(1H) = 8.5, 7.5 and 2.0, H4), 
7.84 (2H, dt, J(1H) = 8.0 and 1.0, H3), 8.26 (1H, t, J(1H) = 1.5, H2'), 8.72 (2H, dq, J(1H) 
= 5.0 and 1.0, H6). 13C {1H} NMR (176 MHz, CDCl3) C = 112.2 (s, CK), 114.0 (s, C4'), 
118.7 (s, C2'), 120.9 (s, CI), 121.1 (s, C3), 122.7 (s, C5), 124.0 (s, CG), 127.8 (s, CJ), 
129.4 (s, CH), 131.0 (s, C), 131.6 (s, C), 131.8 (s, C), 134.8 (s, CE), 137.0 (s, C4), 138.5 
(s, CL), 141.5 (s, C1'). 143.9 (s, CN), 149.8 (s, C6), 156.0 (s, CM), 157.1 (s, C2), 159.9 (s, 
C5'), 191.3 (s, CF). HRMS (ES+): m/z 557.2071 [100%, M+H+], 579.1889 [93, M+Na+]; 
calcd for [C35H29N2O5] 557.2077.  
 
6.3 Synthesis of Platinum(II) Complexes  
 
6.3.1 General Procedures 
 
6.3.1.1 General Complexation Procedure #1 
K2PtCl4, the appropriate terdentate ligand and concentrated glacial acetic acid were 
placed in a Schlenk tube. The mixture was degassed by five freeze-pump-thaw cycles, 
then heated under nitrogen at 130 °C for three days. After allowing to cool to room 
temperature, the mixture was centrifuged (5 min, 2000 rpm), then the acetic acid was 
removed with a pipette. The solid was washed with methanol, centrifuged (5 min, 2000 
rpm) and the methanol was removed. The solid was also washed with water, ethanol 
and ether (same procedure as before). The solid was then extracted several times into 
DCM, until the extracts became colourless. The DCM extracts were then reduced in 
vacuo. 
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6.3.1.2 General Complexation Procedure #2 
The appropriate terdentate ligand was placed in a Schlenk tube and dissolved in 
CH3CN. A condenser was added, and the mixture was degassed by five freeze-pump-
thaw cycles, then placed under nitrogen. K2PtCl4 and water were placed in a two-necked 
round bottom flask fitted with a suba-seal, and were also degassed and placed under 
nitrogen. The K2PtCl4/water solution was transferred to the Schlenk tube under 
nitrogen. The mixture was heated to 120 °C under nitrogen, and left for three days. 
After allowing to cool to room temperature, the mixture was centrifuged (5 min, 2000 
rpm), the liquid was removed and the precipitate was washed with MeOH, water, EtOH 
and ether. It was then extracted several times into DCM, until the extracts remained 
colourless. The solvent was removed in vacuo. 
 
6.3.1.3 Chloride Metathesis Reaction 
The appropriate complex was suspended in acetone in a round-bottom flask. To this, 
silver triflate (AgOTf) was added, and the reaction was stirred for 1-1.5 h at room 
temperature, during which time, the complex dissolved and silver chloride precipitated. 
The solution was separated from the silver chloride via centrifugation. The potassium 
salt of the new ancillary ligand was added to the acetone solution, which was stirred at 
room temperature for 1-2 h. The complex precipitated from the reaction, and was 
isolated via centrifugation. The solid was washed with ethanol (10 mL), water (10 mL) 
and ether (10 mL) then dried under high vacuum. 
 
6.3.1.4 Oxidation to Pt(IV) 
The specified Pt(II) complex was suspended in chloroform (15 mL). The solution was 
stirred at room temperature and chlorine gas was bubbled through at a moderate rate for 
30 min – 1 h. After removal of the Cl2 gas supply, the solvent was removed in vacuo, 
yielding the desired Pt(IV) complex. 
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6.3.2 Synthetic Details and Characterisation 
 
 [PtL2Cl] 
N N
4´
3´
2´
2
3
4
5
6Pt
Cl
1´
F F
 
This complex was prepared by procedure #1.  Reagents: 1,3-Di(2-pyridyl)-4,6-
difluorobenzene (0.075 g, 2.8 x 10-4 mol), K2PtCl4 (0.12 g, 2.8 x 10-4 mol). Solvent: 
Concentrated glacial acetic acid (3 mL). The product, [PtL2Cl], was initially obtained a 
bright yellow solid, but turned bright orange as the DCM fully evaporated (0.085 g, 
1.71 x 10-4 mol, 61%). 1H NMR (300 MHz, CDCl3) H = 6.72 (1H, t, J(19F) = 11.0, H4'), 
7.32 (2H, ddd, J(1H)  = 5.0, 2.0 and 1.0, H5), 7.92 (2H, d, J(1H) = 7.0, H3), 7.97 (2H, td, 
J(19F) = 8.0 and 2.0, H4), 9.35 (2H, dq, J(1H) = 6.0 and 1.0, 3J(195Pt) = 42.0, H6). 19F 
NMR (376 MHz, CDCl3) F = -108.7 (2F, d, J(1H) = 11.5, 4J(195Pt) = 54.0). HRMS (EI): 
m/z 497.0068 [M]; calcd for [C16H935ClF2N2195Pt], 497.0065. Anal. C16H9ClF2N2Pt 
(497.8): calcd C, 38.60; H, 1.82; N, 5.63; found C, 38.56; H, 1.79; N, 5.60. 
 
[PtL3Cl] 
N N
4´
3´
2´
2
3
4
5
6Pt
Cl
1´
NO2
 
This complex was prepared by procedure #1.  Reagents: 1,3-Dipyridyl-5-nitrobenzene 
(0.072 g, 2.6 x 10-4 mol), K2PtCl4 (0.11 g, 2.6 x 10-4 mol). Solvent: Concentrated glacial 
acetic acid (3 mL). The solid obtained after the washing sequence had very low 
solubility in DCM.  The non-extracted solid was characterised (data given here), and 
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was found to be the desired product (0.072g, 55%). 1H NMR (300MHz, DMSO) H = 
7.65 (2H, td, J(1H) = 7.0 and 1.0, H5), 8.28 (2H, td, J(1H) = 8.0 and 1.0, H4), 8.56 (2H, 
d, J(1H) = 8.0, H3), 8.69 (2H, s, H3'), 9.15(2H, d, J(1H) = 6.0, 3J(195Pt) = 40.0,  H6). 
HRMS (EI): m/z 506.0099 [M]; calcd for [C16H1035ClN3O2195Pt], 506.0109. 
 
Attempted Synthesis of [PtL4Cl] 
N N
4´
3´
2´
2
3
4
5
6Pt
Cl
1´
NH2
 
Complexation of this ligand was attempted via procedure #1. 1,3-Di(2-pyridyl)-5-
aminobenzene (0.017 g, 7 x 10-6 mol), K2PtCl4 (0.029 g, 7 x 10-6 mol).Solvent: 
Concentrated glacial acetic acid (2 mL). A dull brown solid (0.015 g) was obtained. The 
material was only sparingly soluble in the DCM – an NMR was run on the remaining 
solid in DMSO, but was inconclusive as to whether the product, [PtL4Cl], had formed 
(too noisy). The brown solid was washed with triethylamine to deprotonate the amine. 
Unfortunately the solid was still relatively insoluble, and attempts to get a decent NMR 
failed.  
 
[PtL5Cl] 
N N
4´
3´
2´
2
3
4
5
6Pt
Cl
1´
 
This complex was prepared via procedure #1. Reagents: 1,3-Di(3-methyl-2-
pyridyl)benzene (0.060 g, 2.31 x 10-4 mol) and K2PtCl4 (0.096 g, 2.31 x 10-4 mol). 
Solvent: Concentrated glacial acetic acid (5 mL). The product was obtained as a yellow 
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solid (0.052 g, 46%). 1H NMR (400 MHz, CDCl3) H = 2.78 (6H, s, CH3), 7.23 (2H, m, 
H5), 7.72-7.76 (5H, m, H4, H3' and H4'), 9.48 (2H, dd, J(1H) = 6.0 and 1.5, 3J(195Pt) = 
38.0, H6). MS (MALDI): m/z 489.1 [100%, M], 943.6 [20, 2M-Cl], HRMS (MALDI): 
m/z 453.0846 [87%, M-Cl], HRMS (ASAP): m/z 453.0853 [85%, M-Cl] calcd for 
[C18H1535ClN2194Pt], 489.0571, calcd for [C18H15N2194Pt], 453.0857.   
 
[PtL7Cl] 
N N
4´
3´
2´
2
3
4
5
6Pt
Cl
1´
 
This complex was prepared via procedure #1. Reagents: K2PtCl4 (0.080 g, 1.9 x 10-4 
mol) and 1,3-di(5-methyl-2-pyridyl)benzene (0.050g, 1.9 x 10-4 mol). Solvent: 
Concentrated glacial acetic acid (6mL). The product was obtained as a yellow solid 
(0.061 g, 65%). 1H NMR (400 MHz, CDCl3), H = 2.38 (6H, s, 2CH3), 7.13 (1H, t, J(1H) 
= 7.5, H4'), 7.31 (2H, d, J = 7.5, H3'), 7.51 (2H, d, J = 8.0, H3), 7.68 (2H, dd, J = 8.0 and 
1.0, H4), 9.10 (2H s, 3J(195Pt) = 42.0, H6). HRMS (ASAP): m/z 453.0843 [90%, M-Cl]; 
calcd for [C18H15N2194Pt], 453.0862.  
 
[PtL8Cl] 
N N
4´
3´
2´
2
3
4
5
6Pt
Cl
1´
 
This complex was prepared via procedure #1. Reagents: K2PtCl4 (0.090 g, 2.2 x 10-4 
mol) and 1,3-di(6-methyl-2-pyridyl) benzene (0.056 g, 2.2 x 10-4 mol). Solvent: 
Concentrated glacial acetic acid (6 mL). The product was obtained as a yellowy orange 
solid, [Pt(L8)Cl] (0.034 g, 32%). 1H NMR (400 MHz, CDCl3), H = 3.28 (6H, s, 2CH3), 
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7.14-7.20 (3H, m, H4' and H3'), 7.35 (2H, d, J(1H) = 8.0, H5), 7.50 (2H, dd, J(1H) = 8.0, 
and 1.0, H3), 7.73 (2H, t, J(1H) = 8.0 H4). HRMS (FAB): m/z 489.0569 [M+H+]; calcd 
for [C18H1635ClN2194Pt], 489.0566. 
 
[PtL9Cl]  
N N
4´
3´
2´
2
3
4
5
6Pt
Cl
1´
F F
 
This complex was prepared via procedure #1. Reagents: 1,3-Di(3-Methyl-2-pyridyl)-
4,6-difluorobenzene (0.055 g, 1.9 x 10-4 mol), and K2PtCl4 (0.077 g, 1.9 x 10-4 mol). 
Solvent: Concentrated glacial acetic acid (5 mL). 2,6-di(3-methyl-2-pyridyl)-3,5-
difluorobenzene platinum(II) chloride, [Pt(L9)Cl],  was obtained as a bright yellow solid 
(0.056 g, 57%). 1H NMR (400 MHz, CDCl3), H = 2.57 (6H, d, J(19F) = 10.0, 2CH3), 
6.61 (1H, t, J(19F) = 12.0, H4'), 7.17 (2H, dd, J(1H) = 8.0 and 5.5, H5), 7.70 (2H, dd, 
J(1H) = 8.0, 1.5, H4), 9.37 (2H, dd, J = 5.5 and 1.5, 3J(195Pt) = 40, H6). 19F NMR (376 
MHz, CDCl3) F = -92.1 (2F, m), 19F {1H} NMR (470 MHz, CDCl3) F = -92.1 (2F, s, 
4J(195Pt) = 24.0). HRMS (EI): m/z 524.0357 [M]; calcd for [C18H1335ClF2N2194Pt], 
524.0356. Anal. C18H13ClF2N2Pt (525.83): calcd. C, 41.11; H, 2.49; N, 5.33, found C, 
40.78; H, 2.41; N, 5.05. 
 
[PtL10Cl] 
N N
4´
3´
2´
2
3
4
5
6Pt
Cl
1´
F F
 
This complex was prepared via procedure #2. Reagents: 1,3-Di(4-methyl-2-pyridyl)-
4,6-difluorobenzene (0.055 g, 1.9 x 10-4 mol) and K2PtCl4 (0.077g, 1.9 x 10-4 mol). 
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Solvents: CH3CN (6 mL) and water (2 mL). The desired product was obtained as a 
bright yellow solid (0.081 g, 77%). (Note: subsequent complexation of this ligand was 
performed via procedure #1: these experiments gave comparable yields to that reported 
here.) H = 2.49 (6H, s, 2CH3), 6.70 (1H, t, J(19F) = 11.5, H4'), 7.11 (2H, dd, J(1H) = 6.0 
and 1.5, H5), 7.72 (2H, d, J(1H) = 1.5, H3), 9.15 (2H, d, J(1H) = 6.0, 3J(195Pt) = 40, H6). 
19F NMR (376 MHz, CDCl3) F = -109.3 (2F, d, J(1H) = 11.0, 4J(195Pt) = 55.0). HRMS 
(EI): m/z 525.0383 [M]; calcd for [C18H1335ClF2N2195Pt], 525.0378. Anal. 
C18H13ClF2N2Pt (525.83): calcd. C, 41.11; H, 2.49; N, 5.33, found C, 40.44; H, 2.46; N, 
5.31. 
 
[PtL11Cl] 
N N
4´
3´
2´
2
3
4
5
6Pt
Cl
1´
F F
 
This complex was prepared via procedure #1. Reagents: K2PtCl4 (0.048 g, 1.2 x 10-4 
mol) and 1,3-di(5-methyl-2-pyridyl) benzene (0.034 g, 1.2 x 10-4 mol). Solvent: 
Concentrated glacial acetic acid (6 mL). The product was obtained as a yellow solid, 
(0.049 g, 81%). 1H NMR (400 MHz, CDCl3), H = 2.43 (6H, s, 2CH3), 6.53 (1H, t, 
J(19F) = 11.0, H4'), 7.6-7.8 (4H, m, H3 and H4), 9.01 (2H, s, 3J(195Pt) = 41.0, H6). 19F 
NMR (376 MHz, CDCl3) F = -110.3 (2F, d, J(1H) = 11.5, 4J(195Pt) = 54.0). HRMS 
(ASAP): m/z 525.0460 [12%, M+H+], 489.0641 [87, M-Cl]; calcd for 
[C18H1335ClF2N2194Pt], 524.0362, [C18H14ClF2N2194Pt], 525.0440 [C18H13F2N2194Pt], 
489.0674.   
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[PtL12Cl]  
N N
4´
3´
2´
2
3
4
5
6Pt
Cl
1´
F F
 
This complex was prepared via procedure #1. Reagents: 1,3-Di(6-Methyl-2-pyridyl)-
4,6-difluorobenzene (0.059 g, 2.0 x 10-4 mol), K2PtCl4 (0.082 g, 2.0 x 10-4 mol). 
Solvent: Concentrated glacial acetic acid (5 mL). The product was not very soluble in 
DCM, so was obtained without extraction. The product was obtained as an orange solid, 
(0.046 g, 44%). 1H NMR (400 MHz, DMSO), H = 3.26 (6H, s, 2CH3), 6.71 (1H, t, 
J(19F) = 12.0, H4'), 7.18 (2H, dd, J(1H) = 6.5 and 3.0, H5), 7.76 (4H, m, H3 and H4). 19F 
NMR (376 MHz, DMSO) F =  -109.2 (2F, d, J(1H) = 12.0, 4J(195Pt) = 57.0). HRMS 
(EI): m/z 489.0676 [85%, 194Pt, M-Cl]; calcd for [C18H1335ClF2N2194Pt], 525.0362, calcd 
for [C18H13F2N2194Pt], 489.0674. 
 
[PtL13Cl] 
N N
4´
3´
2´
2
3
4
5
6Pt
Cl
1´
 
This complex was prepared via procedure #1. Reagents: 1,3-di(3-methyl-2-pyridyl-4,6-
dimethylbenzene (0.024 g, 8.3 x 10-5 mol), K2PtCl4 (0.035 g, 8.3 x 10-5 mol). Solvent: 
acetic acid (3 mL). The product was obtained as a orangey yellow oily solid (0.017 g, 
3.3 x 10-5 mol, 40%). 1H NMR (400 MHz, CDCl3) H = 2.39 (6H, s, CH3), 2.48 (6H, s, 
CH3) 6.83 (1H, s, H4'), 7.17 (2H, dd, J(1H) = 8.0 and 5.5, H5), 7.72 (2H, dd, J(1H) = 8.0 
and 1.0, H3), 9.33 (2H, dd, J(1H) = 5.5 and 1.0, 4J(195Pt) = 43.0, H6). HRMS (ASAP): 
m/z 516.0884 [8%, M], 481.1174 [80, M-Cl]; calcd for [C20H1935ClN2194Pt], 516.0882, 
calcd for [C20H19N2194Pt], 481.1175. 
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[PtL14Cl] 
N N
4´
3´
2´
2
3
4
5
6Pt
Cl
1´
 
This complex was prepared via procedure #1. Reagents: 1,3-di(5-methyl-2-pyridyl)-4,6-
dimethylbenzene (0.052 g, 1.8 x 10-4 mol), K2PtCl4 (0.076 g, 1.8 x 10-4 mol). Solvent: 
acetic acid (3 mL). The product was obtained as a yellow solid (0.065 g, 1.2 x 10-4 mol, 
69%).1H NMR (400 MHz, CDCl3) H = 2.40 (6H, s, CH3-ph), 2.61 (6H, s, CH3-py), 
6.75 (1H, s, H4'), 7.65-7.75 (4H, m, H3 and H4), 9.31 (2H, dd, J(1H) = 1.5 and 1.0, 
3J(195Pt) = 41.0, H6). HRMS (ASAP): m/z 481.1153 [85%, M-Cl]; calcd for 
[C20H1935ClN2194Pt], 516.0864, calcd for [C20H19N2194Pt], 481.1175. Anal. C20H19CN2Pt 
(517.90): calcd. C, 46.38; H, 3.70; N, 5.41, found C, 40.18; H, 4.16; N, 3.78. 
 
[PtL15Cl] 
N N
4´
3´
2
3
4
5
6Pt
Cl
1´
F F
MeO OMe2´
 
This complex was prepared via procedure #1. Reagents: 1,3-di(4-methoxy-2-pyridyl)-
4,6-difluorobenzene (0.030 g, 9.1 x 10-5 mol), and K2PtCl4 (0.038 g, 9.1 x 10-5 mol). 
Solvent: Concentrated glacial acetic acid (2 mL). The product was obtained as a light 
yellow solid (0.031 g, 5.6 x 10-5 mol, 61%). 1H NMR (500 MHz, CDCl3) H = 3.98 (6H, 
s, OCH3), 6.68 (1H, t, J(19F) = 11.0, H4'), 6.78 (2H, dd, J(1H) = 6.5 and 3.0, H5), 7.39 
(2H, d, J(1H) = 3.0, H3), 9.08 (2H, dd, J(1H) = 6.5 and 0.5, 3J(195Pt) = 39.0, H6) 19F 
NMR (376 MHz, CDCl3) F = -109.2 (2F, d, J(1H) = 11.0, 4J(195Pt) = 62.0). MS 
(MALDI): m/z 556.0 [M], 1077.0 [2M-Cl], HRMS (MALDI): m/z 521.05514 [85%, M-
Cl]. HRMS (ASAP): m/z 521.0558 [80%, M-Cl]; calcd for [C18H1335ClF2N2O2194Pt], 
556.0260, calcd for [C18H13F2N2O2194Pt], 521.0572. 
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This complex was prepared via procedure #1. Reagents: 1-(4-Methoxy-2-pyridyl)-3-(2-
pyridyl)-4,6-difluorobenzene (0.040 g, 1.4 x 10-4 mol) and K2PtCl4 (0.056 g, 1.4 x 10-4 
mol). Solvent: Acetic acid (6 mL). The product was obtained as a yellow solid (0.035 g, 
6.8 x 10-5 mol, 49%). 1H NMR (400 MHz, CDCl3) H = 3.99 (3H, s, OCH3), 6.69 (1H, t, 
J(19F) = 11.0, H4'), 6.79 (1H, dd, J(1H) = 6.5 and 3.0, H5), 7.30 (1H, dd, J(1H) = 7.0 and 
1.5, H5*), 7.41 (1H, dd, J(1H) = 3.0 and 1.0, H3), 7.92 (2H, m, H3* and H4*), 9.08 (1H, d, 
J(1H) = 6.5, 3J(195Pt) = 39, H6), 9.35 (1H, dq, J(1H) = 7.0 and 1.0, H6*). 19F NMR (188 
MHz, CDCl3) F = -109.1 (1F, t, J(1H) = 12.0), -108.8 (1F, t, J(1H) = 12.0). MS 
(MALDI): m/z 527.1 [M], 1019.2 [2M-Cl]. HRMS (ASAP): m/z 526.0173 [8%, M], 
491.0464 [78, M-Cl]; calcd for [C17H1135ClF2N2O194Pt], 526.0155, calcd for 
[C17H11F2N2O194Pt], 491.0466. Anal. C17H11ClF2N2OPt (527.80): calcd C, 38.68; H, 
2.10; N, 5.31; found C, 37.56; H, 2.68; N, 4.43 
 
[PtL17Cl] 
N N
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1´
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This complex was prepared via procedure #2. Reagents: 1,3-di(4-dimethylamino-2-
pyridyl)-4,6-difluorobenzene (0.040 g, 1.1 x 10-4 mol), K2PtCl4 (0.047 g, 1.1 x 10-4 
mol). Solvents: CH3CN (3 mL), water (1 mL). Purification: This complex requires an 
additional washing with acetone. The product was obtained as a light green solid (0.044 
g, 7.54 x 10-5 mol, 67%). 1H NMR (400 MHz, CDCl3) 3.13 (12H, s, CH3), 6.38 (2H, dd, 
J(1H) = 7.0 and 3.0, H5), 6.63 (1H, t, J(19F) = 11.5, H4'), 7.08 (2H, d, J(1H) = 3.0, H3), 
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8.77 (2H, d, J(1H) = 7.0, 3J(195Pt) = 37.0, H6). 19F NMR (376 MHz, CDCl3) F = -111.5 
(2F, d, J(1H) = 11.0, 4J(195Pt) = 59.0). MS (MALDI): m/z 584.1 [M], 1129.1 [2M-Cl] 
HRMS (MALDI): 547.1200 [100%, M-Cl]. HRMS (ASAP): m/z 547.1215 [80%, M-
Cl]; calcd for [C20H1935F2N4195Pt], 547.1205. Anal. C20H19ClF2N4Pt (583.91): calcd. C, 
41.14; H, 3.28; N, 9.60, found C, 40.12; H, 2.81; N, 8.05.  
 
[PtL20Cl] 
N N
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This complex was prepared via procedure #1. Reagents: 1,3-di(4-trifluoromethyl-2-
pyridyl)-4,6-difluorobenzene (0.040 g, 9.9 x 10-5 mol), K2PtCl4 (0.041 g, 9.9 x 10-5 
mol). Solvent: acetic acid (2 mL). The product was obtained as  bright yellow solid 
(0.032 g, 5.1 x 10-5 mol, 51%). 1H NMR (400 MHz, CDCl3) H = 6.84 (1H, t, J(19F) = 
11.0, H4'), 7.55 ( 2H, dd, J(1H) = 6.0 and 1.5, H5), 8.09 (2H, s, H3), 9.54 (2H, d, J(1H) = 
6.0, 3J(195Pt) = 41.0, H6). 19F NMR (376 MHz, CDCl3) F = -105.6 (2F, d, J(1H) = 11.0, 
4J(195Pt) = 49.0), -65.6 (6F, s, CF3) MS (MALDI): m/z 633.0 [M], 1231.0 [2M-Cl], 
HRMS (ASAP): m/z 631.9783 [M]; calcd for [C18H7ClF8N2194Pt], 631.9797. Anal. 
C18H7ClF8N2Pt (633.78): calcd. C, 34.11; H, 1.11; N, 4.42, found C, 33.33; H, 1.93; N, 
3.27. 
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N N
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This complex was prepared via procedure #1. Reagents: 1-(4-methoxy-2-pyridyl)-3-(4-
trifluoromethyl-2-pyridyl)-4,6-difluorobenzene (0.040 g, 1.1 x 10-4 mol), K2PtCl4 
(0.045 g, 1.1 x 10-4 mol). Solvent: acetic acid (3 mL). The product was obtained as a 
greeny yellow solid (0.046 g, 7.7 x 10-5 mol, 71%), 1H NMR (400 MHz, CDCl3) H = 
3.99 (3H, s, CH3), 6.74 (1H, t, J(19F) = 11.0, H4'), 6.81 (1H, dd, J(1H) = 6.5 and 2.5, H5), 
7.41 (1H, d, J(1H) = 2.5, H3), 7.49 (1H, d, J(1H) = 5.5, H5*), 8.04 (1H, s, H3*), 9.03 (1H, 
d, J(1H) = 6.5, 3J(195Pt) = 40.0, H6), 9.56 (1H, d, J(1H) = 5.5, 3J(195Pt) = 39.0, H6*). 19F 
NMR (376 MHz, CDCl3) F = -107.9 (1F, t, J(1H) = 13.5, 4J(195Pt) = 55.0), -107.1 (1F, t, 
J(1H) = 13.5, 4J(195Pt) = 55.0), -65.52 (3F, s, CF3). HRMS (ASAP): m/z 559.0325 [85%, 
M-Cl]; calcd for [C18H1035ClF5N2O194Pt], 594.0028, calcd for [C18H10F5N2O194Pt], 
559.0340. 
  
[PtL22Cl] 
N N
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This complex was prepared via procedure #1. Reagent: 1,3-Di(5-fluoro-2-pyridyl) 
benzene (0.046 g, 1.7 x 10-4 mol), K2PtCl4 (0.071 g, 1.7 x 10-4 mol). Solvent: 
Concentrated glacial acetic acid (5 mL). The product was obtained as a bright yellow 
solid (0.042 g, 50%). 1H NMR (200 MHz, CDCl3) H = 7.23 (1H, m, H4'), 7.40 (2H m, 
H3), 7.72 (4H, m, H3´ and H4), 9.30 (2H, td, J(1H) = 3.0 and 1.0, 3J(195Pt) = 23.0,  H6). 
MS (MALDI): m/z 497.0 [M], 959.0 [2M-Cl]. HRMS (ASAP): 496.0069 [8%, M], 
461.0343 [85, M-Cl]; calcd for [C16H935ClF2N2194Pt], 496.0049, calcd for 
[C16H9F2N2194Pt], 461.0361. Anal. C16H10ClF2N2Pt (497.78): calcd C, 38.60; H, 1.82; 
N, 5.63; found C, 38.25; H, 1.76; N, 5.28. 
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This complex was prepared via procedure #1. Reagents: 2-[6-(3-pyridin-2-yl-phenyl)-
pyridin-2-yl]-phenol (0.040 g, 1.2 x 10-4 mol) and K2PtCl4 (0.051 g, 1.2 x 10-4 mol). 
Solvent: Acetic acid (4 mL). The product was obtained as a yellowy green solid (0.047 
g, 8.5 x 10-5 mol, 69%). 1H NMR (400 MHz, CDCl3) H = 7.96 (2H, d, m, Hc, and H4'), 
7.34 (1H, ddd, J(1H) = 8.5, 7.0 and 1.5, H5*), 7.59 (1H, ddd, J(1H) = 8.0, 6.0 and 1.0, 
Hd), 7.75 (1H, dd, J(1H) = 8.0 and 2.0, He), 8.1-8.3 (5H, m, H3, H4, H5, H3* and H4*), 
8.34-8.38 (2H, m, H5' and Hb), 8.43 (1H, d, J(1H) = 8.5, H3'), 9.51 (1H, ddd, J(1H) = 6.0, 
1.5 and 0.5, H6*). HRMS (ASAP): m/z 517.0807 [85%, M+H+]; HRMS (ASAP – dry 
calibration source): m/z 516.0728 [85%, M]; calcd for [C22H14N2OPt], 516.0733, calcd 
for [C22H15N2OPt], 517.0811 
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This complex was prepared via procedure #1. Reagents: 3-[2-(3,5-Di-pyridin-2-yl-
phenoxy)-ethoxy]-2-phenyl-chromen-4-one (L23) (0.039 g, 7.6 x 10-5 mol) and K2PtCl4 
(0.047 g, 1.1 x 10-4 mol). The solvent used was acetic acid (6 mL). The product was 
obtained as an oily orangey yellow solid (0.029 g, 53%). 1H NMR (700 MHz, CDCl3) 
H = 4.29 (2H, m, CH2), 4.56 (2H, m, CH2), 6.94 (2H, s, H3'), 7.25 (2H, m, H5), 7.4-7.5 
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(4H, m, HG, HN and HO), 7.56 (3H, m, H3 and HI), 7.70 (1H, ddd, J(1H) = 8.5, 7.0 and 
1.5, HH), 7.93 (2H, td, J(1H) = 8.0 and1.5, H4), 8.16 (2H, dd, J(1H) = 8.0 and 1.5, HM), 
8.29 (1H, dd, J(1H) = 8.0 and 1.5, HF), 9.31 (2H, dd, J(1H) = 5.5 and 1.0, H6). MS 
(MALDI): m/z 742.3 [M], 1448.3 [2M-Cl]. HRMS (ASAP): m/z 740.0962 [M]; calcd 
for [C33H2335ClN2O4194Pt], 740.0973. 
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This complex was prepared via procedure #1. Reagents: 3-{2-[2-(3,5-Di-pyridin-2-yl-
phenoxy)-ethoxy]-ethoxy}-2-phenyl-chromen-4-one (0.026 g, 4.7 x 10-5 mol) and 
K2PtCl4 (0.019 g, 4.7 x 10-5 mol). Solvent: Glacial acetic acid (5 mL). The product was 
obtained as a yellowy orange oily solid (0.013 g, 1.7 x 10-5 mol, 35%). 1H NMR 
(400 MHz, CDCl3) H = 3.81 (2H, m, CH2), 3.87 (2H, m, CH2), 4.11 (2H, m, CH2), 4.37 
(2H, m, CH2), 7.09 (2H, s, H3'), 7.2-7.6 (8H, m, HI, HJ, HK, HO, HP and HQ), 7.65 (2H, 
ddd, J(1H) = 8.0, 6.5 and 2.0, H5), 7.91 (2H, td, J(1H) = 8.0 and 1.5, H4), 8.17 (2H, dd, 
J(1H) = 8.0 and 2.0, H3), 8.23 (1H, ddd, J(1H) = 8.0, 1.5 and 0.5, HH), 9.32 (2H, ddd, 
J(1H) = 5.5, 1.5 and 0.5, 4J(195Pt) = 39.0, H6). HRMS (ASAP): m/z 784.1253 [55%, M]; 
calcd for [C35H2735ClN2O5194Pt], 784.1235. 
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This complex was prepared via chloride metathesis reaction. Reagents: [PtL2Cl] (0.025 
g, 5.0 x 10-5 mol), AgOTf (0.016 g, 5.5 x 10-5 mol) and KCN (0.007 g, 1.1 x 10-4 mol). 
Solvent: Acetone (6 mL). Purification: The crude solid was washed with water (10 mL), 
EtOH (10 mL) and ether (10 mL), then dried in vacuo. The product, [PtL2CN] was 
obtained as a bright yellow solid (0.020 g, 4.1 x 10-5 mol, 81%). 1H NMR (400 MHz, 
CDCl3) H = 6.67 (1H, t, J(19F) = 11.0, H4'), 7.26 (2H, m, H5), 7.93 (2H, d, J(1H) = 8.0, 
H3), 7.92 (2H, td, J(1H) = 8.0, H4), 9.22 (2H, ddd, J(1H) = 6.0, 1.5 and 1.0, 3J(195Pt) = 
47.0, H6), 19F NMR (376 MHz, CDCl3) F = -108.4 (2F, d, J(1H) = 11.5, 4J(195Pt) = 
33.0). HRMS (ASAP): m/z 488.0470 [45%, M]; calcd for [C17H9F2N3195Pt], 487.7712. 
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This complex was prepared via the chloride metathesis reaction. Reagents: [PtL15Cl] 
(0.012 g, 2.2 x 10-5 mol) , AgOTf (0.007 g, 2.4 x 10-5 mol) and KCN (0.003 g, 4.6 x 10-5 
mol). Solvent: Acetone (3 mL). Purification: The crude solid was washed with water 
(10 mL), EtOH (10 mL) and ether (10 mL), then dried in vacuo. The product, [PtL15CN] 
was obtained as a bright yellow solid (0.010 g, 1.8 x 10-5 mol, 85%). 1H NMR (400 
MHz, CDCl3) H = 3.98 (6H, s, CH3), 6.62 (1H, t, J(19F) = 11.0, H4'), 6.69 (2H, dd, J(1H) 
= 7.0 and 3.0, H5), 7.37 (2H, d, J(1H) = 3.0, H3), 8.96 (2H, d, J(1H) = 7.0 3J(195Pt) = 44, 
H6), 19F NMR (376 MHz, CDCl3) F = -109.0 (2F, d, J(1H) = 11.0 4J(195Pt) = 40.0). 
HRMS (ASAP): m/z 547.0609 [12%, M]; calcd for [C19H13F2N3O2Pt], 547.0603. 
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This complex was prepared via the chloride metathesis reaction. Reagents: [PtL17Cl] 
(0.020 g, 3.4 x 10-5 mol), AgOTf (0.011 g, 3.8 x 10-5 mol) and KCN (0.005 g, 7.5 x 10-5 
mol). Solvent: Acetone (5 mL). Purification: The crude solid was washed with water 
(10 mL), EtOH (10 mL) and ether (10 mL), then dried in vacuo. The product was 
obtained as an orangey yellow solid (0.014 g, 2.4 x 10-5 mol, 71%). 1H NMR (400 
MHz, CDCl3) H = 3.14 (6H, s, CH3), 6.28 (2H, dd, J(1H) = 7.0 and 3.0, H5), 6.57 (1H, 
t, J(19F) = 11.5, H4'), 7.06 (2H, d, J(1H) = 3.0, H3), 8.66 (2H, d, J(1H) = 7.0, 3J(195Pt) = 
37.0, H6), 19F NMR (376 MHz, CDCl3) F = -111.3 (2F, d, J(1H) = 12.0). HRMS 
(ASAP): m/z 573.1216 [15%, M]; calcd for [C21H19F2N5195Pt], 573.1235. 
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This complex was prepared via the chloride metathesis reaction. Reagents: [Pt L1Cl] 
(0.027 g, 5.9 x 10-5 mol), AgOTf (0.019 g, 6.5 x 10-5 mol) and KBr (0.018 g, 1.5 x 10-4 
mol). Solvent: Acetone (5 mL). The complex, [PtL1Br], was obtained as a bright yellow 
solid (0.022 g, 4.4 x 10-5 mol, 74%). 1H NMR (400 MHz, CDCl3) H = 7.24-7.28 (3H, 
m, H5 and H4'), 7.45 (2H, d, J(1H) = 7.5, H3'), 7.69 (2H, ddd, J = 8.0, 1.5 and 1.0, H3), 
7.92 (2H, ddd, J(1H) = 8.5, 8.0 and 1.5, H4), 9.56 (2H, ddd, J = 5.0, 1.5 and 1.0, 3J(195Pt) 
= 42, H6). HRMS (ASAP): m/z 503.1086 [4%, M], 425.0544 [86, M-Br]; calcd for 
[C16H1179BrN2194Pt], 503.9731, calcd for [C16H11N2194Pt], 425.0549. 
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This complex was prepared via the chloride metathesis reaction. Reagents: [Pt L1Cl] 
(0.020 g, 4.3 x 10-5 mol), AgOTf (0.014 g, 4.8 x 10-5 mol) and KI (0.014 g, 8.7 x 10-5 
mol). Solvent: Acetone (5 mL). The product, [PtL1I] was obtained as a bright yellow 
solid (0.018 g, 3.3 x 10-5 mol, 75%).  1H NMR (400 MHz, CDCl3) H = 7.2-7.3 (3H, m, 
H4' and H5), 7.45 (2H, d, J(1H) = 7.5, H3'), 7.69 (2H, ddd, J(1H) = 8.0, 1.0 and 0.5, H3), 
7.92 (2H, td, J(1H) = 8.0 and 1.5, H4), 9.89 (2H, ddd, J(1H) = 6.0, 1.5 and 0.5, 3J(195Pt) = 
44.0, H6). HRMS (ASAP): m/z 425.0545 [88%, M- I]; calcd for [C16H11IN2194Pt], 
551.9593, calcd for [C16H11N2194Pt], 425.0549. 
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This complex was prepared by oxidation of [PtL2Cl], using the oxidation to Pt(IV) 
method. Reagents: [PtL9Cl] (0.010 g, 2.0 x 10-5 mol) and Cl2 (excess). Solvent: 
Chloroform (15 mL). The product was obtained as a light yellow solid (0.009 g, 1.6 x 
10-5 mol, 79%). 1H NMR (400 MHz, CDCl3) H = 6.99 (1H, t, J(19F) = 12.0, H4'), 7.54 
(2H, ddd, J(1H) = 7.0, 6.0 and 1.5, H5), 8.08 (2H, td, J(1H) = 8.0 and 1.0, H4). 8.16 (2H, 
d, J(1H) = 8.0, H3), 9.52 (2H, ddd, J(1H) = 6.0, 1.5 and 0.5, 3J(195Pt) = 30.0, H6), 19F 
NMR (376 MHz, CDCl3) F = -103.0 (2F, d, J(1H) = 11.0). HRMS (ASAP): m/z 
564.9587 [M-H], 530.9720 [M-Cl]; calcd. for [C16H835Cl3F2N2194Pt] (M), 565.9425, 
calcd for [C16H935Cl2F2N2194Pt] (M-Cl), 530.9738. 
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This complex was prepared by oxidation of [PtL7Cl] using the oxidation to Pt(IV) 
method. Reagents: [PtL7Cl] (0.011 g, 2.3 x 10-5 mol) and Cl2 (excess). Solvent: 
Chloroform (15 mL). The product was obtained as a light yellow solid (0.008 g, 1.4 x 
10-5 mol, 63%). 1H NMR (400 MHz, CDCl3) H = 2.53 (6H, s, CH3), 7.43 (1H, t, J(1H) 
= 8.0, H4'), 7.67 (2H, dd, J(1H) = 8.0 and 1.5, H4), 7.83 (4H, m, H3' and H3), 9.34 (2H, s, 
3J(195Pt) = 21.0, H6). HRMS (ASAP): m/z 559.0027 [M+H+], 523.0214 [M-Cl]; calcd 
for [C18H1635Cl3N2Pt] ([M+H+]), 559.0006, calcd for [C18H1535Cl2N2Pt] ([M-Cl]) 
523.0239. 
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This complex was prepared by oxidation of [PtL9Cl] using the oxidation to Pt (IV) 
method. Reagents: [PtL9Cl] (0.010 g, 1.9 x 10-5 mol) and Cl2 (excess). Solvent: 
Chloroform (15 mL). The product was obtained as a light yellow solid (0.009 g, 1.5 x 
10-5 mol, 79%). 1H NMR (400 MHz, CDCl3) H = 2.75 (6H, s, CH3), 6.95 (1H, t, J(19F) 
= 12.0, H4'), 7.44 (2H, t, J(1H) = 6.0, H5), 7.89 (2H, d, J(1H) = 8.0, H4), 9.65 (2H, d, 
J(1H) = 6.0, 3J(195Pt) = 25.0, H6), 19F NMR (376 MHz, CDCl3) F = -86.5 (2F, m). 
HRMS (ASAP): m/z 592.9774 [M-H], 559.0054 [M-Cl], 523.0370, [(M-2Cl)-H], 
489.0689 [M-3Cl]; calcd for [C18H13Cl3F2N2Pt] ([M]), 593.9738, calcd for 
[C18H13Cl2F2N2Pt] ([M-Cl]), 559.0051, calcd for [C18H13ClF2N2Pt] ([M-2Cl]), 
524.0362, calcd for [C18H13F2N2Pt] ([M-3Cl]), 489.0674.     
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This complex was prepared by oxidation of [PtL10Cl] using the oxidation to Pt (IV) 
method. Reagents: [PtL10Cl] (0.008 g, 1.5 x 10-5 mol), Cl2 (excess). Solvent: 
Chloroform (15 mL). The product was obtained as a pale yellow solid (0.009 g, 1.5 x 
10-5 mol, 100%).1H NMR (400 MHz, CDCl3) H = 2.68 (6H, s, CH3), 6.96 (1H, t, J(19F) 
= 11.0, H4'), 7.33 (2H, d, J(1H) = 5.5, H5), 7.93 (2H, s, H3), 9.30 (2H, d, J(1H) = 5.5 
3J(195Pt) = 24.0, H6), 19F NMR (376 MHz, CDCl3) F = -103.7 (2F, d, J(1H) = 11.5). 
HRMS (ASAP): m/z 592.9736 [M-H], 559.0032 [M-Cl], 523.0333 [(M-2Cl)-H], 
489.0636 [M-3Cl]; calcd for [C18H13Cl3F2N2Pt] ([M]), 593.9738, calcd for 
[C18H13Cl2F2N2Pt] ([M-Cl]), 559.0051, calcd for [C18H13ClF2N2Pt] ([M-2Cl]), 
524.0362, calcd for [C18H13F2N2Pt] ([M-3Cl]), 489.0674.     
 
[PtL11Cl3] 
NN Pt
Cl
F F
1´ Cl
Cl
2´
3´
4´
2
3
4
5
6
 
This complex was prepared by oxidation of [PtL11Cl] using the oxidation to Pt (IV) 
method. Reagents: [PtL11Cl] (0.010 g, 1.9 x 10-5 mol) and Cl2 (excess). Solvent: 
Chloroform (15 mL). The product was obtained as a light yellow solid (0.008 g, 1.3 x 
10-5 mol, 71%). 1H NMR (400 MHz, CDCl3) H = 2.53 (6H, s, CH3), 6.28 (2H, dd, J(1H) 
= 7.0 and 3.0, H5), 6.57 (1H, t, J(19F) = 11.5, H4'), 7.06 (2H, d, J(1H) = 2.5, H3), 8.66 
(2H, d, J(1H) = 7.0, 3J(195Pt) = 23.0, H6), 19F NMR (376 MHz, CDCl3) F = -104.7 (2F, 
d, J(1H) = 11.0, 4J(195Pt) = 29.0). HRMS (ASAP): m/z 592.9825 [M-H], 559.0031 [M-
Cl]; calcd for [C18H13Cl3F2N2Pt] ([M]), 593.9738, calcd for [C18H13Cl2F2N2Pt] ([M-
Cl]), 559.0051. 
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A.1 Crystallographic Data 
 
Crystal data and structure refinement for HL2 
Identification code  07srv131 
Empirical formula  C16 H10 F2 N2 
Formula weight  268.26 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C 2/c 
Unit cell dimensions a = 19.3935(18) Å α= 90°. 
 b = 7.1540(7) Å β= 115.037(2)°. 
 c = 19.2906(18) Å γ = 90°. 
Volume 2424.9(4) Å3 
Z 8 
Density (calculated) 1.470 Mg/m3 
Absorption coefficient 0.110 mm-1 
F(000) 1104 
Crystal size 0.04 x 0.08 x 0.12 mm3 
Theta range for data collection 2.32 to 26.37°. 
Index ranges -20<=h<=24, -8<=k<=8, -24<=l<=20 
Reflections collected 6995 
Independent reflections 6995 [R(int) = 0.0000] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction None 
Max. and min. transmission . and . 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6995 / 0 / 182 
Goodness-of-fit on F2 1.020 
Final R indices [I>2sigma(I)] R1 = 0.0530, wR2 = 0.1212 
R indices (all data) R1 = 0.0862, wR2 = 0.1387 
Largest diff. peak and hole 0.198 and -0.328 e.Å-3 
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Crystal data and structure refinement for HL7 
Identification code  07srv405 
Empirical formula  C18 H14 F2 N2 
Formula weight  296.31 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 6.2629(3) Å α= 90°. 
 b = 11.8780(5) Å β= 96.2500(10)°. 
 c = 18.9531(7) Å γ = 90°. 
Volume 1401.55(10) Å3 
Z 4 
Density (calculated) 1.404 Mg/m3 
Absorption coefficient 0.102 mm-1 
F(000) 616 
Crystal size 0.25 x 0.1 x 0.1 mm3 
Theta range for data collection 2.03 to 26.37°. 
Index ranges -7<=h<=6, -14<=k<=14, -23<=l<=23 
Reflections collected 9329 
Independent reflections 2858 [R(int) = 0.0442] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction None 
Max. and min. transmission . and . 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2858 / 0 / 201 
Goodness-of-fit on F2 0.954 
Final R indices [I>2sigma(I)] R1 = 0.0474, wR2 = 0.1238 
R indices (all data) R1 = 0.0665, wR2 = 0.1354 
Largest diff. peak and hole 0.345 and -0.224 e.Å-3 
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Crystal data and structure refinement for HL22 
Identification code  07srv404 
Empirical formula  C16 H10 F2 N2 
Formula weight  268.26 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P n m a 
Unit cell dimensions a = 7.3752(3) Å α= 90°. 
 b = 25.8010(9) Å β= 90°. 
 c = 6.3567(2) Å γ = 90°. 
Volume 1209.60(8) Å3 
Z 4 
Density (calculated) 1.473 Mg/m3 
Absorption coefficient 0.110 mm-1 
F(000) 552 
Crystal size 0.10 x 0.08 x 0.04 mm3 
Theta range for data collection 1.58 to 26.36°. 
Index ranges -7<=h<=9, -32<=k<=32, -7<=l<=7 
Reflections collected 7450 
Independent reflections 1260 [R(int) = 0.0476] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction None 
Max. and min. transmission . and . 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1260 / 0 / 94 
Goodness-of-fit on F2 1.040 
Final R indices [I>2sigma(I)] R1 = 0.0331, wR2 = 0.0853 
R indices (all data) R1 = 0.0450, wR2 = 0.0905 
Largest diff. peak and hole 0.185 and -0.159 e.Å-3 
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Crystal data and structure refinement for [PtL2Cl] 
Identification code  07srv248 
Empirical formula  C16 H9 Cl F2 N2 Pt 
Formula weight  497.79 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/n 
Unit cell dimensions a = 4.4712(13) Å α= 90°. 
 b = 13.743(3) Å β= 94.705(7)°. 
 c = 21.664(5) Å γ = 90°. 
Volume 1326.8(6) Å3 
Z 4 
Density (calculated) 2.492 Mg/m3 
Absorption coefficient 10.796 mm-1 
F(000) 928 
Crystal size 0.08 x 0.03 x 0.03 mm3 
Theta range for data collection 3.51 to 28.28°. 
Index ranges -5<=h<=5, -18<=k<=18, -28<=l<=28 
Reflections collected 14466 
Independent reflections 3265 [R(int) = 0.0437] 
Completeness to theta = 25.00° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.0000 and 0.6677 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3265 / 0 / 199 
Goodness-of-fit on F2 1.088 
Final R indices [I>2sigma(I)] R1 = 0.0256, wR2 = 0.0459 
R indices (all data) R1 = 0.0369, wR2 = 0.0482 
Largest diff. peak and hole 0.801 and -1.538 e.Å-3 
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Crystal data and structure refinement for [PtL7Cl] 
Identification code  07srv408 
Empirical formula  C18 H15 Cl N2 Pt 
Formula weight  489.86 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/n 
Unit cell dimensions a = 9.6035(6) Å α= 90°. 
 b = 12.9196(8) Å β= 107.5130(10)°. 
 c = 12.9266(9) Å γ = 90°. 
Volume 1529.51(17) Å3 
Z 4 
Density (calculated) 2.127 Mg/m3 
Absorption coefficient 9.345 mm-1 
F(000) 928 
Crystal size 0.12 x 0.05 x 0.05 mm3 
Theta range for data collection 2.28 to 28.28°. 
Index ranges -12<=h<=12, -17<=k<=15, -8<=l<=17 
Reflections collected 10349 
Independent reflections 3787 [R(int) = 0.0590] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.627 and 0.428 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3787 / 0 / 201 
Goodness-of-fit on F2 1.003 
Final R indices [I>2sigma(I)] R1 = 0.0363, wR2 = 0.0704 
R indices (all data) R1 = 0.0628, wR2 = 0.0779 
Largest diff. peak and hole 1.104 and -1.107 e.Å-3 
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Crystal data and structure refinement for [PtL9Cl] 
Identification code  08srv477 
Empirical formula  C18 H13 Cl F2 N2 Pt 
Formula weight  525.84 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P bcn 
Unit cell dimensions a = 11.1153(4) Å α= 90°. 
 b = 16.4508(6) Å β= 90°. 
 c = 8.1531(3) Å γ = 90°. 
Volume 1490.84(9) Å3 
Z 4 
Density (calculated) 2.343 Mg/m3 
Absorption coefficient 9.615 mm-1 
F(000) 992 
Crystal size 0.20 x 0.19 x 0.18 mm3 
Theta range for data collection 2.21 to 26.37°. 
Index ranges -13<=h<=13, -20<=k<=20, -10<=l<=10 
Reflections collected 16160 
Independent reflections 1528 [R(int) = 0.0218] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.177 and 0.119 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1528 / 0 / 112 
Goodness-of-fit on F2 1.091 
Final R indices [I>2sigma(I)] R1 = 0.0123, wR2 = 0.0289 
R indices (all data) R1 = 0.0169, wR2 = 0.0317 
Largest diff. peak and hole 1.299 and -0.602 e.Å-3 
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Crystal data and structure refinement for [PtL10Cl] 
Identification code  09srv092 
Empirical formula  C18 H13 Cl F2 N2 Pt 
Formula weight  525.84 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C 2/c 
Unit cell dimensions a = 15.3727(13) Å α= 90°. 
 b = 13.3686(11) Å β= 108.552(2)°. 
 c = 7.8281(6) Å γ = 90°. 
Volume 1525.2(2) Å3 
Z 4 
Density (calculated) 2.290 Mg/m3 
Absorption coefficient 9.398 mm-1 
F(000) 992 
Crystal size 0.40 x 0.03 x 0.02 mm3 
Theta range for data collection 2.07 to 26.37°. 
Index ranges -19<=h<=11, -16<=k<=16, -9<=l<=9 
Reflections collected 3572 
Independent reflections 1553 [R(int) = 0.0436] 
Completeness to theta = 25.00° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.829 and 0.504 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1553 / 0 / 112 
Goodness-of-fit on F2 1.028 
Final R indices [I>2sigma(I)] R1 = 0.0323, wR2 = 0.0614 
R indices (all data) R1 = 0.0438, wR2 = 0.0642 
Largest diff. peak and hole 1.106 and -0.984 e.Å-3 
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Crystal data and structure refinement for [PtL11Cl] 
Identification code  08srv479 
Empirical formula  C18 H13 Cl F2 N2 Pt 
Formula weight  525.84 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 7.6487(2) Å α= 90°. 
 b = 11.9204(4) Å β= 99.0620(10)°. 
 c = 17.4214(5) Å γ = 90°. 
Volume 1568.58(8) Å3 
Z 4 
Density (calculated) 2.227 Mg/m3 
Absorption coefficient 9.138 mm-1 
F(000) 992 
Crystal size 0.40 x 0.04 x 0.02 mm3 
Theta range for data collection 2.08 to 25.01°. 
Index ranges -9<=h<=9, -14<=k<=13, -20<=l<=19 
Reflections collected 9039 
Independent reflections 2759 [R(int) = 0.0380] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.833 and 0.540 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2759 / 0 / 219 
Goodness-of-fit on F2 1.044 
Final R indices [I>2sigma(I)] R1 = 0.0245, wR2 = 0.0600 
R indices (all data) R1 = 0.0293, wR2 = 0.0633 
Largest diff. peak and hole 1.892 and -1.400 e.Å-3 
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Crystal data and structure refinement for [PtL12Cl] 
Identification code  07srv534 
Empirical formula  C18 H13 Cl F2 N2 Pt 
Formula weight  525.84 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 7.0679(4) Å α= 90°. 
 b = 11.8698(7) Å β= 96.7990(10)°. 
 c = 18.9947(10) Å γ = 90°. 
Volume 1582.35(15) Å3 
Z 4 
Density (calculated) 2.207 Mg/m3 
Absorption coefficient 9.059 mm-1 
F(000) 992 
Crystal size 0.12 x 0.10 x 0.02 mm3 
Theta range for data collection 2.03 to 26.37°. 
Index ranges -8<=h<=8, -14<=k<=10, -23<=l<=23 
Reflections collected 9361 
Independent reflections 3233 [R(int) = 0.0460] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.834 and 0.482 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3233 / 0 / 219 
Goodness-of-fit on F2 1.022 
Final R indices [I>2sigma(I)] R1 = 0.0289, wR2 = 0.0560 
R indices (all data) R1 = 0.0390, wR2 = 0.0589 
Largest diff. peak and hole 0.812 and -0.918 e.Å-3 
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Crystal data and structure refinement for [PtL13Cl] 
Identification code  10srv021 
Empirical formula  C20 H19 Cl N2 Pt 
Formula weight  517.91 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 11.9563(3) Å α= 90°. 
 b = 13.5393(4) Å β= 102.892(3)°. 
 c = 10.8295(3) Å γ = 90°. 
Volume 1708.89(8) Å3 
Z 4 
Density (calculated) 2.013 Mg/m3 
Absorption coefficient 8.370 mm-1 
F(000) 992 
Crystal size 0.170 x 0.115 x 0.024 mm3 
Theta range for data collection 2.75 to 26.37°. 
Index ranges -14<=h<=14, -16<=k<=16, -13<=l<=13 
Reflections collected 13159 
Independent reflections 3488 [R(int) = 0.0774] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.598 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3488 / 24 / 221 
Goodness-of-fit on F2 0.820 
Final R indices [I>2sigma(I)] R1 = 0.0356, wR2 = 0.0641 
R indices (all data) R1 = 0.0917, wR2 = 0.0718 
Largest diff. peak and hole 2.582 and -0.942 e.Å-3 
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Crystal data and structure refinement for [PtL22Cl] 
Identification code  09srv002 
Empirical formula  C16 H9 Cl F2 N2 Pt 
Formula weight  497.79 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 4.7014(3) Å α= 90°. 
 b = 18.1958(11) Å β= 91.822(2)°. 
 c = 15.9873(10) Å γ = 90°. 
Volume 1366.95(15) Å3 
Z 4 
Density (calculated) 2.419 Mg/m3 
Absorption coefficient 10.479 mm-1 
F(000) 928 
Crystal size 0.40 x 0.02 x 0.02 mm3 
Theta range for data collection 1.70 to 26.37°. 
Index ranges -5<=h<=5, -22<=k<=21, -19<=l<=19 
Reflections collected 8689 
Independent reflections 2777 [R(int) = 0.0508] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.811 and 0.536 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2777 / 0 / 199 
Goodness-of-fit on F2 1.068 
Final R indices [I>2sigma(I)] R1 = 0.0323, wR2 = 0.0741 
R indices (all data) R1 = 0.0456, wR2 = 0.0817 
Largest diff. peak and hole 2.941 and -1.800 e.Å-3 
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Crystal data and structure refinement for [PtL25Cl] 
Identification code  08srv186 
Empirical formula  C33 H23 Cl N2 O4 Pt 
Formula weight  742.07 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 7.3169(6) Å α= 100.203(2)°. 
 b = 18.7896(15) Å β= 90.904(2)°. 
 c = 21.8375(18) Å γ = 94.254(2)°. 
Volume 2945.4(4) Å3 
Z 4 
Density (calculated) 1.673 Mg/m3 
Absorption coefficient 4.895 mm-1 
F(000) 1448 
Crystal size 0.40 x 0.03 x 0.02 mm3 
Theta range for data collection 1.90 to 25.03°. 
Index ranges -8<=h<=8, -17<=k<=22, -25<=l<=25 
Reflections collected 15782 
Independent reflections 10347 [R(int) = 0.0528] 
Completeness to theta = 25.00° 99.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.907 and 0.737 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10347 / 210 / 739 
Goodness-of-fit on F2 0.910 
Final R indices [I>2sigma(I)] R1 = 0.0524, wR2 = 0.1036 
R indices (all data) R1 = 0.1022, wR2 = 0.1141 
Largest diff. peak and hole 1.044 and -1.332 e.Å-3 
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Crystal data and structure refinement for [PtL1Br] 
Identification code  09srv360 
Empirical formula  C16 H11 Br N2 Pt 
Formula weight  506.27 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C 2/c 
Unit cell dimensions a = 10.5841(8) Å α= 90°. 
 b = 14.2348(10) Å β= 99.5960(10)°. 
 c = 9.0530(7) Å γ = 90°. 
Volume 1344.86(17) Å3 
Z 4 
Density (calculated) 2.500 Mg/m3 
Absorption coefficient 13.393 mm-1 
F(000) 936 
Crystal size 0.40 x 0.14 x 0.08 mm3 
Theta range for data collection 2.86 to 25.01°. 
Index ranges -11<=h<=12, -12<=k<=16, -10<=l<=10 
Reflections collected 3385 
Independent reflections 1192 [R(int) = 0.0311] 
Completeness to theta = 25.00° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.502 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1192 / 0 / 93 
Goodness-of-fit on F2 1.058 
Final R indices [I>2sigma(I)] R1 = 0.0198, wR2 = 0.0480 
R indices (all data) R1 = 0.0209, wR2 = 0.0485 
Largest diff. peak and hole 1.408 and -1.069 e.Å-3 
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Crystal data and structure refinement for [PtL1I] 
Identification code  10srv022 
Empirical formula  C16 H11 I N2 Pt 
Formula weight  553.26 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C 2/c 
Unit cell dimensions a = 10.6754(5) Å α= 90°. 
 b = 14.5303(7) Å β= 100.8170(10)°. 
 c = 9.1764(4) Å γ = 90°. 
Volume 1398.12(11) Å3 
Z 4 
Density (calculated) 2.628 Mg/m3 
Absorption coefficient 12.234 mm-1 
F(000) 1008 
Crystal size 0.19 x 0.18 x 0.02 mm3 
Theta range for data collection 2.40 to 25.02°. 
Index ranges -12<=h<=12, -17<=k<=17, -10<=l<=10 
Reflections collected 7007 
Independent reflections 1236 [R(int) = 0.0397] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.597 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1236 / 0 / 93 
Goodness-of-fit on F2 1.065 
Final R indices [I>2sigma(I)] R1 = 0.0203, wR2 = 0.0477 
R indices (all data) R1 = 0.0225, wR2 = 0.0488 
Largest diff. peak and hole 0.916 and -1.188 e.Å-3 
 
382 
 
Crystal data and structure refinement for [PtL1Cl3] 
Identification code  09srv361 
Empirical formula  C16 H11 Cl3 N2 Pt 
Formula weight  532.71 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/n 
Unit cell dimensions a = 8.2638(2) Å α= 90°. 
 b = 14.2957(3) Å β= 105.045(2)°. 
 c = 13.6951(3) Å γ = 90°. 
Volume 1562.44(6) Å3 
Z 4 
Density (calculated) 2.265 Mg/m3 
Absorption coefficient 9.489 mm-1 
F(000) 1000 
Crystal size 0.14 x 0.13 x 0.11 mm3 
Theta range for data collection 2.62 to 26.37°. 
Index ranges -10<=h<=10, -17<=k<=17, -17<=l<=17 
Reflections collected 12522 
Independent reflections 3196 [R(int) = 0.0393] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction Analytical 
Max. and min. transmission 0.741 and 0.297 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3196 / 0 / 199 
Goodness-of-fit on F2 0.898 
Final R indices [I>2sigma(I)] R1 = 0.0219, wR2 = 0.0412 
R indices (all data) R1 = 0.0350, wR2 = 0.0426 
Largest diff. peak and hole 1.210 and -0.510 e.Å-3 
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Crystal data and structure refinement for [PtL12Cl3] 
Identification code  07srv249 
Empirical formula  C18 H13 Cl3 F2 N2 Pt 
Formula weight  596.74 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P 21 21 21 
Unit cell dimensions a = 7.76220(10) Å α= 90°. 
 b = 14.4415(2) Å β= 90°. 
 c = 15.4510(2) Å γ = 90°. 
Volume 1732.02(4) Å3 
Z 4 
Density (calculated) 2.288 Mg/m3 
Absorption coefficient 8.589 mm-1 
F(000) 1128 
Crystal size 0.20 x 0.10 x 0.05 mm3 
Theta range for data collection 3.72 to 30.43°. 
Index ranges -10<=h<=11, -19<=k<=20, -21<=l<=21 
Reflections collected 36530 
Independent reflections 4875 [R(int) = 0.0723] 
Completeness to theta = 25.00° 99.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.686 and 0.439 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4875 / 0 / 237 
Goodness-of-fit on F2 1.040 
Final R indices [I>2sigma(I)] R1 = 0.0234, wR2 = 0.0508 
R indices (all data) R1 = 0.0252, wR2 = 0.0514 
Absolute structure parameter -0.015(5) 
Largest diff. peak and hole 1.268 and -1.791 e.Å-3 
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Crystal data and structure refinement for [PtL15Cl3] 
Identification code  08srv328 
Empirical formula  C18 H13 Cl3 F2 N2 O2 Pt 
Formula weight  628.74 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/n 
Unit cell dimensions a = 9.4001(10) Å α= 90°. 
 b = 10.7203(10) Å β= 100.68(1)°. 
 c = 19.1167(12) Å γ = 90°. 
Volume 1893.1(3) Å3 
Z 4 
Density (calculated) 2.206 Mg/m3 
Absorption coefficient 7.872 mm-1 
F(000) 1192 
Crystal size 0.17 x 0.10 x 0.09 mm3 
Theta range for data collection 2.17 to 26.37°. 
Index ranges -11<=h<=11, 0<=k<=13, 0<=l<=23 
Reflections collected 4916 
Independent reflections 4917 [R(int) = 0.0000] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.492 and 0.346 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4917 / 0 / 256 
Goodness-of-fit on F2 0.978 
Final R indices [I>2sigma(I)] R1 = 0.0226, wR2 = 0.0473 
R indices (all data) R1 = 0.0300, wR2 = 0.0490 
Largest diff. peak and hole 1.351 and -0.669 e.Å-3 
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